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 ABSTRACT 
The E6 protein of oncogenic α-human papillomaviruses encodes a conserved C-terminal PDZ 
binding motif (PBM). Conservation of an overlapping kinase recognition site has shown that 
phosphorylation negatively regulates the E6:PDZ interaction. Many E6 PDZ targets are 
associated with signalling complexes that regulate cell proliferation and polarity. This study used 
primary keratinocyte-based models of HPV16 and 18 life cycles to investigate the expression of 
PDZ targets and the functional role of PBM phosphorylation. 
The data indicate that changes in total levels of major E6 PDZ targets are not associated with 
E6-PBM activity. Interestingly, transcription profiles of E6-PBM targets DLG1, PATJ and 
PTPN13 are dramatically changed in the presence of HPV16 and 18, whilst others remain 
unaffected. Further analysis of transcriptional changes of DLG1 revealed upregulation of specific 
alternatively spliced isoforms, including a novel isoform containing an exon previously thought 
to be intronic.  
This investigation revealed that phosphorylation of the PBM is linked to oncoprotein stability, 
presenting a potential regulatory mechanism of E6 PDZ interactions during the virus life cycle. 
Together, these data offer interesting new perspectives on interactions between oncogenic HPV 
types and PDZ domain-containing targets and indicate that deregulation of their function by the 
virus may occur through multiple mechanisms. 
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 CHAPTER 1: INTRODUCTION 
1.1 Papillomaviruses 
Papillomaviruses were first discovered in 1907, when the Italian scientist Gieseppe Ciuffo 
inoculated himself with the cell-free extract of warts to prove that the growths were caused 
by a transmissible agent (Ciuffo, 1907). More than twenty years later, while Francis Peyton 
Rous was investigating transmissible agents causing tumours in chickens, virologists 
Richard Shope and E. Weston Hurst were studying warts taken from wild cottontail 
rabbits. In the soluble extracts of these warts, they found a transmissible agent, the 
cottontail rabbit papillomavirus (CRPV), that was capable of inducing benign growths 
when introduced to uninfected rabbits (Shope and Hurst, 1933). The pair passed on tissue 
to the aforementioned Rous, who used it to infect a domestic species of rabbit. These 
rabbits failed to form warts, which would have been evidence of normal successful viral 
replication, but instead developed aggressive skin carcinomas (Rous and Beard, 1935). 
Rous went on to establish retroviruses as cancer-causing agents in chickens, but it would be 
more than 30 years until human papillomaviruses (HPVs) were linked to human cancers 
and accepted as a human tumour virus. 
Papillomaviruses, named for the papilla (buds in Latin) that infected cells form, are a highly 
diverse group of small, double-stranded DNA viruses. Their diversity is reflected in the 
wide range of hosts that they infect, which includes reptiles, birds and mammals (Herbst et 
al., 2009; Chen et al., 1982; Schulz et al., 2009; Bernard et al., 2010). There are more than 300 
known papillomaviruses, 170 of which are officially human-specific, with other types 
pending classification (Bernard et al., 2010; de Villiers, 2013; van Doorslaer et al., 2013). The 
viruses are classified by the nucleotide sequence encoding the conserved L1 open reading 
frame (ORF); this is the most conserved gene within the genome. Members of the same 
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papillomavirus genus are denoted by Greek letters (i.e. α, β, γ, µ) and share more than 60% 
nucleotide sequence identity in the L1 ORF (Bernard et al., 2010; de Villiers, 2013; de 
Villiers et al., 2004). These are sub-divided into HPV types, which are numbered (e.g. 
HPV16, HPV18; both α-papillomaviruses) and defined by an L1 region containing DNA 
sequence that differs by more than 10% to the closest known type (Figure 1.1, Table 1.1). 
Virus variants are further classified (e.g. HPV16 114/B, HPV16 114/K), by containing a 
less than 2% difference in the L1 region (Bernard et al., 2010; de Villiers, 2013; de Villiers et 
al., 2004).  
Table 1.1: Biological properties associated with different HPV genus 
Genus Biological Properties Examples 
Alpha-
papillomavirus  
Mucosal and cutaneous lesions in humans and primates  
Many high-risk types under this genus 
HPV6, HPV11, 
HPV16, 
HPV18 
Beta-
papillomavirus  
Cutaneous lesions in humans 
Predominantly latent infection, re-activated in 
immunosuppressed conditions 
Close association with Epidermodysplasia verruciformis 
(EV) 
HPV8 HPV12 
Gamma-
papillomavirus  Cutaneous lesions in humans HPV60 
Nu- 
papillomavirus 
Benign and malignant cutaneous lesions  HPV41 
Mu-papillomavirus Cutaneous lesions HPV1 
The major human-tropic genus are mentioned here. Adapted from de Villiers et al., 2004.  
HPVs infect cutaneous or mucosal epithelial (Table 1.1), causing a variety of lesions; from 
benign plantar, flat and common warts and genital warts, to cervical neoplasia and cancer 
(Table 1.2). As such, HPV types can be classified as high- or low-risk, according to their 
capacity to promote malignant growth. 
1.2 Benign HPV infection 
A number of HPV types cause benign growths in mucosal and cornified epithelia. 
Infection with low-risk types of HPV can cause condylomata acuminata (genital warts) or 
Figure 1.1: Human papillomavirus classification  
Classification of  papillomavirus types is based on the DNA sequence of  the L1 
gene; HPV types differ by more than 10% in the DNA sequence of  the L1, 
whereas HPV variants differ by less than 2% in L1 sequence. Members of  the 
same genus share >60% nucleotide sequence identity in the L1. HPVs are 
contained within evolutionary groups. The outermost semicircular symbols 
indicate papillomavirus genera, e.g. alpha-papillomavirus. The number at the inner 
semicircular symbol refers to papillomavirus species e.g. HPV16. The HPV types 
that infect the cervix come from the Alpha group which contains over 60 
members. HPV types from the Beta, Gamma, Mu and Nu groups primarily infect 
cutaneous sites. Adapted from de Villiers, 2004. 
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verrucae (skin warts). Genital warts are the most prevalent sexually-transmitted infection 
worldwide (Baseman and Koutsky, 2005), with the HPV types 6 or 11 found in 100% of 
cases and co-infection with high-risk types associated with 25% of cases (Lacey, 2005; 
Brown et al., 1999; Greer et al., 1995). Genital warts are highly infectious, with a 
transmission rate of about 65% and an incubation period of between 3 weeks and 8 
months, with the majority developing warts at around 2–3 months (Oriel, 1971). After 
regression, it has been suggested that asymptomatic infection persists for life (Stanley, 
2010).  
Verrucae, caused by HPV infection of cornified epithelium, are most common in children 
and adolescents, the majority of whom clear the growths spontaneously (Williams et al., 
1993). The many and varied types of warts are classified based upon the site of infection 
and pathology (Table 1.2). Painful and unsightly warts can be treated by removal, but there 
is still a requirement for the immune system in disease clearance (Sterling et al., 2001).  
Although infection with low-risk viruses is largely benign, immunocompromised 
individuals can experience more damaging effects. Patients with the rare heritable disease, 
epidermodysplasia verruciformis (EV), are susceptible to β-HPV infection and are at risk 
of developing non-melanoma skin cancer (NMSC); 30-60% of the patients develop 
carcinoma (Akgül et al., 2006). EV patients exhibit an inability to control HPV infection, 
resulting in the development of scaly growths, particularly on the hands and feet. This is 
attributed to a defect in the immune system’s ability to reject the HPV-positive 
keratinocytes (Majewski and Jabłońska, 1995; Majewski and Jablonska, 2002; Baadsgaard et 
al., 1990). This is reinforced by the fact that β-HPVs are ubiquitous in the general 
population and EV-like conditions develop in HIV infected individuals as well as other 
immunosuppressive conditions (Majewski and Jabłońska, 1995). In addition, genetic 
screening has revealed that loss of function mutations in the EVER1 and EVER2 genes, 
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which encode zinc-transporting proteins, are responsible in a majority of cases (Ramoz et 
al., 1999; 2000; 2002). It has been suggested that the EVER genes affect the virus life cycle 
by limiting the accessibility of Zn2+ ions to the viral zinc binding proteins E6 and E7, and 
that somatic mutations remove this anti-HPV activity (Lazarczyk et al., 2008). It is also 
thought that the loss of EVER gene function impairs T-cell activation and proliferation, 
by impairing regulation of lymphocyte Zn2+ concentration, thus impairing immunity against 
HPV in EV patients (Lazarczyk et al., 2012). UV light is also influential in thep[ 
development of EV associated squamous cell carcinoma (SCC); although warts develop on 
all body sites, carcinomas occur exclusively on sites exposed to the sun (Majewski and 
Jabłońska, 1995). Thus, the pathology of EV demonstrates the interplay between multiple 
factors, genetic and environmental in HPV mediated carcinogenesis.  
1.3 HPV infection and cancer  
It was not until the late 1980s that papillomaviruses were established as the etiological 
agent of cervical cancer in humans, and now HPVs are associated with more human 
cancers than any other virus (WHO). Infection with high-risk HPV is responsible for 4.8% 
of the world’s cancer burden, causing over 610,000 cases per year worldwide (de Martel et 
al., 2012; Forman et al., 2012). The discovery was made by Nobel laureate Harald zur 
Hausen, who was studying the genital condylomata-causing virus in women (Hausen et al., 
1974). HPV has subsequently been shown as the causative agent in a number cancers of 
the anogenital tract, as well as important factors in the development of NMSC and in 
carcinomas of the oral and oropharyngeal mucosa (Parkin and Bray, 2006; Lowy and 
Schiller, 2012). To date, twelve HPV types have been defined by the World Health 
Organisation (WHO) as ‘high-risk’ with respect to causing cancer (IARC Group 1), and a 
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further ten types are recognised as ‘probably’ and ‘possibly’ cancer-causing (IARC Group 
2A and 2B, Table 1.3, Bouvard et al., 2009).  
Table 1.2: HPV types associated with human disease 
Adapted from Cubie, 2013. 
1.3.1 Anogenital cancers 
Altogether, there are more than 530,000 new cases and 275,000 deaths from cervical cancer 
per year (Ferlay et al., 2012). In identifying HPV as a cause of cervical cancer, Harald zur 
Disease Most frequently associated HPV types 
Common warts HPV2, 4, 7; occasionally other types in immunosuppressed (e.g. HPV 75, 76, 77) 
Flat plane warts HPV3, 10, occasionally types 26–29 and 41 
Plantar warts HPV1, 2, 4   
Epidermodysplasia 
verruciformis (EV) 
Plane warts HPV3, 10 
Scale-like plaques HPV5, 8; less commonly 9, 12, 14, 15, 17, 19, 20, 21–25, 36–39, 47, 49 
Squamous cell 
carcinomas of sun-
exposed skin 
HPV5, 8, less commonly 14,17,20 and 47   
External warts HPV6, 11, 40, 42, 43, 44, 54, 61, 72, 81, 89 
Anogenital Warts 
Buschke–Lowenstein 
tumour HPV6 
 Bowenoid papulosis HPV16, 55   
Anogenital cancers 
and precancers 
IARC Group 1: 
Carcinogenic 
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66 
IARC Group 2A: 
Probably carcinogenic  HPV68   
IARC Group 2B: 
Possibly carcinogenic HPV26, 53, 64, 65, 66, 67, 69, 70, 73, 82 
Oral Lesions 
Oral papillomas 
 
HPV2, 6, 7, 11, 16, 18, 32, 57   
Laryngeal papillomas HPV6, 11 
Focal hyperplasia 
(Heck's disease) HPV13, 32 
Oropharyngeal 
carcinoma Predominantly HPV16 
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Hausen determined the presence of HPV16 and 18 DNA in cancer tissue; together these 
α-HPVs contribute to more than 70% of cervical cancer cases worldwide (Li et al., 2011). 
HPV-induced cancer of the cervix is the most characterized; stages of cervical neoplasia are 
clinically categorized by cytological and histological examination; pre-malignant phases are 
termed cervical intraepithelial neoplasia (CIN) and are graded 1 to 3 (Woodman et al., 
2007). These pre-malignant changes represent a spectrum ranging from mild dysplasia 
(CIN1), moderate dysplasia (CIN2), to severe dysplasia and carcinoma (CIN3) (Figure 1.2). 
These progressively malignant changes are associated with the increased expression of 
HPV encoded oncoproteins E6 and E7, which together provide the primary transforming 
activity of high-risk HPVs (Section 1.4.2). The most common HPV types found in cervical 
cancers are HPVs 16, 18, 58, 52, 31 and 33 (Clifford et al., 2006). In the cervix, HPV-driven 
cancers arise from squamous cells and adenomatous glandular cells. Squamous cell 
carcinomas (SCC) account for 80% of cervical cancer cases, of which 62% are HPV16 
associated (de Sanjose et al., 2010; Walboomers et al., 1999). By contrast, adenocarcinomas 
are less frequent and are more commonly associated with HPV18 (de Sanjose et al., 2010; 
Green et al., 2003).  
Table 1.3: IARC classification of HPV carcinogenic risk 
IARC Group HPV types 
Group 1 - carcinogenic 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
Group 2A - probably carcinogenic 68 
Group 2B - possibly carcinogenic 26, 53, 66, 67, 70, 73, 5, 8, 6, 11 
Adapted from Bouvard et al., 2009. 
Other anogenital malignancies associated with high-risk HPV include penile and vulvo-
vaginal cancers, where 40% of incidences are attributed to HPV, and anal carcinomas, 
where 90% of incidences are attributed to HPV (Parkin and Bray, 2006; Ferlay et al., 2012). 
The high proportion of HPV associated with anogenital cancers indicates the necessity for 
Figure 1.2: Stages of  cervical intraepithelial neoplasia 
HPV is thought to access basal cells via micro-abrasions in the cervical epithelium. 
Following infection, viral DNA replicates and exists as episomes (purple nuclei). In 
the upper layers of  epithelium, the viral genome is replicated further, and progeny 
virions form in the nucleus. Low-grade intraepithelial lesions support productive 
viral replication. An unknown number of  high-risk HPV infections progress to 
high-grade cervical intraepithelial neoplasia (CIN). These pre-malignant changes 
represent a spectrum of  histological abnormalities ranging from CIN1 (mild 
dysplasia), CIN2 (moderate dysplasia), to CIN3 (severe dysplasia/carcinoma in 
situ). The progression of  untreated lesions to microinvasive and invasive cancer is 
associated with the integration of  the HPV genome into the host chromosomes 
(red nuclei). Adapted from Woodman et al. 2007. 
Normal cervix Invasive cancerSquamous intraepithelial lesion
Low grade High grade
Cervical intraepithelial neoplasia (CIN)
Grade 1 Grade 2 Grade 3
Infectious virus particles
Episomal HPV DNA
Integrated HPV DNA
Basal cells
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viral infection in cancer development. However, not all infections with HPV lead to 
invasive disease; it has been suggested that 80 to 90% of HPV infections persist for 12 to 
18 months and are cleared by the immune system (Bodily and Laimins, 2011; Stanley, 
2012). As with EV, a number of co-factors have been reported to aid the development of 
high-risk HPV-driven anogenital carcinoma, including hormones, smoking and 
immunosuppression (Green et al., 2003; Kjellberg et al., 2000; Coutlee et al., 2012; 
Hildesheim et al., 1990; Harper et al., 1994). Smoking has been shown to be the most 
significant cofactor in cervical cancer development; current smokers are twice as likely as 
non-smokers to be diagnosed with CIN (Collins et al., 2010; Kjellberg et al., 2000). 
Chemical carcinogens found in cigarette smoke are thought to influence carcinogenesis by 
causing DNA damage and impairing the immune system; there is no evidence to suggest 
that HPV infection is prolonged by the effects of smoking (Collins et al., 2010; Castellsagué 
and Muñoz, 2003). As with low-risk types, immunosuppressed patients are susceptible to 
the development of HPV-driven cancers. For example, HPV infection is more common 
and more likely to persist in HIV-positive compared to HIV-negative women (Clifford et 
al., 2006). Whilst the exact mechanisms are unclear, co-factors are proposed to influence 
progression to carcinogenesis via suppression of the immune system, increased viral 
persistence, and/or inducing DNA damage. 
1.3.1.1  Screening and vaccination  
Rates of cervical cancer have fallen in developed countries over the last few decades, 
thanks to the implementation of screening programs, which allow the early detection and 
treatment of pre-cancerous cervical lesions (Feldman, 2014). In the UK, the Papanicolaou 
(Pap) test of exfoliated cervical cells was introduced nationally in 1988, since which 
mortality rates of cervical cancer have decreased by 80% (Peto et al., 2004). Despite the 
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decrease in SCC rates, the rates of adenocarcinoma have been reported to increase, which 
is attributed to cervical screening being less efficient at the detection of adenocarcinoma; 
the disease presents minor cytological abnormalities compared to SCC and so screening is 
less likely to identify and interrupt disease progression (Clifford et al., 2003; Muñoz et al., 
2003; Feldman, 2014; Woodman et al., 2007; 2001).  
A recent development in the protection against cervical carcinoma has been achieved in the 
licensing of two prophylactic vaccines against HPV infection: the quadrivalent vaccine 
Gardasil®, which protects against HPV types 16, 18, 6 and 11 and the bivalent vaccine 
Cervarix®, which protects against HPV16 and 18. Both vaccines show a level of cross-
protection against infection with other HPV types, including types HPV31 and HPV45 
(Bonanni et al., 2009; Toft et al., 2014). Cervical cancer screening is an expensive 
preventative health care measure; in England, it costs the NHS around £175 million a year, 
including treatment (http://www.cancerscreening.nhs.uk/). A vaccination program may 
alleviate some of this cost, but screening will still be required for those who are missed by 
the vaccination program, and to catch cancers induced by the high-risk HPV types not 
targeted by the vaccines (Villa, 2011). As the incidence of cervical cancer decreases in the 
developed world due to a better understanding and improved screening protocols, it 
remains constant in the developing world where screening and treatment are difficult and 
expensive to implement (Forouzanfar et al., 2011; Parkin and Bray, 2006). The HPV-
associated cancer burden is disproportionally spread geographically; more than 76% of 
cervical cancers occur in developing countries, where there is a 80% lower chance of 
successful treatment, compared to women living in more developed countries (Baseman 
and Koutsky, 2005; Parkin et al., 2001; de Martel et al., 2012). As in the case of screening 
programs, poor infrastructure and high costs make implementation of vaccination in 
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developing countries unfeasible, and so better methods of prevention are still required in 
countries where disease burden is greatest (de Martel et al., 2012).  
Interestingly, vaccine development is being explored as a treatment against HPV-positive 
tumour cells; using peptide sequences corresponding to E6 and E7 to induce an immune 
response against these proteins and thus against E6 and E7-expressing tumor cells. This is 
currently under development, but has been effective in inducing a response from 
lymphocytes during a study of HPV-positive vulvar intraepithelial neoplasia (VIN) patients 
(Le Buanec et al., 1999; Wieking et al., 2012; Wang et al., 2000).  
1.3.2 Non-genital cancers 
1.3.2.1 Non-melanoma skin cancer 
NMSC is the most prevalent malignancy in the Caucasian population worldwide (Alam and 
Ratner, 2001). The term includes both basal cell carcinomas (BCCs) and squamous cell 
carcinomas (SCCs); the former being more common and contributing to 80% of NMSC 
(Rubin et al., 2005). Ultraviolet (UV) irradiation is a well characterised risk factor in the 
development of NMSC and molecular studies have identified HPV as a co-factor also; 
HPV DNA has been identified in 30% to 50% of NMSCs in the non-immunosuppressed 
population (Meyer et al., 2001; Berkhout et al., 1995; Pfister, 2003). A number of HPV types 
have been associated with NMSC; notably types 5, 8, 14, 17, 20 and 47 (Harper et al., 2013; 
Jemal et al., 2013). Unlike in anogenital cancers, the number of copies of HPV genomes per 
cell in NMSCs is low; only 1 in 20-50,000 cells contain HPV DNA (Pfister, 2003; 
Weissenborn et al., 2005). Both the requirement for UV radiation in carcinogenesis and the 
low viral DNA copy number suggests that HPVs promote the initiation and progression of 
NMSCs, but are not essential for the maintenance of a malignant phenotype (Majewski and 
Jabłońska, 1995). The influence of HPV in promoting NMSC has not been fully elucidated; 
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in contrast to mucosal HPVs, the E6 and E7 oncoproteins of cutaneous HPVs have weak 
or no transforming properties in vitro (Akgül et al., 2005). However, E6 and E7 from 
HPV49 have been shown to efficiently deregulate p53 and Rb pathways in a similar fashion 
to their mucosal equivalents (Cornet et al., 2012). Furthermore, current thinking suggests 
that the E6 and E7 proteins of cutaneous HPV types inhibit the normal DNA damage 
repair response or UV-induced apoptosis (Muschik et al., 2011; Jackson and Storey, 2000; 
Underbrink et al., 2008; Viarisio et al., 2011). According to this hypothesis, infected cells are 
less able to efficiently repair any genetic errors induced by UV radiation, leading to the 
accumulation of mutations, changes in cellular phenotype and the development of cancer 
(Hanahan and Weinberg, 2011). The E6 proteins of HPV5 and 18 prevent the 
translocation of apoptosis-inducing factors to the nucleus (Leverrier et al., 2007) and 
HPV38 E6 has been shown to interact with the histone acetyltransferase (HAT) p300 to 
inhibit p53 acetylation, and thus inhibit p53-mediated growth arrest and apoptosis 
(Muench et al., 2009; Muschik et al., 2011). Similarly, E6 proteins of HPV types 5, 10 and 77 
have been shown to prevent UV-induced apoptosis, by abrogating the anti-apoptotic 
functions of Bak (Underbrink et al., 2008; Holloway et al., 2014; Simmonds and Storey, 
2008). As with other HPV infections, the immune status of the host is an important co-
factor in the development of NMSC; organ-transplant recipients have a 10-fold increased 
risk of BCC and up to a 100-fold increased risk of SCC (Pfister, 2003). The 
immunomodulatory functions of E6 and E7 have been suggested to play a role in NMSC 
progression; it is argued that the secretion of anti-inflammatory cytokines by just a few 
HPV-positive cells can impair the cancer cell elimination by the host immune system 
(Harwood and Proby, 2002; Pfister, 2003). 
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1.3.2.2 Oropharyngeal cancers 
Oropharyngeal carcinoma (OPC) is one of the many cancers associated with smoking and 
alcohol consumption, and results in more than 300,000 deaths per year worldwide (Blot et 
al., 1988; Ang and Sturgis, 2012; Canova et al., 2010). Since HPV DNA has been found to 
be more prevalent in OPC tumour than in adjacent normal tissue, the virus is considered 
an etiological agent for disease (D'Souza et al., 2007). In both the USA and Europe, the 
incidence of HPV-related OPC has been increasing since the early 1990s, although the 
proportion of OPC caused by HPV varies widely; in North America 40 to 80% of OPCs 
are associated with HPV, whereas in Europe the proportion varies from 20 to 90% 
(Kreimer et al., 2005a; Hansson et al., 2005; Applebaum et al., 2007; Pintos et al., 2008; 
Smith et al., 2004; Tachezy et al., 2009; Termine et al., 2008; Du et al., 2011; Attner et al., 
2009; Mehanna et al., 2012; Chaturvedi et al., 2008). Unlike in cervical carcinomas, HPV16 
is more commonly found than HPV18, with 60% of HPV associated OPC in the USA 
containing HPV16 genomes (Kreimer et al., 2005b; Marur et al., 2010; Herrero et al., 2003).  
Perhaps counter-intuitively, patients with HPV-positive OPC have a better prognosis than 
those without; presence of HPV is associated with better tumor control and survival 
outcomes following radiotherapy, chemotherapy and combined radiation with cisplatin 
(Lassen et al., 2011; Fakhry et al., 2008; Posner et al., 2011; Ang et al., 2010; Rischin et al., 
2010). The mechanism for this is not known, although HPV-positive tumours are on 
average smaller than HPV-negative carcinomas at diagnosis and it has been suggested that 
the virus promotes sensitivity to therapy. Furthermore, HPV-mediation of OPC 
development has been suggested to follow a similar pathway as anogenital cancers (Oh et 
al., 2013). Ongoing studies aim to identify driver mutations and predicative biomarkers of 
this disease in order to improve treatment outcome (Ang and Sturgis, 2012). 
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1.4 The HPV life cycle 
Compared to many other viruses, the HPV genome is small, comprising of 8 kb double-
stranded DNA and encoding 8 open reading frames (ORFs, Figure 1.3, Table 1.4). These 
ORFs encode 6 early proteins, E1, E2, E4, E5, E6 and E7, and 2 late structural proteins, 
L1 and L2, which form the icosahedral capsid of the virus (Buck et al., 2013; Finnen et al., 
2003). With the exception of the helicase E1, these ORFs do not encode enzymatic 
functions, and so viral replication requires cellular machinery. As such, the papillomavirus 
life cycle is closely tied to the biology of keratinocytes. 
Whether or not a productive HPV life cycle is completed depends upon the nature of the 
epithelial site where infection occurs. A specific population of cells in the cervix (at the 
squamo-columnar junction) have been identified as having the potential of developing 
HPV-related CIN, while cells located elsewhere do not (Herfs et al., 2012). As previously 
indicated, HPV infection can also depend upon the presence of external factors such as 
hormones and cytokines (Gariglio et al., 2009; de Jong et al., 2004).  
Initial HPV infection occurs via micro-abrasions in the epithelium, enabling viral access to 
the basal lamina (Kines et al., 2009). Viral entry into basal keratinocytes is mediated by L1 
and L2; L1 interacts with heperin sulphate molecules, as well as laminin, on the surface of 
the basal lamina (Combita et al., 2001; Giroglou et al., 2001; Finnen et al., 2003; Johnson et 
al., 2009; Culp et al., 2006; Joyce et al., 1999). L1 binding induces structural changes in the 
virion capsid, exposing L2 for cleavage by furin and thus facilitating virus interaction with a 
secondary receptor on the keratinocyte surface and subsequent internalization of virus 
(Richards et al., 2006; Johnson et al., 2009; Kines et al., 2009; Surviladze et al., 2012). The 
mechanism of virus internalisation has not been fully resolved for all HPV types and 
findings are disparate. Most recently, it has been suggested that entry of HPV types 16, 18 
Figure 1.3: HPV genome organisation 
The HPV genome has a circular double standed DNA genome, encoding 8 ORFs. 
Splicing of  mRNA creates a number of  gene products. Viral genes are transcribed 
in a clockwise direction to produce 6 early, non structural proteins (E1, E2, E4, 
E5, E6 and E7), and 2 late transcripts encoding structural proteins (L1 and L2, 
light blue). The major oncoproteins E6 and E7 are highlighted in green, and the 
transcriptional control region (long control region; LCR, highlighted in grey). The 
LCR contains a DNA replication origin and functions as the regulator for the 
DNA replication. This region contains binding sites for cellular transcription 
factors (e.g. SP1, AP1, Oct1), and for the viral E2 protein, which control viral gene 
expression. The HPV genome contains two promoter elements (P Early and P 
Late, indicated in red) which regulate the expression of  differentially-spliced 
mRNAs. The genome also contains two polyadenylation sites, (Poly A Early and 
Late, indicated in red). 
Adapted from Kajitani et al. 2012 and Doorbar et al. 2012 . 
 
HPV18
7857 bp
LCR
E1
E4
Poly A (Late)
Poly A (Early)
P Early
P Late
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and 31 are all independent of clatherin, caveolin, and dynamin, but require actin 
polymerization and the tetraspanin CD151 (Spoden et al., 2013).  
Following internalisation, the viral capsid disassembles in the endosome compartment and 
L2 mediates relocation of the viral genome from the endosomal compartment to the 
nucleus, where genomes are replicated and maintained at a low copy number in basal cells 
(Richards et al., 2006; Day et al., 2003; Pyeon et al., 2009; Parish et al., 2006; McBride, 2008). 
The initial round of viral DNA replication occurs independently of the cell cycle, and 
results in amplification of the viral genome to around 50–100 copies per cell (Moody and 
Laimins, 2010). Here, the viral transcription factor E2 is important for the initiation of viral 
replication and segregation of viral genomes into infected daughter cells (Lehman and 
Botchan, 1998; Sanders and Stenlund, 2000; Mohr et al., 1990). There are multiple E2 
binding sites in the viral LCR, which enable E2 to recruit the helicase E1 along with 
cellular transcriptional machinery to position it at the viral origin of replication and 
promote HPV gene transcription (Stubenrauch et al., 1996; Mohr et al., 1990; Sanders and 
Stenlund, 2000). At this stage, HPV genes are transcribed from the early promoter (Figure 
1.3). E2 also acts to tether HPV genomes to mitotic chromosomes via interaction with 
Brd4 and is able to activate or repress cellular gene transcription, depending on the context 
of the binding sites and nature of the associated cellular factors (Bernard et al., 1989; 
Dostatni et al., 1991; Dong et al., 1994; You et al., 2004).  
Following the initial replication stage, known as establishment, the infected cell leaves the 
basal compartment and migrates upwards in the epithelia. During a normal, uninfected, life 
cycle, basal keratinocytes divide and migrate upwards, differentiating as they do so (Figure 
1.4). Basal cells divide asymmetrically; one daughter cell migrates, leaving a basal layer of 
dividing epithelial stem cells (Figure 1.4). However, entering the differentiation program 
requires exit from the cell cycle and poses an obstacle to HPV genome replication, which 
Figure 1.4: Epithelial differentiation and the HPV life cycle 
The right-hand side depicts the structure of  uninfected differentiated epithelia and 
the main characteristics of  each cell layer. Basal cells in the cervical epithelium rest 
on the basal lamina, which is supported by the dermis. Basal cells divide 
asymetrically, and a daughter cell migrates upwards as differentiation occurs, in 
which cells exit the cell cycle and progressively accumulate cytoplasmic keratin. 
The left-hand side depicts the HPV infectious cycle. Initially, HPV infects basal 
cells via microabrasions in epithelia. Infected basal cells form the reservoir of  
virus. In these cells, the early genes E1, E2, E5, E6 and E7 are expressed and the 
viral DNA establishes as episomes within the nuclei of  cells. As cells migrate 
upwards, the viral episomes are maintained at a copy number of  100-1000 
genomes per cells. The late productive life cycle occurs in upper layers of  the 
epithelia, where the viral genome is amplified, and the late genes L1 and L2, and 
E4 are expressed. Virions are assembled and released from cornified keratinocytes 
as they slough off, and are able to produce a new infection.  
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depends upon host replication substrates and machinery. To overcome this, HPV 
expresses the early proteins E6 and E7. The combined actions of these proteins reactivates 
cellular DNA synthesis in non-dividing cells, inhibits apoptosis, and uncouples the 
differentiation program of the infected keratinocyte from the cell cycle (Section 1.4.1).  
Table 1.4: High-risk HPV ORFs 
HPV ORF Function(s) Target Factors 
E6 
Reactivation of cellular replication 
mechanisms  
Proliferation, immortalisation, inhibition of 
apoptosis 
 Maintenance of viral genome  
Co-operates with E7 to immortalise primary 
keratinocytes 
p53, ADA3, p300/CBP, E6AP, 
SP1, c-myc, NFX1- 91,TERT, 
FAK, FADD, Caspase 8, BAX, 
BAK, IRF3, PDZ domain proteins  
 
E7 
Reactivation of cellular replication 
mechanisms  
Proliferation, immortalisation, inhibition of 
apoptosis   
Maintenance of viral genome  
Binds retinoblastoma protein (pRb), 
deregulates the G1/S checkpoint 
Co-operates with E6 to immortalise primary 
keratinocytes 
RB, p107, p130, HDAC, E2F6, 
p21, p27, CDK/cyclin, ATM, ATR, 
gamma-tubulin  
 
E4 Interacts with cytoskeletal proteins, allows viral assembly   
Cytokeratin 8/18 
E5 Weak transforming activity Upregulates growth factor receptors 
EGFR, PDGFR, V-ATPase, 
MHC1, TRAIL receptor, FAS 
receptor  
E1 Replication of viral genome: Helicase, ATPase, ATP-binding protein   
RPA, topoisomerase, polymerase 
alpha-primase 
E2 
Viral genome replication, transcription and 
maintenance: Acts as a transcription factor, 
facilitates initiation of HPV DNA replication, 
important for genome encapsidation 
Brd4, ChlR1  
HPV E1 
L1 Major capsid function - 
L2 Minor capsid function - 
 Adapted from Stanley, 2001 and Kajitani et al., 2012. 
Next follows a phase where viral gene expression is minimal and, importantly, the 
expression of the oncogenes E6 and E7 is tightly control by E2 (Gammoh et al., 2009). As 
infected keratinocytes enter the differentiating compartment of the epithelia, there is an 
expansion in viral gene expression, including abundant expression of E6 and E7 (Chow et 
al., 1987)Figure 1.4). Transcription occurs from the differentiation-dependent late 
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promoter (P late) located within the E7 ORF, and terminates at the late polyadenylation 
site (Figure 1.3), amplifying viral genomes to more than 1000 copies per cell (Lambert, 
1991; Bedell et al., 1991). This promoter drives the expression of E1, E2, E4 and E5 
proteins as well as the late proteins L1 and L2 (Hummel et al., 1992; Ozbun and Meyers, 
1998; 1997), Figure 1.4). Both E1^E4 (a fusion protein comprising the first amino acids of 
E1 and the E4 ORF) and E5 proteins contribute to this differentiation-dependent phase of 
the viral life cycle (Wilson et al., 2005; Peh et al., 2004). Cleavage of E1 by cellular caspases 
and activation of the ATM (ataxia telangiectasia mutated protein)-mediated DNA damage 
pathway are necessary for viral genome amplification as cells enter G2 (Moody et al., 2007; 
Moody and Laimins, 2009). It is suggested that the subsequent induction of the 
homologous recombination pathway recruits cellular DNA repair factors to facilitate HPV 
DNA replication, thus enabling the virus to replicate in an S phase independent manner, in 
the differentiating compartment of stratified epithelia (Gillespie et al., 2012).  
Little is known about the actions of E5 during the HPV life cycle, although it has been 
shown to downregulate MHC class I expression to promote viral immune evasion, as well 
as activating epidermal growth factor (EGF) signal cascades to induce keratinocyte 
proliferation (Petti et al., 1991; Belleudi et al., 2011; Pim et al., 1992; Crusius et al., 1998; 
Straight et al., 1993). The sequences of the high-risk HPV E5 proteins are conserved, and it 
has been shown to have weak transforming properties (Bouvard et al., 1994a; Straight et al., 
1993; Stöppler et al., 1996). The E5 protein has also been shown to form pore structures, 
thought to allow the maturation of endosomes during viral entry and/or release (Wetherill 
et al., 2012). Similarly, the function of E4 in the upper layers of the epithelia has not been 
fully elucidated although it is abundantly expressed (Figure 1.4). The E4 protein is 
translated from spliced transcripts which includes the first 5 amino acids of E1 to generate 
E1^E4 fusion proteins (Chow et al., 1987). Several studies have shown that E4 is able to 
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arrest transition of the cell cycle from G2 to M, and inhibit entry into S phase as well as 
inhibiting cellular DNA replication (Knight et al., 2004; Davy et al., 2009; Peh et al., 2004). 
However Knight et al. (2011) showed that G2 arrest was not associated with viral genome 
amplification. Together, the functions of E4 produce an environment which is suitable for 
viral DNA replication without competition from the host, as well as optimising viral 
genome amplification and the expression of capsid proteins (Wilson et al., 2007; 2005; 
Nakahara et al., 2005).  
In the final stages of the viral life cycle, the L1 and L2 proteins encapsulate viral genomes 
to form infectious virus particles (Figure 1.4). Virus capsids are assembled in the nucleus 
from 360 molecules of L1 and variable number of L2 molecules, arranged into 72 
pentameric units to form an icosahedral structure, stabilized by intermolecular disulphide 
bonds between L1 proteins (Buck et al., 2008; Finnen et al., 2003). Infectious virions are 
released during the natural sloughing of keratinocytes, a process which may be facilitated 
by E4-mediated disruption of the keratin cytoskeleton (Roberts et al., 1997; Doorbar et al., 
1991). The entire life cycle takes 2-3 weeks in vivo; the time taken for a basal keratinocyte to 
migrate up the epithelial layers and differentiate (Figure 1.4).  
1.4.1 HPV E6 and E7 in the HPV life cycle 
The E6 and E7 proteins of both high and low-risk viruses are translated from a bicistronic 
E6E7 mRNA (Tang et al., 2006). Together they target a number of cellular factors, 
including those involved in cell cycle regulation, gene expression, DNA replication and cell 
signalling, culminating in the uncoupling of keratinocyte differentiation from division to 
promote an environment favorable for viral replication. 
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1.4.1.1 HPV E7 
The functions of E7 induce cellular DNA synthesis, bypass cellular growth arrest, prevent 
cellular senescence and modulate immune responses.  
The interaction of E7 with the retinoblastoma protein (pRb) family is a well-characterised 
example of E7 acting upon the cell cycle (Figure 1.5). The interaction occurs via a 
conserved LXCXE motif at the N-terminus of high-risk HPV E7 proteins (Münger et al., 
1989b). The pRb family of proteins, consisting of p105, p107 and p130, regulate the 
transition of the cell cycle from G1 to S phase by acting upon the activity of the 
transcription factor family E2F (Dyson et al., 1989). In quiescent cells, pRb is 
hypophosphorylated, which promotes its ability to bind to E2F (Neuman et al., 1994; 
Hiebert et al., 1992; Morkel et al., 1997). The pRb:E2F heterodimer prevents binding of the 
transcription factor to the promoter region of genes required for G1 to S phase transition, 
thus repressing transcription of E2F-responsive genes (Jones et al., 1997; DeGregori and 
Johnson, 2006; Zwicker et al., 1996). In the presence of mitogenic signals, pRb is 
progressively phosphorylated during G1 by active CDK:cyclin complexes CyclinD1:CDK4, 
CyclinD1:CDK6 and CDKE:cyclin2, which causes the complex to dissociate thus allowing 
transcription of E2F-responsive genes. These genes are required in nucleotide synthesis, 
DNA replication and progression of the cell cycle into S phase. For example, cyclin A is 
transcribed, which binds to CDK2 to activate the kinase, allowing the phosphorylation of 
target proteins to activate S phase specific processes, including DNA replication (Jeffrey et 
al., 1995; Harper et al., 1993). HPV E7 mimics the phosphorylation of pRb, disrupts the 
pRb:E2F complex and causes proteasomal degradation of pRb (Figure 1.5, Dyson et al., 
1989; Huh et al., 2007). This enables the constitutive expression of E2F-responsive genes; 
inducing infected cells to enter S phase despite absence of mitogenic signals (Cheng et al., 
1995; Chellappan et al., 1992).  
Figure 1.5: E7 acting upon the cell cycle  
E2F transcription factors form heterodimeric complexes with members of  the 
pRb family and regulate the transcription of  several genes during the cell cycle. In 
quiescent cells, pRb is present in a hypophosphorylated form and associates with 
E2F molecules, thereby inhibiting their transcriptional activity. When quiescent 
cells are exposed to mitogenic signals, genes encoding the G1 specific D-type 
cyclins (D1, D2 and D3) are activated. Subsequently, cyclins associate with a 
cyclin-dependant kinase, CDK4 or 6, transport into the nucleus and phosphorylate 
pRb in mid-G1 phase. Phosphorylation of  pRb releases active E2F complexes and 
progression into S phase. E7 binding to pRb mimics its phosphorylation, 
promoting its proteasomal degradation. Thus, E7 expressing cells can enter S 
phase in the absence of  a mitogenic signals.  
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High-risk α-HPV E7 affects CDK2 via a number of mechanisms to promote cell cycle 
progression from G1 to S phase. E7 binds to the CDK2 inhibitors p21 and p27, preventing 
their inhibitory activity, and E7 expression induces increased CDC25 transcription; the 
phosphatase dephosphorylates and consequently activates CDK2 (Zerfass-Thome et al., 
1996; Funk et al., 1997; Jones and Münger, 1997; Nguyen et al., 2002). Similarly, E7 
upregulates the transcription of cyclin E to promote cell cycle progression and increases 
transcription of the senescence inhibitor protein DEK (Wise-Draper et al., 2005). 
Moreover, E7 affects S phase-specific gene expression by interacting with transcription 
factors; E7 binds to E2F to act as a transcriptional activator (Hwang et al., 2002).  
The viral protein is able to modulate transcription directly via the zinc finger domain. This 
domain allows E7 to bind and recruit chromatin modifiers such as histone deacetylases 
(HDACs) to repress the activity of specific promoters, including E2F responsive ones 
(Brehm et al., 1998; Longworth et al., 2005; Longworth and Laimins, 2004a). Furthermore, 
E7 is able to facilitate the removal of HDAC at other promoters, in order to activate 
transcription of growth-promoting genes (Brehm et al., 1999). This interaction is important 
in S phase promotion but has also been shown to influence the maintenance of episomal 
genomes (Longworth et al., 2005; Longworth and Laimins, 2004b).  
The transcriptional upregulation of interleukin-8 (IL-8) induced by E7 not only prevents 
cellular senescence, but also enables infected cells to evade immune detection (Walker et al., 
2011). Furthermore, E7 expression has recently been shown to increase the levels IL-18 
binding protein (IL-8BP), an antagonist of the proinflammatory cytokine IL-18 (Richards et 
al., 2014). This enables infected keratinocytes to evade immune detection by interfering 
with IL-18-mediated lymphocyte activation (Richards et al., 2014). The multifarious nature 
of E7 can also be seen in the inhibition of tumour necrosis factor α (TNFα)-mediated cell 
cycle arrest by the oncoprotein, where the proteins ability to interrupt translation also 
CHAPTER 1: INTRODUCTION 
-19- 
inhibits TNFα-mediated differentiation and apoptosis and aids immune evasion (Basile et 
al., 2001; Thompson et al., 2001; Boccardo et al., 2010). All of which enables the virus to 
evade detection as well as promote cell survival despite the activation of apoptotic signals. 
During the viral life cycle, E7 expression and activity is regulated by E2; HPV16 E2 protein 
directly binds to E7 to inhibit degradation of pRb (Gammoh et al., 2009). Disruption of the 
cell cycle by E7 induces p53-dependent apoptosis and stabilises p53; degradation of pRb 
leads to an increase p53 protein and would trigger apoptotic pathways and end viral 
propagation, were it not for the functions of E6 (Demers et al., 1994). 
1.4.1.2 HPV E6  
Full-length E6 protein is transcribed from the bicistronic E6E7 mRNA to produce a 
protein of approximately 150 amino acids in length, which resides in the cytoplasm and 
nucleus of infected cells (Howie et al., 2009; Tao et al., 2003). It has been suggested that E6 
forms a dimer in high concentrations of salt and protein but remains predominantly 
monomeric under physiological conditions (Lipari et al., 2001). Like E7, E6 contains two 
zinc finger motifs (Figure 1.6) and the protein is known to interact with a number of 
cellular targets, via which it affects a range of cellular processes, including apoptosis, cellular 
differentiation, cell-cell adhesion, polarity and proliferation (Figure 1.7, Barbosa et al., 1989; 
Grossman and Laimins, 1989).  
The association between HPV E6 proteins and the cellular ubiquitin ligase E6AP occurs via 
an LXLL motif within the oncoprotein and allows E6 to promote the proteasomal 
degradation of a number of targets, as well as increasing E6 stability (Huibregtse et al., 
1993b; Tomaić et al., 2009; Daniels et al., 1998b). One of the most well known targets is the 
DNA damage response protein, p53, which ordinarily is not targeted for degradation via 
E6AP (Camus et al., 2003). However, E6 binding both E6AP and p53 facilitates 
Figure 1.6: Structure of  E6 
(A)  Schematic of  HPV E6 protein domain structure. E6 proteins are 
approximately 150 amino acids in length and contain two zinc-finger domains 
and a C terminus PDZ binding motif  (PBM, highlighted in pink). Numbers 
correlate to the amino acid sequence of  HPV18 E6.  
(B)  The 3D structure of  E6 from Zanier et al. 2013, shows that the PBM (pink) is 
disordered in NMR structural studies and adopts a β-strand confirmation 
upon binding to the PDZ domain of  MAGI-1 (red ribbon structure). The 
right-hand image shows the protein rotated by 180 degrees relative to the left-
hand image. Region in green indicates E6AP binding (LXXLL) motif, with the 
interacting helix of  E6AP shown (green). Blue indicates region of  E6 involved 
in self-association, with a ribbon stricture indicating a second E6 molecule. 
The white region indicates residues which are potentially available to interact 
with p53.   
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Figure 1.7: E6 interacts with a number of  cellular proteins 
From Howie et al. 2009. E6 alters numerous cellular pathways through the binding 
of  proteins. The interactions predominantly function to promote cell-cycle 
progression for the propagation of  virus, but promote transformation of  infected 
cells when the protein is deregulated, aiding the progression of  cancer and 
highlighting the role of  E6 as a viral oncoprotein.  
Examples of  proteins involved are indicated below the affected pathways.   
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ubiquitination and subsequent degradation of the cellular tumour suppressor (Huibregtse et 
al., 1993a; Werness et al., 1990; Crook et al., 1991; Muench et al., 2010). Interestingly, the 
association between HPV16 E6 an E6AP is stronger than between E6AP and HPV18 E6, 
and drives the degradation of p53 more efficiently than HPV18 E6 (Scheffner et al., 1990). 
E6 proteins also disrupts the function of p53 directly; binding to the protein interferes with 
the DNA-binding activity and blocks transcription of p53-dependent genes (Lechner and 
Laimins, 1994). E6 further disrupts p53 activity by binding to the histone acetyltransferases 
p300 and CREB binding protein (CBP), inhibiting p53 acetylation, which would otherwise 
stabilize the cellular protein, and increasing E6 stability (Patel et al., 1999; Zimmermann et 
al., 1999). A decrease in p53 provides the infected cell with resistance to apoptosis; E6-
expressing cells are able to continue promoting cell proliferation without disruption. In this 
respect, the HPV oncoproteins E6 and E7 act synergistically; where E7 puts the cell at risk 
of p53-mediated apoptosis, E6 intervenes removing p53 and allowing the cell to continue 
providing substrates for DNA synthesis and viral propagation (Figure 1.8). Moreover, loss 
or abrogation of E6-directed p53 degradation impairs the ability of HPV16 to maintain 
genomes and silencing E6 in the context of HPV18 negatively affects viral genome 
amplification (Park and Androphy, 2002; Wang et al., 2009c; 2009b; 2009a; Kho et al., 
2013). Similarly, HPV11 encoding a non-functional E6 were unable to maintain episomal 
genomes, indicating the importance of HPV E6 in viral replication (Oh et al., 2004). 
HPV E6 is also able to affect p53-independent apoptotic pathways to prevent virally 
induced cell-death. This was first observed in transgenic mouse models expressing HPV16 
E6 and E7 in the mouse eye lens; expression of E7 alone induced apoptosis, which was 
partially rescued by knocking down p53 (Pan and Griep, 1994; Griep et al., 1993). Although 
both high and low-risk HPV E6 proteins promote the degradation of pro-apoptotic factor 
Bak, only high-risk E6 has been shown to bind to procaspase 8, an event which induces 
Figure 1.8: HPV oncoprotein cooperation in cervical carcinogenesis 
The ability of  E6 and E7 to target cellular regulators of  proliferation, apoptosis, 
immortalization and genomic stability collectively bestows cells with a growth 
advantage and an increased propensity for transformation and malignant 
progression. The viral proteins work synergistically; the induction of  
hyperproliferation by the E7 protein triggers cellular apoptotic pathways, which is 
blocked by the actions of  the E6 protein. Cells are therefore immortalized via the 
cooperative actions of  E6 and E7, although these functions are potentiated by the 
actions of  E5. Adapted from Moody and Laimins 2010. 
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conformational changes that interrupt downstream signalling and the cells response to pro-
apoptotic stimuli (Thomas and Banks, 1999; 1998; Underbrink et al., 2008; Tungteakkhun 
and Duerksen-Hughes, 2008; Filippova et al., 2004).  
Table 1.5: Protein partners of E6 
Function E6 Binding partner 
E3 ubiquitin ligase E6AP 
Mediators of apoptosis p53, Bak, c-myc, procaspase-8, 
FADD, TNFR1 
Transcriptional regulation CBP/p300, NFκB 
Immune regulation IRF3 
Chromosomal stability Mcm7, hTERT 
Epithelial differentiation and 
organisation 
E6-BP, fibulin-1, zyxin, Notch 
pathway 
Cell polarity, adhesion and 
proliferation 
PDZ proteins* 
Adapted from Howie et al., 2009; Vande Pol and Klingelhutz, 2013. *Cell polarity proteins are discussed in 
more detail in Section 1.6 
 
During HPV infection, keratinocyte differentiation must be tightly controlled in order to 
balance the promotion of viral genome amplification in the spinous layer of epithelia with 
keratinocyte differentiation in the granular and cornified layers (Figure 1.4). High-risk E6 
proteins modulate keratinocyte differentiation and it is likely that these functions of E6 are 
temporally regulated (Alfandari et al., 1999; Sherman et al., 1997). In cell culture and mouse 
models, E6 has been shown to enhance the activity of the Wnt signalling pathway, which is 
involved in cell proliferation, in an E6AP dependent manner (Lichtig et al., 2010; Bonilla-
Delgado et al., 2012). Moreover, E6 activates the mTOR receptor tyrosine kinase cascade 
by enhancing phosphorylation of the kinase mTOR which activates downstream signalling 
pathways, culminating in the stimulation of protein synthesis (Spangle and Münger, 2010; 
Spangle et al., 2012). The oncoprotein also acts on the Notch pathway, which is central to 
epithelial differentiation; cutaneous HPV E6 proteins are able to downregulate the pathway 
by binding to MAML1 protein, and E6 proteins have been shown to repress pathway 
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components transcriptionally (Brimer et al., 2012; Meyers et al., 2013; Henken et al., 2012; 
Tan et al., 2012). However, HPV has been shown to potentiate the Notch pathway in 
keratinocytes via transcription factor NFX-123 (Vliet-Gregg et al., 2013; 2015). 
Interestingly, a recent study indicated that NFκB activation by E6 is cell context specific; 
whereas E6-mediated activation of the pathway in ectocervical cells increased proliferation, 
it inhibited growth in cells derived from the endocervix (Vandermark et al., 2012). Further 
complexity is added by the addition of a temporal aspect; it is likely that E6 differentially 
modulates Notch signalling during the viral life cycle, repressing and enhancing signalling 
in the spinous and upper layers respectively (Brimer et al., 2012; James et al., 2006; Nees et 
al., 2001; Yuan et al., 2005; Havard et al., 2005; D'Costa et al., 2012; Vandermark et al., 2012).  
In addition, the C-terminus of high-risk α-HPV E6 proteins contains a conserved motif 
that is able to interact with a number of PDZ-domain containing proteins involved in 
differentiation and the regulation of epithelial polarity. The relationship between high-risk 
HPV E6 and these polarity proteins is discussed in more depth in Section 1.5.4.  
By interacting with transcription factors, such as p300/CBP and c-myc, E6 is able to 
influence the regulation of gene transcription (Crook et al., 1991; Desaintes et al., 1992; 
Ronco et al., 1998; Patel et al., 1999). By activating c-myc, high-risk HPV E6 is able to 
regulate the expression of hTERT a telomerase complex which prevents telomeric DNA 
loss during repeated cell replication cycles (Oh et al., 2001; Kiyono et al., 1998). This is 
beneficial to the viral life cycle as it extends the replicative potential of infected cells, 
however chronic activation leads to an immortal phenotype, promotes chromosomal 
instability and mutation accumulation, all of which are oncogenic phenotypes (Figure 1.5). 
Furthermore, the expression of HPV16 E6 causes downregulation of a number of genes 
involved in keratinocyte differentiation, including IFN-responsive genes, including IFNα 
and IFNβ (Nees et al., 2001; Vandermark et al., 2012). The same study observed an 
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upregulation in expression of proliferation promoting genes, including IL-8 and NFκB 
pathway components, in the presence of E6 alone (Nees et al., 2001). Moreover, it has 
recently been observed that expression of high-risk E6 alone is sufficient to cause 
transcriptional upregulation of APOBEC3B, which encodes a DNA deaminase (Vieira et 
al., 2014). It has been suggested that this is an effect of E6-mediated p53 abrogation, rather 
than a direct interaction with cellular DNA, but it must be noted that E6 is able to effect 
gene expression more directly. For example, E6 proteins have been shown to bind and 
target the HAT ADA3 for degradation; as such, interaction with chromatin remodeling 
machinery is a mechanism by which E6 can alter host gene expression (Kumar et al., 2002). 
The effect of E6 upon transcription contributes to the proteins ability to delay cell 
differentiation and promote a favourable environment for viral genome replication. 
Another feature of high-risk HPV E6 proteins is their ability to regulate cellular microRNA 
(miRNA) expression (Martinez et al., 2008; Wang et al., 2009c; Wald et al., 2011; McKenna 
et al., 2014; Yablonska et al., 2013). For example, HPV16 E6 downregulates miR34a, which 
targets cell cycle control genes (Wang et al., 2009c). The mechanism by which E6 regulates 
miRNAs is not known, but it has been suggested to that the reduction in p53 and the 
increase in E2F activity when E6 and E7 are present plays a role (Yablonska et al., 2013). 
1.4.1.2.1 Spliced forms of E6 
Variations of the E6 protein, denoted E6*I and E6*II, are produced via alternative splicing 
(Smotkin and Wettstein, 1986). The splice site is highly conserved, and causes expression 
of the first 42 or 44 amino acids of HPV16 or HPV18 E6 respectively followed by a 
variable sequence (Comerford et al., 1995). The functions of E6 spliced variants remain 
unclear, although interactions with both E6AP and full-length E6 have been observed (Pim 
et al., 1997). The overexpression of HPV18 E6*I promotes the proteasome-dependent 
degradation of junctional proteins DLG1, MAGI-1 and PATJ which are also targets of 
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full-length E6 (Pim et al., 2009; Storrs and Silverstein, 2007). Moreover, both HPV16 and 
HPV18 E6*I have been shown to target the HAT TIP60 for degradation (Jha et al., 2010). 
Conversely, the kinase AKT has been identified as a target of E6*I, but is not targeted by 
the full-length protein (Pim et al., 2009). 
The actions of E6*I appear to antagonize some functions of the full-length protein. For 
example, in vitro HPV18 E6*I is able to inhibit E6-mediated p53 degradation and stabilize 
procaspase 8 (Pim et al., 1997; Tungteakkhun et al., 2010; Pim and Banks, 1999). It has been 
suggested that the antagonistic functions of E6* controls the activity of full-length E6 
during the virus life cycle by preventing complete removal of cellular p53 (Mantovani and 
Banks, 2001). Interestingly, the full-length and E6*I versions bind to different regions of 
procaspase 8 (Tungteakkhun et al., 2010; Filippova et al., 2007). 
1.4.2 HPV oncogenesis 
HPVs are well adapted to their host; in most instances the virus manages to proliferate and 
is maintained in the host population without causing any apparent disease (Woodman et al., 
2007; Liaw et al., 1999; Wallin et al., 1999). However, malignant growth can be a side effect 
of infection, with the time from initial exposure to invasive growth spanning a period of 
15-30 years (Woodman et al., 2007; Bekkers et al., 2004). The progression of infected cells 
from neoplastic lesions to invasive cancer is associated with failure of the immune system 
to clear persistent infection and the integration of the HPV genomes into host 
chromosomes (Cricca et al., 2006; Andersson et al., 2005; Peitsaro et al., 2002; Berumen et 
al., 1995; Fuchs et al., 1989; Cooper and McGee, 1992; Das et al., 1992; Hausen, 2002; 
Collins et al., 2009). Although integrated HPV genomes are present in the majority of 
cervical cancers and the frequency of integration increases with severity of cervical 
neoplasia, it should also be noted that integration of viral genomes is an early event 
(Wentzensen et al., 2004; Xu et al., 2013; Collins et al., 2009). While no integration hotspots 
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have been confirmed, it has been suggested that preferential integration occurs at a site 
near the c-myc gene and that genomes integrate at naturally occurring regions of host 
genomic instability, known as fragile sites (Ziegert et al., 2003; Ferber et al., 2003; Akagi et 
al., 2014). Integration of the genome is influential in HPV oncogenesis; in epithelial cell 
culture, integration of HPV16 genomes is associated with a selective growth advantage and 
an increased proliferative capacity (Jeon et al., 1995; Jeon and Lambert, 1995). HPV 
genome transcription is regulated by the viral E2 protein, which represses early gene 
expression and regulates copy number (Bouvard et al., 1994b). Integration disrupts the viral 
genome, often interrupting E1 and E2 expression and thus removing the regulatory 
influence of E2 over the expression of early viral genes (Pett and Coleman, 2007). This was 
demonstrated in culture, when reintroduction of E2 into HPV18-positive cancer cells 
containing integrated genomes caused cellular senescence (Goodwin and DiMaio, 2000; 
Francis et al., 2000). Furthermore, the expression of E6 and E7 oncoproteins is retained in 
cancers, and the transcripts expressed from integrated genomes are more stable than from 
episomes (DeFilippis et al., 2003; Hausen, 1999; Schwartz, 2013; Jeon et al., 1995; Jeon and 
Lambert, 1995). Replication of integrated genomes also results in the activation of host 
DNA repair and recombination systems, which increases the likelihood of acquiring 
cellular mutations, increased genomic instability and, eventually, malignant progression 
(Kadaja et al., 2009). It has also been suggested that the coexistence of episomal genomes 
with integrated copies may be important in carcinogenesis; Kadaja et al. (2009) propose that 
expression of HPV E1 and E2 from episomal genomes can initiate DNA replication from 
integrated viral origins, resulting in the induction of chromosomal abnormalities as well as 
viral gene transcription, leading to genomic instability. Thus, there is a significant role for 
HPV genome integration in the transformation of infected cells to cervical cancer, and the 
viral oncoproteins E6 and E7 are important in maintaining a transformed phenotype.  
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1.4.2.1 HPV E6 and E7 in oncogenesis 
There is a wealth of evidence demonstrating the ability of HPV oncoproteins E6 and E7 to 
drive immortalisation of cells. Expression of the E6 protein from high-risk HPV types 16, 
18, and 31 have been shown to extend keratinocyte lifespan (Münger et al., 1989a; Hudson 
et al., 1990; Sedman et al., 1991; Woodworth et al., 1989). Expression of high-risk HPV E7 
immortalises human primary keratinocytes in culture at low frequency, but is unable to 
immortalise mammary cells alone (Hawley-Nelson et al., 1989). Moreover, mouse models 
of cervical cancer have shown that E6 and E7 are able to induce dysplasia independently, 
with E7 expression generating a more invasive phenotype than E6 (Riley et al., 2003). Mice 
expressing E6 under the control of a keratin promoter develop epithelial hyperplasia 
(Herber et al., 1996; Song and Pitot, 1999). In this transgenic mouse model, expression of 
E7 alone is sufficient to induce high-grade cervical dysplasia and invasive cervical 
malignancies (Arbeit et al., 1996). Similarly, expression of HPV16 E7 in transgenic 
embryonic mouse lens led to induction of hyperplastic growth (Howes et al., 1994; Pan and 
Griep, 1994). When E6 was induced alongside E7 in this system, an increased susceptibility 
to tumour development was observed (Howes et al., 1994; Pan and Griep, 1994; 1995). In 
raft culture, expressing both E6 and E7 induced cellular changes are comparable to 
changes seen in the development of CIN (McCance et al., 1988). Although the 
oncoproteins have transformative properties alone, concurrent expression produced larger 
and more extensive cancers, highlighting the cooperative nature of E6 and E7 in driving 
tumour development (Riley et al., 2003).  
Despite the ability of high-risk E6 and E7 to immortalise primary cells efficiently, HPV 
immortalised cells are not tumorigenic in nude mouse models (Hawley-Nelson et al., 1989; 
Münger et al., 1989a; Kaur and McDougall, 1988). In order to develop tumourigenic 
capabilities, HPV-immortalised cells require the coexpression of additional oncogenes, 
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such as v-ras, or extensive passaging in tissue culture (Durst et al., 1989; Pei et al., 1998; 
Hurlin et al., 1991). Transgenic mice expressing high-risk E6 and E7 in epithelial cells 
develop squamous carcinomas when treated with oestrogen, highlighting hormone levels as 
a cofactor in cervical cancer development (Arbeit et al., 1996). Furthermore, murine 
experiments have suggested that, during the development of HPV-associated cancers, E6 
contributes to the later stages of oncogenesis, whereas the functions of E7 contribute to 
the early stages (Song et al., 2000; Simonson et al., 2005). 
The same functions that promote cell growth during the HPV life cycle, when deregulated, 
allow E6 and E7 to drive cell proliferation and survival, as well as promoting genetic 
instability and immune evasion, all of which contribute to HPV-driven oncogenesis (Figure 
1.8). For example, the activation of hTERT by E6 leads to an immortal phenotype, 
promotes chromosomal instability and mutation accumulation (Oh et al., 2001). 
Furthermore, there is a strong correlation between the ability of HPV E6 to activate 
hTERT and the ability of the HPV type with association cancer (van Doorslaer and Burk, 
2012). Interestingly, whilst low-risk HPV E6 proteins are able to associate with E6AP as 
well as high-risk types, this does not result in p53 degradation, indicating that this 
interaction plays an important role in E6-driven transformation (Brimer et al., 2007; 
Lechner and Laimins, 1994). Similarly, low-risk HPV E7 proteins associate with pRb, but 
are less efficient than high-risk proteins at activating E2F responsive genes (Longworth and 
Laimins, 2004a). Moreover, only high-risk HPV E7 proteins have been identified as able to 
bind to HDACs via conserved sequences, indicating that this mechanism of controlling 
gene transcription is significant to the contribution of E7 to transformation (Figure 1.9). 
Figure 1.9: E6 and E7 affect a number of  cellular targets in carcinogenesis 
By targeting cellular proteins, E6 and E7 are able to affect a number of  cellular 
processes (boxed) culminating in transformation of  E6 and E7 expressing cells. 
Factors targeted by E7 are indicated in purple, at the left-hand side of  the cellular 
processes and factors affected by E6 are indicated in green at the right-hand side. 
Adapted from  Yugawa and Kiyono, 2009. 
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1.4.2.2 HPV E5 in oncogenesis 
Although E6 and E7 provide the primary functions in HPV driven oncogenesis, the 
functions of E5 have also been shown to contribute to tumour progression (Stöppler et al., 
1996). E5 promotion of cell proliferation has been observed in tissue culture when 
expressed with E6 and E7, and to a lesser extent when expressed alone (Petti et al., 1991; 
Valle and Banks, 1995; Bouvard et al., 1994a). In transgenic mice expressing HPV16 E5 in 
the skin, epithelial hyperproliferation is observed, eventually leading to tumour formation 
and oestrogen treatment of mice induces cervical cancers when E5 is expressed (Maufort et 
al., 2010; 2007). It is suggested that the protein provides a supporting role in tumour 
progression and the involvement of this protein during the HPV life cycle and oncogenesis 
has yet to be fully elucidated.  
 
1.5 Epithelial polarity 
Epithelial tissues comprise the foundation of the majority of human organs, and 90% of 
cancers are epithelia-derived carcinomas (Tanos and Rodriguez-Boulan, 2008). Epithelia 
line the cavities of the body and are specialised to perform secretion, absorption, 
protection and sensory functions. These functions depend largely upon the establishment 
of tissue polarity and integrity of cell-cell attachments, which enable cells to form a sheet-
like structure, and to distinguish between the surfaces of epithelial sheets (Figure 1.10).  
Individually, all cell types exhibit polarity, in that structures and membrane domains are 
organised assymetrically. Such cell shape is fundamental during the development of an 
organism, in defining tissue architecture and maintaining tissue homeostasis. The 
deregulation of mechanisms regulating cell polarity can lead to developmental disorders, 
tissue degeneration or cancer (Humbert et al., 2003). 
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Figure 1.10: Epithelial polarity and junction complexes 
(A)  Epithelial differentiation, as depicted in Figure 1.4. Basal cells rest on the basal 
lamina, which is supported by the dermis, and divide asymmetrically. A 
daughter cell migrates upwards as differentiation occurs, in which cells exit the 
cell cycle and progressively accumulate cytoplasmic keratin.  
(B)  Cells themselves are polar and epithelia also exhibits planar and apical-basal 
polarity, allowing the trafficking of  molecules and specialized functions on 
different faces of  the tissue.  
(C)  There are three main complexes involved in the organization of  epithelial cell-
cell junctions. Tight junctions coordinate the zona occludens, a belt-like 
structure which ties planes of  epithelia together. 
(D) The Crumbs complex (red) consists of  PATJ, PALS and Crumbs proteins. 
Tight-junctions (green) involve the Par complex, made up of  PAR3, PAR6 and 
atypical PKC, as well as associated tight junction PDZ-domain containing 
proteins MAGI-1, MUPP1, ZO-1 and ZO-2. Adherens junctions (purple) 
contain the Scribble complex, made up of  SCRIB, DLG1 and LGL. 
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As a tissue, epithelial polarity requires the vertical organisation of individual cells, such that 
specialized structures (e.g. adherens junctions) are orientated along the apical-basolateral 
axis, known as apical-basolateral polarity (ABP), as well as the positioning of cells within 
the plane of epithelial tissues, known as planar cell polarity (PCP, Figure 1.10 B). 
Furthermore, epithelial polarity is retained during cell division via asymmetrical replication; 
in basal cells, orientation of the mitotic spindle enables division to occur in parallel to or 
perpendicular to the epithelial sheet (Lechler and Fuchs, 2005). Division of basal cells 
within the plane of the epithelium functions to expand cell number, whereas division 
perpendicular to the plane produces stratified epithelia (Kim et al., 2009).  
The correct regulation of both apico-basal polarity (ABP) and planar cell polarity (PCP) is 
accomplished via the precise localisation of polarity proteins and other molecules such as 
lipids (Knust and Bossinger, 2002; Wodarz and Näthke, 2007). Central to ABP regulation 
are the Scribble, Par (Partitioning defective) and Crumbs protein complexes (Yamanaka 
and Ohno, 2008; Assémat et al., 2008, Table 1.6). These complexes link cell polarity with 
the regulation of cell–cell contact via junctional complexes, as well as with regulation of cell 
proliferation, migration and apoptosis. The main junctional complexes involved in 
epithelial organisation and integrity are the tight junctions (TJs) and the adherens junctions 
(AJs), formed at the apical and basolateral domains of a cell, respectively (Table 1.6, Figure 
1.10).  
1.5.1 Polarity complexes 
In order to distinguish between the outer and inner surfaces of epithelial sheets, the 
membrane of epithelial cells is segregated into apical and basolateral domains with an 
asymmetric distribution of trafficking machinery and membrane proteins (St Johnston and 
Ahringer, 2010). Within a cell, the apical and basolateral regions are separated by the zonula 
adherens (ZA), a belt-like structure circling the apical side of the cell (Figure 1.10 C). The 
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apical and basolateral membrane regions are defined by the distinct lipid components, 
creating distinct functions, and polarity is further determined and regulated by a number of 
interacting protein complexes forming scaffolds, signalling complexes and trafficking 
systems (Figure 1.10).  
Table 1.6: Cell polarity and adhesion complex components 
 Complex Components Function 
Cell polarity 
complexes 
Scribble SCRIB, DLG1 and LGL Apical-Basal polarity 
Crumbs  CRB, PALS1 and PATJ 
Apical plasma 
membrane 
establishment 
Par PARD3, PAR6, CDC42 and aPKC 
Apical-Lateral 
polarity 
Cell adhesion 
complexes 
Adherens 
junctions 
Cadherins, catenins, nectins 
and afadins Adherens junction 
Tight 
junctions 
ZO-1, ZO-2, ZO-3, Occludin, 
Claudin and JAM Tight junction 
 
The Scribble complex was first identified in Drosophila melanogaster and consists of Scribble 
(SCRIB), Discs large (DLG1) and Lethal giant larvae (LGL1) proteins. In epithelial cells, 
the Scribble complex is located at the basolateral region and is required for membrane 
organisation and maintenance (Figure 1.10, (Woods et al., 1996; Yates et al., 2013; Humbert 
et al., 2012). The Crumbs complex was also identified in Drosophila. The complex consists 
of Crumbs, Pals1 (Protein associated with Lin seven 1) and Pals1-associated tight junction 
(PATJ, also known as INADL) proteins (Figure 1.10 D). The partitioning defective (Par) 
complex was initially identified in Caenorhabditis elegans, and in humans consists of the 
proteins PARD3, PAR6 and an atypical protein kinase C (aPKC, Figure 1.10 D, 
(Kemphues et al., 1988). The Par complex is localised to the apical region of epithelial cells 
and, together with Crumbs, regulates the maintenance of the apical membrane. The 
complexes do not exist in isolation; Par and Crumbs act in a mutually antagonistic fashion 
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with the Scribble complex (Bilder et al., 2003). In the Par complex, aPKC negatively 
regulates LGL in the Scribble complex by phosphorylation, which prevents the protein’s 
apical localisation (Betschinger et al., 2003). Conversely, the kinase is required for the 
stabilization of the Crumbs complex, possibly via PAR6 binding or directly by 
phosphorylation of Crumbs proteins (Sotillos et al., 2004).  
Both the polarity and junctional complexes of epithelia involve proteins containing the 
PDZ (PSD/DLG/ZO) interaction domain, forming polarity complexes and defining the 
polarity required for epithelial functions.  
1.5.2 The PDZ domain 
PDZ domains are one of the most widely distributed protein-protein interaction domains; 
the human genome encodes over 320 PDZ-domain containing proteins (Fan and Zhang, 
2002). The PDZ domain is an evolutionarily conserved domain of approximately 90 amino 
acids folded into six β-sheets and two α-helices (Figure 1.11). A groove between the 
second β-strand and the second α-helix forms a hydrophobic pocket that interacts with 
specific C-terminal sequence motifs of target proteins (Songyang et al., 1997; Niethammer 
et al., 1998). The structure of the PDZ domain does not change upon ligand binding; the 
PDZ binding motif (PBM) peptide serves as an extra β-strand and participates in the 
extensive hydrogen-bonding pattern with main chain PDZ domain residues (Doyle et al., 
1996). Crystal structures of PDZ domains in complex with peptides reveal that a loop at 
the end of the binding groove, which contains a conserved motif (R/K-X-X-X-G-L-G-F), 
is involved in positioning the target peptide within the binding groove (Figure 1.11). In the 
PBM:PDZ complex, the terminal COOH of the PBM is coordinated by a network of 
hydrogen bonds to main-chain amide groups in this loop (Tochio et al., 1999; Daniels et al., 
1998a). When bound to the PDZ domain groove, the side chain of the terminal and -3 
Figure 1.11: The PDZ domain structure 
The secondary (A) and tertiary (B) protein structure of  the PDZ domain. A 
groove between the second -strand (B) and the second -helix (indicated 
with *) forms a hydrophobic pocket that interacts with specific target proteins. The 
ten core domain binding sites are highlighted in blue and the bound peptide 
(orange). A schematic of  the bond formation between residues in the PDZ 
binding groove and peptide is shown in C. Residues in the binding pocket are 
shown in black and the peptide is shown in blue. Hydrogen bonds are indicated by 
red dotted lines, and hydrophobic packing is indicated by green arcs. Adapted from 
Subbaiah et al. 2011, Hui et al. 2013 and Harris and Lim, 2001. 
A
βA$ βB$ βC$ βD$ βE$ βF$αA$ αB$* *
B
*
C
**
C
CHAPTER 1: INTRODUCTION 
-32- 
residues of the PBM peptide point towards the base of the peptide-binding groove. As 
such, interactions with these residues provide much of the PBM binding specificity 
(Songyang et al., 1997; Doyle et al., 1996). For example, the preference of the first PDZ 
domain of NHERF1 for a C-terminal PBM leucine is attributed to its large hydrophobic 
pocket (Karthikeyan et al., 2001). In some cases, recognition of the PBM involves residues 
outside of the four amino acid consensus motif, enabling specificity of interactions unique 
to individual PDZ domains (Niethammer et al., 1998). In terms of PBM sequence, there are 
three classes, with different C-terminal consensus sequences (Table 1.7). Although PDZ 
domains are mainly known for their ability to bind to the short C-terminal peptides of their 
target proteins, they have also been shown to recognize internal sequences that form a beta 
hairpin fold, other PDZ domains, and membrane phospholipids (Zimmermann et al., 2002; 
Zhang et al., 2009; Wong et al., 2003; Hillier et al., 1999; Brenman et al., 1998; Gee et al., 
1998; Penkert et al., 2004). Lipid binding further enables PDZ proteins to locate to specific 
membrane domains lipid rafts. For example, Syntenin-1 binding to phosphoinositide 
containing lipids localises the PDZ protein to the cell membrane and phosphatase and 
tensin homologue (PTEN) binding to membrane lipids aids the clustering of the Par 
complex proteins to cell membrane junctions (Feng et al., 2008).  
Table 1.7: Classes of PDZ-binding motif 
Class Consensus  Position Example 
Class I X-S/T-X- L/V C-terminal DLG4 binding shaker type K+ channel (Kim et al., 
1995) 
Class II X-Y-X- V/Y C-terminal CASK binding Neurexin (Songyang et al., 1997) 
Class III X-X-C C-terminal SITAC binding L6 antigen (Borrell-Pagès et al., 
2000) 
 Adapted from Harris and Lim, 2001. 
 
As a protein-protein interaction module, PDZ-domain containing proteins often comprise 
more than one PDZ domain and/or more than one type of interaction module (Figure 
1.12). DLG1 encodes three PDZ domains alongside an SH3, L27 and GUK domains, all 
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of which are involved in protein-protein interactions and, by contrast, MUPP1 consists 
solely of 13 PDZ domains (Figure 1.12). The presence of modular domains within a single 
protein allows PDZ proteins to form interactions with many partner proteins 
simultaneously and act as a scaffold; organising large protein complexes at specific sub-
cellular locations (Giallourakis et al., 2006).  
 
Cell-cell junction complexes comprise a number of PDZ domain containing proteins 
(Figure 1.10). These proteins form complexes at the cell membrane and form interactions 
with junctional complexes in adjacent cells, providing integrity and connecting extracellular 
space to intracellular components, allowing communication via signalling between the two 
(Figure 1.10, Laura et al., 2002; Balda and Anderson, 1993; Stucke et al., 2007; Yates et al., 
2013). For example PATJ is essential for TJ formation, it is important for localisation of 
PARD3 to the junction complex, and also in localising PARD3 to the leading edge of 
migrating cells (Lemmers, 2002). The expression of PATJ in turn is regulated by fellow 
PDZ protein MUPP1, indicating the wide-ranging effects and diverse roles of PDZ 
domain containing proteins (Assémat et al., 2013). PDZ domain containing proteins are 
also involved in the destination and recycling of target proteins; for example, DLG4 is 
crucial for endocytic recycling of NMDA receptors and β2-adrenergic receptors at the 
synapse and in muscle cells, affecting the cells response to signals such as adrenaline 
(Lavezzari et al., 2003; Xiang et al., 2002). As well as acting at the cell membrane, PDZ-
containing proteins have been implicated in targeting proteins to intracellular organelles 
and protein trafficking around the cell. The PDZ interactor with cellular kinase 1 (PICK1) 
protein targets PKC to mitochondria (Wang et al., 2003), thus affecting the access of the 
kinase to target proteins and downstream signalling. 
Figure 1.12: PDZ domain containing protein domain structure 
Schematic to show the organization of  several human PDZ domain containing 
proteins. MAGUK family proteins grouped at the top, contain an inactive 
guanylate kinase domain. Known PDZ targets of  high-risk HPV E6 proteins are 
indicated by a star (*). 
SH3, Src Homology 3; PDZ, PSD/DLG/ZO; GK, Guanylate kinase; L27, Lin2-7; CARD, caspase 
activation and recruitment domain; CAMK, Ca2+/Calmodulin dependant protein kinase; ww, 
tryptophan fold; LRR, Leucine rich repeat; EB, Ezrin binding; PTP, Protein tyrosine phosphatase; 
FERM, 4.1/Ezrin/Radixin/Moesin. 
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Thus, there is a huge range and number of interactions that PDZ proteins can form and yet 
they are able direct interactions with many target proteins in a specific fashion, enabling 
PDZ domain containing proteins to perform roles in organizing multimeric signalling 
complexes, forming cell-cell interactions and organizing junctional complexes (Figure 1.10).  
1.5.3 Alternative splicing 
PDZ protein diversity is further extended via alternative processing of mRNA (Figure 
1.13). Alternative splicing generates a variety of protein isoforms expressed from a single 
gene. Notable examples of PDZ protein splicing include the Erbb2 interacting protein 
(ERBIN), which has 7 known mRNA variants, including some with a truncated PDZ 
domain, and the Enigma homolog protein, which has more than 100 predicted variants 
(Yamazaki et al., 2010; Favre et al., 2001). Differential expression of spliced variants may 
depend upon cellular context; in the case of PDZ proteins, alternative splicing has been 
shown to generate isoforms specific to cell context and to developmental stages (Sierralta 
and Mendoza, 2004). Both MAGI-1 and MAGI-3 encode three spliced variants that differ 
in the C-terminal sequence and are expressed in a tissue specific fashion; two of the 
MAGI-1 isoforms are brain specific (Dobrosotskaya et al., 1997; Hirao et al., 2000; Laura et 
al., 2002). Furthermore, expression of alternative exons not only defines tissue specificity 
variant, but also cellular localisation; in a cellular context one MAGI-1 isoform (MAGI-1c) 
is predominantly nuclear, whereas the other two are absent from the nucleus (MAGI-1a 
and b), when expressed exogenously (Laura et al., 2002). Different spliced isoforms may 
have different roles or interacting partners in different tissues; whilst all of the PARD3 
isoforms associate with tight junctions in epithelial cells, they are differentially expressed in 
epithelial and haematopoietic cells and have different binding affinities with other Par 
complex components, PAR6 and aPKC (Gao et al., 2002; Zhou et al., 2008). 
Figure 1.13: Patterns of  alternative splicing 
The inclusion or exclusion of  exons can occur in many splicing patterns. 
Consensus splice site sequence (A) derived from Srebrow et al. 2006, Ghinga et al. 
2008 and Harris and Senapathy, 1990. Solid rectangles represent exons, and 
dotted lines the pattern of  inclusion. Intron retention (B), alternative 5" splice site 
selection (C), alternative 3" splice-site selection (D), cassette-exon inclusion or 
skipping (E) and mutually exclusive exon inclusion (F). 
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Deregulation of PDZ protein expression can lead to inappropriate isoform expression and 
promotion of carcinogenesis, for example spliced variants of DLG2 have been identified as 
transcriptionally upregulated in kidney cancer precursor growths (Zubakov et al., 2006). 
With such diversity in form and function, PDZ domain containing proteins have 
significant oncogenic potential when deregulated at a transcriptional, translational or post-
translational level. Alternative splicing of DLG1 will be discussed in more depth in Chapter 
4. 
1.5.4  PDZ domain containing proteins in cancer  
Epithelial cancers are characterized by epithelial-mesenchymal transition (EMT, Huber et 
al., 2005). EMT is caused by a loss of ABP and cell–cell adhesion; cell-to-cell junctions 
become disrupted so that neighboring cells begin to dissociate from each other, no longer 
forming tight junctions or the interface that characterises their function (Moreno-Bueno et 
al., 2008; Huber et al., 2005). Since cell polarity is crucial for tissue integrity and 
homeostasis, it is logical that loss results in tissue disorganisation and facilitates both 
initiation and progression of cancer (Figure 1.14). Deregulation of epithelial polarity leads 
to abnormal cellular trafficking, signalling and migration, all of which contribute to the 
development of carcinomas and progression to an invasive phenotype (Tanos and 
Rodriguez-Boulan, 2008; Hanahan and Weinberg, 2011). As PDZ proteins have extensive 
roles in cell polarity and signalling, their deregulation has been implicated in a number of 
human diseases (Table 1.8).  
In the Scribble complex, a reduction in DLG1 protein expression has been described in the 
later stages of a number epithelial cancers, including cervical and colon (Watson et al., 2002; 
Cavatorta et al., 2004; Lin et al., 2004). Furthermore, mutations in the DLG1 gene which are 
suggested to affect the binding of DLG1 to adenomatous polyposis coli (APC) and PTEN 
proteins, are associated with mammary carcinomas (Navarro et al., 2005; Fuja et al., 2004).  
Figure 1.14: Differential expression of  PDZ proteins in tumour progression 
The localization and abundance of  PDZ proteins is regulated in normal tissues by 
transcriptional, post-transcriptional and post-translational mechanisms. Several 
tumours exhibit mislocalisation of  PDZ proteins, with gradual loss of  the protein 
at cell–cell contacts, and increased protein in the cytoplasm during early stages of  
tumorigenesis. Downregulation of  polarity proteins is usually associated with a 
more invasive phenotype, and late stages of  carcinogenesis. The light blue area 
represents the basal membrane. TFs, transcription factors. From Facciuto et al. 
2012.  
Tumour progression
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Table 1.8: PDZ proteins in human disease 
PDZ Protein Function Disease associations 
DLG1 
(SAP97) 
Cell polarity, proliferation, migration and 
adhesion, cell division, synapse formation 
Breast, cervical and colon 
cancers, schizophrenia, 
Chron’s disease 
DLG2 
(PSD93) 
Cell polarity, proliferation, synapse formation Retinoblastoma 
DLG3 
(SAP102) 
Cell polarity, proliferation, synapse formation Schizophrenia 
DLG4 
(PSD95) 
Receptor clustering Schizophrenia, Alzheimer’s, 
epilepsy 
DLG5 Cell polarity, proliferation, invasion and 
migration, cell division 
Breast and prostate cancer, 
Crohn's disease, 
inflammatory bowel disease 
DLG6 
(MPP4) 
Cell polarity, proliferation, synapse formation Retinopathies 
PALS1 
(MPP5) 
Cell polarity, proliferation, synapse formation Prostate cancer 
SCRIB Cell polarity and integrity, proliferation, 
apoptotic signalling 
Breast, colon, endometrial 
and prostate cancers 
PTPN13 
(FAP-1) 
Fas-associated phosphatase, cell growth 
signalling, apoptotic signalling 
Pancreatic, ovarian and 
colon cancers, autoimmune 
thyroid disease 
PARD3 
(PAR3) 
Cell polarity, asymmetrical cell division Esophageal and breast 
cancers, glioblastomas 
PAR6 Cell polarity, asymmetrical cell division Breast cancer  
CASK Cell polarity and migration, synapse formation Renal failure, cerebellar 
hypoplasia, idiopathic ataxia 
ZO-1 Cell polarity and migration Breast and liver cancer, 
kidney disease, 
cardiopathies 
ZO-2 Cell polarity and migration Breast cancer, kidney 
disease, Pancreatic 
adenocarcinoma 
ZO-3 Cell polarity and migration Kidney disease 
MAGI-1 Cell polarity, synapse formation, apoptosis Leukemia, hepatocellular 
carcinoma 
MAGI-2 Cell polarity, synapse formation, apoptosis Hepatocellular carcinoma 
MAGI-3 Cell polarity, synapse formation, apoptosis Hepatocellular carcinoma 
MUPP1 
(MPP1) 
Cell polarity, proliferation Retinopathies, inflammatory 
bowel disease 
NHERF1 Regulation of GPCRs, cytoskeletal anchoring Hypouricemia 
Adapted from Facciuto et al., 2012. Commonly used alternative protein names in brackets. 
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Similarly, loss of SCRIB has been demonstrated in breast carcinomas, and loss of MAGI-1 
is observed in colon and liver carcinomas (Navarro et al., 2005). In Madin-Darby canine 
kidney (MDCK) cells, expression of MAGI-1 suppresses cell invasion by recruiting PTEN 
to cell–cell contacts (Kotelevets et al., 2005). In the Par complex, PAR6 has been shown to 
be overexpressed in breast cancer, and is thought to activate growth signalling cascades and 
promote cell proliferation independently of growth factor signalling (Aranda et al., 2008; 
Nolan et al., 2008). Downregulation of PARD3 has been implicated in oesophageal cancer, 
breast cancers and glioblastomas (Zen et al., 2009; Tokes et al., 2012; Rothenberg et al., 
2010), this is suggested to be due to the disassembly of the Par complex that occurs when 
PARD3 is decreased (Tokes et al., 2012).  
Furthermore, colon cancers exhibit a loss of the non-junctional PDZ protein PTPN13, 
whilst protein levels are increased in aggressive breast cancers (Wang et al., 2004; Glondu-
Lassis et al., 2010). This apparent dissimilarity reiterates the fact that the role of PTPN13 
(and indeed PDZ proteins) is cell context specific; often it is not clear whether to define 
PDZ proteins as an oncogene or a tumour suppressor, as their roles depend upon cellular 
localisation and tissue type (Roberts et al., 2012). A change in abundance and localisation of 
PDZ proteins disturb the balance of protein function and has severe consequences, namely 
carcinogenesis. 
1.5.5 Virus interactions with PDZ domain containing proteins 
A number of human viruses encode proteins containing PDZ-binding motifs (Table 1.9). 
Given that viral genomes are limited in size, the inclusion of a PBM indicates that the 
ability to interact with cellular PDZ proteins plays an important role in viral propagation.  
Computational screening has identified a C-terminal PBM in over 99% of Influenza A 
virus NS1 proteins (Obenauer et al., 2006). The importance of this PBM to the virulence of 
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Influenza A was demonstrated by studies showing that deletion or masking of the motif 
attenuated the virus (Soubies et al., 2010a; Cauthen et al., 2007; Li et al., 2006). Removal of 
the PBM decreases efficacy of influenza H1N1 virus transmission, as well as virus 
replication, and increases interferon expression in infected cells (Kim et al., 2014; Soubies et 
al., 2013; Thomas et al., 2011). Moreover, switching the PBM for the sequence of an avian-
specific strain increased virus virulence (Jackson et al., 2008; Zielecki et al., 2010). The NS1 
PBM of the human strain H5N1 has been shown to interact with the PDZ domains of 
MAGI-1, MAGI-2, MAGI-3, DLG1 and SCRIB (Golebiewski et al., 2011; Liu et al., 2010). 
Despite the homology of the MAGI proteins, the strength of NS1 binding to each is not 
equal, indicating that viral PBM interactions are highly specific, and are determined by both 
the PDZ domain and the PBM sequences (Liu et al., 2010; Thomas et al., 2011). The swine-
specific strain H6N6 NS1 alters the subcellular localisation of polarity regulator MAGI-1 
and H5N1 NS1 colocalises with DLG1 and SCRIB, disrupts cellular tight junctions and 
produces a similar phenotype to cells in which DLG1 and SCRIB have been knocked 
down (Golebiewski et al., 2011). It has been suggested that such disruption of cell junctions 
may benefit viral dissemination within the host, and/or spread to other hosts (Golebiewski 
et al., 2011; Liu et al., 2010). Furthermore, targeting SCRIB abrogates the pro-apoptotic 
function of the protein and may therefore protect infected cells from viral induction of 
apoptotic pathways, thus supporting viral propagation (Liu et al., 2010; Thomas et al., 2011). 
The PBM has also been suggested to aid viral immune evasion, by downregulating the 
cellular interferon response (Soubies et al., 2010b; 2013; Kumar et al., 2012). 
Propagation of the RNA viruses tick borne encephalitis virus (TBEV) and dengue virus 
(DV) is dependent upon two virally-encoded PBMs within the NS5 proteins; mutations in 
the PBM negatively affect viral replication (Melik et al., 2012; Ellencrona et al., 2009). 
Interestingly, both viruses target the PDZ protein ZO-1, but via different approaches; 
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where TBEV NS5 is stabilised at the cell membrane by the interaction, DV NS5 colocalises 
with ZO-1 in the nucleus (Ellencrona et al., 2009). The viruses have also been shown to 
interact with IL-16, a chemotactic cytokine which contains a PDZ domain (Werme et al., 
2008). A number of PDZ proteins have been identified as able to interact with TBEV NS5 
protein with varying affinities; the viral factor binds strongly to ZO-2, and less strongly to 
TIP2, CASK (calcium/calmodulin-dependent serine protein kinase) and GRIP2 (glutamate 
receptor interacting protein 2, Werme et al., 2008). Furthermore, TBEV NS5 has a high 
affinity for SCRIB, an interaction which has been suggested to be important in viral protein 
localisation and in preventing the host anti-viral interferon response, via the JAK-STAT 
pathway (Werme et al., 2008). 
Expression of the core protein of fellow flavivirus hepatitis C virus (HCV) leads to a 
decrease in DLG1 protein and mislocalisation of SCRIB from cell-cell contacts in liver and 
kidney epithelial cells (Awad et al., 2013). A redistribution of PDZ proteins E-cadherin, 
claudin and ZO-1 has also been observed in in HCV infected cells, which leads to 
disruption of cell polarity and aids the cell-cell transmission of virus (Mee et al., 2010). 
Interaction with cellular PDZ-domain containing proteins has been reported to promote 
the entry of human immunodeficiency virus 1 (HIV-1); knockdown of the cytoskeletal 
protein PDZD8 inhibits HIV-1 infection and negatively affects viral capsid stability 
(Henning et al., 2010; Guth and Sodroski, 2014). The PDZ protein Syntenin-1 has been 
implicated in HIV-1 entry; Gordón-Alonso et al. (2012) suggest that the PDZ protein is 
recruited to the membrane by HIV-1 protein Env and clusters HIV-1 entry receptors on 
the cell membrane. Furthermore, overexpression of PDZD8 enhances infection by HIV-1 
and related retroviruses murine leukemia virus (MLV), simian immunodeficiency virus 
(SIV, Henning et al., 2011; 2010). HIV also acts upon the tight junction proteins ZO1, 
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occludin and claudin, disrupting their localisation and epithelial integrity, as well as 
downregulating their expression at a transcriptional level (Nazli et al., 2010).  
Rhinovirus also appears to affect tight junction proteins at a transcriptional level; ZO-1, 
claudin, occludin and E-cadherin gene expression is decreased by rhinovirus in cultured 
epithelia (Yeo and Jang, 2010). This may be the cause of the loss of ZO-1 from tight 
junctions observed in Rhinovirus infected cells (Sajjan et al., 2008). It is not yet clear which 
viral factors are responsible for this, but it is suggested that the function promotes viral 
transmission (Yeo and Jang, 2010). Similarly, the consequences of PDZ binding during the 
infectious cycle of Hepatitis B virus (HBV) have yet to be fully characterized, although it 
has been suggested that PTPN3 suppresses the expression of viral genes and HBV core 
protein has been shown to interact with TIP-2 (Razanskas and Sasnauskas, 2010).  
SARS coronavirus E protein interacts with Crumbs complex protein PALS1 and Syntenin-
1 (Teoh et al., 2010; Jimenez-Guardeño et al., 2014). The former interaction has been 
shown to effect epithelial polarity and tight junction formation (Teoh et al., 2010). SARS E 
protein is crucial to viral virulence and the PBM is a determinant of virus pathogenicity; 
deletion of the PBM had no effect on viral growth in cell culture but attenuated viral 
infection of mice, where less lung damage and no mortality occurred in mice infected with 
a PBM-deletion virus compared to wild-type virus (Jimenez-Guardeño et al., 2014; 
DeDiego et al., 2007; 2008).  
Rabies pathogenicity is associated with the ability of the envelope G protein to interact 
with PDZ proteins PTEN, PTPN4 and MAST2 (Prehaud et al., 2010; Terrien et al., 2012). 
Both attenuated and virulent strains of Rabies exhibit an affinity for PDZ proteins, but it 
has been suggested that virulence is not associated solely with the ability to bind PDZ 
proteins generally, but rather the ability to bind and target proteins specifically (Prehaud et 
al., 2010).  
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Intriguingly, the F11 protein of vaccinia virus encodes both a C-terminal PBM and a 
central PDZ-like domain (Handa et al., 2013). Removal of the PBM results in the 
production of less infectious virus, and the PDZ domain has been shown to act as a 
scaffold protein and enhance viral spread (Handa et al., 2013).  
Table 1.9: Virus interactions with PDZ proteins 
Virus/viral 
protein Interacting PDZ protein Reference 
Adenovirus 
E4ORF1 
DLG1, MAGI-1, MUPP1, ZO-2 
Tight junction disruption, loss of cell 
polarity 
Glaunsinger et al., 2000; Lee et 
al., 1997 
Influenza A 
NS1 
Interactions with DLG1, SCRIB, MAGI-1, -
2, -3 and PDLIM2 
Mislocalisation of ZO-1 
Golebiewski et al., 2011; Liu et 
al., 2010 
Rotavirus 
NSP4           
VP8 
Localisation of ZO-1 disrupted 
TJ formation blocked 
Tafazoli et al., 2001; Nava et al., 
2004 
Hepatitis B 
core protein TIP-2 
Razanskas and Sasnauskas, 
2010 
SARS 
coronavirus 
envelope 
protein E 
PALS1, Syntenin-1  Jimenez-Guardeño et al., 2014; Teoh et al., 2010) 
Rhinovirus ZO-1 and E-cadherin mRNA and protein downregulation 
Yeo and Jang, 2010; Sajjan et 
al., 2008 
Tick borne 
encephalitis 
virus NS5 
SCRIB, TIP2, CASK, ZO-1 Melik et al., 2012; Werme et al., 2008; Ellencrona et al., 2009) 
HTLV-1 Tax DLG1 and MAGI-3 mislocalisation, pro-IL16 
Suzuki et al., 1999; Rousset et 
al., 1998; Wilson et al., 2003; 
Ohashi et al., 2004 
*High-risk α-
HPV E6 
DLG1, SCRIB, MAGI-1, -2, -3, PTPN13, 
NHERF1, etc. 
Kiyono et al., 1997; Kranjec and 
Banks, 2011; Thomas et al., 
2002; Spanos et al., 2008b; 
Accardi et al., 2011; Nakagawa 
and Huibregtse, 2000 
rhPV1 E7 PARD3 Tomaic et al., 2009 
CRPV DLG1 Du et al., 2005 
HIV-1 gp120 Inhibit localisation of ZO-1, occludin and claudin to TJs Nazli et al., 2010 
Rabies G 
protein DLG1, PTPN13, MUPP1 Prehaud et al., 2010 
Adapted from Banks et al., 2012; Javier, 2008. *A comprehensive list of PDZ targets of HPV E6 is shown in 
Table 1.10.  
 
A number of human viruses encode PBMs, which have been implicated in viral entry, 
propagation and immune evasion. They appear to do so via common PDZ targets proteins, 
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namely DLG1, SCRIB and MAGI-1, -2 and -3, which is highly suggestive of the important 
roles that these proteins play in cellular polarity, proliferation, immune evasion and 
apoptosis, the interruption of which are fundamental in viral replication. 
1.5.6 PDZ domain containing proteins in viral oncogenesis 
The oncogenic viruses HTLV-1 and adenovirus 9, as well as tumourigenic papillomaviruses 
rhPV1 (rhesus papillomavirus), CRPV (cottontail rabbit papillomavirus) and HPVs have 
also been shown to affect PDZ domain containing proteins, and this function has been 
linked to the oncogenic potential of the virus as well as their infectious cycles (Figure 1.15, 
Weiss et al., 1997; Rousset et al., 1998). 
1.5.6.1 HTLV-1 Tax 
Mutational studies have demonstrated the importance of the Tax PBM in viral persistence 
and to the induction of proliferation in infected cells (Xie et al., 2006). These studies also 
revealed the PBM is not essential to HTLV-1 mediated immortalisation, although its 
presence enhances the ability of HTLV-1 to transform rodent cells and enables Tax to 
transform mouse lymphocytes in cooperation with NFκB (Hirata et al., 2004; Xie et al., 
2006). In human cells, the Tax PBM is also required for Tax-induced proliferation of T-
cells (Xie et al., 2006; Higuchi et al., 2007). In vitro assays show that the protein kinase CK2 
phosphorylates Tax within the PBM, at threonine 351, suggesting that phosphorylation of 
the PBM can regulate viral protein binding to PDZ proteins (Bidoia et al., 2010).  
Yeast two-hybrid screening experiments identified a number of PDZ domain containing 
Tax-interacting proteins, including DLG4, TIP-1, TIP-2 and PAR6 (Rousset et al., 1998). 
Additionally, in cell culture, overexpressed Tax was shown to interact with MAGI-3 
whereas the PBM mutant protein did not (Ohashi et al., 2004). The interaction results in 
altered localisation of the viral protein from the nucleus to the cytoplasm and increased 
Figure 1.15: Viral proteins target common cellular PDZ proteins 
A number of  PDZ proteins involved in the formation and maintenance of  cell 
polarity are commonly targeted by viruses. The oncoproteins Tax, E4ORF1 and 
E6, from oncogenic viruses HTLV-1, adenovirus and HPV respectively, 
specifically target a number of  PDZ substrates. 
From Javier and Rice, 2011. 
 
Flu A, influenza A virus; AJ, adherens junction;, TJ, tight junction 
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Tax stability (Ohashi et al., 2004). MAGI-3 is involved in cell polarity and in cell survival 
signalling; the ability of Tax to target such pathways is suggested to promote viral 
replication, as well as promoting aberrant growth and transformation of infected cells 
(Ohashi et al., 2004). Tax was also identified as interacting with PDZ domain containing 
protein Erbin during screening experiments (Ress and Moelling, 2006). This interaction 
was confirmed by immunoprecipitation of endogenous Erbin in epithelial cells with Tax 
protein encoding an intact PBM, but not when the PBM was absent (Song et al., 2009). The 
first PDZ domain of the T-cell specific interleukin-16 precursor (Pro-IL16) binds to the 
Tax PBM in both human T-cells and immortalized monkey fibroblasts, where both 
proteins colocalise in the nucleus (Wilson et al., 2003). The presence of an intact PBM 
enables Tax-expressing cells to overcome pro IL-16-driven cell cycle arrest, suggesting a 
role for the interaction in overcoming the growth inhibitory activity of pro IL-16 and 
promoting cell cycle progression (Wilson et al., 2003). Such progression is favourable for 
viral propagation and is likely to contribute to the overproliferative phenotype of 
transformed cells. 
The first target of HTLV-1 Tax to be identified was DLG1 (Lee et al., 1997). Expression of 
wild-type but not PBM-mutant Tax protein hampers DLG1 inhibition of S phase 
progression in mouse fibroblasts (Suzuki et al., 1999). Furthermore, Tax causes a 
redistribution in DLG1 protein from the soluble to the insoluble compartment of T-cells 
in a PBM dependent manner (Hirata et al., 2004). Sequestering of DLG1 has been 
suggested to be a mechanism of DLG1 inactivation by Tax (Tsubata et al., 2005; Ishioka et 
al., 2006). However, depletion of DLG1 does not complement transformation in the 
absence of the Tax PBM, although it does augment transformation by wild-type virus, 
altogether suggesting that HTLV-1 transformation does not depend on the Tax PBM 
binding and inactivating DLG1 (Tsubata et al., 2005; Ishioka et al., 2006). Yeast two-hybrid 
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screening experiments revealed that HTLV-1 Tax binds to fellow Scribble complex 
member SCRIB (Arpin-Andre and Mesnard, 2007). This interaction was confirmed in vivo 
by the detection of a Tax and SCRIB complex in infected human T-cells, where Tax caused 
SCRIB mislocalisation (Aoyagi et al., 2010). Both DLG1 and SCRIB block T-cell receptor 
(TCR)-induced activation via NFAT a key regulator of T-cell activation and differentiation 
(Round et al., 2007b; Xavier et al., 2004). In wild-type Tax expressing T-cells, this activity of 
SCRIB was inhibited, whereas inhibition still occurred when the Tax PBM was mutated 
(Arpin-Andre and Mesnard, 2007). DLG1 is important in the formation and organisation 
of the immunological synapse (Cullinan et al., 2002). HTLV-1 infected T-cells fail to 
establish proper apical-basal polarity (Barnard et al., 2005). Together, this suggests that the 
interaction between Tax and DLG1 or SCRIB disrupts T-cell polarity, migration, and 
signalling as well as immune synapse formation, resulting in the stimulation of cell 
proliferation and prohibition of immune activation by the virus, thus aiding HTLV-1 
persistence (Ludford-Menting et al., 2005; Rebeaud et al., 2007; Rincon and Davis, 2007; 
Round et al., 2005; 2007b). 
Interestingly, the association between the Tax oncoprotein and the PDZ domain 
containing ubiquitin E3 ligase PDLIM2 does not occur between the viral PBM and the 
PDLMI2 PDZ domain (Fu et al., 2010). Instead, Tax binds to PDLIM2 via multiple regions 
in Tax and an α-helical motif in PDLIM2, unlike the multiple PDZ targets which have 
been identified to interact via the PBM of the viral protein (Fu et al., 2010). The interaction 
causes transport of the viral protein to the nucleus and subsequent proteasome-mediated 
degradation, thereby suppressing Tax’s transforming activity (Yan et al., 2009b). 
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1.5.6.2 Adenovirus E4ORF 
Adenovirus type 9 causes benign eye infections in humans, but is capable of causing 
mammary tumours in rats in the presence of high levels of oestrogen and of transforming 
cells in culture (Graham et al., 1984; Horwitz, 2001). Adenovirus 9-induced transformation 
is driven by the viral factor E4ORF1 and, more specifically, the PBM at the C-terminus of 
E4ORF1 has been shown to be crucial in this oncogenesis (Weiss and Javier, 1997). 
Furthermore, expression of the E4ORF1 causes tight junction defects in epithelial cells in a 
PBM-dependent manner, but does not affect the structure of adherens junctions (Latorre et 
al., 2005).  
DLG1 was the first identified target of E4ORF1, shown to interact via PDZ domains 1 and 
2 (Lee et al., 1997). Subsequently, it was demonstrated that E4ORF1 was able to bind to the 
cellular PDZ proteins MUPP1, PATJ, MAGI-1, and ZO-2 (Glaunsinger et al., 2000; Lee et 
al., 2000; Latorre et al., 2005; Glaunsinger et al., 2001). Interestingly, there are differences in 
PDZ protein binding between the monomeric and trimeric forms of the E4ORF1 protein; 
where monomeric E4ORF1 interacts with MAGI-1, PATJ, MUPP1 and ZO-2, the trimer 
only binds to DLG1 (Chung et al., 2008). E4ORF1 expression causes the sequestering of 
MUPP1, PATJ, MAGI-1, and ZO-2 away from tight junctions into cytoplasmic membrane 
vesicles, disrupting cell adhesion and polarity (Glaunsinger et al., 2000; Lee et al., 2000; 
Glaunsinger et al., 2001; Latorre et al., 2005). E4ORF1 trimers promote DLG1 
translocation to the plasma membrane, which may contribute to the junctional defects 
observed in adenovirus infected cells (Laprise et al., 2004; Stucke et al., 2007). However, 
E4ORF1 monomers exert a gain-of-function upon DLG1, as the interaction constitutively 
activates the PI3K signalling pathway via the PDZ protein (Frese et al., 2003). The 
association of the E4ORF1 with DLG1 facilitates adenovirus activation of the 
phosphatidylinositol 3-kinase (PI3K) signalling cascade via oncogene RAS, which 
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culminates in an increase in cellular metabolism and thus increases cellular substrates 
available for viral replication (Kong et al., 2014; Frese et al., 2006; Kumar et al., 2014). This 
interaction also induces anchorage independent growth (AIG), a characteristic or 
transformed cells (Frese et al., 2003; 2006).  
It has been suggested that both Tax and E4ORF interfere with the interaction between 
DLG1 and the cellular tumor suppressor adenomatous polyposis coli protein (APC) by 
competing for binding to the same PDZ domain (Javier and Rice, 2011; Frese et al., 2006). 
The APC:DLG1 interaction has growth-inhibitory consequences; viral protein binding 
DLG1 would prevent APC binding and thus lead to an increase in cell proliferation, due to 
increased growth promoting signalling (Ishidate et al., 2000; Matsumine et al., 1996; Javier, 
2008).  
1.5.6.3 Papillomavirus oncoproteins 
Both animal and human PVs are able to target PDZ proteins. The E6 protein of CRPV has 
also been shown to interact with cellular DLG1, underlining a commonality in viral PDZ 
protein targeting (Du et al., 2005). Although expression of CRPV E6 is able to immortalise 
rabbit keratinocytes, the protein does not bind cellular p53 (Muench et al., 2010). 
Furthermore, CRPV is able to induce skin cancer in rabbits without additional co-factors 
(Ganzenmueller et al., 2008; Jeckel et al., 2002; Muench et al., 2010). Together this suggests 
that DLG1 binding may contribute to CRPV E6 mediated immortalization, in the absence 
of this tumorigenic interaction. 
Interestingly, the oncogenic rhesus papillomavirus type 1 (RhPV1) E7 oncoprotein, but not 
the E6 protein, contains a C-terminal PBM, via which it interacts with the polarity protein 
PARD3 (Tomaic et al., 2009). RhPV1 drives mucosal neoplasia in rhesus macaques, in an 
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analogous fashion to high-risk HPVs, again indicating a potential carcinogenic role for the 
E6 PBM. 
The β-papillomaviruses do not encode an E6 PBM, but do encode a conserved C-terminal 
hydrophobic motif (YXDW). In HPV5, this motif interacts with the adhesion protein β1-
integrin and disrupts normal signalling (Du et al., 2005). Furthermore, the 
β-papillomavirus HPV8 encodes an alternative mechanism to regulate the PDZ protein 
Syntenin-2 by influencing transcription (Lazic et al., 2012). Both HPV5 and HPV8 are 
associated with the development of skin cancer, and a level of control over adhesion 
proteins may be important to the cancer-causing capability of viruses as well as functioning 
during normal papillomavirus life cycle. 
The commonality in viral PDZ targets further highlights oncogenic potential of the 
proteins as well as their importance in cellular proliferation (Figure 1.15). Viral PBMs 
function to promote a favourable cellular environment for viral replication, but are also 
important in driving oncogenesis. By activating cellular proliferation and anti-apoptotic 
pathways, PBMs contribute to transformation of infected cells which, when combined with 
additional mutations and carcinogenic environmental influences, can lead to cancerous 
growth.  
1.6 High-risk HPV E6 and cellular PDZ proteins 
Like Tax and E4ORF1, the E6 oncoproteins of high-risk HPVs encode a C-terminal PBM 
(Figure 1.16). To date, more than 15 PDZ domain containing proteins have been shown to 
interact with high-risk HPV E6 oncoproteins. The proteins identified encompass a variety 
of roles in cell polarity, tissue integrity, scaffold formation, signalling and intracellular 
trafficking (Table 1.10). The biological consequences of HPV E6 PBM binding PDZ 
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proteins are varied, and have been investigated in cell-based models of papillomavirus 
oncogenesis and life cycle. 
1.6.1 The E6 PBM in viral life cycle 
The E6 protein functions to decouple keratinocyte differentiation from proliferation 
(Section 1.4.1.2). The interaction of the E6 PBM with a subset of cellular PDZ proteins is 
influential in the life cycle of high-risk HPVs, where E6 is expressed at physiological levels. 
The motif may contribute to the overall function of E6 by promoting disruption of cell 
polarity and enabling proliferation in cells that would otherwise differentiate. 
Studies in mice have revealed that the E6 PBM promotes DNA replication; in mouse 
epithelia the interaction between E6 and PDZ proteins correlates with the induction of 
suprabasal DNA synthesis by the oncoprotein (Nguyen et al., 2003). Deletion of the PBM 
in the context of whole HPV genomes has shown that the motif contributes to HPV-
driven keratinocyte proliferation; where stratified cells containing HPV18 or HPV31 
genomes exhibited a thicker spinous layer, PBM mutant genome containing cells exhibited 
a morphology that resembled normal keratinocytes (Lee and Laimins, 2004; Delury et al., 
2013). In addition, the HPV31 E6 PBM is necessary for the induction of keratinocyte 
proliferation in both undifferentiated and stratified cell culture and keratinocyte growth is 
lessened in cells containing a HPV18 E6 PBM mutant compared to cells containing the 
wild-type genome or to normal keratinocytes (Lee and Laimins, 2004; Delury et al., 2013). 
Similarly, in both undifferentiated and stratified primary keratinocytes, Choi et al. (2013) 
demonstrated that the PBM of HPV16 E6 is required for the increased growth seen in cells 
expressing E6 as well as in cells containing both E6 and E7 oncoproteins.  
Deletion within the context of the whole HPV genome affects the viral genome; the loss of 
the E6 PBM of HPV16, HPV18 and HPV31 reduces the capacity of the virus to maintain 
episomes (Nicolaides et al., 2011; Delury et al., 2013; Lee and Laimins, 2004; Brimer and 
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Vande Pol, 2014). Indeed, the PBM is essential to viral propagation; its absence results in a 
lack of genome amplification and late protein expression (Delury et al., 2013). 
It has been suggested that removal of the PBM destabilizes the E6 protein; Nicolaides et al., 
(2011) demonstrated an enhanced proteasomal degradation rate of HPV16 E6 in the 
absence of a PBM, as well as an increase in the levels of E6 protein when the PDZ target 
SCRIB was overexpressed. However, deletion of the HPV18 and HPV31 E6 PBM does 
not affect E6 stability in primary keratinocytes (Lee and Laimins, 2004; Delury et al., 2013). 
Furthermore, phosphorylation of the E6 PBM has been implicated in E6 stability, 
suggesting a more complex interplay (Boon and Banks, 2012b). 
The PBM has been implicated in protecting cells from TNF-induced apoptosis; HPV16 E6 
activates nuclear factor kappa B (NFκB) in human airway epithelial cells and subsequently 
inhibits downstream apoptotic signalling in a PBM dependent manner (James et al., 2006). 
A number of known PDZ targets of E6 have roles in apoptotic signalling, including 
PTPN13 and SCRIB, and it may be that these interactions have anti-apoptotic 
consequences, but it is likely that such activation also promotes epithelial proliferation and 
thus viral replication (Nakagawa and Huibregtse, 2000; Spanos et al., 2008b; James et al., 
2006).  
Thus there is evidence that the PBM function contributes to E6-mediated promotion of 
viral propagation. Such functions are also influential in the transformation of infected cells, 
under conditions where E6 is deregulated.  
1.6.2 The E6 PBM in viral oncogenesis 
The E6 PBM is found exclusively in the high-risk type HPVs (Figure 1.16), and in culture 
this PBM is required for E6-mediated transformation of rodent cells (Kiyono et al., 1997; 
Spanos et al., 2008a). In primary human tonsil keratinocytes (HTKs) containing HPV16, 
Group 1
HPV 16 CMSCC      RSSRTRRETQL  
HPV 18 CHSCCNRARQE RLQRRRETQV  
HPV 31 CIVCW        RRPRTETQV  
HPV 33 CAACW      RS  RRRETAL
HPV 35 CMSCW        KPTRRETEV
HPV 39 CRRCWTTKRED RRLTRRETQV
HPV 45 CNTCCDQARQE RLRRRRETQV
HPV 51 CANCW    Q  RTRQRNATQV
HPV 52 CSECW         RPRPVTQV 
HPV 56 CLGCW   RQ  TSREPRESTV
HPV 58 CAVCW  RPRRRQTQV
HPV 59 CRGCRTRARHLRQQRQARSETV 
 
Group 2A
HPV 68 CRHCWTSKRED RRRTRQETQV
 
Group 2B
HPV 26 CTNCW       RPRRQTETQV 
HPV 30 CLQCW       RHTTSTETAV
HPV 34 CRQCW          RPSATVV 
HPV 53 CLTCW       RHTTATESAV
HPV 66 CLQCW     RHTSRQATESTV 
HPV 67 CSVCW        RPQRTQTQV 
HPV 69 CTNCW      RPRREATETQV 
HPV 70 CRHCWTSNRED RRRIRRETQV
HPV 73 CTRCW    RPSATVV
HPV 82 CANCRTAA   RQRSETQV 
HPV 85 CRRCMTRA QE QQGSRRETQV
HPV 97 CNSCYNQSRQE RLSRRRETQV
 
Group 3
HPV 6       CLHCWTTCMED       MLP
HPV 11 CLHCWTTCMED       LLP
HPV 8 CRLCKHLYHDW
 
 XSTXLV
Consensus motif
Figure 1.16: C-terminal alignment of  high- and low-risk HPV E6 proteins 
E6 protein To date, twelve HPV types have been defined by the WHO as high-risk 
with respect to causing cancer - these are designated as IARC Group 1- and a 
further ten types are recognised as ‘possibly’ (Group 2A) and ‘probably’ cancer-
causing (Group 2B). HPV6 and 11 are included as examples of  low risk virus. 
HPV8 is associated cutaneous SCC, and has been shown to effect the transcription 
of  PDZ protein Syntenin-2. 
The canonical PBM sequence (XSTXLV) is shown above the highlighted region, 
which indicates the E6 PBM sequence. Phospho acceptor sites within the PBM are 
highlighted in bold. Adapted from Delury et al. 2013. 
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PBM deletion depleted the efficiency of HPV-driven immortalisation of cells, and removed 
the ability of HPV16 E6 to induce AIG (Spanos et al., 2008a). Similarly, the expression of 
HPV18 E6 in human keratinocytes led to disrupted cell-cell junctions and promotion of a 
fibroblast-like morphology, phenotypes which are characteristics of EMT and these were 
reduced when the PBM was deleted (Watson et al., 2003). 
As in cell culture, E6 is able to induce epithelial hyperplasia in transgenic mice 
independently of interactions with p53 (Song et al., 2000; Kiyono et al., 1997). In 
concordance with this, mouse models expressing HPV16 E6 under a keratin promoter 
have demonstrated that the PBM is key to the development of hyperplasia of the skin, the 
cervix and the eye, although the E6 PBM is not required for the immortalisation of other 
keratinocytes (Nguyen et al., 2003; 2005; Shai et al., 2010). Furthermore, murine studies 
have shown that the E6 PBM promoted greater invasive properties and tumour size, and 
that the cooperation of E6 and E7 in driving tumour growth was shown to be dependent 
upon the E6 PDZ binding function (Nguyen et al., 2003; Simonson et al., 2005).  
A number of PDZ proteins have been identified to interact with the high-risk HPV E6 
PBM (Table 1.10), and have been investigated in systems that resemble a cancer-like 
cellular environment, highlighting interactions that may be crucial in promoting the HPV 
life cycle.  
1.6.3 PDZ targets of high-risk E6  
As with other oncogenic viruses, the PDZ proteins DLG1 and SCRIB are common targets 
of both high-risk HPV types 16 and 18 (Kiyono et al., 1997; Nakagawa and Huibregtse, 
2000). Furthermore, the different HPV types display differing affinities for targets; despite 
the PBM differing by a single amino acid, HPV16 preferentially binds SCRIB over DLG1, 
and HPV18 DLG1 over SCRIB, these affinities can be altered within the context of whole 
E6 by switching the PBM sequences (Pim et al., 2000; Thomas et al., 2001). In addition, 
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DLG4 has been shown to be a stronger target for HPV18 than for HPV16, whilst GOPC 
was found to bind more strongly to HPV16 E6 than HPV18 (Handa et al., 2007; Kranjec 
and Banks, 2011; Jeong et al., 2007).  
The binding of PDZ proteins themselves are formed in a select fashion; despite the 
presence of more than one PDZ domain per cellular protein, only one domain is thought 
to interact with E6. Specificity is determined by the sequence of the viral PBM, sequence 
upstream of the PBM and the target PDZ domain (Thomas et al., 2001; 2002). The first 
two PDZ domains of DLG1 (PDZ1 and PDZ2) are important for HPV18 E6 binding 
(ETQV) and the threonine residue of the PBM is essential for the interaction; substitutions 
with either neutral or acidic residues abolishes binding and subsequent ubiquitin ligase 
recruitment (Gardiol et al., 1999). Structural analysis confirmed this, and indicated that the 
arginine residues proximal to the PBM form additional contacts with PDZ2 to strengthen 
the interaction (Liu et al., 2007). Similarly, the structure of MAGI-1 PDZ1 bound to 
HPV16 E6 confirmed that residues located inside and outside the binding groove 
contribute to binding, notably lysine 499 of the junctional protein is important in the 
specificity of the E6 interaction (Fournane et al., 2011). E6 PDZ targeting is also specific to 
cellular location; in the case of DLG1 and MAGI-1, HPV18 E6 preferentially induces the 
degradation of the cytoplasmic and nuclear forms (Massimi et al., 2004; Kranjec and Banks, 
2011; Narayan et al., 2009).  
Although hundreds of PDZ domains exist in a human keratinocyte, HPV E6 has been 
shown to associate with seventeen (Table 1.10). Recent screening studies have identified an 
additional number of PDZ targets which have yet to be confirmed in vivo (Belotti et al., 
2013). The identified targets of the E6 PBM comprise a range of cellular proteins involved 
in epithelial cell polarity, tissue integrity and proliferation (Table 1.10). PDZ targets of E6 
have been identified from the Scribble, Par and Crumbs polarity complexes (Figure 1.15), 
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as have a number of cellular PDZ proteins involved in cell signalling. Specific E6 PDZ 
targets are discussed in more detail in Chapter 3. 
1.6.3.1 Kinase recognition of HPV E6 PBM  
The PBM of high-risk HPV types lies in close proximity to a canonical serine/threonine-
specific kinase recognition site (Figure 1.16). X-ray crystal structures predict that 
phosphorylation of the PBM would sterically hinder the ability of E6 to fit within the PDZ 
binding groove (Ainsworth et al., 2008; Charbonnier et al., 2011; Liu et al., 2007). In vitro 
experiments have shown that HPV18 E6 PBM phosphorylation reduces DLG1 binding 
and activation of the PKA pathway in cell culture decreases degradation of DLG1 by E6, 
which suggests that phosphorylation of the PBM negatively affects E6 PDZ binding ability 
(Kühne et al., 2000). Furthermore, in vitro protein kinase A (PKA) phosphorylates the E6 
PBM of high-risk HPV types 16 and 18, and a site proximal to the PBM of HPV31 (Boon 
et al., 2014). Moreover, different E6 proteins exhibit different susceptibilities to 
phosphorylation. HPV18 E6 shows a higher susceptibility to PKA phosphorylation than 
HPV16, and HPV31 is only weakly phosphorylated by PKA (Kühne et al., 2000; Boon et 
al., 2014). The kinase AKT (also known as protein kinase B, PKB) is a serine/threonine 
kinase family member which has been also shown to act upon both HPV16, 58 and 31 E6 
PBMs in vitro (Boon et al., 2014). It is therefore likely that other kinases recognize these 
sites, and perhaps recognize certain E6 PBMs better than others. 
Investigations by the Roberts lab have indicated that E6 PBM phosphorylation may 
function to regulate interactions with PDZ proteins during the virus life cycle (Delury et al., 
2013). By reversibly interrupting PDZ binding, it is hypothesized that phosphorylation may 
provide a mechanism of regulating PDZ-PBM interactions during the viral life cycle and 
during epithelial differentiation. In addition to interrupting PDZ interactions, 
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phosphorylation has been shown to introduce a novel interaction; phosphorylation of the 
HPV18 E6 PBM facilitates binding of the phospho-tyrosine binding scaffold protein 14-3-
3ζ (Boon and Banks, 2012b). This indicates that E6 PBM function depends on the 
phosphorylation status, mediating interactions with either PDZ domain containing 
substrates or 14-3-3 !family members. 
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Table 1.10: PDZ targets of high-risk HPV E6 proteins 
PDZ 
protein 
(Gene 
Symbol) 
Alternative 
Name(s) 
Cellular Functions Effect of 
Interaction with 
E6 
References 
DLG1 SAP97 Cell polarity, cell 
proliferation, migration 
and adhesion 
Degradation, 
mislocalisation 
Kiyono et al., 1997 
Gardiol et al., 1999 
SCRIB Scribble, 
Vartul, 
LAP4 
Cell polarity and 
integrity, proliferation, 
apoptotic signalling 
Degradation Nakagawa and 
Huibregtse, 2000 
INADL PATJ Tight junction 
formation, cell polarity 
Degradation 
E6* also able to 
target 
Latorre et al., 
2005; Storrs and 
Silverstein, 2007 
SLC9A3R1 NHERF1, 
EBP50 
GPCR regulation, 
cytoskeleton 
anchoring  
Degradation Accardi et al., 2011 
PTPN13 FAP-1, 
PTPL-1, 
PTP-BAS, 
PTPBL 
Fas-associated 
phosphatase, cell 
growth signalling, 
apoptotic signalling 
Degradation Spanos et al., 
2008b 
MPDZ MUPP1 Receptor clustering, 
scaffold protein 
Degradation Lee et al., 2000 
MAGI-1 AIP3, 
WWP3 
Cell polarity, 
invasiveness, synapse 
formation, apoptosis 
Degradation Glaunsinger et al., 
2000 
MAGI-2 AIP1 Cell polarity, 
invasiveness, synapse 
formation, apoptosis 
Degradation Thomas et al., 
2002 
MAGI-3 - Cell polarity, 
invasiveness, synapse 
formation, apoptosis 
Degradation Thomas et al., 
2002 
DLG4 PSD95, 
SAP90, 
TIP15 
Receptor clustering Degradation Handa et al., 2007 
PTPN3 PTPH1 Phosphatase, cell 
growth signalling, 
apoptotic signalling 
Degradation Jing et al., 2007; 
Töpffer et al., 2007 
TAX1BP3 TIP-1 Wnt pathway inhibitor  - Hampson et al., 
2004 
GIPC1 Synectin, 
TIP-2 
Cell surface receptor 
expression and 
trafficking, TGFβ 
signalling 
Degradation Favre-Bonvin et 
al., 2005 
GOPC CAL Intracellular trafficking Degradation Jeong et al., 2007 
PARD3 PAR3 Cell polarity, 
asymmetrical cell 
division 
Mislocalisation Facciuto et al., 
2014 
 
SDCBP2 Syntenin-2 Cell adhesion, growth 
factor signalling 
Decreased 
transcription 
Lazic et al., 2012 
PDZRN3 LNX3 E3 ubiquitin ligase Degradation  Thomas and 
Banks, 2014 
E6* is a truncated isoform of E6. Underlined symbols indicate nomenclature used in this thesis. 
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1.7 Hypothesis and Aims 
The E6 PBM is a conserved feature of high-risk α-HPV types and a number of cellular 
PDZ proteins have been identified as interacting with this motif. In many cases, the 
E6:PDZ interaction leads to proteasome-mediated degradation of the cellular protein. 
However, the effect of HPV genome replication upon PDZ protein expression has not 
been fully characterized. Moreover, the physiologically relevant targets and the 
consequences of the E6:PDZ interaction remains unclear. Furthermore, the PBM overlaps 
with a kinase recognition site, which may function to regulate PDZ interactions during the 
viral life cycle. Given the large number of cellular PDZ domain containing proteins and the 
specificity of PDZ:PBM binding, it is likely that E6 targets specific proteins at certain 
subcellular locations and at specific times during the HPV life cycle. Thus, this thesis aims 
to investigate PDZ protein expression in a primary keratinocyte model of the HPV life 
cycle. 
 1. To investigate PDZ domain containing protein expression during the life cycle 
of high-risk HPV types 16 and 18 (Chapter 3). 
 2. To characterize the expression of E6 PDZ target DLG1 in epithelia and during 
the HPV16 and 18 life cycles (Chapter 4). 
 3. To determine the effect of PKA phosphorylation upon the HPV18 E6 PDZ 
binding domain motif (Chapter 5). 
 CHAPTER 2: MATERIALS AND METHODS 
Unless otherwise stated, materials and chemicals were obtained from commercial sources 
(Section 2.5). For cell culture reagents and stock solution recipes, see Appendix III. 
2.1 Cell culture 
Media and solutions were prepared as described below, or purchased from indicated 
suppliers. All culture procedures were performed under sterile conditions in a Holton 
Laminair S2000 1.2 microbiological safety cabinet (Thermo Fisher Scientific, UK). Culture 
media components were filter sterilised using 0.22 µm hydrophilic polyvinylidene fluoride 
(PVDF) membrane filters. Cells were cultured in sterile dishes (BD Biosciences, UK) in the 
appropriate growth medium, and were incubated in a cell culture incubator at 37°C and 
with 5% CO
2 in air. 
2.1.1  Culture of cell lines 
The cancer-derived cell lines HeLa, Caski, HEK293T, H1299 and SiHa were all cultured in 
Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich, UK) supplemented with 4 
mM L-glutamine (Gibco, UK) and either 10% v/v foetal bovine serum (FBS, Gibco) or 
foetal calf serum (FCS, Gibco, see Table 2.1). The HPV-negative cervical cancer cell line 
C33A was cultured in RPMI-1640 (Roswell Park Memorium Institute) medium (Sigma-
Aldrich) supplemented with 10% v/v FCS and 4 mM L-glutamine (Gibco). The head and 
neck cancer derived cell lines Vu40T, Vu147, SCC040 and SCC154 were cultured in 
DMEM supplemented with 10% v/v FBS, 1% v/v penicillin streptomycin (PenStrep, 
Sigma-Aldrich) and 4 mM L-glutamine. Primary cervical epithelial cells, Cx129 were 
cultured in serum-free media (SFM, Sigma-Aldrich). For subculture, cells were first washed 
with 5 mL sterile phosphate-buffered saline (PBS, Sigma-Aldrich) and then incubated with 
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1 mL TrypLE (Life Technologies, UK) until cells were no longer adherent. The TrypLE 
was quenched with media and the entire suspension transferred to a sterile tube for 
centrifugation at 10000 × g for 5 min. The cell pellet was resuspended in the appropriate 
culture media, cells were counted and cells were seeded at the desired density into 10 cm 
dishes with 10 ml of warmed medium.  
Table 2.1: Cell lines 
Cell Line Tissue of origin Media requirements HPV status 
HeLa Cervical adenocarcinoma  
DMEM, 10% v/v FBS, 
4mM L-glutamine  
 
HPV18 integrated 
Caski 
Cervical 
carcinoma 
 
DMEM, 10% v/v FCS, 
4mM L-glutamine  
 
HPV16 positive 
SiHa 
Cervical 
carcinoma 
 
DMEM, 10% v/v FBS, 
4mM L-glutamine  
 
HPV16 positive 
SCC154 Oropharyngeal SCC 
DMEM, 10% v/v FBS, 
4mM L-glutamine, 1% 
v/v PenStrep 
Positive 
Vu147 HNSCC 
DMEM, 10% v/v FBS, 
4mM L-glutamine, 1% 
v/v PenStrep 
Positive 
H1299 Lung carcinoma 
DMEM, 10% v/v FCS, 
4mM L-glutamine  
 
Negative 
Cx129 Primary cervical epithelia SFM Negative 
C33A HPV negative cervical epithelia 
RPMI-1640, 10% v/v 
FCS, 4mM L-glutamine  
 
Negative 
HEK293T 
Adenovirus 
transformed 
embryonic 
kidney 
DMEM, 10% v/v FCS, 
4mM L-glutamine  
 
Negative 
SCC040 Oropharyngeal SCC 
DMEM, 10% v/v FBS, 
4mM L-glutamine, 1% 
v/v PenStrep 
Negative 
Vu40T HNSCC 
DMEM, 10% v/v FBS, 
4mM L-glutamine, 1% 
v/v PenStrep 
Negative 
 
For storage of stocks in liquid nitrogen, two million cells were counted, pelleted and 
resuspended in cryopreservation media consisting of media (DMEM or SFM as 
CHAPTER 2: MATERIALS AND METHODS 
-58- 
appropriate), supplemented with 20% (v/v) FCS or FBS and 10% (v/v) dimethyl 
suphoxide (DMSO, Sigma-Aldrich). 
2.1.2  Cell counting 
During cell harvest, disposable Glasstic TM
 
slides (Hycor Biomedical Ltd., UK) were used to 
determine cell concentration in culture. Ten microlitres of cell suspension was pipetted into 
a well on the Glasstic TM
 
slide. Using an inverted light microscope, all live (bright spherical) 
cells contained within three large squares of the GlassticTM grid were counted. This number 
was divided by three to obtain an average count of cell number, which was multiplied by 
104
 
to calculate the number of cells per ml of culture medium. Typically, cells were then 
made up to a density of 2×106 cells per ml. 
2.1.3  Mycoplasma testing 
All cell lines were periodically tested using the MycoAlert mycoplasma detection kit 
(Lonza, UK), as per the manufacturer’s instructions and were found to be consistently 
negative for mycoplasma. 
2.1.4  Generation and maintenance of HPV genome-containing cell lines 
2.1.4.1  Maintenance of primary foreskin keratinocytes prior to transfection 
Normal primary human foreskin keratinocytes (HFKs) were isolated from neonate foreskin 
by Dr Sally Roberts following the protocol described by Meyers and Laimins (1994). 
Foreskin tissues were obtained from circumcisions (carried out by Dr Joseph Spitzer) with 
informed parental written consent (Regional Ethics Committee approval number 
06/Q1702/45, Roberts). Also, HFKs were purchased from Lonza (Clonetics). Throughout 
this thesis, the donor number assigned to cells derived from the same background is 
consistent (Donor 1-4). HFKs were cultured on collagen-coated tissue culture dishes in 
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serum-free keratinocyte growth medium (Invitrogen, UK) and media was replaced every 
two days. Cells were grown to 80% confluency, at which point they were passaged by 
removal of media followed by a wash with sterile PBS and the addition of 1 ml of 0.05% 
trypsin/EDTA (Gibco). This was incubated for 5 minutes at 37°C, in a similar procedure 
as described for cell lines. Trypsin was inactivated by the addition of 1 ml trypsin inhibitor 
(TI; 0.25 mg/ml soyabean trypsin inhibitor in Dulbecco’s PBS without calcium or 
magnesium, pH 7.2, Invitrogen). Cells were then transferred to a 15 ml conical tube and 
pelleted by centrifugation at 10000 × g for 5 minutes at room temperature. The supernatant 
was subsequently removed and the pellet resuspended in SFM. Typically, a 10 cm tissue 
culture dish was seeded with 2×105 cells in 10 ml SFM.  
2.1.4.2 Cryopreservation of HFKs 
Cells were frozen at a density of between 1 and 2×106 cells per vial. Freezing media 
consists of SFM supplemented with 10% (v/v) FCS and 10% (v/v) DMSO. HPV genome-
containing HFKs were frozen in E-medium supplemented with 10% (v/v) Hyclone™ FCS 
(Thermo Fisher Scientific) and 20% (v/v) glycerol (Thermo Fisher Scientific). 
2.1.4.3 Generation of HPV genome-containing HFKs 
Generation of HFK cell lines was undertaken according to the methods described by 
Wilson and Laimins, (2005, see Figure 2.1). In preparation, HFKs were seeded into 
uncoated 5 cm tissue culture dishes and allowed to grow. Once the cells reached 50-60% 
confluency, recircularised HPV genomes (Section 2.2.3.6) were co-transfected into HFKs 
alongside pCDNA3.1 (Invitrogen), a plasmid that carries the neomycin resistance gene. 
Control transfections carried out in parallel include; the pCDNA3.1 (Neo) alone, E green 
fluorescent protein (EGFPc1; Clontech, France) reporter expression vector, and a no 
plasmid vector DNA. For each transfection, 94 µl of SFM was dispensed into a 
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polypropylene conical tube (BD Biosciences), followed by the addition of 6 µl FuGene 6 
Transfection Reagent (Roche, UK). In a separate tube, 100 µl of SFM, 1 µg of HPV 
genomic plasmid DNA and 1 µg of neomycin resistance plasmid were mixed. The contents 
of two tubes were combined and then incubated at room temperature for 30 min. Media 
from the HFKs was replaced with SFM media (Gibco), and the transfection mixture was 
added to the dish dropwise, rocked gently to mix and incubated at 37oC and 5% CO2 for 
24 hrs. 
Transfection efficiency was measured by observation of the GFP control transfection, 
using a Zeiss Axiovert 100 microscope, with GFP-expressing cells typically representing 
5% of the total population. Transfected keratinocytes were then removed from the dish by 
trypsin treatment and re-plated onto 10 cm tissue culture dishes previously seeded with 
2×106
 
γ-irradiated J2-3T3 fibroblasts in complete E medium (CEM, Section 2.1.4.5). Over 
the next 8 days the HFKs underwent a selection process, with the alternate addition of 
selection-containing media and 1×106
 
irradiated J2-3T3 cells. The selection period began 
with the replacement of CEM with CEM containing 100 µg/ml G418 (PAA Laboratories, 
UK). After two replenishments with 100 µg/ml G418 CEM (typically 4 days), selection was 
increased to 200 µg/ml G418 for two replenishments (typically 4 days). Following the last 
day of G418 treatment, media was replaced with normal CEM and 2×106
 
irradiated J2-3T3 
cells were added. In the event that cells reached 80% confluence during the selection 
process, the dish was split equally onto two dishes previously seeded with 2×106
 
irradiated 
J2-3T3 fibroblasts in the presence of normal CEM and the selection process was resumed 
the following day.  
Once colonies reached approximately 2 cm in diameter, typically observed 1 month after 
completion of the selection process, the dishes were pooled and transferred onto a single 
dish pre-seeded with γ-irradiated J2-3T3 cells. Upon reaching 80% confluence, HFKs were 
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passaged onto five 10 cm tissue culture dishes. Once 70-80% confluence was reached, cell 
pellets were harvested by trypsin treatment, washed with ice-cold saline and prepared for 
RNA, DNA and protein analysis, as well as samples cryopreserved in liquid nitrogen. 
2.1.4.4  Maintenance of HFKs following transfection of HPV genomes 
Genome-containing HFKs were cultured on a feeder layer of 2×106
 
irradiated J2-3T3 
fibroblast feeder cells in CEM. CEM consists of Dulbecco’s modified eagle media 
(DMEM, 60% v/v, Gibco), Ham’s F12 (32% v/v, Gibco), the antibiotics penicillin and 
streptomycin (2% v/v PenStrep, Gibco), hydrocortisone (0.1% v/v, Sigma-Aldrich), 
Hyclone™ FCS, (10% v/v, Thermo Fisher Scientific), mouse epidermal growth factor 
(EGF, 0.5% v/v, BD Biosciences), L-glutamine (2% v/v, Gibco), cholera toxin A (0.1% 
v/v, MP Biomedicals, USA), insulin (0.2% v/v, Sigma-Aldrich), transferrin (0.2% v/v, 
Sigma-Aldrich), tri-iodo–lL-thyronine (T3, 4 nM,Sigma-Aldrich) and adenine (36 µM, 
Sigma-Aldrich). The media was replaced every two days and the cells grown to a 
confluency of no greater than 80% prior to passaging. Irradiated J2-3T3 cells were seeded 
onto 10 cm dish containing 10 ml E-medium at least 2 h, or 24 h, prior to addition of 
HFKs. HFKs were passaged by first removing the J2-3T3 feeder layer, using 0.5 mM 
EDTA (ethylene diamine tetraacetic acid) in PBS. Once the feeder cells were detached, a 
transfer pipette was used to aspirate the EDTA and the dish was washed twice with 5 ml of 
sterile PBS. HFKs were then removed with 2 ml TrypLE and incubated at 37°C for 5-10 
minutes with regular checks for cell detachment. The TrypLE was quenched with CEM 
and dishes washed with 10 ml media, all of which was transferred to a sterile conical tube.. 
HFKs were pelleted by centrifugation at 538 × g for 5 minutes at room temperature. The 
supernatant was removed and the cells resuspended in warmed CEM. HFKs were counted 
and seeded out at a density of 2×105
 
cells per dish onto 2×106
 
irradiated J2-3T3 cells. The 
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plates were gently rocked several times to ensure thorough mixing and the cells incubated 
at 37°C and 5% CO2. The media was replaced every 2 days, with cells taking typically 5-7 
days to reach a confluency of 80%. At each passage, aliquots of 5×105 cells were pelleted 
by centrifugation, washed with phosphate buffered saline (PBS) and stored at -80oC for 
further analysis. The establishment and maintenance of HPV episomes was confirmed by 
blot analysis of total DNA (Section 2.2.2.3). 
Cell lines containing the HPV16 114/B, HPV16 114/K (Kanda et al., 1988; Roden et al., 
1996) or HPV18 (Wilson et al., 2007) episomal genomes were cultured alongside 
untransfected HFKs derived from the same donor.  
2.1.4.5  Maintenance and irradiation of J2-3T3 fibroblasts 
Following transfection of primary keratinocytes with HPV genomes, cells were cultivated 
with a feeder layer of irradiated NIH J2-3T3 mouse fibroblasts. J2-3T3 cells were cultured 
in DMEM supplemented with L-glutamine (2% v/v) and newborn calf serum (10% v/v, 
Gibco) and were grown to a confluency of no greater than 90% before passaging. For 
subculture, 3T3 cells were first washed with 5 mL sterile PBS and then incubated with 1 
mL TrypLE until cells were no longer adherent (typically 5 min). Trypsin was quenched 
and cells washed off of the dish with medium. The suspension transferred to a sterile tube 
for centrifugation at 10000 × g for 5 min. Cells were resuspended in culture media, counted 
and seeded into 10 cm dishes with 10 ml of prewarmed medium. J2-3T3 cells were grown 
to no more than passage 25 and then replaced with earlier passage J2-3T3 cells. When J2-
3T3 cells were required as feeder cells, they were harvested by trypsinisation and 
resuspended in CEM at 2×106
 
cells/ml. Cells were irradiated with 50 Grays of a Caesium-
137 source and were stored in CEM at 4oC for up to 5 days.  
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For cryopreservation, 2×106
 
J2-3T3 cells were resuspended in 1 ml DMEM supplemented 
with 20% (v/v) newborn calf serum, and 10% (v/v) DMSO.  
2.1.4.6  Organotypic raft culture 
Organotypic raft cultures were prepared as described by Wilson and Laimins (2005). Each 
collagen plug was prepared in 3 cm dishes using 2.4 ml Rat-tail collagen (BD Biosciences, 
UK) diluted to 4mg/ml with 0.02 M acetic acid. Per plug, 2×106 3T3-J2 cells were 
reconstituted in 0.3 ml 10× filtered DME and 0.3 ml 10× filtered reconstitution buffer 
(0.05 M NaOH, 260 mM NaHCO3, 200 mM Hepes; all Sigma-Aldrich). To this, the acetic 
acid and collagen were added and mixed using an ice-cold strippette. The pH of plug 
mixture was adjusted by addition of 1 M NaOH dropwise, before the addition of 3 ml per 
3 cm dish. Plugs were incubated overnight at 37oC 5% CO2. Typically, 2×10
6 untransfected 
or genome-containing HFKs were grown on a collagen plug pre-seeded with 2×106 J2-3T3 
fibroblasts in a 3 cm tissue culture dish. Media was replaced daily, and cells were allowed to 
expand on the plugs until the media turned yellow (24-48 hr), after which the collagen plug 
was carefully lifted and placed on top of a wire mesh platform (known as a grid), and 
placed in a 10 cm tissue culture dish. This was then filled CEM lacking EGF, in order to 
create an air/liquid interface (see Figure 2.2). Rafts were grown for 13 days; the media was 
replaced every 2 days. Six hours before fixing, 20 µM of the thymidine analogue 5-Bromo-
2’-deoxyuridine (BrdU, BD Biosciences) was added to media. BrdU is incorporated into 
the newly synthesized DNA of replicating cells, and thus it allows the detection of 
replicating cells. In preparation for downstream immunofluoresent analysis (Section 2.3), 
rafts were fixed by flooding the raft-containing dish with 4% (w/v) paraformaldehyde in 
DMEM. Rafts were paraffin embedded and sections (4 microns) were prepared for staining 
by Propath Ltd, UK.  
Culture medium
Metal grid support
Keratinocyte monolayer
Collagen plug containing fibroblasts
Figure 2.2: Organotypic raft culture 
(A)  Schematic of  the organotypic raft culture system. HFKs containing HPV 
genomes are seeded onto collagen plugs containing fibroblasts in a 3 cm tissue 
culture dish and cultured in complete E media.  
(B)  When HFKs reach confluence, indicated by media turning yellow, the collagen 
plugs are lifted onto stainless steel support grids. This is cultured with E media 
supplemented with L-glutamine, forming an air-liquid interface at the raft grid. 
This induces differentiation of  the HFKs, leading to the production of  a 
stratified epithelium. 
A
B
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The metal grids were prepared by cutting squares of wire mesh approximately 4 x 4 cm and 
bending two opposite edges down evenly. Use of a spirit level confirmed the creation of a 
level surface. Grids were then sterilized by incubation for 2 hours in concentrated (24 M) 
sulphuric acid (Thermo Fisher Scientific). For safety, this took place in a glass beaker in a 
fume cupboard. The grids were rinsed by placement of the beaker under cold running 
water overnight, after which they were dried on paper, placed in a Pyrex beaker and 
autoclaved. 
2.1.4.7 !Protein extraction from raft cultures 
Protein was extracted from raft cultures by peeling off the stratified HFKs from the 
collagen layer followed by homogenization in 1 ml of UTB lysis buffer (8 M urea, 50 mM 
Tris-HCl pH 8, 0.15 M β-mercaptoethanol, Sigma-Aldrich) supplemented with protease 
and phosphatase inhibitors (Sigma-Aldrich) in a glass Dounce homogeniser. Lysate was 
incubated for 30 minutes on ice before being transferred by transfer pipette into a pre-
cooled microcentrifuge tube. This was centrifuged at 16000 × g for 15 minutes at 4oC. The 
supernatant was subsequently removed and designated as the ‘soluble fraction’. The pellet 
was thus designated the ‘insoluble fraction’, and was solubilised in 250 µl of Laemmlli 
buffer (BioRad, UK) supplemented with 5% (v/v) β-mercaptoethanol. The soluble fraction 
was aliquoted at a 1:1 ratio into Laemmlli buffer supplemented with 5% (v/v) β-
mercaptoethanol, heated at 95oC for 5 minutes prior to storage at -20oC and/or SDS-
PAGE and subsequent analysis.  
2.1.4.8  RNA extraction from raft cultures 
Similar to the extraction of protein, RNA extraction from raft culture began with removal 
of the HFKs from the collagen layer using sterile forceps. This was then placed into a 15 
ml collection tube and homogenized in 100 µl of RNA Stat-60 (AMS Biotechnology, UK) 
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using a glass Dounce homogenizer. HFKs were incubated for 5 minutes at room 
temperature in the RNA Stat-60, which is a monophase solution containing phenol and 
guanidinium thiocyanate. Once 200 µl of chloroform was added and the sample shaken 
vigorously for 15 seconds, the homogenate separated into two phases, the aqueous and the 
organic. After centrifugation at 12000 × g for 5 minutes at 4oC, the total RNA in the 
aqueous phase was transferred to a fresh collection tube, leaving any DNA and proteins in 
the organic phase. Addition of 500 µl isopropanol and incubation at room temperature for 
5 minutes allowed precipitation of the RNA from the aqueous phase. This was centrifuged 
at 12000 × g for 10 minutes at 4oC and the pelleted washed by resuspension in 1 ml 75% 
(v/v) ethanol and centrifugation at 7500 × g for 5 minutes at 4oC. Once the pellet had been 
dried briefly, it was resuspended in 40µl of nuclease-free water.  
2.1.5  Treatment and manipulation of cells 
2.1.5.1  Subcellular fractionation 
Subcellular fractionation was carried out on HeLa cells and HFKs using the 
ProteoExtract® subcellular proteome extraction kit (EMD Millipore, USA), and was 
optimised for use on untransfected and genome-containing HFKs grown in monolayer. All 
buffers were supplemented with protease and phosphatase inhibitors, and Buffer III was 
also supplemented with the endonuclease benzonase®. Firstly, supporting 3T3-J2 
fibroblasts were first removed and cells washed with ice-cold PBS. Cells were then washed 
with 1 mL Wash Buffer before incubation in 500 µl extraction Buffer I with gentle 
agitation at 4oC for 15 min. All traces of the buffer were removed and transferred into a 
pre-cooled microcentrifuge tube and designated fraction 1 (F1), representing the 
cytoplasmic fraction of cell contents. Next, 500 µl extraction Buffer II was added to the 
dish of cells and incubated at 4oC for 30 minutes with gentle agitation. The buffer was then 
CHAPTER 2: MATERIALS AND METHODS 
-66- 
transferred to a pre-cooled microcentrifuge tube and designated fraction 2 (F2), the 
membrane fraction. A final incubation in 250 µl extraction Buffer III at 4oC for 10 minutes 
with gentle agitation was transferred to a pre-cooled 1.5 ml microcentrifuge tube and 
designated fraction 3 (F3), the nuclear fraction. The remaining fraction, the cytoskeletal 
fraction, was resuspended in 250 µl extraction Buffer IV, transferred to a pre-cooled 1.5 ml 
microcentrifuge tube and designated fraction 4 (F4). For subsequent SDS-PAGE and 
subsequent protein analysis, 10 µl of each fraction was aliquotted into 10 µl Laemmlli 
buffer supplemented with 5% (v/v) β mercaptoethanol, and treated as a western blot 
(Section 2.2.4.2). 
2.1.5.2  Proteasome inhibition 
Untransfected or HPV genome-containing HFKs were seeded into a 6 cm dishes 
containing 2×105 irradiated J2-3T3 fibroblasts as a feeder layer. HFKs were allowed to 
grow for 48 h before the addition of the proteasome inhibitor MG132 (z-Leu-Leu-Leu-
CHO), which was dissolved in DMSO and applied at a final concentration of 40 µM in cell 
culture medium. As a control, vehicle (DMSO) treated cells were cultured and harvested 
alongside MG132 treated cells. Cells were harvested at 4 and 6 h post-treatment; feeder 
cells were removed and cells pelleted by trypsinisation, as described previously. Cell pellets 
were washed by resuspension in ice-cold saline and centrifuged for 10000 × g for 5 minutes 
at 4oC, before being lysed in UTB buffer and subject to downstream western blot analysis 
(Section 2.2.4.2). 
2.1.5.3  Protein kinase A activation and inhibition 
As for MG132 treatment, in preparation for treatment with protein kinase A (PKA) 
inhibitors or activators, untransfected or HPV genome-containing keratinocytes were 
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seeded into a 6 cm dishes containing a feeder layer of 2×105 irradiated J2-3T3 fibroblasts. 
HeLa cells were seeded at a density of 2×105 cells/dish. Cells were allowed to attach for 24 
h before the addition of specific PKA activating or inhibiting compounds. The PKA 
activators forskolin (FK) and 3-isobutyl-1-methylxanthine (IBMX, both Sigma-Aldrich) 
were dissolved in DMSO and used in combination at the final concentrations of 50 µM 
and 1 mM in culture medium, respectively. The more specific PKA activator PKI and 
cyclic AMP (cAMP) analogue, dibutryl cAMP (dbcAMP, EMD Millipore) was dissolved in 
Hank’s balanced salt solution (HBSS) and diluted in culture medium to a final 
concentration of 1 mM. The PKA inhibitor H89 (Sigma-Aldrich, UK) was dissolved in 
DMSO and added to the culture medium at a final concentration of 10 µM. Exogenous 
expression of the PKI peptide was induced by transfection with mPKI plasmid (Section 
2.1.5.4, gift from M. Diskar). Vehicle treated cells were cultured and harvested alongside 
those treated with activators or inhibitors. Cells were harvested at various time points up to 
96 hr; feeder cells were removed and washed off before cells were harvested by 
trypsinisation, washed in saline and lysed in UTB for western blot analysis as described in 
Section 2.2.4.2. 
2.1.5.4  Transfection of cells 
HeLa, C33A and HFKs were cultured overnight in serum free medium prior to 
transfection. Cells were transfected at 80% confluency with 3-5 µg DNA in XtremegeneTM 
transfection reagent (Roche), at a ratio of 2 µl per 1 µg of DNA, in 500 µl Optimem 
(Invitrogen). Reagent, DNA and Optimem were incubated together for 30 minutes at 
room temperature before dropwise addition to cells. Cells were then incubated at 37oC 
with 5% CO2 for 48 hours before harvesting. Transfection with plasmid expressing the 
peptide PKA inhibitor mPKI was confirmed by observation of GFP expression, using a 
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Zeiss Axiovert 100 microscope. Cells were washed with ice-cold saline before downstream 
protein analysis (Section 2.2.4). 
2.2 Molecular biology 
2.2.1  RNA analysis 
2.2.1.1  RNA isolation from cultured cells 
Total RNA was extracted from 1×106 cells using an RNeasy Mini kit (QIAgen, UK) and 
treated with DNase (Promega), according to manufacturer’s instructions. Cultured cells 
were centrifuged and collected as a cell pellet at the time of passage. The pellet was then 
washed by resuspension in 500 µl PBS and centrifuged for 5 minutes at 16000 × g. The 
supernatant was discarded and cells resuspended in 750 µl lysis buffer containing 
guanidinium thiocyanate, a strong denaturant which lyses cell membranes and rapidly 
inactivates ribonucleases (Chomczynski and Sacchi, 1987). This was mixed thoroughly by 
pipetting; any vortex mixing was avoided throughout the preparation in order to prevent 
shearing of RNA. One volume (750 µl) of 70% ethanol was added to the pellet lysate, and 
the mixture passed at least 5 times through a 0.9 mm (20 gauge) needle attached to a sterile 
plastic syringe (BD Biosciences). Lysate was then transferred to a silica filter cartridge 
inserted into a 1.5 ml collection tube. Centrifugation for 30 seconds at 16000 × g in a 
microcentrifuge 5415 R, refrigerated benchtop centrifuge (Eppendorf, UK), allowed the 
mix to be drawn through the filter and the RNA to bind the silica matrix. The bound RNA 
was then washed by the addition of 700 µl wash buffer RW1 and centrifuged for 30 
seconds at 16000 × g. The flow through was discarded. Two sequential washes with 500 µl 
wash buffer RPE followed; first for 30 seconds at 16000 × g and the second for 2 minutes 
at 16000 × g, to remove any traces of salts remaining from previous buffer washes. The 
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flow through was discarded each time. The filter cartridge was then transferred to a clean 
collection tube and centrifuged for 2 minutes at 16000 × g, in order to remove any last 
traces of ethanol from the wash solutions. The cartridge was placed into a sterile 1.5 ml 
collection tube and RNA eluted by the application of 30 µl RNase-free water to the filter, 
incubation at room temperature for 1 minute, followed by centrifugation for 2 minutes at 
16000 × g. To ensure maximum RNA yield, a second application of 30 µl RNase-free water 
and a final centrifugation for 1 minute at 16000 × g followed. 
2.2.1.2  RNA extraction from tissue 
In order to extract RNA, tissue samples were first homogenised in 1 mL RNA stat-60 
(AMS Biotechnology) per mg of tissue, using a glass Dounce homogeniser. This was 
incubated for 5 minutes at room temperature in the RNA Stat-60, and 200 µl of 
chloroform added per 1 ml of RNA stat-60. The sample was shaken vigorously for 15 
seconds and incubated for 5 minutes at room temperature. After centrifugation at 12,000 × 
g for 15 minutes at 4oC, the total RNA in the aqueous phase was transferred to a pre-
cooled collection tube, leaving any DNA and proteins in the organic phase. To this, 500 µl 
isopropanol was added, and incubated at room temperature for 5 minutes to allow the 
precipitation of the RNA from the aqueous phase. This was centrifuged at 12000 × g for 
10 minutes at 4oC and the pelleted washed by resuspension in 1 ml 75% (v/v) ethanol and 
centrifugation at 7500 × g for 5 minutes at 4oC. Once the pellet had been dried briefly, it 
was resuspended in 40µl of nuclease-free water.  
2.2.1.3  DNase treatment of RNA 
RNA was treated with DNase in order to degrade any contaminating DNA. One 
microgram of eluted RNA was mixed with 1 µl of 10× DNase buffer (Promega, UK; 100 
mM Tris-HCl, 25 mM MgCl2, 1 mM CaCl2), 1 µl DNase I (2000 units/ml, Promega) and 
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water to a final volume of 10 µl. This was incubated at 37oC for 30 min, after which the 
reaction was inactivated by the addition of 1 µl stop solution and incubation at 65 oC for 10 
min. This was stored at -20oC for short term, or at -80oC for longer term. 
2.2.1.4  Spectrophotometry of nucleic acids 
RNA and DNA samples were quantified using a NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific). The sample pedestal was first cleaned with 2 µl nuclease-free 
water and then calibrated with 1 µl elution solution, to provide a reference measurement of 
background light absorbance against which sample light absorbance could be compared. 
One µl of each sample was pipetted onto the sample pedestal and it’s absorbance measured 
at 280 nm. The ND-1000 Spectrophotometer v 3.2 software (Thermo Fisher Scientific) 
calculated the concentration (ng/µl) using a modified form of the Beer-Lambert equation 
and the wavelength-dependant molar absorptivity (or extinction) coefficient to correlate 
measured light with sample concentration: 
! = !!×!!!  
   Where:  c = nucleic acid concentration (ηg/µl) 
    A = Absorbance (absobance units, AU) 
    e = extinction coefficient (ng-cm/ul) 
    b = light path length (cm) 
 
2.2.1.5  Reverse transcription 
RNA from cultured cells was reverse transcribed using the Promega MLV reverse 
transcription (RT) system to produce complementary DNA (cDNA). One microgram of 
RNA was preincubated with random hexodeoxynucleotide (100 mM) or oligodT (100 mM) 
primers at 72oC for 10 minutes in a reaction volume made up to 12 µl with sterile distilled 
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water. This was then cooled on ice, to denature any secondary RNA structures that would 
interfere with primer annealing. To this mixture, 5 µl of 5× reaction buffer, 
deoxynucleotides (10 mM, Promega), 1 µl Moloney murine leukemia virus reverse 
transcriptase (MLV RT, 20 units/µl, Promega), 1 µl RNase inhibitor (40 units/µl, 
Promega) and nuclease-free water, were added to a final volume of 25 µl (Thermo Fisher 
Scientific). Reactions were incubated in a heat block at 37oC for 1 hour, after which the 
enzyme was denatured by incubation at 70oC for 10 min. To confirm the absence of 
genomic DNA during downstream applications, concurrent reactions were performed in 
the absence of reverse transcriptase.  
2.2.1.6  Oligonucleotide primer design 
Oligonucleotide primers were designed using primer 3 software (www.primer3.com) and 
previously published genomic and mRNA transcript sequences available from the NCBI 
Genbank database (http://www.ncbi.nlm.nih.gov/genbank/). The following formula was 
used to calculate the melting temperature (Tm) of designed primers: 
!" = %!"!×!0.41 + 64.9 − ! 600!  
 
   where:  Tm = melting temperature of primers 
    %GC = percentage of G and C bases in primer 
    n = total number of bases in primer 
Primer sets (forward and reverse pairs) were designed to have similar GC content and total 
number of base pairs (bp) to produce complementary primers with similar annealing 
temperatures, at around 60oC ( 
Table 2.2). Basic local alignment search tool (BLAST) searches 
(http://www.ncbi.nlm.nih.gov/BLAST/) were performed in all cases to ensure that 
primers were not complementary to other regions of the genome and bound specifically to 
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the target sequences. Following oligonucleotide synthesis (Alta Bioscience, Birmingham 
UK), optimum conditions for each primer set were determined by performing parallel 
reverse transcription polymerase chain reactions (RTPCR) at different temperatures based 
around the calculated Tm ( 
Table 2.2).  
Table 2.2: qRTPCR primers 
Target 
protein 
Forward primer sequence  
(5’-3’) 
Reverse primer sequence 
(5’-3’) 
Amplified 
Fragment 
(bp) 
Tm 
(oC) 
SCRIB CCTGCCAGCTCCAGCACCAC CGGCTGGGGTGGGGCAGTTA 147 59 
INADL AGATCGGAGTTTTGCAGAGG
T 
TCGAAGCAATGTTCTTGACCCA  100 59 
NHERF1 TCACCAATGGGGAGATACAG GTCTTGGGAATTCAGCTCCT 126 59 
PTPN13 ATGAAACCTGTGCTAGGGAT
TATA  
CGACCTCCCAGGCTCAAGTAG  286 60 
MAGI-1 GACTGTGAAGGAGTTCTTGG TCGTGATCACTTTCCCACTG 125 59 
MAGI-2 TTCAAGGGACAGCACAACC GGAAGAACAGCAGACTTTGC 146 59 
MAGI-3 CCACAAACTGCAGCAAGTGA AATGCTCCACTCTCTTCCAG 150 59 
B2M GCCTGCCGTGTGAACCATGT GCAGCCTCCTAGAGCTACC 296 59 
DLG1α CAGTCGAGGAGGCAATACTA AGCGTGAAGGTTCTGGCTCA 103 59 
DLG1β  
 
CGGAAGCAAGATACCCAGAG AATTGGTTCAGACGGCTTTG 113 59 
DLG1 HOOK 
region 
GCCCATTCCTAGCGCATGAA
CTCC 
GCCATTCTGGTGGATGGCAGAG 
 
98 59 
Tm indicates annealing temperature used in PCR reactions, having calculated predicted Tm and carried out 
reactions at several temperatures to obtain an optimal Tm. B2M – β2-microglobulin. 
 
2.2.1.7  Reaction conditions for RTPCR  
RTPCR reactions were set up on ice using filter pipette tips (StarLab, UK). Each 25 µl 
RTPCR reaction contained; 5 µl cDNA, 12.5 µl hotstart GoTaq mastermix (Promega) and 
0.1 nM of forward and reverse primers, with nuclease-free water made up to the final 
volume. Reactions were performed in a 2720 Thermocycler (Applied Biosystems, UK), 
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beginning with 10 minutes at 95oC, in order to activate the polymerase. This was followed 
by 40 cycles of denaturation at 95°C for 30 seconds, annealing for 50 seconds) and an 
extension step at 72°C for 1 minute.  
Table 2.2 details the primer sequences and optimal annealing temperatures. Amplified 
DNA fragments of expected length were visualized by 1% (w/v) agarose gel 
electrophoresis and ethidium bromide staining.  
2.2.1.8  Agarose gel electrophoresis 
DNA from PCR, as well as plasmid DNA, was visualised using agarose gel electrophoresis. 
Fragments were resolved on a 1-2% (v/w) agarose gel, prepared by heating 1.5-3 g of 
molecular grade agarose (Bioline) in 150 ml 0.5× TBE buffer (0.1 nM Tris-HCl, 0.1 nM 
Boric acid, 100 mM EDTA). Ethidium bromide was added to a final concentration of 0.5 
µg/ml prior to cooling and the entire solution poured into a Mini Sub Gel GT 
Electrophoresis Tank (BioRad). Once set, this was submerged in 0.5× TBE buffer. DNA 
samples were combined with 5 µl loading buffer (30% v/v glycerol, 0.3% w/v 
bromophenol blue, 0.1% xylene cyanol FF, 10× TBE) and loaded onto the gel, alongside a 
lane containing 2 µl DNA marker (1kb plus, Invitrogen). A potential of 100 V was applied 
across the gel for approximately 1 hr. Ethidium bromide is an intercalating agent that 
fluoresces when exposed to ultraviolet (UV) light, allowing the visualization of DNA, using 
a Gene Flash UV light box (Syngene Bio Imaging, UK). 
For the resolution of genomic DNA prior to Southern blot analysis, 0.8% (w/v) agarose 
gels were prepared as described and cast in Fisherband horizontal gel electrophoresis tanks 
(Thermo Fisher Scientific), run at 50 V overnight. 
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2.2.1.9  Purification of cDNA from agarose gels 
cDNA was isolated from agarose gels and purified using the QIAquick Gel Extraction Kit 
(QIAgen), as per the manufacturer’s instructions. Each DNA band (approximately 100 mg 
of gel) was excised from the gel using a sterile scalpel and placed in a sterile 
microcentrifuge tube. Once weighed, three volumes (typically 300 µl) of QG buffer was 
added and the gel dissolved by incubation at 50oC with occasional agitation. Once the gel 
had completely dissolved (approximately 15 min), 1 volume (typically 100 µl) isopropanol 
was added and mixed by inversion of the tube several times, aiming to precipitate the 
DNA. The solution was transferred to a QIAquick Spin column placed in a fresh 
microcentrifuge tube and drawn through the column by centrifugation at 16000 × g for 1 
minute, allowing cDNA to bind to the filter cartridge. The flow-through was discarded, 
and any traces of agarose were washed away by the addition of 500 µl QG buffer and 
centrifugation at 16000 × g for 1 minute. To remove salts and ethidium bromide, a second 
wash was performed by the addition of 750 µl PE buffer and centrifugation at 16000 × g 
for 1 minute. The flow-through was discarded after each wash stage. The filter column was 
again centrifuged at 16000 × g for 1 minute to remove any remaining PE buffer before 
being transferred into a sterile microcentrifuge tube. Thirty microlitres of sterile, nuclease-
free water was added to the centre of the filter and the column incubated for 1 minutes at 
room temperature. The column was then centrifuged at 16000 × g for 1 minutes to elute 
the DNA. This addition of water was repeated for a second time, and DNA concentration 
measured using a NanoDrop spectrophotometer before storage at -20oC. 
2.2.1.10 DNA sequencing 
RTPCR products were sequenced in order to confirm that the intended genes of interest 
had been amplified. Sequencing was performed by the Functional Genomics facility 
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(Department of Biosciences, University of Birmingham, UK). In preparation, 10 ηg of 
RTPCR product and 5 picomoles forward or reverse primer was made up to a final volume 
of 10 µl with nuclease-free water. Returned chromatograms were viewed using FinchTV 
software (GeoSpiza Inc.) and the EMBL-EBI Clustal-Omega facility 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) used to align sequencing results to published 
sequences and confirm homology. 
Table 2.3: DLG1  primers 
Primer name Sequence (5’-3’) Region of DLG1 
DLG1 F1 CCCAGAGAGCATTGCACC α N terminus 
DLG1 F2 CAGAGATTGAGAATGTCC Nts 428-446 
DLG1 F3 CTCGACCAGTGATCATATTG Nts 2140-2160 
DLG1 F4 CTGGAACAGGAGTTACTG Nts 2577-2596 
DLG1 R1 GCCTGAAAGAGGTTGCTCTG GUK domain 
DLG1 I2Fwd GAGATCCCTGACGACATGGG Insertion 2 
DLG1 I5Rev TTCACTATCGCTGGCATTAGAA Insertion 5 
DLG1 GUKRev CCTGTCTTTCATAGGTCCCA GUK domain 
 
2.2.1.11  Quantitative RTPCR (qRTPCR) 
qRTPCR reactions were performed to determine the level of expression of particular genes 
of interest, using SYBR green chemistry. SYBR Green I is an assymetrical cyanine dye 
which intercalates into the minor groove of double-stranded DNA (dsDNA) and produces 
a complex that emits a green fluorescent signal (524 ηm) upon excitation with blue light 
(485 ηm) (Zipper et al., 2004). The intensity of the fluorescent signal is proportional to the 
amount of SYBR-bound DNA present and so measurement of the fluorescent signal can 
be used to quantify DNA. During the qPCR reaction, the fluorescent signal is measured at 
every cycle of PCR and immediately following the product extension phase. During the 
reaction, the number of copies of the gene increases exponentially as described by the 
following equation (Livak and Schmittgen, 2001): !! = !!!×! 1 + !!! ! 
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  Where: !! = number of molecules of gene of interest at cycle n 
   !! = initial number of molecules of gene of interest 
   !! = efficiency of amplification of gene of interest 
   n = number of completed cycles 
The values obtained for the genes of interest were referenced to the values of expression of 
the housekeeping gene β2-microglobulin, as an internal control to account for difference in 
cell number and initial RNA load (Schmittgen and Zakrajsek, 2000). Prior to analysis of 
gene expression, several housekeeping genes of choice were compared by qRTPCR for 
consistency of expression across cDNA samples. The result of gene expression 
quantification was then given as a ratio of the levels of mRNA transcripts of the gene of 
interest in an experimental sample (HPV genome-containing keratinocytes) to a defined 
control sample (untransfected HFK).  
Each qRTPCR reaction contained 40 ηg cDNA template, 12.5 µl SYBR green mastermix 
(Applied Biosystems) and 0.1 ηM forward and reverse primer, made up to a total volume 
of 25 µl with nuclease-free water. Reactions were set up in triplicate on ice in 96-well 
reaction plates (Applied Biosystems) and analysed using the ABI Prism 7700 Sequence 
Detection System (Applied Biosystems). Samples were initially subjected to a denaturation 
step at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 20 seconds, 
annealing for 45 seconds and an extension step at 72°C for 1 minute. Primers specific to 
the housekeeping gene β2-microglobulin were included on each qRTPCR plate, to account 
for loading variability.  
2.2.1.12 Comparative Ct method (ddCt) for relative quantitation of gene expression 
The delta-delta (dd)Ct method enables relative quantitation of transcripts without the need 
for standard curves when looking at expression levels of a target gene relative to an 
endogenous control (e.g β2-microglobulin, Livak and Schmittgen, 2001). This method was 
CHAPTER 2: MATERIALS AND METHODS 
-77- 
used to measure the amount of target gene transcripts in different samples. Firstly, the 
difference (dCt) between the Ct values of the target gene and the endogenous gene was 
calculated for each sample studied (dCt = target Ct - endogenous Ct). The sample selected 
as the baseline sample for expression of the target gene is referred to as the reference 
sample. Here, untransfected, non-HPV containing keratinocytes were used as the reference 
sample, to which gene expression in the HPV-containing keratinocytes were normalised, 
unless otherwise stated. The difference between the dCt values of each sample and its 
reference sample was calculated, generating a ddCt value (ddCt = reference dCt - target 
dCt). The ddCt for each sample was then converted to an absolute value using the 
following equation: 
fold!change!in!expression!level = 2!!!"# 
    Where: dCt = target Ct - endogenous Ct 
     ddCt = reference dCt - target dCt 
2.2.2  DNA analysis  
2.2.2.1  DNA extraction 
DNA was extracted from cells using a standard phenol-chloroform method: 2×106 cells 
were resuspended in lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM EDTA; 400mM NaCl; 
all Sigma-Aldrich), treated with RNAse A at a final concentration of 50 µg/ml for 30 
minute at 37oC, and digested overnight by proteinase K (50 µg/ml final concentration, 
Sigma-Aldrich) at 37oC with 0.2% (w/v) SDS. The resulting digestion was passed through a 
blunt 0.8 gauge needle 10 times to shear the DNA. The DNA was extracted firstly by 
washing twice with 2 volumes of phenol:chloroform:isoamylalcohol (25:24:1, Sigma-
Aldrich), mixing thoroughly and centrifuging at 16000 × g and washing once with 2 
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volumes of chlorofom:isoamyl alcohol (24:1). Following each wash, the liquid phase was 
transferred to a fresh 15 ml conical tube. DNA was precipitated by incubation in two 
volumes of 100% ethanol, with 0.3 M sodium acetate (pH 5.2), overnight at -20oC. Tubes 
were centrifuged for 30 minutes at 4oC, the pellet was washed with ice-cold 70% ethanol 
and centrifuged for 15 minutes at 4oC. The resulting pellet was dried and resuspended in 
100 µl TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). DNA concentration was 
measured, as previously described, using a NanoDrop ND-1000 Spectrophotometer.  
2.2.2.2  DNA digestion 
Restriction enzyme digestions were typically performed upon 2-10 µg of plasmid DNA, 
using enzymes purchased from New England Biolabs (NEB, UK). Enzymes, DNA and the 
appropriate buffer were incubated in a total volume of 20-50 µl at 37oC overnight. After 
incubation, enzymes were heat-inactivated by incubation at 65°C for 10 minutes followed 
by cooling on ice for 2 minutes. Digestion with multiple restriction enzymes were carried 
out by selecting the appropriate buffer for the activity of both restriction enzymes, 
according to the manufacturer’s guidelines. 
2.2.2.3  Preparation of DNA for Southern analysis 
For the analysis of HPV genomes, 5 µg of genomic DNA extracted from cells was 
subjected to restriction enzyme digest (Table 2.4). All digestions also included the enzyme 
DpnI (NEB) to remove residual input DNA. Digested genomic DNA was analysed by 
electrophoresis using a 0.8% (w/v) agarose gel. To enable quantification of genome copy 
umbers, copy number standards were generated by digestion of pGEMII-HPV18 with 
EcoRI (NEB) to release the HPV18 genome from the vector and the equivalent 5 and 50 
genome copies/cell were run alongside samples as standards. In the case of HPV16 copy 
number standards were generated by digestion of pUC-HPV16 with BamHI (NEB). 
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Table 2.4: Restriction enzymes used to assess HPV genome status 
HPV genome 
Restriction Enzyme 
Linearises genome Non-cutter 
HPV16 HindIII BamHI 
HPV18 EcoRI BglII 
 
2.2.2.4  Transfer of DNA from agarose gel to nylon membrane 
Prior to blotting, the agarose gel was washed twice in 250 mM HCl for 20 minutes (the 
depurination stage), and twice in 400 mM NaOH for 30 minutes (denaturation and 
neutralization stages), all at room temperature. To set up the transfer of DNA from the 
agarose gel to a Gene Screen Plus nylon membrane (Perkin Elmer, UK), a tray was filled 
with 1 L of 400 mM NaOH and a glass plate rested on top. Three sheets of 24 × 33 cm 
WhatmanTM 3MM paper were soaked in 400 mM NaOH, laid across the glass plate with 
both ends submerged in the NaOH reservoir, and all the bubbles removed. The washed 
agarose gel was placed on top of this paper wick, with the loading wells facing downwards. 
A 20 × 22.5 cm sheet of Gene Screen Plus nylon membrane (Perkin Elmer) pre-soaked in 
NaOH was placed on top. Four layers of 21 × 23.5 cm WhatmanTM soaked in 0.4 M 
NaOH were placed onto the membrane and the bubbles removed. On top of this, two 
stacks of absorbent paper towels were placed, to reach approximately 10 cm in height and 
covering the filter paper layers, with no gaps between the stacks. A glass plate was placed in 
top of the towels, and a weight centered on top. The filter paper layer was separated from 
the wick via plastic wrap placed between the top and bottom filter paper layers. This set up 
was left overnight for DNA to transfer by capillary action.  
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Upon disassembly, the position of the loading wells was marked onto the membrane with a 
pencil, and the DNA crosslinked to the membrane using a UV crosslinker 90 (Stratalinker, 
Stratagene, UK) on auto-crosslink mode. Following rinsing in 2× saline-sodium citrate 
(SSC; 300 mM NaCl, 30 mM sodium citrate, pH 7.0), the membrane was stored at -20°C in 
plastic wrap.  
2.2.2.5 Preparation of radiolabelled DNA probe 
In preparation for generation of a HPV18 DNA probe, the pGEMII-HPV18 vector was 
linearised by EcoRI digestion. To generate a HPV16 DNA probe, the pUC-HPV16 vector 
was linearised by digestion with BamHI. Probe DNA was separated from the vector 
backbone by agarose gel electrophoresis, and purified as previously described. Fifty 
nanograms of DNA was subsequently diluted into 45 µl of TE buffer and the DNA 
denatured by heating to 95°C for 5 minutes, followed by incubation on ice slurry for 2 
minutes. The denatured DNA was then used as a template for radiolabelled probe 
generation using the Ready To Go DNA labelling beads-dCTP kit (Amersham Biosciences, 
UK), according to manufacturer’s instructions. Following re-suspension of the labelling 
beads with the denatured linear DNA, 50 µCi of [α-32P] dCTP (Perkin Elmer) was added 
and the mixture left to incubate at 37°C for 30 minutes. The labelled probe was purified 
using an Illustra Probe Quant G-50 microcolumn (Amersham Biosciences), a radiolabelled 
probe purification kit, following manufacturer’s instructions. 
2.2.2.6  Hybridisation of radiolabelled probe to DNA 
To prepare the hybridisation buffer, a 2× hybridisation buffer (5× SSC; 750 mM NaCl, 1.5 
M sodium citrate, pH 7.0), 10× Denhart’s (0.2% w/v ficoll 400, 0.2% w/v 
polyvinylpyrolilone, 0.2% w/v BSA fraction V, and 20% w/v dextran sulphate, all Sigma-
Aldrich), was diluted with deionized formamide (Sigma-Aldrich) at a 1:1 ratio, and SDS 
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added to a final concentration of 0.1% (w/v). A 200 µl aliquot of 10 mg/ml salmon sperm 
DNA (Invitrogen) was denatured by heating to 95°C for 5 minutes, cooled on ice slurry for 
2 minutes, and subsequently diluted into 10 ml of 1× hybridisation buffer; this constituted 
the pre-hybridisation buffer. The nylon membrane onto which the DNA was immobilised 
was then defrosted and placed onto a damp square of gauze. Together, the gauze and 
membrane were rolled and carefully placed into a glass hybridisation canister (Hybaid, UK). 
The pre-hybridisation buffer was added and the canister incubated in a hybridisation oven 
(Hybaid), rotating at 42°C for 1 hr, during which hybridisation buffer containing the 
radiolabelled DNA probe was prepared. A 200 µl aliquot of (10 mg/ml) salmon sperm 
DNA was added to the radiolabelled probe, followed by denaturation 95°C for 5 minutes 
and cooling on ice slurry for 2 minutes. This was added to 10 ml 1× hybridisation buffer. 
Once the pre-hybridisation buffer was removed, the hybridisation buffer containing the 
probe was added to the canister and this was incubated overnight, rotating at 42°C. 
2.2.2.7 Stringency washes 
Following removal from the hybridisation canister, the nylon membrane was rinsed in 
Buffer I (2× SSC, 0.1% w/v SDS), using a sponge to firmly wipe the surface of the 
membrane to remove excess, unbound probe. The membrane was then washed twice for 
15 minutes in the same buffer, with gentle agitation. Two successive 15 minute washes in 
Buffer II (0.5× SSC, 0.1% w/v SDS) followed, and then two 15 minute washes in Buffer 
III (0.1× SSC, 0.1% w/) SDS), both with gentle agitation at room temperature. Following 
this, the membrane was then washed in Buffer IV (0.1× SSC, 1% w/v SDS) at 65oC for 30 
min. The membrane was then wrapped in plastic wrap and exposed to autoradiography 
film (GE Healthcare), in a cassette containing an intensifying screen. In order to slow the 
β-particles, this was stored at -20oC. Films were typically developed after 24 h and another 
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after 1 week exposure times, using a Compact ×4 automatic processor (Xograph 
Healthcare, UK). 
2.2.3  Bacterial culture 
2.2.3.1  Bacterial growth 
The DH5α strain of Escherichia coli (E. coli) was used as a bacterial host for the amplification 
of plasmid vectors. Bacteria were grown on Agar plates consisting of 5% w/v agar in 
Luria-Bertani (LB) medium (1% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 1% 
w/v NaCl, all Sigma-Aldrich), which was sterilized by autoclaving. To make up ampicillin 
plates, the agar medium was melted, cooled to approximately 50°C and ampicillin (Sigma-
Aldrich) added to a final concentration of 100 µg/ml. This was then dispensed into petri 
dishes in 25 ml aliquots and left in a sterile environment to dry. Excess plates were sealed 
and stored at 4oC prior to use. 
2.2.3.2  Bacterial transformation 
The chemically competent DH5α strain was used to amplify plasmids. To do so, E. coli was 
first thawed on ice and 30-50 µl of cells pipetted into a pre-cooled tube. To this, 1-2 µg of 
plasmid DNA containing ampicillin resistance gene, was added directly into the thawed 
cells and incubated on ice for 30 min. The E.coli were heat shocked at 42°C for 45 seconds, 
followed by a 2 minute incubation on ice and the addition of 500 µl LB media (1% w/v 
bacto-tryptone, 0.5% w/v bacto-yeast extract, 1% w/v NaCl). This was incubated at 37°C 
shaking at 200 rpm for 1 hr. From this, 50-200 µl of transformed cells were plated onto 
ampicillin agar plates and incubated overnight at 37oC.  
A starter culture of transformed cells was prepared by inoculating 6 ml LB media 
supplemented with 100 µg/ml antibiotic, with a single bacterial colony and incubating 
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overnight in a shaker at 37°C. Glycerol stocks were also prepared from the starter culture 
by the addition of 500 µl of sterile 80% (v/v) glycerol solution to a 500 µl aliquot of 
bacteria. To amplify bacteria, the 6 ml preparation was added to 200 ml of ampicillin-
supplemented LB and grown overnight in a 2 L conical flask, shaking at 200 rpm at 37°C. 
2.2.3.3  Storage of E.coli 
Bacteria were grown from glycerol stocks by streaking out the bacteria across the surface of 
an agar plate with a sterile fine loop, which was then incubated overnight at 37°C. 
Transformed bacteria were stored on agar plates for short periods of time at 4°C, or for 
longer periods of time, stored as a glycerol stock at -80°C. Untransformed stocks of E.coli 
were stored at -80°C. 
2.2.3.4 Purification of plasmid DNA  
Following incubation overnight in 200 ml LB supplemented with antibiotic, the overnight 
culture was pelleted by centrifugation at 13,000 rpm in a Sorvall GS3 rotor at 4°C for 20 
min. Amplified plasmid DNA was extracted using the QIAprep Spin MaxiPrep Kit 
(Qiagen), following manufacturer’s instructions. The purification procedure involved lysis 
of bacterial cells using alkaline lysis buffer, adsorption of plasmid DNA onto a silica filter 
in the presence of high salt buffer, followed by washing and elution of plasmid DNA from 
that filter. 
Plasmid DNA was precipitated by the addition of 0.7 volumes of isopropanol (Thermo 
Fisher Scientific) and the sample was then centrifuged at 3000 × g in a Sorvall SS-34 rotor 
for 40 minutes at 4°C. The pellet was then washed with 5 ml 70% (v/v) ethanol and 
centrifuged for a further 15 minutes at 4°C. DNA was air-dried and resuspended in 50 µl 
of 1× Tris-EDTA (TE) buffer for storage at 4oC (short term) or -20oC (long term). The 
concentration of DNA was determined by spectrophotometry (Nanodrop). 
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2.2.3.5  Plasmid vectors 
The pGEMII-HPV18 plasmid contains the total HPV18 genome (accession number: NC 
001357) cloned into the pGEMII vector at the EcoRI restriction site at residue 2440. The 
pUC-HPV16 plasmid contains the total HPV16 genome cloned into the pUC vector at the 
BamHI restriction site. The HPV18 genome containing plasmid was a gift from Frank 
Stubenrauch, University of Tubingen, and the HPV16 114/K (HPV16K) and 114/B 
(HPV16B) containing plasmids were both provided by Ethel de Villiers, the German 
Cancer Research Centre, Heidelberg. 
2.2.3.6  Preparation of HPV genomes for transfection 
To extract the HPV18 genome from the bacterial vector, 10 µg of pGEMII-HPV18 wild 
type or mutant genomes were digested with EcoRI. Similarly, the HPV16 genome was 
extracted from the pUC-HPV16 genome by digestion with BamHI; both digestions 
occurred in a total volume of 50 µl and were incubated overnight at 37oC. Digested HPV 
genomes were recircularised in 900 µl total volume ligation reaction mix with T4 DNA 
ligase containing 400 units/ml (NEB), to encourage self-ligation of the HPV genomes. 
This was incubated overnight at 16°C. HPV DNA was then precipitated by the addition of 
2 volumes of isopropyl alcohol and 1/5 volume of 5 M NaCl, followed by vortexing and 
subsequent incubation at -20°C overnight. DNA was pelleted by centrifugation at 16,100 × 
g for 30 minutes at 4°C, the supernatant removed and the pellet washed with 70% ethanol 
(pre-cooled to -20°C), prior to centrifugation at 16,100 × g for a further 15 minutes at 4°C. 
The supernatant was subsequently removed and the DNA pellet resuspended in 12 µl of 
1× TE buffer. The DNA concentrations were then estimated by running a 1 µl aliquot on 
an agarose gel alongside 1 µl of DNA marker (1 µg/ml, 1kb plus ladder, Invitrogen) 
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2.2.4 Protein analysis 
2.2.4.1  Protein extraction and preparation 
Cells were harvested by trypsinisation, washed twice with PBS and finally with ice-cold 
saline. Pelleted cells were lysed in RIPA (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% v/v 
SDS, 2% sodium deoxycholate, 1% v/v Triton-x-100), UTB or NP40 (200 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.5% v/v NP40, Sigma-Aldrich) lysis buffers, as appropriate and 
incubated on ice for 20 minutes and then sonicated for ten seconds at 2 watts. This was 
then centrifuged at 4oC for 20 minutes at 16000 × g, to remove the insoluble fraction. The 
amount of protein was quantified by Bradford assay. Bradford reagent (Biorad) was diluted 
1:4 in distilled water, and standards of bovine serum albumin (BSA) at 4, 8, 12, 16 and 20 
µg/mL set up. The standard curve was set up and absorbance measured using an 
Eppendorf Biophotometer (Eppendorf).  
Prior to loading, the protein of samples were heated to 95oC in an equal volume of 2× 
Laemmlli buffer (Sigma-Aldrich) supplemented with 5% (v/v) β-mercaptoethanol, for 5 
min, cooled on ice and spun quickly to collect the contents of the tube.  
2.2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels were set up 
in two phases using the mini-Protean 3 Bio-rad apparatus. A 10 or 12% resolving gel 
containing 30:1 acylamide:bisacrylamide (Bio-rad), 390 mM Tris-HCl pH 8.8, 0.1% w/v 
SDS (Sigma-Aldrich), 0.06% w/v N,N,N’,N’- tetramethylethylenediamine (TEMED, 
Sigma-Aldrich) and 0.1% w/v ammonium persulphate (APS, Sigma-Aldrich) was made. A 
layer of isopropanol was applied to the top to give a uniform surface. Once this had set, 
the ispopropanol was remoced and a stacking gel containing 3% acrylamide, 125 mM Tris-
HCl pH 6.8, 0.1% w/v SDS, 0.1% w/v TEMED and 0.1% w/v APS was poured on top of 
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the resolving gel, a comb was placed in the stacking gel and allowed to set for 30 min. 
Protein lysates were added to equal volumes of loading buffer (5% v/v β-mercaptoethanol 
in Laemmli buffer), heated at 95oC for 5 min, cooled on ice and centrifuged quickly to 
collect. Samples were then loaded into each SDS-PAGE gel well alongside a lane 
containing 7 µl of ColorPlus Prestained protein ladder (NEB), and separated by 
electrophoresis at 100V for 1 hr. Gels were run using Mini Protean® 3 Cell (BioRad) tanks, 
containing 1× running buffer consisting of 25 mM Tris-HCl pH 7.5, 2 mM glycine 
(Thermo Fisher Scientific) and 10% SDS. 
2.2.4.3 Electrophoretic protein transfer 
Two pieces of sponge, two pieces of WhatmanTM
 
chromatography paper (Sigma-Aldrich) 
and one piece of BioTrace NT membrane (VWR International, UK), cut to gel size, were 
soaked in transfer buffer (25 mM Tris-HCl pH 7.5, 2 mM glycine, 20% v/v methanol in 
distilled water). The ‘transfer sandwich’ was set up in (BioRad), ensuring air bubbles were 
pushed out between each layer, in the following order: sponge, filter paper, gel, BioTrace 
NT membrane, filter paper, sponge. The transfer module was then placed into the transfer 
tank (BioRad) and filled with transfer buffer. Protein was then transferred from the gel to 
the BioTrace NT membrane at 350 mAmp for 3 hr.  
2.2.4.4 Protein visualisation 
Successful transfer was assessed by Ponceau S stain (0.1% w/v Ponceau S, 5% acetic acid), 
which was then rinsed off in phosphate- or Tris-HCl-buffered saline (PBS or TBS) as 
appropriate. Non-specific protein binding was blocked by incubating the membrane for 1 h 
at room temperature in 2-5% (w/v) non-fat milk (Marvel, Premier Foods) or 2% (w/v) 
BSA (Sigma-Aldrich) dissolved in PBS or TBS. The membrane was incubated overnight at 
4oC in primary antibody, diluted in the appropriate milk/BSA PBS/TBS solution (see  
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Table 2.5). To assess for equal loading, the levels of housekeeping genes β-actin or 
GAPDH were determined using a mouse anti-β-actin monoclonal antibody, or mouse anti-
GAPDH antibody, respectively. After three 15 minute washes in TBS or PBS with 0.1% 
(v/v) Tween-20, the membrane was incubated for 1 h in HRP-conjugated secondary IgG 
(Table 2.6) and then washed as before, with the last wash in TBS or PBS without Tween. 
Antibody-protein complexes were detected using the enhanced chemiluminescence (ECL) 
kit (Amersham Biosciences). 1 ml of each ECL reagent was mixed in a universal tube 
immediately prior to use. The membrane was incubated in the ECL mixture for 1 minutes 
before being wrapped carefully in plastic wrap and placed into an
 
autoradiography cassette, 
containing X-ray film (HyperfilmTM, Amersham Biosciences) and developed for between 30 
seconds to 1 hr, using a Compact ×4 automatic processor (Xograph Healthcare) at various 
exposure times (typically 30 seconds, 5 minutes and 30 minutes). 
2.2.4.5 Generation of DLG1α specific antibody 
An immunogenic peptide was selected from the N-terminus sequence unique to DLG1α. 
This peptide (KGSSDELQAEPEPSR) was inoculated into rabbits by a commercial 
company (Generon, UK). The subsequent antibody (DLG1α 1524) recognised the peptide 
in ELISA based assay (performed by Generon). Rabbit serum extracted before exposure to 
imunogen (pre-immune) was taken for use as a control for non-specific binding. 
2.3 Immunocytochemical techniques 
2.3.1  Immunofluorescence 
A heat-induced epitope retrieval (HIER) technique using an EDTA buffer was applied to 
paraffin-embedded and formalin-fixed samples, in order to unmask the antigens in the 
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formalin-fixed sections and thus enhance the staining intensity of antibodies (Watson et al., 
2002). Firstly, 4 nm raft sections were incubated for 5 minutes in Histo-ClearTM
 
(National 
Diagnostics, UK), to clear the paraffin. This was followed by hydration for 15 minutes in 
100% ethanol (IMS). Slides were then rinsed three times in water, incubated for 10 minutes 
in 0.3% (v/v) hydrogen peroxide, and washed three times in water again. The sections were 
immersed overnight in EDTA buffer (1 mM EDTA NaOH pH 8, 0.1% v/v Tween) 
heated to 65oC and continually agitated on a stirrer. 
Retrieved raft sections were blocked in 5% v/v heat-inactivated goat serum (HINGS) with 
0.1% w/v BSA in PBS, for 1 h at room temperature. During the staining procedure, 
incubations took place in a humidified chamber, in order to prevent the evaporation of 
solutions. Primary antibody was made up in blocking buffer, applied to raft sections and 
incubated overnight at 4oC. Excess antibody was removed by washing slides in agitated 
PBS for 10 min, three times. The appropriate secondary fluorophore-conjugated antibody 
(Molecular probes®, Life Technologies), made up in the same blocking buffer, was applied 
to each slide, incubated for an hour at 37oC and washed in agitated PBS as before. The 
final wash contained 1 µl of 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich), a blue 
(461 nm) fluorescent stain that binds strongly to A-T rich regions of DNA, highlighting the 
nuclei of cells. Slides were mounted onto coverslips in 80% (v/v) glycerol in PBS 
containing 2% 4-Diazabicyclo-2,2,2-octane (DABCO, Sigma-Aldrich) and visualized on a 
Nikon Eclipse E600 microscope (Nikon, USA). Images were captured using a Leica 
DC200 camera and software. Slides were stored at -20oC. 
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2.4 Computational methods 
2.4.1  Protein and nucleotide sequence alignment 
Protein and nucleotide sequences were obtained from NCBI and Ensembl databases 
(http://www.ncbi.nlm.nih.gov, Altschul et al., 1990 and 
http://www.ensembl.org/index.html, Flicek et al., 2014), and sequence alignments were 
performed using ClustalW software (http://www.ebi.ac.uk/Tools/msa/clustalw2/, Larkin 
et al., 2007). Nucleotide sequences resulting from sequencing reactions were aligned using 
the NCBI basic local alignment search tool (BLAST, http://blast.st-
va.ncbi.nlm.nih.gov/Blast.cgi, Altschul et al., 1990), which finds regions of similarity 
between sequences, and compares sequences to sequence databases and calculates the 
statistical significance of matches (Altschul et al., 1990; Johnson et al., 2008). 
2.4.2  Protein motif prediction 
Protein sequences were analysed for hypothetical secondary structure motifs using the 
programs Scansite (www.scansite3.mit.edu, Obenauer et al., 2003), and Prosite 
(http://prosite.expasy.org, Sigrist et al., 2010). These sites scan an input amino acid 
sequence and, using a database of consensus sequences, provide a prediction and 
probability score for the presence of secondary structure motifs found within that 
sequence. 
2.4.3  Nucleotide motif analysis 
Splice site analysis was performed using nucleotide sequences from DLG1 variants, and 
from sequencing data. Analysis was performed on more than one platform; the Maximum 
Entropy (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html, Yeo and 
Burge, 2004) program and the Human Splicing Finder (HSF, http://www.umd.be/HSF/, 
Desmet et al., 2009), which are designed to predict the effects of mutations on splicing 
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signals or to identify splicing motifs in any human sequence. Results were also compared to 
known splice site recognition motifs (Harris and Senapathy, 1990; Srebrow and Kornblihtt, 
2006; Ghigna et al., 2008). 
2.4.4 Densitometry analysis 
Western blot films were scanned in and .tif images analysed using ImageJ software 
(Schneider et al., 2012). Once quantified, the area values for absorbance peaks were 
transferred to Microsoft Excel, where normalising and comparison calculations took place 
and graphs created. 
 
Table 2.5: Primary antibodies used in western blotting and immunofluorescence 
Category Protein 
detected 
Size 
(kDa) 
Supplier/No. Animal Dilution 
for WB 
Dilution 
for IF 
PDZ Proteins 
DLG1 135 
NAG Rabbit 1/1000 1/500 
Santa Cruz 
2D11 
Mouse 1/1000 1/30 
Sant Cruz H-60 Rabbit 1/500 - 
NT- Gift from L. 
Banks 
Rabbit 1/500 - 
I2 specific, 
Roberts Lab 
Rabbit 1/200 - 
I3 specific Rabbit 1/200 - 
INADL 196 Gift from R. Javier 
Rabbit 1/200 - 
NHERF1 50 BD Biosciences Mouse 1/500 1/500 
PTPN13 250 Santa Cruz  Rabbit 1/300 1/50 
SCRIB 210 Santa Cruz Goat 1/2000 1/100 
MAGI-1 120,130, 170 
Sigma Rabbit 1/500 - 
MUPP-1 219 Gift from R. Javier 
Rabbit 1/500 - 
PARD3 151 Sigma Rabbit 1/500 - 
CASK 105 Cell Signaling Technology 
Rabbit 1/400 1/50 
ZO-2 134 Cell Signaling Technology  
Rabbit 1/500 1/100 
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ZO-1 240 BD Biosciences Mouse 1/1000 1/100 
Housekeeping 
Genes 
 
p53 53 Gift from R. Grand 
Mouse 1/100 1/10 
β-actin 42 Sigma Mouse 1/50000 - 
GAPDH 37 Santa Cruz  Mouse 1/3000 - 
Keratin 18 46 Sigma CK5  Mouse 1/1000 - 
E-Cadherin 120/80 BD Biosciences Mouse 1/1000  
GRB2 25 Cell Signaling Technology  
Rabbit 1/1000 - 
HPV proteins 
 
HPV18 E6 17 Santa Cruz Mouse 1/100* - 
Phosphorylated 
HPV18 E6 
 
17 
Gift from L. 
Banks 
Rabbit 1/200* - 
HPV18 E7 17 Abcam  Mouse 1/1000 - 
HPV18 E4 12 R424 Rabbit 1/5000 1/1000 
HPV18 E4 12 1D11 Mouse - 1/10 
Signalling 
Proteins 
 14-3-3ζ 30 Santa Cruz Rabbit 1/1000 1/500 
Antibodies were diluted in 2% w/v Milk (Marvel) PBS, * indicates requirement for 2% w/v BSA PBS. 
 
Table 2.6: Secondary antibodies used in western blotting and immunofluorescence 
Category Protein detected Isotype Supplier Animal Dilution for WB 
Dilution 
for IF 
Secondary 
Antibodies 
(HRP 
conjugated) 
Anti-mouse HRP - Sigma Goat 1/3000 - 
Swine anti-rabbit HRP - Sigma Swine 1/2000 - 
Rabbit anti-Goat HRP - Sigma Rabbit 1/2000 - 
Secondary 
Antibodies 
(Fluorophore 
conjugated) 
AlexaFluor® 488 anti-mouse IgG Invitrogen Goat - 1/3000 
AlexaFluor® 594 anti-goat IgG2a Invitrogen Rabbit - 1/3000 
AlexaFluor® 594 anti-rabbit IgG Invitrogen Rabbit - 1/3000 
Antibodies were diluted in 5% v/v heat-inactivated goat serum (HINGS) with 0.1% w/v BSA in PBS 
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2.5 List of suppliers 
Abcam, 330 Cambridge Science Park, Cambridge, CB4 0FL, UK 
Agilent Technologies, 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA 
Alta Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
Amersham Pharmacia Biotech UK Ltd, Amersham Place, Little Chalfont, Bucks, HP7 
9NA, UK 
AMS Biotechnology Limited, 184 Park Drive, Milton Park, Abingdon, OX14 4SE, UK 
Applied Biosystems, Lingley House, 120 Birchwood Boulevard, Birchwood, WA3 7QH, 
UK 
BD Biosciences, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK 
BioRad Laboratories Ltd., Maxted Road, Hemel Hempstead, Hertfordshire, HP2 7DX, 
UK 
Cell Signaling Technology Inc., 3 Trask Lane, Danvers, MA 01923, USA 
Clonetics Biowhittaker, 8830 Biggs Ford Rd, Walkersville, MD 21793-8415, USA 
DAKO UK Ltd, Cambridge House, St Thomas Place, Ely, CB7 4EX, UK 
EMD Millipore Headquarters, 290 Concord Road, Billerica, MA 01821, USA 
Eppendorf UK Ltd, Endurance House, Chivers Way, Histon, Cambridge, CB24 9ZR, UK 
GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St Giles, Bucks, HP8 4SP, 
UK 
Genron Ltd., 12 Rawcliffe House, Howarth Road, Maidenhead, Berkshire, SL6 1AP 
Gibco-Invitrogen, 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK 
Hycor Biomedical Ltd., Douglas House, Bush Loan, Penicuik, Midlothian, EH26 0PL, UK 
Hybaid Ltd, Solaar House, 19 Mercers Row, Cambridge, CB5 8BZ, UK 
Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, USA 
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Life Technologies, 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK 
MP Biomedicals Inc., 1263 S. Chillicothe Road, Aurora, OH 44202, USA 
National Diagnostics, Unit 4 Fleet Business Park, Itlings Lane, Hessle, Yorkshire HU13 
9LX 
New England Biolabs, 240 County Road, Ipswich, MA 01938-2723, USA 
Nikon Inc, 1300 Walt Whitman Road, Melville, NY 11747-3064, USAPAA Laboratories 
Ltd, Termate Close, Houndstone Business Park, Yeovil, BA22 8YG, UK 
Perkin Elmer Ltd, Post Office Lane, Beaconsfield, Buckinghamshire, HP9 1QA, UK 
Promega, Delta House, Chilworth Research Centre, Southampton, SO16 7NS, UK 
Propath, Willow Court, Netherwood Road, Hereford, HR2 6JU, UK 
Qiagen, QIAGEN House, Fleming Way, Crawley, West Sussex, RH10 9NQ, UK 
Roche Diagnostics, Bell Lane, Lewes, East Sussex, BN7 1LG, UK 
SantaCruz Biotechnology Inc., Bergheimer Str. 89-2, 69115 Heidelberg, Germany 
Sigma-Aldrich Company Ltd., Fancy Road, Poole, Dorset, BH12 4QH, UK 
Starlab (UK) Ltd., 5 Tanners Drive, Blakelands, Milton Keynes, MK14 5BU, UK 
Stratagene, 11011 N. Torrey Pines Road, La Jolla, CA 92037, USA 
Syngene (UK), Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK 
Takara Bio Europe (Clontech), 2 Avenue du President Kennedy, 78100 Saint-Germain-en-
Laye, France 
Thermo Fisher Scientific Ltd, Bishop Meadow Road, Loughborough, LE11 5RG, UK 
Vector Laboratories Ltd., 3 Accent Park, Bakewell Road, Orton Southgate, PE2 6XS, UK 
VWR International Ltd., Hunter Boulevard, Magna Park, Lutterworth, LE17 4XN, UK 
Xograph Healthcare, Xograph House, Ebley Road, Stonehouse, Gloucestershire, 
GL10 2LU, UK 
Zeiss, 15 - 20 Woodfield Road, Welwyn Garden City, Hertfordshire, AL7 1JQ, UK 
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3.1 Introduction 
The E6 PBM is a highly conserved feature of high-risk α-papillomaviruses types, which is a 
strong indication that a PDZ targeting function is important in the life cycle of this group 
of viruses (Figure 3.1). This concept was reinforced by the discovery of a PDZ binding 
motif in the E7 protein of fellow papillomavirus RhPV and the identification of a mode of 
PDZ targeting by HPV8 (Tomaic et al., 2009; Lazic et al., 2012). The human genome 
encodes over 300 PDZ domain-containing proteins and to date seventeen of these have 
been identified as targets of high-risk E6 proteins (Table 3.1), with several more suggested 
from high-throughput screening experiments (Belotti et al., 2013). The identified PDZ 
substrates of E6 comprise a number of proteins involved in a range of functions, including 
defining cell polarity, cell-cell attachment, and organising cell signalling pathways associated 
with these functions (Figure 1.10, Table 3.1).  
The first proteins shown to interact with the E6 PBM were the Scribble complex 
components DLG1 and SCRIB (Kiyono et al., 1997; Nakagawa and Huibregtse, 2000). The 
second PDZ domain of DLG1 is required for HPV16 E6 binding, whereas HPV18 E6 is 
able to bind all three DLG1 PDZ domains independently (Gardiol et al., 1999; Kiyono et 
al., 1997). Moreover, of the four PDZ domains encoded by SCRIB, HPV binds to only one 
(PDZ3); indicating a specificity in HPV PDZ targeting, even within a protein (Nakagawa 
and Huibregtse, 2000). It was further discovered that the co-expression of HPV16 or 
HPV18 E6 alongside the PDZ proteins induced their degradation by the proteasome, and 
that E6*, a spliced isoform of E6 which lacks a PBM, is able to target endogenous DLG1, 
and to a lesser extent SCRIB, for degradation (Gardiol et al., 1999; Nakagawa and 
Group 1
HPV 16 CMSCC      RSSRTRRETQL  
HPV 18 CHSCCNRARQE RLQRRRETQV 
HPV 31 CIVCW   RRPRTETQV  
HPV 33 CAACW   RS     RRRETAL
HPV 35 CMSCW        KPTRRETEV
HPV 39 CRRCWTTKRED RRLTRRETQV
HPV 45 CNTCCDQARQE RLRRRRETQV
HPV 51 CANCW    Q  RTRQRNATQV
HPV 52 CSECW    RPRPVTQV 
HPV 56 CLGCW   RQ  TSREPRESTV
HPV 58 CAVCW   RPRRRQTQV
HPV 59 CRGCRTRARHLRQQRQARSETV 
 
Group 2A
HPV 68 CRHCWTSKRED RRRTRQETQV
 
Group 2B
HPV 26 CTNCW  RPRRQTETQV 
HPV 30 CLQCW       RHTTSTETAV
HPV 34 CRQCW     RPSATVV 
HPV 53 CLTCW       RHTTATESAV
HPV 66 CLQCW     RHTSRQATESTV 
HPV 67 CSVCW   RPQRTQTQV 
HPV 69 CTNCW      RPRREATETQV 
HPV 70 CRHCWTSNRED RRRIRRETQV
HPV 73 CTRCW     RPSATVV
HPV 82 CANCRTAA    RQRSETQV 
HPV 85 CRRCMTRA QE QQGSRRETQV
HPV 97 CNSCYNQSRQE RLSRRRETQV
HPV 8  CRLCKHLYHDW
 
Group 3
HPV 6       CLHCWTTCMED    MLP
HPV 11 CLHCWTTCMED    LLP
 
 XSTXLV
Consensus motif
Figure 3.1: C-terminal alignment of  high- and low-risk α-HPV E6 proteins 
To date, twelve HPV types have been defined by the WHO as high-risk with 
respect to causing cancer - these are designated as IARC Group 1- and a further 
ten types are recognised as ‘probably’ (Group 2A) and ‘possibly’ cancer-causing 
(Group 2B). HPV6 and 11 are included as examples of  low risk virus. HPV8 is a 
β-papillomavirus associated with cutaneous SCC, and has been shown to effect the 
transcription of  PDZ protein Syntenin-2. 
The canonical PBM sequence (XSTXLV) is shown above the highlighted region, 
which indicates the E6 PBM sequence.  
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Huibregtse, 2000; Pim et al., 2009). It has been suggested that SCRIB degradation by E6 is 
dependent upon the oncoprotein binding to the cellular ubiquitin ligase E6AP, and that 
this is not the case for DLG1; E6-mediated degradation of DLG1 still occurs in the 
absence of E6AP (Pim et al., 2000; Nakagawa and Huibregtse, 2000; Grm and Banks, 2004; 
Massimi et al., 2008). However, studies also demonstrated only a modest rescue of DLG1 
and SCRIB in HPV-positive cancer cell lines where E6AP is silenced, suggesting that other 
cellular ligases may be recruited, the identity of which remain elusive (Kranjec and Banks, 
2011; Massimi et al., 2008). Furthermore, E6AP was initially identified as important in the 
E6-mediated degradation of DLG4 in co-expression studies, but this was not observed in 
HPV-positive cancer cell lines, indicating that the different cellular conditions may 
contribute to the mechanism of E6-mediated PDZ protein degradation (Handa et al., 2007; 
Kranjec and Banks, 2011). Although co-expression studies have demonstrated E6-
mediated DLG1 degradation, endogenous levels of DLG1 and SCRIB protein remain 
unaltered in primary human keratinocytes expressing HPV16 E6 and E7 (Choi et al., 2013; 
Lee et al., 2000; Lee and Laimins, 2004). In addition, no change in abundance or subcellular 
localisation of these PDZ proteins was observed in HPV31 genome containing HFKs (Lee 
and Laimins, 2004). Furthermore, in mice expressing HPV16 E6 under the K14 promoter, 
no change was observed in DLG1 or SCRIB protein levels or distribution compared to the 
equivalent skin of non-transgenic mouse (Simonson et al., 2005). These discrepancies 
between in vitro and in vivo experimental results highlight differences between the 
experimental models and the requirement to validate these targets in a relevant model of 
the HPV life cycle. 
The Par complex includes PDZ proteins PARD3 and PAR6, and the complex associates 
with MUPP1 and the MAGUK family members MAGI-1, -2 and -3 (Figure 1.10). MUPP1 
has been identified as a target of HPV18 E6, leading to degradation of the PDZ protein 
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(Lee et al., 2000). In addition, MAGI-1, -2 and -3 have all been shown to be targeted for 
degradation by HPV16 and HPV18 in vitro (Glaunsinger et al., 2000; Thomas et al., 2002). 
Moreover, E6 mediated degradation was demonstrated in the HPV16 and 18 positive 
cancer cell lines Caski and HeLa, where the oncoprotein was shown to target membrane 
bound and nuclear pools of MAGI-1 (Kranjec and Banks, 2011).  
Conversely, the recently shown interaction between HPV18 E6 and PARD3 does not lead 
to degradation of the PDZ protein (Facciuto et al., 2014). Instead, it was observed that 
HPV18 E6 redistributes the protein; a loss of PARD3 from the apical domain cell 
junctions and an increase in cytoplasmic and nuclear protein was observed when the viral 
protein was expressed (Facciuto et al., 2014). In addition, cellular protein TIP-1 was 
identified as interacting with HPV16 E6, but no degradation of the protein was seen during 
co-expression of the two proteins (Hampson et al., 2004). It was also observed that 
knockdown of endogenous E6 in Caski and HeLa did not affect TIP-1 protein levels 
(Kranjec and Banks, 2011), reiterating that not all known E6 PDZ interactions promote 
PDZ protein degradation. 
The Crumbs complex protein PATJ associates with both HPV16 and HPV18 E6, via its 
fourth and fifth PDZ domains (Storrs and Silverstein, 2007). The resulting PATJ 
degradation does not require E6AP, and was the first example of a PDZ substrate 
degraded by E6* and thus revealed an alternative method of E6 association with PDZ 
proteins (Storrs and Silverstein, 2007). 
The signalling proteins PTPN13, PTPN3 and NHERF1 have also been identified as targets 
of high-risk HPV E6 proteins. Jing et al. and Töpffer et al. showed that both HPV16 and 
HPV18 target the protein tyrosine phosphatase PTPN3, and that resulting degradation of 
the phosphatase is dependent upon both E6AP and proteasome. However, silencing of E6 
in HeLa and Caski cervical cancer cell lines does not rescue PTPN3 protein levels and, as 
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PTPN13 decreases in these conditions, it was suggested that E6 and E7 stabilises PTPN13 
in the cancer cell lines (Kranjec et al., 2014). In primary keratinocytes, expression of HPV16 
E6 using retroviral vectors induced the PBM-dependent degradation of PTPN13, and 
expression of both HPV16 and HPV18 E6 led to the proteasomal degradation of 
NHERF1 (Spanos et al., 2008b; Accardi et al., 2011). In the latter experiments, HPV16 E7 
activation of CDKs promoted NHERF1 phosphorylation and E6 preferentially targeted 
these phosphorylated forms for proteasome-mediated degradation in a PBM-dependent 
manner (Accardi et al., 2011). These findings suggest a cooperative mechanism of action on 
the PDZ protein NHERF1. 
More recently, immunoprecipitation and yeast two hybrid screening experiments have 
identified interactions between the HPV16 E6 PBM and the known interacting proteins 
DLG1, SCRIB, MAGI-1, MAGI-3, MUPP1 and PTPN3 as well as highlighting potential 
novel targets SNTA1, SNTB1, SNX27, CASK and LIN7C (Belotti et al., 2013). Similar 
methods were used to identify TIP-2, a known target of HTLV-1 Tax, as an interacting 
protein of HPV18 E6 (Favre-Bonvin et al., 2005; Rousset et al., 1998), and GOPC as able to 
interact with both HPV16 and HPV18 E6 PBM sequences (Jeong et al., 2007). Most 
recently, PDZRN3 has been identified as a target for proteasomal degradation by both 
HPV16 and HPV18 E6 (Thomas and Banks, 2014). Silencing of E6 in the HPV18 positive 
HeLa cells rescued PDZRN3 protein levels (Thomas and Banks, 2014).  
High-risk HPV E6 proteins exhibit differing specificities for cellular PDZ proteins. 
(Kranjec and Banks, 2011). For example, both HPV16 and HPV18 E6 proteins are able to 
target DLG1 and SCRIB, but exhibit different preferences in binding the PDZ proteins; 
HPV16 E6 preferentially binds SCRIB over DLG1 and vice versa for HPV18 (Thomas et al., 
2005, ). The PBM of these two oncoproteins only differs by a single amino acid and, 
notably, the specificity for DLG1 and SCRIB can be switched within the context of the 
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whole E6 protein by switching the last residue (Thomas et al., 2005). In the same study, 
HPV18 exhibited a stronger affinity for MAGI-1 than HPV16 (Thomas et al., 2005). 
Similarly, GOPC was found to bind more strongly to HPV16 E6 than HPV18 and DLG4 
has been shown to be a stronger target for HPV18 than for HPV16 (Handa et al., 2007; 
Kranjec and Banks, 2011). PDZ targeting by E6 is also specific to subcellular localisation; 
the cytoplasmic and nuclear pools of both DLG1 and MAGI-1 are preferentially targeted 
by HPV18 for degradation over protein at cell-cell contacts (Massimi et al., 2004; Kranjec 
and Banks, 2011; Narayan et al., 2009). 
Interestingly, Lazic et al. revealed that expression of the skin-cancer associated HPV8 E6 
significantly downregulated syntenin-2 transcription, with HPV16 E6 also producing a 
decrease in syntenin-2 mRNA, but to a lesser extent (Lazic et al., 2012). This study suggests 
alternative mechanisms by which HPVs modify PDZ protein expression, a field that 
requires further investigation.  
While the E6 PDZ interaction is highly specific, it has been suggested that, at high enough 
concentrations, the E6 PBM may recognize any class I PDZ domain (Zhang et al., 2007). 
Thus, analyses in overexpression conditions are more analogous to the interactions during 
HPV-driven oncogenesis (Zhang et al., 2007). In terms of interactions with cellular targets, 
it is unclear which are the important PDZ targets in driving HPV propagation and, indeed, 
they may vary at different stages of the HPV life cycle. 
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Table 3.1: PDZ proteins associated with high-risk HPV E6 proteins 
PDZ 
protein 
(Gene 
Symbol) 
Alternative 
Name(s) 
Cellular Functions Effect of 
Interaction 
with E6 
References 
DLG1 SAP97 Cell polarity, proliferation, 
migration and adhesion 
Degradation, 
Mislocalisatio
n 
Kiyono et al., 1997 
Gardiol et al., 1999 
SCRIB Scribble, 
Vartul, 
LAP4 
Cell polarity and integrity, 
proliferation, apoptotic 
signalling 
Degradation Nakagawa and 
Huibregtse, 2000 
INADL PATJ Tight junction formation, 
cell polarity 
Degradation Latorre et al., 2005; 
Storrs and 
Silverstein, 2007 
SLC9A3R1 NHERF1, 
EBP50 
GPCR regulation, 
cytoskeleton anchoring  
Degradation Accardi et al., 2011 
PTPN13 FAP-1, 
PTPL-1, 
PTP-BAS, 
PTPBL 
Fas-associated 
phosphatase, cell growth 
signalling, apoptotic 
signalling 
Degradation Spanos et al., 
2008b 
MPDZ MUPP1 Receptor clustering, 
scaffold protein 
Degradation Lee et al., 2000 
MAGI-1 AIP3, 
WWP3 
Cell polarity, invasiveness, 
synapse formation, 
apoptosis 
Degradation Glaunsinger et al., 
2000 
MAGI-2 AIP1 Cell polarity, invasiveness, 
synapse formation, 
apoptosis 
Degradation Thomas et al., 2002 
MAGI-3 - Cell polarity, invasiveness, 
synapse formation, 
apoptosis 
Degradation Thomas et al., 2002 
DLG4 PSD95, 
SAP90, 
TIP15 
Receptor clustering Degradation Handa et al., 2007 
PTPN3 PTPH1 Phosphatase, cell growth 
signalling, apoptotic 
signalling 
Degradation Jing et al., 2007; 
Töpffer et al., 2007 
TAX1BP3 TIP-1 Wnt pathway inhibitor  - Hampson et al., 
2004 
GIPC1 Synectin, 
TIP-2 
Cell surface receptor 
expression and trafficking, 
TGFβ signalling 
Degradation Favre-Bonvin et al., 
2005 
GOPC CAL Intracellular trafficking Degradation Jeong et al., 2007 
PARD3 PAR3 Cell polarity, assymetrical 
cell division 
Mislocalisatio
n 
Facciuto et al., 
2014 
 
SDCBP2 Syntenin-2 Cell adhesion, growth 
factor signalling 
Decreased 
transcription 
Lazic et al., 2012 
PDZRN3 LNX3 E3 ubiquitin ligase Degradation  Thomas and 
Banks, 2014 
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3.2 Hypothesis and Aims 
Studies to date have demonstrated that the high-risk HPV E6 PBM interacts with PDZ 
targets, yet the function of the E6 PBM in the context of the viral life cycle, where E6 is 
expressed at physiological levels, remains to be investigated. This study aims to investigate 
within the context of a physiologically relevant model of the HPV16 and HPV18 life cycle 
to identify relevant PDZ protein targets of the E6 PBM.  
Thus, using a primary human foreskin keratinocyte (HFK) model of the HPV life cycle, the 
experiments described in this chapter aimed to: 
i. Investigate the effect of HPV16 or HPV18 replication on transcription of E6 PDZ 
targets.  
ii. Determine the abundance and distribution of E6 PDZ targets in HPV genome 
containing cells.  
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3.3 Results 
3.3.1 Generation of cell-based models of the HPV16 and HPV18 life cycle 
In order to study the life cycle of high-risk HPVs, primary human keratinocyte cell lines 
containing HPV16 and 18 genomes were generated in two donor backgrounds. Two 
separate HPV16 genome variants were utilised, 114/B (HPV16B) and 114/K (HPV16K). 
Variants are defined by having a less than 2% difference in the L1 ORF nucleotide 
sequence compared to the reference genome (Chen et al., 2011; Chan et al., 1995). Both 
HPV16B and HPV16K were originally derived from productive cervical lesions, and differ 
by a single amino acid; L1 asparagine 379 in HPV16K is replaced by a histidine residue in 
HPV16B (Kirnbauer et al., 1993). Early passage (p2) primary foreskin keratinocytes were 
co-transfected with the recircularised viral genomes and a neomycin resistance plasmid (see 
Section 2.1.4.4). Following drug selection and growth of cells, the presence of viral DNA 
was confirmed by Southern blot analysis (Section 2.2.2). Analysis of early passages of 
HPV16 and HPV18 genome containing keratinocytes confirmed the presence of HPV 
genomes in the two donors (Figure 3.2). These genomes migrate as supercoiled (SC) and 
open circle (OC) forms when digested with non-cutting restriction enzymes (HPV16, 
HindIII; HPV18, BglII), indicating that the HPV genome has established as episomes in 
these cells (Figure 3.2).  
In a previous study by the Roberts group, HPV18 genomes were generated in which the 
E6 gene sequence was mutated to encode an E6 protein lacking the four amino acid C-
terminal PDZ binding motif (ΔPDZ). At the same time, HPV18 genomes were generated 
with a mutation which abrogates PKA recognition of a sequence (RRXS) that overlaps 
with the PBM (ΔPKA) (Figure 3.3, Delury et al., 2013). Since loss of the E6 PBM function 
is known to affect the episomal genome maintenance upon increased population doubling 
16K
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Figure 3.2: Generation of  HPV16 and HPV18 genome containing primary 
keratinocyte cell lines 
Southern blot analysis of  total DNA isolated from two donor lines transfected 
with HPV16B, HPV16K (A) or HPV18 (B) genomes. DNA was digested with 
HindIII (HPV16B and HPV16K) or BglII (HPV18), which do not cut within the 
HPV genome. The addition of  DpnI digests residual input DNA. Radiolabelled 
genomic HPV16 (A) or HPV18 (B) DNA was used as a probe. Episomal genomes 
migrate as open circle (OC) and supercoiled (SC) forms. 
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Figure 3.3: Confirmation of  episomal genomes in HPV18 genomes with 
modified PDZ binding activity  
(A) Southern blot of  keratinocytes containing HPV18 wild-type, ΔPKA and 
ΔPDZ genomes. Total DNA was extracted and digested with EcoRI or BglII, 
alongside DpnI. HPV18 genomes are linearised by digestion with EcoRI, but 
remain uncut by BglII. Radiolabelled genomic HPV18 DNA was used as a 
probe. Episomal genomes migrate as open circle (OC) and supercoiled (SC) 
forms.  
(B)  Schematic of  mutations within the HPV18 mutation taken from Delury et al. 
2013. The ΔPDZ mutation encodes a deletion of  the E6 PBM (ETQV), 
whereas the ΔPKA mutation abrogates the PKA recognition site which 
overlaps with the PBM (RRXST).  
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(Delury et al., 2013), the presence of viral episomes in early passages of the cell lines 
containing these genomes was also confirmed by Southern blot analysis (Figure 3.3). In the 
cell lines used, both mutant HPV genomes migrated as open circle and supercoiled forms, 
indicating replication of unintegrated episomes (Figure 3.3). 
When grown in monolayer culture, these HPV16 and HPV18 genome containing cell lines, 
recapitulate the non-virus producing stages of the virus life cycle. 
3.3.2 Transcription of E6 PDZ targets in keratinocytes containing high-risk α-
papillomavirus genomes 
The primary cell lines described above formed the basis for the following systematic 
analysis of PDZ protein expression. Although many studies have reported alterations in 
PDZ protein levels where high-risk HPV E6 is expressed, few have reported upon the 
transcriptional activity of the genes encoding this group of cellular proteins in the presence 
of HPV. It has been shown that the high-risk β-papillomavirus HPV8 E6 protein inhibits 
the transcription of the PDZ protein syntenin-2, leading to the downregulation of protein 
expression (Lazic et al., 2012). Although the same study identified a low level of 
transcriptional inhibition of syntenin-2 by HPV16, there has been no in-depth analysis of 
PDZ protein gene expression in cells replicating HPV genomes. Therefore, this study 
aimed to investigate the transcription of known E6 PDZ targets using the cell-based 
models of the HPV16 or HPV18 life cycle.  
Prior to this study, a microarray gene analysis (Affymetrix) had been performed on 
monolayer cultures of HPV16 and HPV18 containing keratinocytes prepared in a different 
donor keratinocyte background to those used in this thesis (Leonard et al., unpublished 
data). Scrutiny of the array data for the expression of known E6 PDZ targets showed an 
CHAPTER 3: THE INVESTIGATION OF PDZ PROTEIN EXPRESSION DURING THE HPV LIFE CYCLE 
-103- 
increase in the transcription of selected targets in the presence of both high-risk types 
when compared to transcription in untransfected HFKs of the same donor (Table 3.2).  
Table 3.2: Affymetrix microarray analysis of E6 PDZ target expression in HPV16 
and HPV18 genome containing keratinocytes  
Protein Gene Symbol Probe Set ID 
Chromosom
al Location 
Fold change in expression 
HPV16B HPV16K HPV18 
DLG1 DLG1 230229_at 3q29 11.67 10.01 7.50 
SCRIB SCRIB 212556_at 8q24.3 1.57 1.12 2.01 
PATJ INADL 214705_at 1p31.3 4.47 4.04 2.58 
PTPN13 PTPN13 243792_x_at 4q21.3 4.22 7.45 4.40 
MAGI-2 MAGI2 207702_s_at 7q21 3.66 -1.28 2.30 
MAGI-3 MAGI3 226770_at 1p12-p11.2 2.13 1.71 1.57 
PTPN3 PTPN3 203997_at 9q31 1.24 1.04 1.26 
TIP-1 TAX1BP3 209154_at 17p13 -1.75 -1.55 -1.78 
TIP-2 GIPC1 207525_s_at 19p13.1 1.23 -1.17 1.17 
NHERF1 SLC9A3R1 201349_at 17q25.1 -1.23 1.24 -1.08 
p53 TP53 210609_s_at 17p13 -1.67 -1.21 -2.33 
Syntenin-2 SDCBP2 233565_s_at 20p13 1.18 -1.73 -2.01 
 
In the case of genes encoding the E6 PDZ targets MAGI-1, MUPP1, DLG4, PARD3 and 
GOPC, cellular transcript levels were below the detectable limit of the microarray probes, 
and these genes were consequently omitted from further analysis. Of the remaining E6 
targets, transcripts were present. The level of SCRIB, MAGI-2, MAGI-3, MPDZ (MUPP1) 
PTPN3, TAX1BP3 (TIP-1) and GIPC1 (TIP-2) transcripts were not influenced (by more 
than ~2.5 fold) by HPV16 or HPV18 genome replication. In contrast, transcript levels of 
DLG1, PATJ and PTPN13 showed an upregulation of greater than 2.5-fold in the cells 
containing both high-risk genotypes (Table 3.2). The level of increase of both DLG1 and 
PATJ transcripts was much greater in the presence of HPV16 than HPV18. DLG1 
transcription increased by 11.67-fold (HPV16) and 7.5-fold (HPV18) and PATJ 
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transcription was upregulated by 4.47-fold (HPV16) and 2.58-fold (HPV18). PTPN13 
transcription increased equally by just over 4-fold between the two HPV genotypes (Table 
3.2). The level of transcription of TP53, another protein target of high-risk α-HPV types 
was unaffected in keratinocytes containing HPV16 or 18 genomes (Table 3.2). 
A similar profile of gene transcription was seen in a second cell line containing the 
HPV16K variant, indicating that transcriptional changes are not variant specific (Table 3.2). 
Next, qRTPCR analysis was used for verification of the microarray data. Because of the 
changes in transcription seen in the microarray analysis, the E6 PDZ targets DLG1, PATJ 
and PTPN13 were selected for further validation, alongside the known target SCRIB, 
whose transcription remained unaffected. As well as the analysis of DLG1, SCRIB, PATJ 
and PTPN13, a primer set was included for the PDZ protein NHERF1, gene symbol 
SLCR9A3R1, which had recently been identified as a novel target of HPV16 and HPV18 
E6 proteins (Accardi et al., 2011). By including NHERF1 in qRTPCR validation, the 
expression of the PDZ protein could be investigated in a model system where whole HPV 
genomes were present. The microarray analysis indicated that high-risk HPV replication 
does not affect NHERF1 transcription; the fold change detected in the microarray was 
below 2.5 in both HPV16 and HPV18 containing keratinocytes compared to untransfected 
primary cells (Table 3.2). This data is in agreement with the findings of Accardi et al., who 
showed that there was no change in NHERF1 transcription following co-expression of E6 
and E7 in primary keratinocytes.  
Oligonucleotide primer sets for each PDZ target were designed to correspond to the 
region of the gene recognized by the probe used in the microarray analysis (see Section 
2.2.1.2, Table 2.2). Each primer set was initially optimized by performing PCR at a range of 
different annealing temperatures, using DNAse treated cDNA transcribed from the same 
RNA utilized in the microarray (Appendix II). Gene expression quantification by qRTPCR 
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was carried out on RNA isolated from HPV16 and HPV18 genome containing 
keratinocytes in the two donor backgrounds, each harvested at passage 3 (P3) and 
transcribed using oligodT primers (see Section 2.2.1.1). Changes in transcript levels were 
calculated relative to untransfected cells of the same donor. Figure 3.4 shows levels in 
individual donors, each repeated three times, and the data is summarized in Table 3.3 
where the fold change in transcription is given as the mean change averaged across the two 
donors. 
In this analysis, DLG1 transcripts were elevated in both HPV16 and HPV18 genome 
containing cells in both donor backgrounds (Figure 3.4 A). Where HPV16 was present, 
DLG1 expression was increased by ~18-fold (HPV16B) over untransfected, and in HPV18 
genome containing keratinocytes, DLG1 transcription was increased by more than 5-fold 
(Figure 3.4 A). By contrast, transcription of the fellow Scribble complex protein SCRIB 
remained largely unaffected in cells containing the high-risk HPV genomes (Figure 3.4 B). 
However, one donor exhibited a significant 3-fold increase of SCRIB transcripts in cells 
containing the HPV16B variant, but this was not consistently upheld in the other donor 
background, or in the presence of the HPV16K variant (Figure 3.4 B). Other than this, 
analysis of keratinocytes transfected with the two different variants HPV16 genomes 
(HPV16B and HPV16K) showed consistent effects upon the gene expression of the 
selected PDZ proteins; where there was an increase in cells containing the variant 16B 
(DLG1, PATJ, NHERF1 and PTPN13), the same trend occurred in the presence of 
HPV16K (Figure 3.4, summarized in Table 3.3). This analysis indicates that transcriptional 
changes are not variant specific. 
Levels of PATJ transcripts were elevated in HPV16 and HPV18 genome containing cells, 
exhibiting an 11 to 14-fold and 6 to 9-fold increase in transcripts respectively (Figure 3.4 
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Figure 3.4: Quantification of  selected E6-PDZ target transcription in 
HPV16 and HPV18 genome containing keratinocytes 
Transcription analysis of  DLG1 (A), SCRIB (B), PATJ (C), NHERF1 (D) and 
PTPN13 (E) genes in two donor keratinocyte backgrounds. mRNA was extracted 
from primary foreskin keratinocytes following establishment of  stable lines 
containing HPV16 or HPV18 genomes, alongside untransfected keratinocytes at 
passage 3 (P3). This was transcribed to cDNA using oligodT primers and levels 
were measured by qRTPCR. ΔCt values were were calculated relative to the 
housekeeping gene β2-microglobulin, which was normalised to transcript levels in 
untransfected keratinocytes (ΔΔCt) derived from the same donor background 
(indicated by dotted line). Error bars show ±SEM of  three experimental repeats, 
statistical significance indicated by * (p<0.05) and ** (p<0.01).  
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C). Like the DLG1 gene, transcription of PATJ was increased to a greater extent by 
HPV16 genome replication than by replication of HPV18 in monolayer keratinocytes. 
Transcription of the signalling protein NHERF1 was increased by 3 to 4-fold in 
keratinocytes containing the HPV16 variants (Figure 3.4 D). The level of upregulation of 
NHERF1 transcription in HPV18 positive cells was only significant in one donor, where a 
more than 7-fold increase was observed (Figure 3.4 D). This analysis differs from 
published work, which demonstrated no change in NHERF1 mRNA expression in HFKs 
expressing HPV16 E6 and/or E7 (Accardi et al., 2011). 
Like DLG1 and PATJ, PTPN13 transcription was significantly upregulated in the presence 
of both HPV16 and HPV18; there was a ~4-fold increase in PTPN13 mRNA in HPV16 
containing cells, and an ~8- (Donor 1) and ~3- (Donor 2) fold increase in cells replicating 
HPV18 (Figure 3.4 E). 
Transcriptional analysis was extended to the E6 PBM targets MAGI-1, -2 and -3, which 
encode junctional complex components. MAGI-1 transcription was unchanged in HPV16 
genome containing cells, although transcript levels were decreased in HPV18 genome 
containing cells to approximately half the levels of untransfected, in both donor 
keratinocytes (Figure 3.5 A). By contrast, a more than 3-fold increase in MAGI-2 
transcription was observed in the presence of both HPV types analysed and the 
transcription of MAGI-3 remains unchanged by high-risk HPV replication (Figure 3.5 B 
and C).  
Cumulatively, when averaged across donor keratinocyte backgrounds, there is a significant 
increase in the transcription of selected E6 targets in both HPV16 and HPV18 genome 
containing cells (Figure 3.6). The targets DLG1, PATJ, MAGI-2, NHERF1 and PTPN13 
are increased transcriptionally in the presence of both high-risk α-HPV genotypes, 
although to different extents. The largest increase in transcription was seen for the DLG1 
Figure 3.5: Quantification of  MAGI-1, MAGI-2 and MAGI-3 transcription 
in HPV16 and HPV18 genome-containing keratinocytes 
Transcription analysis of  MAGI-1 (A), MAGI-2 (B) and MAGI-3 (C) genes. 
mRNA was extracted from primary foreskin keratinocytes following establishment 
of  stable lines containing HPV16 or HPV18 genomes, alongside untransfected 
keratinocytes at passage 3 (P3). The mRNA was transcribed to cDNA and levels 
were measured by qRTPCR. ΔCt values were first were calculated relative to the 
housekeeping gene β2-microglobulin, and then to untransfected keratinocytes 
(ΔΔCt) derived from the same donor background (indicated by dotted line). Error 
bars show ±SEM of  three experimental repeats, statistical significance indicated by 
* (p<0.05) and ** (p<0.01).  
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Figure 3.6: Cumulative qRTPCR analysis PDZ targets of  E6 expression in 
HPV genome containing HFKs 
Transcription of  E6 PDZ targets in HPV16 and HPV18 genome containing 
keratinocytes as measured by qRTPCR, in two donor backgrounds. Transcription 
of  DLG1, SCRIB, PATJ, NHERF1, PTPN13, MAGI-1, MAGI-2 and MAGI-3 
were averaged following normalization to untransfected HFKs (dotted line). Error 
bars show ± SEM of  three repeats in two donors. **indicates p<0.01, * indicates 
p<0.05. 
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gene in HPV16 positive cells (20-fold), with a similarly large (16-fold) increase in PATJ 
transcription in the same cells. In both HPV16 and HPV18 positive keratinocytes, the 
transcription of these targets, and of NHERF1 and PTPN13, was increased in HPV18 
containing keratinocytes. Notably, the transcription of both SCRIB and MAGI-3 remained 
unaffected by both HPV genotypes (Figure 3.6). Interestingly, MAGI-1 transcription 
decreases in the presence of HPV18, whilst remaining unaffected by HPV16 (Figure 3.6).  
To establish whether the increase in transcription of selected PDZ targets is maintained 
upon cell propagation, qRTPCR was performed on RNA extracted from the cells after a 
further five population doublings (P4). The profile of change in the level of transcripts in 
comparison to the untransfected cells remained the same as found in cells grown to P3 
(Figure 3.7, summarized in Table 3.4). The expression of PATJ, NHERF1 and PTPN13 
remained elevated across the population doublings analysed, with PATJ showing a trend 
towards a further increase in mRNA transcripts in the later passage. 
Table 3.3: Summary of PDZ target qRTPCR analysis 
Gene 
Fold change in expression 
HPV16B HPV16K HPV18 
p3 p4 p3 p4 p3 p4 
DLG1 17.56 17.05 21.45 20.47 5.70 7.12 
SCRIB 2.39 2.30 2.39 2.18 1.55 1.63 
PATJ 12.73 18.06 14.21 14.67 7.87 9.46 
NHERF1 4.74 4.35 5.58 5.33 5.29 4.84 
PTPN13 3.70 5.57 4.31 5.31 6.06 6.72 
MAGI-1 - 2.82 - 1.35 - 0.51 
MAGI-2 - 3.66 - 3.72 - 3.34 
MAGI-3 - 2.13 - 1.79 - 2.53 
Average of two donors. Fold change calculated relative to levels of transcription in HFKs derived from the 
same donor. 
 
To investigate the contribution of the E6 PBM binding function with respect to PDZ 
target gene expression, qRTPCR gene expression analysis was carried out on monolayer 
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Figure 3.7: Quantification of  E6-PDZ target transcription in HPV16 and 
HPV18 genome containing keratinocytes following cell propagation 
Transcription analysis of  DLG1 (A), SCRIB (B), PATJ (C), NHERF1 (D) and 
PTPN13 (E) genes. mRNA was extracted from primary foreskin keratinocytes 
following passage (p4) of  stable lines containing HPV16 or HPV18 genomes in 
two donor backgrounds. mRNA levels were measured in HPV16 and HPV18 
positive keratinocytes, alongside untransfected cells, by qRTPCR. ΔCt values were 
first were calculated relative to the housekeeping gene β2-microglobulin, and then 
to untransfected keratinocytes (ΔΔCt) derived from the same donor background 
(indicated by dotted line). Error bars show ±SEM of  three experimental repeats, 
statistical significance indicated by * (p<0.05) and ** (p<0.01).  
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keratinocytes containing wild-type HPV18 genomes (WT), or the genomes containing a 
PBM deletion (ΔPDZ) or the PKA unresponsive genome ΔPKA. In this analysis, gene 
expression in two donors was carried out and calculated relative to transcript levels in wild-
type genome containing keratinocytes of the same donor background (Figure 3.8). There 
were no significant changes in the transcription of DLG1, SCRIB, PATJ, NHERF1, 
PTPN13, MAGI-1 MAGI-2 or MAGI-3 in both mutant lines (Figure 3.8). These data 
indicate that changes in PBM activity are not linked to the transcriptional change observed 
for selected PDZ proteins. 
In summary, the upregulation of selected PDZ targets in HPV16 and HPV18 observed in 
microarray analysis was confirmed by qRTPCR (Table 3.4). The two donor cell lines 
exhibited a consistent trend towards increased gene expression in the presence of both 
high-risk HPV genomes, which was calculated as significant compared to HFK gene 
expression. Notably, in the presence of both viral genotypes, transcripts of DLG1 were 
substantially increased and SCRIB transcript levels remained largely unchanged.  
Table 3.4: Comparison of microarray and qRTPCR analyses 
Gene 
Average fold change in expression 
HPV16B HPV16K HPV18 
Microarray qRTPCR Microarray qRTPCR Microarray qRTPCR 
DLG1 11.67 17.56 10.01 21.45 7.50 5.70 
SCRIB 1.57 2.39 1.12 2.39 2.01 1.55 
PATJ 4.47 12.73 4.04 14.21 2.58 7.87 
NHERF1 1.54 4.74 1.97 5.58 1.86 5.29 
PTPN13 4.22 3.70 7.45 4.31 4.40 6.06 
MAGI-1 2.82 - 3.53 1.35 3.63 0.51 
MAGI-2 3.66 - -1.28 3.72 2.58 3.34 
MAGI-3 2.13 - 1.71 1.79 1.57 2.53 
MAGI-1 transcripts below detectable level of microarray probe. qRTPCR shows average of 2 donors. 
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Figure 3.8: Quantification of  E6-PDZ target transcription in HPV18 
genome containing keratinocytes 
Transcription of  DLG1 (A), SCRIB (B), PATJ (C), NHERF1 (D) and PTPN13 (E) 
genes in primary keratinocytes replicating HPV18 genomes. mRNA extracted 
from HPV18 encoding wild-type (WT), ΔPDZ or ΔPKA E6 proteins. Expression 
levels in keratinocytes containing mutant (ΔPDZ and ΔPKA) genomes were 
calculated relative to mRNA levels in WT genome containing keratinocytes (dotted 
line) derived from the same donor background. Transcription analysis of  DLG1 
(A), SCRIB (B), PATJ (C), NHERF1 (D) and PTPN13 (E) genes. Graphs show 
results from three technical repeats.  
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3.3.3 Analysis of PDZ protein expression during the HPV life cycle 
Given that the transcription of known E6 PDZ targets were altered in the presence of 
high-risk α-HPV genotypes, the next step was to investigate protein expression in the HPV 
life cycle model. In this study, seven identified targets of high-risk HPV E6 proteins 
(DLG1, SCRIB, PATJ, MAGI-1, MUPP1, NHERF1 and PTPN13) were investigated. This 
was performed alongside analysis of putative targets, suggested by recent screening 
experiments (Belotti et al., 2013, CASK, ZO-1 and ZO-2). These proteins are 
representative of proteins involved in the Scribble, Crumbs and Par epithelial junctional 
complexes, as well as in cellular signalling and scaffold organisation (Figure 1.10). 
For the initial PDZ protein analysis, HPV16 or HPV18 genome containing keratinocytes 
were cultured until they reached 70% confluency (to ensure they remained in an 
undifferentiated state) and were then harvested and solubilised in a lysis buffer containing 8 
M urea, and the protein extracts subjected to western blot analysis (see Section 2.1.4.4). 
PDZ protein expression was also examined in the HPV18 mutant genome containing 
keratinocytes, ∆PDZ and ∆PKA, and compared to wild-type HPV18 positive cells in order 
to assess whether any changes in protein expression were dependent upon the activity of 
the E6 PBM.  
Since it has been shown that specific cellular pools of some PDZ proteins are preferentially 
degraded by E6 (Massimi et al., 2004; Simonson et al., 2005; Kühne et al., 2000; Narayan et 
al., 2009; Kranjec and Banks, 2011; Latorre et al., 2005), the subcellular localisation of PDZ 
proteins was examined in the life cycle model by fractionation of the monolayer-grown 
cells. This process used a series of lysis buffers to sequentially extract the following cellular 
compartments; the cytoplasm, the membrane, the nucleus and the cytoskeleton. The 
resulting protein extracts was subjected to western blot analysis, alongside analysis of host 
cell marker proteins in order to show enrichment of each of cellular fractions; growth 
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factor receptor-bound protein 2 (GRB2) in the cytoplasm, E-cadherin in the membrane, 
p53 in the nucleus and keratin 18 (K18) in the cytoskeleton (Figure 3.9). As can be seen in 
Figure 3.9 A, the fractionation process successfully enriched for the various cellular 
compartments of monolayer-grown keratinocytes. Each marker was found predominantly 
in the expected fraction; both p53 and K18 are exclusively detected in the nucleus and 
cytoskeleton respectively. GRB2 was enriched in the cytoplasmic and membrane fractions 
and E-cadherin was predominantly detected in the membrane fraction with some protein 
present in the nuclear and cytoskeletal fractions (Figure 3.9). The enrichment of these 
proteins was consistent across the cell lines; the presence of HPV16 or 18 genomes does 
not affect their localisation, and thus the distribution of these proteins is a suitable 
indicator for successful subcellular fractionation. 
To investigate changes in PDZ protein expression during the productive phase of the virus 
life cycle, the HPV18 genome containing cells (WT and ∆PDZ) were stratified by growth 
in organotypic raft culture for 13 days (see Section 2.1). The differentiated structures were 
solubilized in urea lysis buffer and the protein extracts subjected to western blot analysis. 
Further analysis of sections of raft structures allowed the analysis of PDZ protein 
localisation during the HPV life cycle by immunofluorescent staining for PDZ targets. 
Thus, the following analysis examined known and indicated targets of high-risk HPV E6 
proteins, proteins involved in the epithelial junction complexes, Scribble, Par and Crumbs, 
each of which contain known targets of E6, as well as PDZ-proteins involved in cellular 
signalling.  
AF1, Cytoplasm   
F2, Membrane   
F3, Nucleus   
F4, Cytoskeleton
  0%
25%
50%
75%
100%
HF
K
HP
V1
6
HP
V1
8
HF
K
HP
V1
6
HP
V1
8
HF
K
HP
V1
6
HP
V1
8
HF
K
HP
V1
6
HP
V1
8
GRB2 E cadherin p53 K18
Pr
op
or
tio
n 
of
 p
ro
te
in
F1 F2 F3 F4 F1 F2 F3 F4 F1 F2 F3 F4
HPV18HPV16HFK
K18
E cadherin
GRB2
p53
25
80
50
50
40
Figure 3.9: Confirmation of  successful enrichment of  protein from 
subcellular fractions 
Subcellular fractionation was carried out on monolayer-grown keratinocytes at 
70% confluency. Protein from subcellular fractions was extracted by treatment 
with sequential lysis buffers. Successful enrichment was confirmed by western blot 
analysis; detection of  the marker proteins GRB2, E-cadherin, p53 and K18 
indicate enrichment of  the cytoplasmic, membrane, nuclear and cytoskeletal 
fractions, respectively. The cell lines containing HPV16 and HPV18 (A) and 
HPV18 PBM mutants (B) were subject to fractionation in parallel. Western blots 
were quantified by densitometry using ImageJ software. Figures representative of  
three experimental repeats carried out on cells derived from two donor 
backgrounds. 
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3.3.3.1 The Scribble complex 
3.3.3.1.1 DLG1 
Despite the increase in transcription of the DLG1 gene, there was no change in DLG1 
protein levels in HPV18 genome containing keratinocytes (Figure 3.10 A). Moreover, 
deletion of the E6 PDZ binding function (ΔPDZ) did not impact upon DLG1 protein 
levels (Figure 3.10 B). Furthermore, altering the E6 sequence to encode a constitutively 
active PBM, via removal of the PKA recognition site (ΔPKA), also had no affect upon the 
level of DLG1 protein (Figure 3.10 B). In the HPV18-positive cancer cell line HeLa, there 
was a 70% decrease in DLG1 protein levels, compared to normal keratinocytes (Figure 
3.10 A), indicating differences between the life cycle model and a late stage carcinogenesis 
cell line. In HPV16 genome containing cells, there was a subtle trend towards a decrease in 
DLG1 protein; in two donors DLG1 protein was 0.7 and 0.8 times the level of 
untransfected cells (Figure 3.10 A). Taken together, no extensive change in protein levels 
was observed in these cells. 
Subcellular fractionation of monolayer grown cells detected the majority of DLG1 in the 
nucleus of primary keratinocytes (Roberts et al., 2007), although the protein was also 
strongly detected in the membrane and weakly detected in the cytoskeleton and cytoplasm 
(Figure 3.11 A). Subcellular distribution of DLG1 protein remained unaffected by the 
presence of HPV16 or HPV18 genomes (Figure 3.11 A), and changes in the activity of the 
E6 PBM did not affect the distribution of DLG1 between subcellular pools (Figure 3.11 
B). The distribution of DLG1 was verified using two antibodies specific for DLG1, a 
mouse monoclonal antibody (2D11) and a polyclonal antibody (NAG, Watson et al., 2002), 
which were raised to different N-terminal regions of DLG1.  
During epithelial differentiation, the subcellular localisation of DLG1 changes (Roberts et 
al., 2007), and so analysis of DLG1 was applied to differentiating keratinocytes. To 
Figure 3.10: DLG1 protein expression in keratinocytes replicating HPV 
genomes 
DLG1 protein levels in keratinocytes containing HPV16 and 18 genomes (A) and 
mutant HPV18 genomes (B). Protein was extracted from cells grown in monolayer 
culture to 70% confluency, quantified by Bradford assay and separated by SDS-
PAGE. Membranes were probed with mouse monoclonal antibody raised against 
DLG1 (2D11), and β-actin as a loading control. Figures representative of  two 
repeats. Western blots were quantified by densitometry using ImageJ software. 
Graphs show relative levels, first normalised to β-actin and then to HFK (A) or 
WT (B) levels. Representative of  two experimental repeats. Markers show 
molecular weight in kDa. 
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Figure 3.11: DLG1 protein distribution in keratinocytes  
Distribution of  DLG1 in keratinocytes containing HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Subcellular 
fractionation was carried out on keratinocytes at 70% confluency. The cytoplasmic, 
membrane, nuclear and cytoskeletal fractions fractions were extracted by treatment 
with sequential lysis buffers, an equal amounts separated by SDS-PAGE. 
Membranes were probed with mouse monoclonal (2D11) or rabbit polyclonal 
(NAG) antibody raised against DLG1, Western blots were quantified by 
densitometry using ImageJ software. Figures representative of  three experimental 
repeats carried out on cells derived from two donor backgrounds. 
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determine if HPV affects DLG1 during stratification, HPV18 genome containing 
keratinocytes were grown in organotypic raft culture and protein was extracted in urea lysis 
buffer (Section 2.1). Detection of DLG1 with the mouse monoclonal antibody 2D11 
indicated a decrease in DLG1 protein where the E6 PDZ binding function was removed, 
compared to cells containing the wild-type HPV18 genome (Figure 3.12). However, 
detection with the NAG antibody indicated no change in DLG1 protein levels in 
differentiated keratinocytes irrespective of E6 PBM function (Figure 3.12). 
Both the 2D11 and NAG antibodies were utilized in analysis of DLG1 localization in 
stratified keratinocytes by immunofluorescence (Figure 3.13). Using both antibodies, 
immunofluorescent staining of raft cultures showed DLG1 located predominantly at the 
cell junctions in the upper layers of HFKs, with a more cytoplasmic form detected in the 
basal layer (Figure 3.13). In HPV18 containing keratinocytes, the cell-cell location of 
DLG1 occurred earlier in the stratification of HPV18 genome containing cells, although 
this was more obvious when using 2D11 to detect DLG1 compared to NAG (Figure 3.13). 
3.3.3.1.2 SCRIB 
While levels of SCRIB protein in keratinocytes containing HPV16 were comparable to 
HFKs, in HPV18 positive cells SCRIB protein increased by approximately 40%, and this 
was consistent between both donors (Figure 3.14 A). In contrast, the polarity protein is 
depleted by 20% in the HPV18 DNA-positive cervical cancer cell line HeLa, compared to 
primary foreskin keratinocytes (Figure 3.14). Interestingly, the observed change on SCRIB 
expression is unrelated to the HPV18 PDZ binding function, as removal of the PBM 
(ΔPDZ) or altering the PKA recognition site (ΔPKA) does not restore the SCRIB protein 
levels to the level found in primary keratinocytes (Figure 3.14 B). 
The localisation of SCRIB, in HPV16 and HPV18 positive keratinocytes as well as in 
normal cells, was predominantly cytoplasmic, nuclear and cytoskeletal (Figure 3.15 A). A 
Figure 3.12: DLG1 protein in differentiated keratinocytes containing HPV18 
genomes  
Keratinocytes containing wild-type (WT) HPV18 genomes or HPV18 encoding an 
E6 without a PBM (ΔPDZ) were grown in organotypic raft culture. After 13 days, 
the raft was harvested, homogenised and lysed in order to extract protein. Protein 
was separated by SDS-PAGE and membranes were probed with mouse 
monoclonal (2D11) or rabbit polyclonal (NAG) antibody raised against DLG1, 
alongside GAPDH as a loading control. Western blots were quantified by 
densitometry using ImageJ software. Graphs show relative levels, first normalised 
to GAPDH and then to WT levels. Figures representative of  two technical repeats. 
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Figure 3.13: Immunofluorescence of  DLG1 in differentiated keratinocytes  
Immunofluorescent staining of  keratinocytes grown in organotypic raft culture. 
Raft cultures were grown for 13 days, harvested and paraformaldehyde 
fixed.Individual sections were cut and stained for DLG1 using 2D11 (A, green) or 
NAG (B, red) antibodies. The nucleus stain DAPI (blue) was also used. Images 
were taken at 40x magnification. 
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Figure 3.14: SCRIB protein levels in HPV genome containing keratinocytes 
SCRIB protein levels in keratinocytes containing WT HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Protein was 
extracted from cells grown in monolayer culture to 70% confluency, quantified by 
Bradford assay assay and separated by SDS-PAGE. Membranes were probed with 
goat polyclonal antibody raised against SCRIB, and β-actin as a loading control. 
Representative of  two repeats. Western blots were quantified by densitometry 
using ImageJ software. Graphs show relative levels, first normalised to β-actin and 
then to HFK (A) or WT (B) levels. 
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subtle change in protein levels was observed in HPV16 genome containing cells, indicating 
an increase in SCRIB at the cytoskeleton and a decrease in the nuclear fraction, but this 
was not consistently observed. This distribution is maintained in the presence of HPV18 
genomes encoding E6 proteins with modified PBM binding activity (Figure 3.15 B).  
Following differentiation of the HPV18 genome containing cells in organotypic raft 
culture, SCRIB protein levels decrease upon abrogation of PDZ binding (Figure 3.16). This 
was trend seen in two donors; in one case there was an almost 50% decrease in protein in 
the presence of ΔPDZ genomes compared to wild-type HPV18 genomes (Figure 3.16). 
Like DLG1, immunofluorescent staining of differentiated keratinocytes indicated that 
SCRIB protein becomes increasingly at the cell periphery as keratinocytes migrate upwards, 
with basal cells exhibiting a predominantly nuclear pattern of SCRIB expression (Figure 
3.17). Compared to untransfected keratinocytes, stratified cells containing HPV18 genomes 
exhibited a more obvious junctional location of SCRIB protein, which occurred in the mid 
layers of the epithelia (Figure 3.17). 
In summary, DLG1 and SCRIB exhibited no marked alterations in protein level or 
subcellular distribution in the presence of HPV16 or HPV18 genomes in monolayer grown 
primary human keratinocytes. An increase in SCRIB protein in the presence of HPV18 was 
not restored by removal of the PBM, although in differentiating cells, the levels of both 
proteins decreased in cells containing HPV18 genomes expressing E6 without a PBM. In 
differentiated culture, the location of SCRIB and DLG1 at the periphery of cells in the 
upper layers is altered in the presence of HPV18 and expression is increased in the mid-
layers. 
3.3.3.1.3 CASK 
CASK is known to interact with DLG1 in epithelia (Nix et al., 2000), and has been 
observed by the Roberts lab to co-immunoprecipitate with DLG1 in human keratinocytes 
Figure 3.15: Distribution of  SCRIB in monolayer keratinocytes 
Distribution of  SCRIB in keratinocytes containing HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Subcellular 
fractionation was carried out on keratinocytes at 70% confluency. The cytoplasmic, 
membrane, nuclear and cytoskeletal fractions fractions were extracted by treatment 
with sequential lysis buffers, an equal amounts separated by SDS-PAGE. 
Membranes were probed with goat polyclonal antibody raised against SCRIB, 
Western blots were quantified by densitometry using ImageJ software. 
Representative of  two donors, each repeated three times. 
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Figure 3.16: SCRIB protein in differentiated keratinocytes containing 
HPV18 genomes  
Keratinocytes containing wild-type (WT) HPV18 genomes or HPV18 encoding an 
E6 without a PBM (ΔPDZ) were grown in organotypic raft culture. After 13 days, 
the raft was harvested, homogenised and lysed in order to extract protein. Protein 
was separated by SDS-PAGE and membranes were probed with goat polyclonal 
antibody raised against SCRIB, alongside GAPDH as a loading control. Western 
blots were quantified by densitometry using ImageJ software. Graphs show relative 
levels, first normalised to GAPDH and then to WT levels. Representative of  two 
technical repeats. 
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Figure 3.17: SCRIB distribution in differentiated keratinocytes 
Immunofluorescent staining of  keratinocytes grown in organotypic raft culture. 
Raft cultures were grown for 13 days, harvested and paraformaldehyde fixed. 
Individual sections were cut and stained for SCRIB (green) and the nucleus stained 
with DAPI (blue). Images were taken at 40x magnification. 
 
SCRIBDAPI Merge
HPV18
HFK
CHAPTER 3: THE INVESTIGATION OF PDZ PROTEIN EXPRESSION DURING THE HPV LIFE CYCLE 
-114- 
(S Roberts, personal communication). Furthermore, the protein sequence exhibits 25% 
sequence homology to DLG1 and is suggested to associate with the HPV16 PBM in yeast-
two hybrid screening experiments (Belotti et al., 2013). To assess whether CASK protein 
expression was affected by HPV16 or HPV18, lysates isolated from monolayer cultures 
were western blotted for CASK protein. There was no alteration in the CASK protein 
levels in keratinocytes containing HPV18 (Figure 3.18 A). Furthermore, removal or 
alteration of the HPV18 PDZ binding ability did not produce any effect upon CASK 
protein (Figure 3.18 A). Next, the distribution of CASK was analysed (Figure 3.18 B and 
C). CASK was detected predominantly in the membrane and the nucleus in untransfected 
keratinocytes, with a small amount present in the cytoplasmic and cytoskeleton fractions of 
the cell (Figure 3.18 B and C). This subcellular distribution was not perturbed by the 
presence of HPV16 or HPV18, nor by alteration in the activity of the E6 PBM (Figure 
3.18). 
3.3.3.2 Crumbs complex 
3.3.3.2.1 PATJ 
In this analysis, the levels of PATJ protein remained constant in HPV16 and HPV18 
positive keratinocytes, compared to untransfected cells. Protein levels remained the same in 
the cancer cell line HeLa as primary keratinocytes (Figure 3.19 A). Furthermore, perturbing 
the PDZ binding function of E6 had no effect on protein levels compared to wild-type 
HPV18 genome containing cells (Figure 3.19 B). (Storrs and Silverstein, 2007) 
demonstrated that the truncated spliced form of E6, E6*, was able to induce PATJ 
degradation, indicating that the effects of E6 on this oncoprotein is PBM independent 
(Storrs and Silverstein, 2007). However, this analysis did not find any overwhelming change 
in PATJ in monolayer grown keratinocytes (Figure 3.20). The expression of adenovirus E4-
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Figure 3.18: CASK protein level and distribution in monolayer grown 
keratinocytes 
(A)  Total protein was extracted from monolayer grown keratinocytes containing 
WT, ΔPDZ or ΔPKA HPV18 genomes, alongside HFKs and seperated by 
SDS PAGE. Representative of  two repeats. 
(B)  Distribution of  CASK in keratinocytes containing HPV16 and 18 genomes 
(C)  Distribution of  CASK protein in keratinocytes containing HPV18 WT and 
mutant genomes 
Cells for B and C were grown in monolayer culture. Subcellular fractionation was 
carried out on keratinocytes at 70% confluency. The cytoplasmic, membrane, 
nuclear and cytoskeletal fractions fractions were extracted by treatment with 
sequential lysis buffers, an equal amounts separated by SDS-PAGE.  
In all cases, membranes were probed with rabbit polyclonal antibody raised against 
CASK. Western blots were quantified by densitometry using ImageJ software. 
Markers show molecular weight in kDa. Representative of  two donors, each 
repeated three times. 
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Figure 3.19: PATJ protein levels in HPV genome containing keratinocytes 
PATJ protein levels in keratinocytes containing WT HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Protein was 
extracted from cells grown in monolayer culture to 70% confluency, quantified by 
Bradford assay and separated by SDS-PAGE. Membranes were probed with rabbit 
polyclonal antibody raised against PATJ, and β-actin as a loading control. 
Representative of  two repeats. Western blots were quantified by densitometry 
using ImageJ software. Markers show molecular weight in kDa. 
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Figure 3.20: Distribution of  PATJ in monolayer keratinocytes 
Distribution of  PATJ in keratinocytes containing HPV16 and 18 genomes (A) and 
mutant HPV18 genomes (B) grown in monolayer culture. Representative of  two 
donors and three repeats. Subcellular fractionation was carried out on 
keratinocytes at 70% confluency. The cytoplasmic, membrane, nuclear and 
cytoskeletal fractions fractions were extracted by treatment with sequential lysis 
buffers, an equal amounts separated by SDS-PAGE. Membranes were probed with 
rabbit polyclonal antibody raised against PATJ. Markers show molecular weight in 
kDa.  
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ORF1 has been shown to cause mislocalisation of PATJ (Latorre et al., 2005), but it is not 
known whether expression of E6 similarly affects the localisation of PATJ protein. Thus, 
the distribution of PATJ was investigated in monolayer keratinocytes containing HPV 
genomes (Figure 3.20). During this analysis multiple bands were detected in all the 
fractions isolated (Figure 3.20). Five isoforms of PATJ have been identified, with molecular 
weights ranging between 125 to 196 kDa (Roh et al., 2002; Philipp and Flockerzi, 1997; 
Soejima et al., 2001). It may be that the bands detected by this western blot analysis 
correspond to PATJ variants; however, the results were inconsistent and therefore 
inconclusive.  
3.3.3.3 The Par complex and other tight junction components 
3.3.3.3.1 PARD3 
Western blot detection of PARD3 revealed an increase in the level of protein, in both 
monolayer and differentiated keratinocytes replicating HPV18 (Figure 3.21 A and D). In 
organotypic raft culture, a decrease in PARD3 was observed in the cells containing the 
HPV18 ΔPDZ mutant genomes, suggesting a role for the E6 PBM in stability of the PDZ 
protein, although this was not the case in cells grown monolayer culture (Figure 3.21 A and 
D). In HeLa cells, the level of PARD3 was similar to HFK (Figure 3.21 A). A recent study 
has shown that HPV18 E6 causes a PBM-dependent change in PARD3 localisation, but 
not proteins levels (Facciuto et al., 2014). However, analysis of subcellular distribution 
showed no alteration in distribution of PARD3 in the viral genome containing cells; 
PARD3 remained predominantly nuclear and cytoskeletal, with some cytoplasmic forms 
(Figure 3.21 B and C). PARD3 exists as several isoforms, ranging from 100 to 200 kDa 
(Jan et al., 2013). Interestingly, PARD3 was detected as a doublet in protein from both 
HFK and HeLa cells, whereas only a single form of PARD3 was detected in HPV genome 
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Figure 3.21: PARD3 protein levels and distribution in primary keratinocytes 
(A) Total protein in monolayer grown keratinocytes, representative of  two 
experimental repeats. 
(B) Subcellular distribution in untransfected, HPV16- and HPV18-containing 
keratinocytes grown in monolayer. 
(C) Subcellular distribution in HPV18 mutant genome containing cells grown in 
monolayer. 
F1, cytoplasmic; F2, membrane; F3, Nuclear; F4, cytoskeletal. Blots representative 
of  three repeats in two donors. 
(D) Total protein levels in keratinocytes grown in organotypic raft culture, 
representative of  two technical repeats. Densitometry shows quantifiction of  
protein in WT and ΔPDZ genome containing cells. 
All blots probed with rabbit polyclonal antibody raised against PARD3. Markers 
show molecular weight in kDa. 
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replicating cells (Figure 3.21 A). Similarly, PARD3 was detected as multiple bands in 
fractionation analysis, which made quantification difficult but indicated that more PARD3 
variants were present in the nucleus and cytoskeleton in all keratinocytes investigated.  
3.3.3.3.2 MAGI-1  
Although MAGI-1 was difficult to detect by western blotting, there is a slight increase in 
protein levels in undifferentiated HPV18 genome containing keratinocytes, but this was not 
reinforced in analysis of differentiated cells (Figure 3.22). Upon subcellular differentiation 
fractionation, the protein exhibited a membrane, nuclear and cytoskeleton distribution in 
all the primary cells analysed and this trend was largely unaffected by replication of the two 
high-risk genomes (Figure 3.22). 
3.3.3.3.3 MUPP1 
MUPP1 protein levels were increased in HPV18 genome containing cells, and this increase 
was independent of the activity of the E6 PBM (Figure 3.23 A). MUPP1 protein was 
detected mainly in nuclear and cytoskeletal fractions, with minor expression in the 
cytoplasm and membrane (Figure 3.23 B and C). The distribution was largely unaffected by 
the viral genomes (Figure 3.23 D).  
3.3.3.3.4 ZO-1 
Although no change in ZO-1 protein levels was observed in the presence of HPV16 
genomes, levels of ZO-1 protein increased in HPV18 genome containing cells (Figure 3.24 
A). This increase may be related to E6 PBM activity; in monolayer cells, a subtle decrease 
was observed when ZO-1 protein was quantified in cells containing genomes where the E6 
PDZ binding function is deleted (ΔPDZ or ΔPKA, Figure 3.24 B). A subtle effect of the 
E6 PBM on ZO-1 levels is also observed in raft cultures of E6ΔPDZ cells (Figure 3.25). 
However, the observed increase in protein does reflect a change in the distribution of ZO-
1 (Figure 3.26). Fractionation indicated that ZO-1 resides mainly in the nucleus and 
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Figure 3.22: MAGI-1 protein levels and distribution in primary keratinocytes 
(A) Total MAGI-1 protein in monolayer grown keratinocytes. Representative of  
two repeats. 
(B) Subcellular distribution of  MAGI-1 in untransfected, HPV16- and HPV18- 
containing keratinocytes.  
(C) Subcellular distribution of  MAGI-1 in HPV18 mutant genome containing 
cells. F1, cytoplasmic; F2, membrane; F3, Nuclear; F4, cytoskeletal.  
B and C representative of  three repeats in two donors. Cells grown to 70% 
confluency before protein extraction, and blots probed with rabbit polyclonal 
antibody raised against MAGI-1. Markers show molecular weight in kDa.  
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Figure 3.23: MUPP1 protein levels and distribution in primary keratinocytes 
(A) MUPP-1 protein in monolayer grown keratinocytes. Representative of  two 
repeats.  
(B) MUPP1 subcellular distribution in untransfected, HPV16- and HPV18- 
containing keratinocytes 
(C) Subcellular distribution of  MUPP1 in HPV18 mutant genome containing cells. 
F1, cytoplasmic; F2, membrane; F3, Nuclear; F4, cytoskeletal. Markers show 
molecular weight in kDa.  
B and C representative of  three repeats in two donors. Cells grown to 70% 
confluency before protein extraction, and blots probed with rabbit polyclonal 
antibody raised against MAGI-1. Markers show molecular weight in kDa.  
Figure 3.24: ZO-1 protein levels in HPV genome containing keratinocytes 
Total ZO-1 protein in keratinocytes containing HPV16 and 18 genomes (A) and in 
keratinocytes containing mutant HPV18 genomes (B). Protein was extracted from 
cells grown in monolayer culture to 70% confluency, quantified by Bradford assay 
and separated by SDS-PAGE. Membranes were probed with mouse monoclonal 
antibody raised against ZO-1, and β-actin as a loading control. Representative of  
two repeats. Western blots were quantified by densitometry using ImageJ software. 
Graphs show relative levels, first normalised to β-actin and then to HFK (A) or 
WT (B) levels. 
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Figure 3.25: ZO-1 protein in differentiated keratinocyte culture 
Total ZO-1 protein in keratinocytes grown in organotypic raft culture. Cells 
containing wild-type HPV18 (WT) genomes or genomes encoding E6 where the 
PBM is deleted (ΔPDZ) were stratified for 13 days and total protein extracted in 
urea buffer. Separated protein was probed for ZO-1, alongside GAPDH as a 
loading control. Representative of  two technical repeats. Western blots was 
quantified using ImageJ and fold change calculated relative to to WT levels. 
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associated with the cytoskeleton of keratinocytes, and that this situation is unperturbed by 
mutation of the HPV18 E6 PBM (Figure 3.26 B). A number of ZO-1 variants become 
apparent in subcellular fractionation analysis, and the distribution of these may be altered 
by the presence of HPV genomes, for example, the lower band detected in the cytoskeletal 
fraction is absent where HPV18 genomes are able to constitutively bind to PDZ proteins 
(Figure 3.26 B). However, as with PATJ and MAGI-1, this makes a conclusion difficult.  
The distribution of ZO-1 was assessed in sections of differentiated keratinocytes, where 
expression was most apparent at the periphery of cells residing in the upper layers (Figure 
3.27). However, in the presence of HPV18 genomes, expression of ZO-1 was more evenly 
spread across the layers of cells and the protein concentrates at regions of the membrane 
(Figure 3.27). Alteration of PBM activity restored the HFK phenotype in part; protein was 
located at the cell membrane in the upper layers of differentiated cells in the presence of 
ΔPDZ genomes, suggesting that the effect of HPV18 upon ZO-1 is PBM-dependent 
(Figure 3.27).  
3.3.3.3.5  ZO-2 
Similarly to ZO-1, ZO-2 protein levels are slightly increased in keratinocytes in the 
presence of HPV18 genomes compared to untransfected cells, but the change is not PBM 
dependent (Figure 3.28). In raft cultures, the level of ZO-2 in ΔPDZ genome containing 
cells was less than cells containing wild-type genomes (Figure 3.28 B). More apparent is the 
decrease in ZO-2 in the presence of HPV16 genomes (Figure 3.28 A). In cultured epithelial 
cells, HPV16 E6 expression has been shown to cause ZO-2 relocalisation to the nucleus 
and cytoplasm from cell borders (Hernandez-Monge et al., 2013). In this study of ZO-2 
cellular distribution, in viral genome containing cells, ZO-2 was detected consistently in the 
membrane, nuclear and cytoskeletal fraction (Figure 3.29). An increase in ZO-2 protein 
was observed in the nuclear fraction of cells containing PBM-deletion mutants, and in 
Figure 3.26: Distribution of  ZO-1 in monolayer keratinocytes 
Distribution of  ZO-1 in keratinocytes containing HPV16 and 18 genomes 
(A) and mutant HPV18 genomes (B) grown in monolayer culture. 
Representative of  two donors and three repeats. Subcellular fractionation 
was carried out on keratinocytes at 70% confluency. The cytoplasmic (F1), 
membrane (F2), nuclear (F3) and cytoskeletal (F4) fractions fractions were 
extracted by treatment with sequential lysis buffers, an equal amounts 
separated by SDS-PAGE. Membranes were probed with mouse monoclonal 
antibody raised against ZO-1. Representative of  three repeats of  two 
donors.  
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Figure 3.27: ZO-1 distribution in differentiated keratinocytes 
Immunofluorescent staining of  keratinocytes grown in organotypic raft culture. 
Raft cultures were grown for 13 days, harvested and paraformaldehyde fixed. 
Individual sections were cut and stained for ZO-1 (green) and the nucleus stained 
with DAPI (blue). Images were taken at 40x magnification. 
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Figure 3.28: ZO-2 protein levels in HPV genome containing keratinocytes 
ZO-2 protein levels in keratinocytes containing WT HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Protein was 
extracted from cells grown in monolayer culture to 70% confluency, quantified by 
Bradford assay and separated by SDS-PAGE. Membranes were probed with rabbit 
polyclonal antibody raised against ZO-2, and β-actin as a loading control. 
Representative of  two repeats. Western blots were quantified by densitometry 
using ImageJ software. Graphs show relative levels, first normalised to β-actin and 
then to HFK (A) or WT (B) levels. 
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Figure 3.29: Distribution of  ZO-2 protein in monolayer keratinocytes 
Distribution of  ZO-2 in keratinocytes containing HPV16 and 18 genomes (A) and 
mutant HPV18 genomes (B) grown in monolayer culture. Representative of  two 
donors and three repeats. Subcellular fractionation was carried out on 
keratinocytes at 70% confluency. The cytoplasmic, membrane, nuclear and 
cytoskeletal fractions fractions were extracted by treatment with sequential lysis 
buffers, an equal amounts separated by SDS-PAGE. Membranes were probed with 
rabbit polyclonal antibody raised against ZO-2. Western blots were quantified by 
densitometry using ImageJ software. 
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HFKs, indicating a PBM-dependent effect upon ZO-2 distribution by HPV. However, 
analysis of differentiated cells revealed no change in ZO-2 protein levels in the presence of 
HPV18 (Figure 3.30).  
3.3.3.4 Signalling proteins 
3.3.3.4.1 NHERF1 
The expression of NHERF1 protein is unaffected by the presence of HPV16 or HPV18 
episomes. Similarly, levels of the cellular PDZ protein are not affected by the activity of the 
E6 PBM (Figure 3.31). Investigation of the subcellular distribution of NHERF1 revealed 
that the pattern of NHERF1 expression is unaltered by viral genome replication (Figure 
3.32). During Western blot analysis, several forms of NHERF1 migrating at different 
molecular weights were identified (Figure 3.32). These are likely to correspond to hypo and 
hyper-phosphorylated forms of the protein (He et al., 2001). NHERF1 protein was 
predominantly detected in the cytoplasm, but was also present at the membrane and 
nuclear fractions (Figure 3.32). A potential hypophosphorylated form of NHERF1 is 
predominantly detected in the cytoskeletal compartment, detected as a faster migrating 
polypeptide (Figure 3.32 He et al., 2001). Although high-risk viruses had no effect to report 
upon NHERF1 protein levels in monolayer culture or differentiated cells compared to 
untransfected cells, levels of NHERF1 protein increased (by 2-fold) in cells upon loss of 
E6 PBM activity (Figure 3.33). Further investigation by immunofluorescent staining of 
differentiated culture sections revealed that, whereas low levels of NHERF1 protein was 
detected throughout differentiated HFKs, in the presence if HPV18 NHERF1 levels 
remained low in the basal layer but expression was increased in the mid and upper layers 
(Figure 3.34). A similar phenotype was observed in the absence of the E6 PBM, although 
the protein is more obviously not at the cell membranes in these sections (Figure 3.34).  
Figure 3.30: ZO-2 protein in differentiated keratinocytes 
Total ZO-2 protein in keratinocytes grown in organotypic raft culture. Cells 
containing wild-type HPV18 (WT) genomes or genomes encoding E6 where the 
PBM is deleted (ΔPDZ) were stratified for 13 days and total protein extracted in 
urea buffer. Separated protein was probed for ZO-2, alongside GAPDH as a 
loading control. Representative of  two technical repeats. Western blots was 
quantified using ImageJ and fold change calculated relative to to WT levels. 
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Figure 3.31: NHERF1 protein levels in HPV genome containing 
keratinocytes 
NHERF1 protein levels in keratinocytes containing WT HPV16 and 18 genomes 
(A) and mutant HPV18 genomes (B) grown in monolayer culture. Protein was 
extracted from cells grown in monolayer culture to 70% confluency, quantified by 
Bradford assay and separated by SDS-PAGE. Membranes were probed with 
mouse polyclonal antibody raised against NHERF1, and β-actin as a loading 
control. Representative of  two repeats. Western blots were quantified by 
densitometry using ImageJ software. Graphs show relative levels, first normalised 
to β-actin and then to HFK (A) or WT (B) levels. 
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Figure 3.32: Distribution of  NHERF1 protein in monolayer keratinocytes 
Distribution of  NHERF1 in keratinocytes containing HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Representative of  
two donors and three repeats. Subcellular fractionation was carried out on 
keratinocytes at 70% confluency. The cytoplasmic (F1), membrane (F2), nuclear 
(F3) and cytoskeletal (F4) fractions were extracted by treatment with sequential 
lysis buffers, an equal amounts separated by SDS-PAGE. Membranes were probed 
with mouse monoclonal antibody raised against NHERF1. Western blots were 
quantified by densitometry using ImageJ software, quantifying the top band only. 
Figure 3.33: NHERF1 protein in differentiated keratinocytes 
Total NHERF1 protein in keratinocytes grown in organotypic raft culture. Cells 
containing wild-type HPV18 (WT) genomes or genomes encoding E6 where the 
PBM is deleted (ΔPDZ) were stratified for 13 days and total protein extracted in 
urea buffer. NHERF1 was detected alongside GAPDH as a loading control. 
Representative of  two technical repeats. Western blots was quantified using ImageJ 
and fold change calculated relative to to WT levels. 
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Figure 3.34: NHERF1 distribution in differentiated keratinocytes 
Immunofluorescent staining of  keratinocytes grown in organotypic raft culture. 
Raft cultures were grown for 13 days, harvested and paraformaldehyde fixed. 
Individual sections were cut and stained for NHERF1 (green) and the nucleus 
stained with DAPI (blue). Images were taken at 40x magnification. 
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3.3.3.4.2 PTPN13  
There was no change in PTPN13 protein levels in undifferentiated keratinocytes containing 
HPV16 or HPV18 genomes, compared to levels in the untransfected HFKs (Figure 3.35 
A). Furthermore, the protein is not perturbed in HeLa compared to normal primary 
keratinocytes (Figure 3.35 A). Abrogation of the HPV18 E6 PBM did not affect cellular 
levels of PTPN13 protein; equivalent levels of PTPN13 were observed in cells containing 
WT, ΔPDZ and ΔPKA genomes (Figure 3.35 B). Although an increase in PTPN13 in the 
membrane fraction can be observed in HPV16 genome containing keratinocytes, the 
number of potential variants detected made the analysis in genome containing cells unclear 
(Figure 3.36). In monolayer, alteration of the E6 PBM led to a higher proportion of 
PTPN13 detected in the nucleus and, in differentiated keratinocytes removal of the PBM 
caused an increase in PTPN13 protein compared to wild-type HPV18 genome containing 
cells (Figure 3.37).  
3.3.4 Proteasomal inhibition of primary keratinocytes 
In the context of cells containing the complete HPV genome, where E6 is expressed from 
its natural promoter, no decrease in PDZ protein levels has been observed, compared to 
control keratinocytes. A number of PDZ proteins, including DLG1, SCRIB, PTPN13 and 
NHERF1, have been identified as targets of high-risk α-HPVs for proteasome-mediated 
degradation, in a PBM dependent manner. Therefore, to assess the expression of these 
proteins in response to inhibition of the proteasome in the viral genome containing cells, 
cells were treated with MG132 for 4 or 6 hours, alongside cells treated with the vehicle 
DMSO. Protein was harvested in urea lysis buffer and subjected to western blot analysis as 
described in Section 2.2.4.  
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Figure 3.35: PTPN13 protein levels in HPV genome containing 
keratinocytes 
PTPN13 protein levels in keratinocytes containing WT HPV16 and 18 genomes 
(A) and mutant HPV18 genomes (B) grown in monolayer culture. Protein was 
extracted from cells grown in monolayer culture to 70% confluency, quantified by 
Bradford assay and separated by SDS-PAGE. Membranes were probed with rabbit 
polyclonal antibody raised against PTPN13, and β-actin as a loading control. 
Representative of  two repeats. Western blots were quantified by densitometry 
using ImageJ software. Graphs show relative levels, first normalised to β-actin and 
then to HFK (A) or WT (B) levels. 
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Figure 3.36: Distribution of  PTPN13 in monolayer keratinocytes 
Distribution of  PTPN13 in keratinocytes containing HPV16 and 18 genomes (A) 
and mutant HPV18 genomes (B) grown in monolayer culture. Representative of  
two donors and three repeats. Subcellular fractionation was carried out on 
keratinocytes at 70% confluency. The cytoplasmic, membrane, nuclear and 
cytoskeletal fractions fractions were extracted by treatment with sequential lysis 
buffers, an equal amounts separated by SDS-PAGE. Membranes were probed with 
rabbit polyclonal antibody raised against PTPN13 and Western blots were 
quantified by densitometry using ImageJ software. 
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Figure 3.37: PTPN13 protein in differentiated keratinocytes 
Total PTPN13 protein in keratinocytes grown in organotypic raft culture. Cells 
containing wild-type HPV18 (WT) genomes or genomes encoding E6 where the 
PBM is deleted (ΔPDZ) were stratified for 13 days and total protein extracted in 
urea buffer. Separated protein was probed for PTPN13, alongside GAPDH to 
indicate equal loading. Representative of  two technical repeats. Western blots were 
quantified using ImageJ and fold change calculated relative to to WT levels. 
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Since p53 is a known target of proteasomal degradation, both in the presence and absence 
of the E6 oncoprotein, the lysates were immunoblotted for p53. As expected, an increase 
in p53 was observed in both HFK and HPV positive cells upon addition of MG132, 
confirming that proteasomal inhibition was successful (Figure 3.38 A). A decrease in p53 
protein was observed when comparing HPV positive cells to untransfected control cells 
(Figure 3.38 B). 
In HFKs under conditions of proteasomal inhibition, DLG1 protein accumulated 
following 4 and 6 hours of inhibition, confirming that the protein is targeted for 
proteasomal degradation (Mantovani et al., 2001, Figure 3.39). By contrast, there was a 
marked decrease in the level of DLG1 protein in viral genome containing untransfected 
keratinocytes treated with proteasomal inhibitor, compared to equivalent cells treated with 
vehicle (Figure 3.39 A and B). As a junction complex protein, it was expected that DLG1 
levels would be increased in cells harvested at a higher density. However, a similar pattern 
was observed in cells harvested at a higher confluency (90% vs. 70%); levels of DLG1 
decreased following proteasomal inhibition (Figure 3.39 C and D). Intriguingly, a similar 
profile was observed for SCRIB, albeit the effect was less marked and was not specific to 
keratinocytes containing viral genomes (Figure 3.40). This response to proteasomal 
inhibition was not consistent between all PDZ proteins tested, because both NHERF1 and 
PTPN13 levels increased upon proteasomal inhibition, irrespective of the presence of HPV 
genomes (Figure 3.41). Moreover, the change in PTPN13 levels in response to MG132 in 
cells containing HPV16 genomes is not striking (Figure 3.41). 
The interaction between high-risk HPV E6 with NHERF1, SCRIB and DLG1 has been 
shown to result in proteasomal degradation of the PDZ proteins (Gardiol et al., 1999; 
Massimi et al., 2008; Accardi et al., 2011; Nakagawa and Huibregtse, 2000). However, 
treatment of primary keratinocytes with proteasomal inhibitor revealed that the presence of 
Figure 3.38: PDZ protein levels in keratinocytes under proteasomal 
inhibition 
(A) Monolayer-grown keratinocytes containing HPV16 or HPV18 genomes were 
treated alongside HFK with vehicle (DMSO, -) or the  proteasomal inhibitor 
MG132 (+), for 4 or 6 hours before protein was extracted using a urea buffer. 
Equal amounts of  protein were separated by SDS-PAGE and p53 levels 
detected alongside β-actin loading control.  
(B)  Comparison of  untreated controls run on the same gels. Equal amounts of  
protein were separated by SDS-PAGE and p53 levels detected alongside β-
actin loading control. Representative of  three repeats in cells derived from one 
donor background. 
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Figure 3.39: DLG1 protein levels in keratinocytes under proteasomal 
inhibition 
DLG1 protein analysis of  keratinocytes treated with vehicle (DMSO, -) or 
proteasomal inhibitor MG132 (+) for four or six hours before harvesting. 
Keratinocytes containing HPV16 (A and C) or HPV18 (B and D) genomes were 
grown alongside untransfected cells to 70% (A and B) or 90% (C and D) 
confluency before treatment. DLG1 was detected using a mouse monoclonal 
antibody (2D11). Representative of  three repeats in cells derived from one donor 
background. 
Figure 3.40: SCRIB protein in keratinocytes under conditions of  
proteasomal inhibition 
SCRIB protein analysis of  keratinocytes treated with vehicle (DMSO, -) or 
proteasomal inhibitor MG132 (+) for four or six hours before harvesting. 
Keratinocytes containing HPV16 or HPV18 genomes were grown alongside 
untransfected cells to 70% confluency before treatment. SCRIB was detected using 
a goat polyclonal antibody. Representative of  three repeats in cells derived from 
one donor background. 
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Figure 3.41: NHERF1 and PTPN13 protein levels in keratinocytes under 
proteasomal inhibition 
NHERF1 and PTPN13 Protein analysis of  keratinocytes treated with vehicle 
(DMSO, -) or proteasomal inhibitor MG132 (+) for four or six hours before 
harvesting. HFKs and HPV16 or 18 genome containing keratinocytes were grown 
to 70% confluency and harvested in urea buffer. Detection of  β-actin was 
included as a loading control. Representative of  three repeats in cells derived form 
one donor background. 
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HPV genomes does not affect the proteasome-mediated degradation of E6 PDZ targets 
SCRIB, PTPN13 and NHERF1. Moreover, proteasome inhibition of primary keratinocytes 
containing high-risk HPVs had an unexpected effect upon DLG1. 
Table 3.5: Summary of PDZ protein analysis 
PDZ 
target 
Compared to untransfected 
keratinocytes 
Compared to HPV18 wild-type 
Monolayer culture Differentiated culture  
HPV16 HPV18 HeLa ΔPDZ ΔPKA ΔPDZ 
DLG1 (-) NC - NC NC - 
SCRIB NC + NC NC NC (-) 
CASK NT NT NT NC NC NT 
MAGI-1 NT (+) NT    
MUPP1 NT + NT NC NC NT 
PARD3 NT + NC NC NC - 
PATJ NC NC NC NC NC NC 
ZO-1 NC + NC (-) (-) (-) 
ZO-2 - NC NC - NC (-) 
NHERF1 NC NC NC NC NC + 
PTPN13 NC NC NC NC NC + 
+, increase; - , decrease; NC, No change; NT, not tested. Bracketed values indicate subtle changes 
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3.4 Discussion 
3.4.1 Transcriptional upregulation in the presence of HPV genomes  
Primary keratinocyte cell lines containing HPV16 or HPV18 were established and 
subjected to analysis of PDZ protein expression. The viral genomes in these lines exist as 
episomes and in monolayer the cell model is comparable to basal infected cells. Both 
microarray and qRTPCR analyses revealed that the polarity proteins DLG1 (Scribble 
complex), MAGI-2 (tight junctions) and PATJ (Crumbs complex), as well as the signalling 
proteins NHERF1 and PTPN13, were upregulated at a transcriptional level in HPV16 and 
HPV18 genome containing cells. This was in contrast to the other PDZ proteins 
investigated, SCRIB (Scribble complex) and MAGI-3 (tight-junctions), whose transcription 
was unaffected. The values of fold change were consistently higher than microarray values 
when quantified by qRTPCR, but the trend in transcriptional change was comparable. 
Differences in values between qRTPCR and microarray quantification may reflect the 
different donor backgrounds utilized, as well as being an indication of the sensitivity of 
each technique (Git et al., 2010). In the case of NHERF1 expression, only qRTPCR 
showed a significant increase in transcription. The difference in NHERF1 gene expression 
compared to work by Accardi et al. may be attributable to the presence of whole HPV16 
genomes in this study; the presence of other viral factors may, directly or via cellular 
processes, affect the transcription of E6 PDZ targets. Similarly, in identifying PTPN13 as a 
HPV16 E6 target, Spanos et al. demonstrated that the presence of HPV16 E6 does not 
affect PTPN13 mRNA levels in primary keratinocytes, whereas this thesis presents an 
upregulation of the PDZ protein in high-risk HPV genome containing keratinocytes. 
Together with our data, this suggests that a protein other than E6 acts to increase the 
transcription of PTPN13 during viral genome replication.  
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A previous study by Lazic et al. demonstrated that HPV8 and HPV16 E6 protein 
expression induced a decrease in syntenin-2 transcript levels, but the transcription of other 
known PDZ targets, including DLG1, SCRIB, MAGI-1, MAGI-3, DLG4 and MUPP1 
were unaffected, indicating that the effect of E6 upon PDZ protein transcription is 
specific. Such specificity was also observed in this study; the targets SCRIB and MAGI-3 
remain transcriptionally unaffected, whilst MAGI-1 transcription was decreased by HPV18 
only.  
By using a PBM deletion mutant, this study ruled out any effects of the motif upon 
transcriptional upregulation; altering the PDZ binding activity of HPV18 revealed 
upregulation consistent results with WT HPV18 containing cells. Thus, the study in this 
thesis is the first in-depth study to indicate that high-risk α-HPVs are able to modulate 
PDZ protein expression, independently of the E6 PBM.  
A potential viral candidate in causing the observed PDZ gene upregulation is the HPV 
protein E2. The N-terminal domain of E2 can regulate transcription from adjacent 
promoters and HPV16 has been shown to increase or decrease transcription of cellular 
genes depending upon the level of E2 protein (Bouvard et al., 1994a). A study by Gauson et 
al. identified more than 40 genes, that were downregulated and more than 30 genes, 
including the PDZ domain containing protein SNTB1, that were upregulated in cells 
expressing HPV16 E2. Thus, it is conceivable that E2 acts to upregulate selected PDZ 
targets of E6 in primary keratinocytes. Recently, E6 has been shown to be influential in 
inducing upregulation of transcription of the cytodine deaminase APOBEC3B (Vieira et al., 
2014). Both the transfection of high-risk HPV genomes and the expression of E6 alone 
induced increased transcription and further experiments showed that this was a 
characteristic of high-risk E6 proteins (Vieira et al., 2014). The authors propose that de-
repression of gene transcription occurs via the inactivation of p53 by E6. Similarly, HPV16 
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E6 has been shown to transcriptionally upregulate components of the NFκB pathway in 
cervical cells and induce upregulation of involucrin gene transcription (Gyongyosi et al., 
2012; Nees et al., 2001). Work by Vliet-Gregg et al. indicated that E6 can induce the 
transcriptional upregulation of NOTCH1 when expressed alongside the transcription 
factor NFX1-123. Thus, there is a precedent for E6 alone causing a change in gene 
transcription. 
3.4.2 Protein distribution in HPV genome containing cells 
3.4.2.1 Comparison to HeLa  
This study shows a downregulation of the junctional proteins DLG1, SCRIB, ZO-1 and 
PARD3 in the HPV18 positive cancer cell line HeLa, compared to keratinocytes, which 
corresponds with data from the Banks lab (Kühne et al., 2000). HeLa express relatively high 
levels of HPV18 E6, and are thus more able to deregulate PDZ proteins than 
keratinocytes. However, the changes cannot solely be attributed to HPV18 E6, there are 
likely many consequences of continuous cell culture, including the accumulation of somatic 
mutations. The levels of NHERF1 protein in HeLa were equivalent to the levels in 
keratinocytes, which differs from the analysis by Accardi et al., who described an increase in 
NHERF1 protein in HeLa. This may be due to the different primary keratinocytes used as 
a comparison, but also highlights the variations seen in extensively cultured cells (Castillo et 
al., 2014).  
3.4.2.2 Tight junction proteins 
The presence of high-risk HPV genomes in monolayer grown keratinocytes had no or an 
undetectable effect upon the levels or distribution of PTPN13 or PATJ proteins, or fellow 
PDZ domain containing proteins CASK PARD3, MAGI-1 and MUPP1. This latter group 
(CASK, PARD3, MAGI-1 and MUPP1), along with PATJ, registered no change in protein 
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levels in differentiated keratinocytes replicating high-risk HPV genomes, despite studies 
which have shown protein interaction (CASK, MAGI-1, MUPP1), redistribution (PARD3) 
and E6AP independent degradation (PATJ. Facciuto et al., 2014; Glaunsinger et al., 2000; 
Belotti et al., 2013; Lee et al., 2000; Storrs and Silverstein, 2007). Additionally, it has been 
shown that E6 can preferentially target PDZ proteins at particular cellular locations, and 
also that E6 is able induce cellular redistribution of PDZ proteins, something that this 
study does not replicate (Narayan et al., 2009; Massimi et al., 2004; Facciuto et al., 2014). In 
monolayer, the distribution of known and putative E6 targets remained the same in 
HPV16 and HPV18 positive and negative keratinocytes. These disparities reflect the 
differences between high throughput and overexpression assays and our primary cell model 
of HPV replication. It is likely that the E6 interactions that promote cancerous growth 
differ from those that are formed during the HPV life cycle, where E6 expression is tightly 
regulated.  
This study also encountered difficulties in detecting MAGI-1, PATJ and MUPP1 proteins, 
preventing the drawing of concrete conclusions. Optimisation of these reagents would 
enable further studies to investigate the abundance and distribution of these proteins in a 
cell-based model of HPV replication 
HPV16 expression leads to an upregulation of ZO-2 in mouse epithelium and a change in 
distribution in MDCK cells (Hernandez-Monge et al., 2013). Here, we show a decrease in 
ZO-2 protein in the presence of HPV16 genomes, whilst there was no effect in HPV18 
genome containing cells. The levels of fellow tight-junction protein ZO-1 were increased in 
HPV18 genome containing cells. Initially, it may seem unexpected for the interaction 
between E6 and ZO-1 results in an increase in the PDZ protein, but it may be that PBM 
binding has a stabilising effect, much like that observed by Nicolaides et al. The stability of 
E6 is aided by interaction with SCRIB, and it is possible that such a stabilising effect can be 
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reciprocated (Nicolaides et al., 2011). It is interesting to note that HPV16 downregulated 
ZO-2 whilst HPV18 upregulated ZO-1, indicating that targeting of one of these tight-
junction components alone is sufficient for viral purposes. Furthermore the interaction 
between ZO-1 and HPV18 E6 is likely to be dependent upon PBM activity, as removal of 
the PBM in monolayer relieved some of the increase in protein level seen in WT genome 
containing cells and analysis or raft cultures revealed that the change in protein distribution 
from the periphery of HFKs to more focussed regions of the membrane of HPV18 
genome containing cells was restored in part by deletion of the PBM. 
3.4.2.3 The Scribble complex 
The two components of the Scribble complex analysed are the main identified targets of 
high-risk α-papillomaviruses. These proteins are targeted for proteasomal degradation by 
HPV16 and HPV18 E6 oncoproteins, with HPV16 preferentially targeting SCRIB, and 
HPV18 targeting DLG1 (Thomas et al., 2005). It is interesting that, despite the different 
affinities of HPV16 and HPV18 E6 for DLG1 protein, both viruses genomes induced an 
increased DLG1 transcript levels, whereas neither had an effect upon SCRIB gene 
expression. Surprisingly, this upregulation did not correspond to an observed increase in 
DLG1 protein in the HPV16 and HPV18 genome containing keratinocytes, and this was 
validated using two detection antibodies. A more in depth analysis of DLG1 expression in 
HPV genome containing cells is provided in Chapter 4.  
Numerous over and co-expression studies have demonstrated the degradation of DLG1 
mediated by high-risk HPV E6 proteins (Lee and Laimins, 2004; Thomas et al., 2005; 
Gardiol et al., 1999). However, it has also been shown that endogenous DLG1 is not as 
readily targeted (Delury et al., 2013; Choi et al., 2013). Moreover, in primary tonsil 
keratinocytes, there was no change in DLG1 protein when overexpressing HPV16 E6 
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(Spanos et al., 2008b). The maintenance of the DLG1 protein distribution in HPV positive 
and negative primary cells observed in this study agrees with data from other high-risk 
HPV types; HPV31 genome containing keratinocytes demonstrate the same localisation of 
cellular DLG1 than untransfected keratinocytes (Lee and Laimins, 2004; Choi et al., 2013).  
Although both HPV types are known to target SCRIB, it is a preferential target of the 
HPV16 E6 PBM (Thomas and Banks, 2005). Thus, it was surprising that there was no 
change in SCRIB protein levels in HPV16 genome containing cells, but an increase in 
protein occurred in the presence of HPV18 genomes. Furthermore, transcription of this 
PDZ protein remained unchanged in HPV16 and HPV18 replicating cells. It was also 
unexpected that membrane protein SCRIB was not detected in membrane fraction in 
monolayer cells. However, the observation was reinforced by the subsequent detection of 
SCRIB in the nucleus of basal cells and at the cytoskeleton in the upper layers of 
differentiated keratinocytes. Simonson et al. suggest that any differences observed in the 
distribution of DLG1 and SCRIB are subtle, and observe no change in differentiated 
culture. Work form the same group suggest that HPV31 does not induce dramatic changes 
in the subcellular distribution of DLG1 when transfected into primary keratinocytes; only a 
subtle reduction in cytoplasmic DLG1 protein was detected (Simonson et al., 2005; Lee and 
Laimins, 2004). 
In differentiated cells replicating HPV18 genomes, the levels of Scribble complex 
associated proteins DLG1, SCRIB and CASK, and the tight junction proteins ZO-1 and 
ZO-2 were influenced by the activity of the E6 PBM; a lower level of these proteins was 
detected in protein extracted from raft cultures containing genomes encoding the E6 PBM 
than those encoding a PBM deletion. However, examination of total protein from stratified 
cells does not indicate which pools of PDZ protein are affected. Furthermore, analysis of 
protein from differentiated culture can be problematic as the raft growth is inconsistent; 
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keratinocytes replicating HPV18 genomes that do not encode an E6 PBM grow more 
slowly than cells containing wild-type HPV18 genomes (Delury et al., 2013).  
Observing sections of differentiated rafts to identify protein location during stratification 
of epithelial cells containing HPV genomes enables observation of protein localisation 
during the full viral life cycle. Perhaps the susceptibility of PDZ proteins to E6-mediated 
degradation depends upon the location of the PDZ target in question; PDZ proteins could 
be more resistant to E6-induced degradation when they are already incorporated into 
cytoskeletal structures around membrane regions of cell–cell contacts. In this study no 
HPV-related changes in DLG1 and SCRIB protein levels were observed in monolayer 
grown cells or in the basal layer of stratified cells. However, observation of organotypic raft 
culture showed an increased detection of these Scribble complex proteins in the mid layer 
of the cultured epithelia, indicating that interactions between HPV E6 and PDZ proteins 
occur specifically during stages of the HPV life cycle. Furthermore, although no changes in 
NHERF1 abundance or distribution were observed in monolayer culture, differentiated 
cells containing HPV18 exhibited an increase in the protein levels. However, as this does 
not correlate with any observed increase in protein extracted from stratified cells, this 
requires more thorough investigation, perhaps utilizing confocal techniques to more 
accurately detect changes in protein abundance and distribution.  
Inhibition of the proteasome revealed that the observed increases in PDZ protein gene 
transcription, and any downstream increase in translation, was not countered by 
proteasomal degradation; no increase in DLG1 protein was observed in HPV genome 
containing cells treated with proteasome inhibitor. This is also true of PTPN13 and PATJ; 
the increase in transcript levels in HPV genome containing keratinocytes did not 
correspond to a change in protein levels in these cells. Counter-intuitively, in HPV16 and 
HPV18 genome containing cells, a decrease in DLG1 protein levels was seen in conditions 
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of proteasome inhibition. It is unclear what occurs to induce this, but the decrease in 
protein may be due to non-specific effects of MG132 on these primary cells.  
 
Taken together, no extensive change in protein levels was observed in these cells. This was 
surprising as DLG1 is a well characterized target of high-risk HPV E6, for proteasome 
degradation (Gardiol et al., 1999; Thomas et al., 2005). However, the observed effects of 
HPV genomes on PDZ targets appears to concentrate on proteins involved in tight 
junction formation and signalling (Figure 3.42). Protein levels of the tight-junction proteins 
ZO-1 and ZO-2 were altered by HPV genomes and mRNA of the tight-junction associated 
MAGI-1 was decreased. Both NHERF1 and PTPN13, which were upregulated 
transcriptionally in the presence of HPV genomes, have roles in tight-junction organisation 
and signalling; NHERF1 has been shown to function in tight junction organization, 
specifically in ZO-1 and occluding localization and PTPN13 is suggested to function in 
junction formation via ephrin (Castellani et al., 2012; Sotelo et al., 2014; Vermeer et al., 
2012). Disruption of epithelial polarity and tight junctions has been linked to activation of 
growth factor signalling and the release of pro-stimulatory transcription factors (Vermeer et 
al., 2003; Balda and Matter, 2003; Betanzos et al., 2004). Indeed, ZO-2 associates with the 
AP-1 components fos and jun at tight junctions, and our observed decrease of the PDZ 
protein in HPV16 positive cells may reveal a mechanism to release the pro-growth 
transcription factor (Betanzos et al., 2004). In addition, ZO-2 blocks cell cycle progression 
by acting upon cyclin D1; the PDZ protein downregulates protein synthesis, increases 
proteasomal degradation and downregulates cyclin D1 transcription via interaction with the 
TF Myc, (Tapia et al., 2009; Huerta et al., 2007; González-Mariscal et al., 2009). This 
culminates in the suppression of epithelial cell proliferation, which is counter to HPV 
Figure 3.42: Summary of  PDZ protein expression in the presence of  high-
risk α-HPV genomes 
The effects of  HPV genomes upon keratinocytes concentrates on the tight 
junctions. 
Red outline and arrows indicate a change in transcription and a black outline 
indicates a change in protein level in the presence of  HPV. The number on the line 
indicates HPV type. 
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proliferation. Thus it is conceivable that, by decreasing ZO-2, HPV16 E6 promotes 
progression of the cell cycle.  
The TJ protein ZO-1 interacts with the transcription factor ZONAB (ZO-1 associated 
nucleic acid binding protein), which is involved in the regulation of epithelial cell 
proliferation (Balda and Matter, 2000; 2003). Perhaps an increase in this protein by HPV18 
functions to promote the PDZ:TF interaction with the aim of promoting cell proliferation. 
Furthermore, it is conceivable that this release of TFs and propagation of growth signalling 
by deregulated E6, promotes an uncontrollable growth that transforms infected cells and 
promotes cancer development. 
By interrupting the junctions, HPV propagation may be favoured by promoting cell growth 
signalling. However, too much disruption of junction complexes may lead to dissociation 
of the epithelia and a halt in differentiation, which would also interrupt viral replication. 
Thus targeting of junctional proteins is selective, and does not result in the complete 
degradation of proteins involved.  
3.4.3 Future directions 
Protein analysis of keratinocytes does not validate existing data that shows E6-mediated 
degradation of PDZ targets. This is not to say that interactions between E6 and PDZ 
proteins do not occur during the HPV life cycle, PARD3 is an example of an E6 target 
which is not degraded as a result of the interaction (Facciuto et al., 2014). However the 
effect of E6 upon PDZ proteins during the HPV life cycle is subtle, and it is still unclear 
which is the major target at a protein level. The PBM of high-risk HPV E6 proteins 
contributes to episomal maintenance, and it has been suggested that the stabilizing effect of 
PBM PDZ interactions contributes to this (Nicolaides et al., 2011). E6 mediated 
degradation may be an artifact of E6 overexpression and the deregulation of viral 
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oncoproteins that occurs in cancer, as such it would be of interest to investigate these 
proteins in cells where the HPV genome has integrated, which occurs in primary 
keratinocytes following serial culture.  
This study identifies a number of targets of the HPV E6 PBM, which are upregulated at a 
transcriptional level in the presence of viral genomes. This does not, however, correspond 
to an increase in protein levels. However, this study was limited to investigating one 
method of protein degradation; it may be that E6 targets these proteins for degradation via 
the lysosomal pathway. It is possible that a viral factor decreases the mRNA stability, 
before translation occurs. Alternatively, the upregulated transcripts may encode less stable 
proteins or not translate as efficiently that other variants. As such, the pattern of DLG1 
expression investigated in more depth in Chapter 4.  
Further investigation may also identify viral factors and cellular pathways involved in the 
observed changes in PDZ target transcription. This could begin with expression analysis of 
cells containing single viral gene products (such as E2), before dissection of mechanisms of 
action.
 -132- 
CHAPTER 4: IDENTIFICATION AND CHARACTERISATION OF A NOVEL 
ISOFORM OF DLG1 
4.1 Introduction 
4.1.1  DLG1 protein structure 
Like other members of the MAGUK family of proteins, DLG1 is composed of modular 
interaction domains that enable a variety of protein-protein interactions. The protein 
consists of 3 PDZ domains, an Src Homology 3 (SH3) domain and a guanylate kinase 
(GK) domain (Figure 4.1). Two isoforms of DLG1 have been identified, one containing an 
N-terminal L27 motif, referred to as DLG1β, and another without this L27 motif termed 
DLG1α. These isoforms correlate to Drosophila DLGS97 and DLGA, respectively (Figure 
4.2, Albornoz et al., 2008; Mendoza et al., 2003). Further diversity in DLG1 is introduced by 
the inclusion of short amino acid sequences designated insertions (I1-I5), produced by 
splicing alternative exons in the DLG1 gene. This splicing occurs in two main regions of 
DLG1, one at the N-terminus and another in the C-terminal HOOK region that lies 
between the SH3 and GK domains (Figure 4.2). Five alternatively spliced insertions have 
been defined to date, I1A and I1B at the N-terminal region, and I2, I3, I4 and I5 within the 
HOOK domain, each of which results in the inclusion of a short (10-30) amino acid 
sequence (Table 4.1). These insertions influence DLG1 localisation as well as potentially 
altering binding partner preferences of DLG1 (McLaughlin et al., 2002). 
The N-terminal L27 motif of DLG1 facilitates dimerization via interaction with the L27 
domains of other proteins as well as other DLG1 molecules (Lin et al., 2013). The region 
remains largely unstructured until association with other L27 motifs, when the motifs 
together form an ordered helical structure and become a compact four-helix bundle 
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(Doerks et al., 2000). In non-neuronal cells, the L27 domain of DLG1 facilitates 
interactions with the first L27 domain of fellow MAGUK protein, calcium/calmodulin-
dependent serine protein kinase (CASK) and stabilises a more extended form of DLG1 
(Jeyifous et al., 2009; Lee et al., 2002; Waites et al., 2009). Moreover, this interaction with 
CASK is important for localization of the β isoform of DLG1 to the baso-lateral 
membrane of epithelia (Lozovatsky et al., 2009). Similarly, this region in the β isoform has 
been shown to mediate membrane localization via association with DLG2 (Hanada et al., 
2003). In neuronal cells, the presence of the α and β isoforms affects the trafficking of 
specific receptors at the synapse; the β isoform associates with AMPA receptors primarily 
at post-synaptic regions and the α form at perisynaptic regions (Waites et al., 2009). In the 
fly, both the DlgA and DlgS97 isoforms are present at larval neuromuscular junctions 
(Mendoza et al., 2003). Recently, DlgA and DlgS97 were shown to be differentially 
expressed in the fly; whereas DlgA is required for adult viability, specific loss of DlgS97 
leads to perturbation of circadian activity and courtship (Mendoza-Topaz et al., 2008). It 
has also been observed that DlgA is predominant in epithelia wheras the DlgS97 is mainly 
expressed in the Drosophila neuronal system (Mendoza et al., 2003; Lee et al., 2002).  
DLG1 encodes three PDZ domains, which influence DLG1 localisation and interact with a 
wide range of cellular proteins. For example, DLG1 binds to the tumour suppressor 
adenomatous polyposis coli (APC) protein, via PDZ1 and PDZ2, forming a complex which 
inhibits cell cycle progression in response to epithelial cell-cell contact, indicating a role for 
DLG1 in controlling progression of cells from G0/G1 to S phase (Ishidate et al., 2000; 
Zhang et al., 2011; Makino et al., 1997). The PDZ domains of DLG1 are known to interact 
with different transmembrane proteins; for example PDZ1 interacts with the AMPA 
receptor subunit GluR1, PDZ2 with the NR2B subunit of NMDA receptor and PDZ3 
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with neuroligin (Kornau et al., 1995; Leonard et al., 1998; Cai et al., 2002; Wang et al., 2005). 
Binding of PDZ domains 1 and 2 of DLG1 to the Rho-GEF NET1 (neuroepithelioma 
transforming gene 1) leads to the relocalisation of both proteins to the nucleus (Garcia-
Mata et al., 2007; Carr et al., 2009). 
Table 4.1: Insertions in DLG1 variants  
Insertion Exon No. Amino acid sequence 
Present in 
variants 
1A 6 PTEAVLPSPPTVPVIPVLPVPAENTVILPTIPQ 1, 2, 6 and 7 
1B 7 ANPPPVLVNTDSLETPTY 1, 2, 3, 4, 6, 7, 8 and 9 
2 21 EIPDDMGSKGLK 1, 3, 5, 6, 7, 8 and 9 
3 20 A/B (Q)SFNPKRKKNLFSRKFPFYKNKDQSEQETSDADQ 2 and 4 
4 23 LILITDEYGCSKG 7 and 9 
5 22 HVTSNASDSESSY 1, 2, 3, 4, 7, 8 and 9 
Brackets indicate alternative inclusion of residue at the beginning of I3 
 
Mammalian SH3 domains bind to proline rich regions of target protein and DLG1 is no 
exception; DLG1 SH3 and GK domains form an interaction with the synaptic protein 
GKHolder (GukH), enabling proper localisation of fellow junctional protein SCRIB 
(Newman and Prehoda, 2009). DLG1 SH3 interactions have been shown to facilitate the 
organization of protein complexes. DLG1 protein colocalizes with E-cadherin at the sites 
of cell-cell contacts in mammary epithelial cells (Reuver and Garner, 1997; Wu et al., 1998; 
Reuver and Garner, 1998). In these cells, depletion of DLG1 altered the integrity of 
adherens junctions or tight junctions (Laprise et al., 2004; Stucke et al., 2007). Furthermore, 
in Drosophila Dlg, loss of the SH3 and GK domains leads to a dissociation of septate 
junctions, reinforcing the importance of DLG1 domains in facilitating the protein 
interactions that form cell-cell contacts (Woods et al., 1996; Hough et al., 1997). 
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In all MAGUK proteins, the GK domain is catalytically inactive, despite sharing a strong 
structural similarity with cellular soluble guanylate kinases (Kuhlendahl et al., 1998; Olsen 
and Bredt, 2003). Studies in C. elegans have shown that the GK domain is important for cell 
viability (Lockwood et al., 2008), suggesting that, though inactive, the domain contributes 
to DLG1 function. Investigation in human cells have revealed that the GK domain forms a 
number of interactions with cellular proteins, including guanylate kinase associated protein 
(GKAP), microtubule-associated protein 1A (MAPlA), guanylate kinase associated kinesin 
(GAKIN), kinesin superfamily protein 13B (KIF13B), brain-enriched guanylate kinase-
associated protein (BEGAIN), SPA-1-like protein (SPAL), and leucine glycine asparagine 
repeat protein (LGN) (Zhu et al., 2011; Sans et al., 2005; Deguchi et al., 1998; Saadaoui et al., 
2014; Brenman et al., 1998; Yamada et al., 2007; Kim et al., 1997). These protein-protein 
interactions facilitate the attachment of DLG1 to cytoskeletal factors, microtubules and 
actin-based transport machinery, as well as aiding the organization of signal transduction 
complexes. The GK domain has also been shown to associate with protein kinase C (PKC) 
and is required for the localization of DLG1 to the synapse (Thomas et al., 2000; O'Neill et 
al., 2011). Recently, the DLG1 GK domain has been shown to bind to phosphorylated 
threonine or serine residues of fellow Scribble complex protein LGL and regulator of 
asymmetric cell division LGN (Zhu et al., 2014; 2011). DLG1 binding to phosphorylated 
LGL has been indicated as a regulatory mechanism in Scribble complex formation and 
binding to phosphorylated LGN has been suggested to be important in localizing DLG1 to 
the midbody along with LGN during cytokinesis (Zhu et al., 2011; 2014). Furthermore, a 
nuclear export signal has been identified in the GK domain (KRKK), removal of which 
restricts DLG1 to the cytoplasm (Kohu et al., 2002). Since a number of DLG1 interacting 
proteins, including protein 4.1 and ErbB4, exist in the nucleus, it has been speculated that 
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DLG1 translocates with these proteins, to function in the nucleus as a transcription factor, 
splicing factor or scaffolding protein (Kohu et al., 2002; Lue et al., 1994; Huang et al., 2000). 
Post-translational modifications of DLG1 have been reported. Commonly, 
phosphorylation is related to the control of DLG1 subcellular localization. In D. 
melanogaster, phosphorylation of Dlg PDZ1 by CAMKII decreases the synaptic localisation 
of the protein (Koh et al., 1999). In human cells, phosphorylation of DLG1 by the MAPK 
p38γ promotes dissociation from GKAP, releasing the protein from the cytoskeleton 
(Sabio et al., 2005). Furthermore, stress conditions induce phosphorylation of DLG1 by 
JNK (Jun N-terminal kinase), which leads to the accumulation of DLG1 at cell-cell 
contacts (Massimi et al., 2006). DLG1 interacts with the mitotic kinase PBK (PDZ binding 
kinase) and both proteins are phosphorylated during mitosis (Gaudet et al., 2000). The 
differential phosphorylation of DLG1 during S phase and mitosis is likely to affect the 
interactions that DLG1 can form and thus function to control the protein interactions 
during the cell cycle (Gaudet et al., 2000). Furthermore, DLG1 is differentially 
phosphorylated during the cell cycle by CDK1 and 2, enhancing nuclear localisation of the 
protein (Narayan et al., 2009; 2008).  
4.1.1.1 DLG1 Insertions  
Extensive alternative processing of the DLG1 gene further diversifies DLG1 protein 
interactions and functions, and this occurs both in Drosophila and in humans (McLaughlin et 
al., 2002). Splice variants differ in the use of alternative exons, which have been identified 
in a region at the N-terminus and in the C–terminal HOOK region, between the SH3 and 
GK domains (Figure 4.2). These insertions have been found in different combinations in 
different variants of DLG1 protein and they affect DLG1 localisation as well as promoting 
interactions with cellular factors (Table 4.1).  
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The N-terminal alternatively spliced region of DLG1 comprises the proline rich insertions 
I1A and I1B, which are able to moderate oligomerisation, forming interactions with other 
DLG1 molecules and with other cellular proteins (Nix et al., 2000; Wu et al., 2000). 
Immunoprecipitation of DLG1 and the pro-proliferative tyrosine kinase Lck in T-cells 
demonstrated that the SH2 domain of the kinase interacts with DLG1 I1A and I1B 
(Hanada et al., 1997). More recently, it has been shown that the I1A-containing DLG1 
isoform is phosphorylated in response to T-cell receptor (TCR) stimulation and that this 
event is mediated by Lck (Crocetti et al., 2014). It has been suggested that this interaction 
allows DLG1 to couple TCR activation to the release of cytotoxic granules via Lck (Round 
et al., 2007a; Crocetti et al., 2014; Hanada et al., 1997). 
The amino acid sequences of insertions I1A and I1B are involved in DLG1 self-association 
(McLaughlin et al., 2002; Hanada et al., 2000; 1997). Furthermore, I1A has been shown to 
influence the activity and surface expression of the voltage-gated potassium channel Kv1.5; 
presence of the insertion enables DLG1 to stimulate Kv1.5-mediated current (Godreau et 
al., 2003; McLaughlin et al., 2002). The stimulatory function of I1A containing isoforms 
may be due to the ability of the protein to organise synaptic channels and facilitate 
interactions with accessory proteins (Hibino et al., 2000; DeMarco and Strehler, 2001).  
The inclusion of insertions affects DLG1 function, for example McLaughlin et al. suggest 
that isoforms containing I1A and I1B are involved predominantly in DLG1 signalling 
functions, whereas isoforms without these insertions are predominantly involved in 
scaffolding. This is perhaps most clearly observed in T-cells where the two expressed 
forms of DLG1 differ by the inclusion or exclusion of I1B. Both forms facilitate cytotoxic 
granule release but the I1B-containing form is unable to coordinate p38 activation and 
proinflammatory cytokine production (Crocetti et al., 2014).  
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Nuclear functions of DLG1 are perhaps mediated by the I2 isoform. Inclusion of I2 in 
DLG1 is associated with relocation of the protein to the nucleus and it has been suggested 
that the I2-form is involved in chromatin reorganization (McLaughlin et al., 2002). During 
epithelial differentiation, I2-containing forms of DLG1 translocate from the nucleus to the 
cytoplasm, suggesting that the nuclear I2-mediated functions are not necessary for 
differentiated keratinocytes (Roberts et al., 2007).  
The alternatively spliced I3 is associated with DLG1 localisation to the cell membrane and 
has been shown to interact with the membrane-bound proteins β1-Adrenergic GPCR, A-
kinase anchor protein 5 (AKAP5) and protein 4.1 (Lue et al., 1996; Nooh et al., 2013; 
Gardner et al., 2007). The I3 containing isoform of DLG1 promotes the recycling of β1-
Adrenergic receptor by DLG1 and provides a weak binding site for CAMKII; in the 
absence of I3, CAMKII is able to bind upstream of I2, indicating that this interaction is 
important for more than one DLG1 isoform (Paarmann et al., 2002). Phosphorylation of I3 
by CAMKII disrupts binding of the PKA organizing protein AKAP5 to the insertion 
sequence (Nikandrova et al., 2010; Schlueter et al., 2006). Protein 4.1 binding to I3 facilitates 
DLG1 recruitment to the neuronal synapse, association with the actin cytoskeleton within 
dendritic spines and association to membranes in both polarized and non-polarized cells 
(Hanada et al., 2003; Lue et al., 1994; Rumbaugh et al., 2003; Nooh et al., 2013). The HOOK 
region also contains a calmodulin binding site, a region which is also able to compete for 
binding to DLG1 I3 in homodimerisation (Paarmann et al., 2002).  
The combinations of insertions included in DLG1 are also dependent upon the tissue in 
which they are expressed. I3 is predominantly expressed in cardiac tissue whereas the I2-
containing form appears to be restricted to neurons and liver (Mori et al., 1998; McLaughlin 
et al., 2002; Godreau et al., 2003). However, both insertions have been detected in epithelia, 
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although the expression of each changes during epithelial differentiation (Godreau et al., 
2003; McLaughlin et al., 2002; Roberts et al., 2007). 
Although the first 65 amino acids of DLG1 direct the recruitment of DLG1 to sites of cell-
cell contact, and the presence of I3 affects the efficiency of this localization, DLG1 
mutants without PDZ domains show a nuclear localization. Insertions and domains all 
influence DLG1 localisation and function (Wu et al., 1998). This is in part due to the fact 
that the interactions formed by DLG1 involve more than one domain interface; for 
example, binding of the SH3 increases affinity of DLG1 to CAMKII and promotes 
calmodulin and protein 4.1 binding to the HOOK domain (Gardoni et al., 2003; Mauceri et 
al., 2007).  
4.1.2  DLG1 expression 
DLG1 mRNA is transcribed from chromosome 3 and consists of 24 described exons 
(Figure 4.3). Transcription of the DLG1 gene is repressed by the snail family of 
transcription factors and a number of transcription factor binding sites have been identified 
in the 5’ untranslated region (UTR) of DLG1, including AP-1, AP-2 NFκB and SP-1 
(Cavatorta et al., 2008). The DLG1 gene contains 50 distinct introns which could be 
transcribed to produce 33 different mRNAs (Thierry-Mieg and Thierry-Mieg, 2006). It has 
been suggested that there are 11 potential alternative promoters and 16 alternative 
polyadenylation sites (Cavatorta et al., 2008; Thierry-Mieg and Thierry-Mieg, 2006). Two 
different 5’ UTRs have been identified by the Gardiol lab (Cavatorta et al., 2011). These 
UTRs are generated by alternative splicing within the 5’ region of DLG1 mRNA and is a 
region which mediates DLG1 transcriptional control, influences mRNA stability, 
localization and translational efficiency (Cavatorta et al., 2011). It is therefore reasonable to 
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assume that the inclusion of different 5’ regions affects DLG1 protein abundance 
(Cavatorta et al., 2011).  
 
Thus, DLG1 is a multi-functional protein, able to form a range of interactions and perform 
cell context and subcellular-specific roles. DLG1 was the first identified PDZ target of 
high-risk α-HPVs and the ability of the E6 oncoprotein to target the protein for ubiquitin 
mediated degradation is well documented (Kiyono et al., 1997; Gardiol et al., 2006; Narayan 
et al., 2009; Thomas et al., 2005). The virus has been shown to target specific subcellular 
pools of DLG1, exhibiting a preference for nuclear, phosphorylated forms of the protein 
(Narayan et al., 2009; Massimi et al., 2004). 
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4.3 Hypothesis and objectives 
A number of forms of the DLG1 protein have been identified, with diversity introduced 
via short, alternatively spliced insertions and expression of alternative N-terminal 
sequences (Figure 4.1 and 4.2). The expression of DLG1 isoforms is tissue and cell context 
specific, and likely affects DLG1 localisation and function within a cell. Moreover, many 
studies of DLG1 have focussed on the β isoform and little is understood of DLG1α 
expression. DLG1 is a major target of high-risk HPV E6 oncoproteins and this study has 
identified an increase in DLG1 transcription in the presence of HPV genomes. Thus, this 
investigation aims to characterize DLG1 expression in epithelia under a number of 
conditions, in the presence of high-risk HPVs, in normal tissue and in cancer tissue.  
The experiments outlined in this chapter aim to:  
i. Characterise DLG1 expression during the HPV life cycle 
ii. Investigate novel DLG1 isoform in the context of mRNA and protein 
iii. Characterise DLG1 isoform expression in cancer cell lines and normal tissue   
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4.4 Results 
4.4.1  Identification of a novel insertion in DLG1 in mRNA 
Previously in this thesis, an investigation into the expression of DLG1 during the HPV life 
cycle was carried out (Chapter 3). During this, it was noted that mRNA expression of the 
DLG1 gene was increased in the presence of high-risk HPV genomes (Chapter 3, Section 
3.3.2). Since DLG1 exists as two main isoforms and is further diversified by the inclusion 
of spliced insertions, it was deemed important to characterise the expression of DLG1 in 
these α-HPV genome containing cells and to determine which of the isoforms were being 
upregulated in the genome containing cells. Microarray and subsequent qRTPCR analysis 
had identified that the increased level of DLG1 expression occurred in transcripts 
containing a region in the HOOK domain. The primers used in qRTPCR analysis were 
designed according to the nucleotide sequence of the Affymetrix probe (230229_at), both 
of which covered the HOOK domain region of DLG1 (Figure 4.3, Table 4.2). It was 
surprising that, upon examination of the probe position and primer sequences (Table 4.2), 
the region under analysis in the Affymetrix array corresponded to was in fact a region of 
the DLG1 gene previously described as intronic, between known exons 21 and 22. Exon 
21 encodes DLG1 insertion I2 and exon 22 encodes I5 (Figure 4.3, Table 4.2). 
Furthermore, Affymetrix included this probe because of the previous identification of two 
cDNA clones from hypothalamus- and brain-derived libraries, containing sequence 
overlapping with this region (Strausberg et al., 2002; Wiemann et al., 2003, Figure 4.3).  
To further examine the sequence of this HPV-upregulated ‘intronic’ region of DLG1, PCR 
primers were designed to the flanking exons of I2 and I5 (I2Fwd and I5Rev, Figure 4.4) and 
used in combination with the HOOK region primers (HOOKFwd and HOOKRev, Figure 
4.4), previously used in qRTPCR (Chapter 3), to amplify from cDNA generated from 
AFigure 4.3: DLG1 HOOK domain corresponding primers and probes 
(A)  Schematic of  the DLG1 gene showing the 23 exons, and the exon start and 
finish nucleotide numbers, according to NCBI. The exons coding for 
insertions I1A, I1B and I2-I5 are shown. The region included in the dashed 
line is the region of  focus in B.  
(B)  Exon 21 and 22 encode I2 and I5, respectively. It is between these exons where 
the microarray probe (blue line) and the HOOK domain primers (blue arrows) 
anneal. This region overlaps with the known cDNA IMAGE clone, derived 
from human hypothalamus, BC037916 (Strausberg et al. 2002), corresponding 
to nucleotides 231928 to 233005 of DLG1 (orange line).  Also in this region is 
an area of  alignment with IMAGE clone DKFZp761P0818 derived from 
amygdala (Wiemann et al. 2003, green line). Further primers were designed to 
known exonic sequence in Exons 21 and 22, indicated by the pink and purple 
arrows. 
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DNAse-treated polyA selected RNA that had been isolated from HPV16 genome positive 
keratinocytes. A control reaction containing water was included. The PCR products were 
separated by ethidium bromide agarose gel electrophoresis and the lower band observed in 
both the cDNA and water control indicated amplification of primer dimers (Figure 4.4). 
The amplified bands were excised; the single band amplified by the HOOK primers and 
the single product amplified by the HOOKFwd in combination with the I5Rev (Figure 4.4). In 
the case of the HOOKFwd I5Rev and I2Fwd I5Rev combinations the brightest and the fainter 
bands was excised (a total of 2 and 3 bands cut out, respectively), but in both cases the 
fainter bands were unsuccessful in sequencing reactions (Figure 4.4). 
Table 4.2: DLG1 primer and array probe positions 
Primer Name Sequence (5’-3’) Position in DLG1 
I5Rev CCTGTCTTTCATAGGTCCCA 230051-230071 
I2Fwd GAGATCCCTGACGACATGGG 223464-223484 
HOOKFwd  GCCCATTCCTAGCGCATGAACTC
C 
228817-228841 
HOOKRev GCCATTCTGGTGGATGGCAGAG 228908-228930 
Affymetix probe 
230229_at  
 227651-228736 
 
Sequencing of excised bands from the I2Fwd I5Rev combination of primers revealed the 
established I2-I5 junction. Successful sequencing of excised bands from I2Fwd HOOKRev 
combination and the HOOKFwd I5Rev combination revealed the presence of 208 nucleotides 
between exon 21 and 22, which has not been shown previously to be transcribed (Figure 
4.5, sequence data Appendix II). The 208 nucleotides corresponded to DLG1 gene 
sequence in a region of the gene between exons encoding I2 and I5, sequence previously 
thought to be intronic (Figure 4.4). Further sequencing reactions confirmed the presence of 
this intronic sequence in mRNA containing I2 and I5, with sequence data covering the 
splice junctions (Figure 4.5). Thus, the region amplified by the HOOK region primers, and 
5’ 3’Exon 22Exon 21
Encodes I2 Encodes I5
I2Fwd! I5Rev!HOOKRev!HOOKFwd!
A
Figure 4.4: Amplification of  the DLG1 HOOK region 
(A)  Schematic of  the primers positioned with respect to the DLG1 gene (Boxes 
indicate exons and the line intronic regions). Primers indicated by arrows, with 
names above. Pink, I2Fwd; Blue HOOKFwd and HOOKRev and purple I5Rev. 
(B)  The PCR products amplified using primer combinations were seperated by 
agarose gel electrophoresis and visualised using ethidium bromide. cDNA was 
transcribed using oligodT primers from DNAse-treated RNA extracted from 
from HPV16-genome containing keratinocytes. PCR containing water was 
included as a control. Bands indicated by the arrow were excised and 
sequenced using the above primers. Primer dimers indicated by *. Fainter 
bands were not successfully sequenced. Ladder shown is 1 µg of  1kb plus 
(Invitrogen). Expected molecular weights of  amplified fragments (Left to 
right) are 98, 149, 222 and 274 bp. 
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Figure 4.5: Sequencing across exon junctions 
(A)  Purified amplified DLG1 fragments were subject to sequencing reactions to 
reveal sequence indicated. Pink corresponds to exon 21 and purple to exon 22. 
Exons are indicted in capitals and intronic sequence in lower case. 
(B)  Sequencing results corresponded to DLG1 sequence and covered the splice 
sites of  exons 19, 21, the novel exon, 22 and 24. The schematic indicates 
DLG1 mRNA with the order of  the exons and the nucleotide sequence of  
splice junctions and the corresponding image of  sequencing peaks below. Red 
dotted line indicates splice junction 
AGTTACCGTGGTCAAGGCCTGATAGTTTT 
TCTTTAGCATGTAATAAAGGGGAGATCC
5’ 3’Exon 19
Encodes end of SH3
Exon 22
Encodes I5
Novel Exon
Encodes I6
Exon 24
Encodes start of GK
3’Exon 21
Encodes I2
A
B
5’AGGGAGATCCCTGACGACATGGGATCAAAAGGCCTGAtagttttacc
agtttgcccattcctagcgcatgaactcccattgctgcatatcattatc
gatgcttgacatgtctgttttgtgttttcattttagccattctggtgga
tggcagagacactctttgtggttataatttgcatttccctgacaagtaa
ttaacttgaacacttttctatatgtttattggttatttgactgtcttct
ttagCATGTAACTTCTAATGCCAGCGATAGTGAAAGTAGTTAC 3’
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covered by the Affymetrix microarray probe 229130_at, is a region that is expressed and is 
upregulated in the presence of HPV genomes. In keeping with DLG1 insertion 
terminology, this exon was termed I6.  
As the data indicated a novel insertion in the HOOK region, flanked by I2 and I5, the next 
stage was to characterise the transcripts containing the I6 insertion in more detail. PCR 
amplification was performed using a combination of forward primers specific to the N-
terminus of either DLG1α or DLG1β isoforms, alongside a reverse primer within the 
novel insertion I6 (Figure 4.6). Both combinations of primers amplified fragments and 
more than 6 bands were visible from each reaction. Successful sequencing was achieved of 
one excised band (~1000 bp), amplified by the DLG1αFwd and HOOKRev combination 
(Figure 4.6). Sequencing of this purified fragment revealed the presence DLG1α specific 
N-terminus along with the first two PDZ domains (Figure 4.6, Appendix II). Thus, this 
data indicates that the I6 insertion is present in α forms of DLG1.  
However, it cannot be ruled out that that I6 is present in DLG1β transcripts; more than 6 
amplified bands were visible, which were not successful in sequencing reactions. The bands 
may be a result of non-specific amplifications due to the increased PCR extension time (1.5 
min) and number of amplification cycles (50); increased cycling increases the opportunity 
for nonspecific amplification and errors (Bustin and Nolan, 2004; Bell and DeMarini, 
1991). This is something that requires further investigation.  
Thus, this study has identified a novel insertion in an established region of extensive DLG1 
alternative splicing. It is likely that mRNAs containing this insertion (I6) also encode the α 
form of the DLG1 N-terminus. Furthermore, I6 is upregulated in the presence of both 
high-risk HPV16 and 18 genomes (Chapter 3, Figure 3.4). The rest of this chapter aims to 
investigate potential consequences of the inclusion of the I6 sequence in DLG1 mRNA. 
AFigure 4.6: Amplification of  the DLG1 N-terminus  
(A)  Schematic of  the primers positioned with respect to the DLG1 N-terminus 
(Boxes indicate exons and the line intronic regions). Primers indicated by 
arrows, with names above. Green, DLGβFwd and Rev; Purple DLGαFwd and Rev. 
(B)  Agarose gel electrophoresis separated PCR products. cDNA was transcribed 
using oligodT primers upon DNAse-treated RNA extracted from from 
HPV16-genome containing keratinocytes, or water as a control. Bands were 
excised and sequenced. Star (*) indicates successfully sequenced band. 
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4.4.1.1 Splice site analysis of novel insertion 
The analysis of DLG1 transcription in the genome containing keratinocytes identified an 
isoform of DLG1 that contained a previously unknown insertion. To examine the splice 
donor and acceptor regions of this novel exon and compare them to the consensus 
sequences, splice site analysis was carried out upon the DLG1 gene sequence between 
exons 21 and 22. Splice site analysis was also carried out on the known DLG1 spliced 
insertions that result in the α or β N-terminus and in the inclusion of I1A I1B, I2, I3, I4 
and I5. A computational splice site analysis programme designed to predict the effects of 
mutations on splicing signals or to identify splicing motifs in any human sequence, was 
used alongside knowledge of known splice site recognition motifs (Table 4.3). The 
consensus sequences included the nucleotides at the 5’ end of the donor exon (A/CAG) and 
3’ of the acceptor exon (C/TAG), as well as intronic sequence proximal to the exons, i.e. 3’ 
of the donor and 5’ of the acceptor exons, with the consensus nucleotides GUA/GAGU 
and CAG, respectively (Table 4.3).  
Table 4.3: Exon and intron comparison to consensus splice nucleotide sequence  
Consensus derived from Srebrow and Kornblihtt, 2006; Ghigna et al., 2008; Harris and Senapathy, 1990. Full 
sequences of exons are listed in Appendix II. 
5’Exon-3’Exon 5’ Donor Intron (5’-3’) 3’ Acceptor 
Consensus -------ACAG GUAGAGU---CAG CTAG-------- 
α N-terminus-I1B CTCCACCCAG GTAACA---AAG GCAAATCCTCC 
β N-terminus-I1B ACCAATAAAG GTAGGA---AAG GCAAATCCTCC 
I1A-I1B CATACCACAG GTTTTT---AAG GCAAATCCTCC 
I2-I5 GGGCCTGAAG GTAAGT---CAG CATGTAACTTC 
I3-I5 GATGCTGACC GTAAGT---CAG AGCATGTAACT 
I2-I6 AAAGGCCTGA GTAAGT---CAG TAGTTTTACCA 
I6-I5 TTTATTTTTC CTTAAA---CAG CATGTAACTTC 
I5-GK AGTAGTTACC GTAAGT---TAG CGTGGTCAAGA 
I5-I4 AGTAGTTACC GTAAGT---AAG TAATCTTGATT 
CHAPTER 4: IDENTIFICATION AND CHARACTERISATION OF A NOVEL ISOFORM OF DLG1  
-146- 
Examination of the known DLG1 exons encoding the insertions revealed that the exons 
corresponding to the α (exon 5) and β (exon 3) N-terminus, and to I1A (exon 6) and I2 
(exon 21), all contain a consensus 5’ AG dinucleotide. However, the exons encoding I3, I5 
and the new insertion I6 contain a 5’ cytosine that does not conform to the consensus 
sequence (Table 4.3). Similarly, the canonical 3’ C/TAG acceptor nucleotides were present 
in exons encoding I5 and I6 but not in the other exons analysed (Table 4.3).  
Although there are consensus sequences, these are not strictly adhered to by all the exons 
of DLG1. The intronic sequence is as important as the donor and acceptor sequences in 
splicing, as it contains the branchpoint adenosine and regions of spliceosome recognition 
(Williams, 2002; Harris and Senapathy, 1990). Screening of the DLG1 gene sequence 
showed conservation of a 5’ GT in all the introns analysed, apart from between I6 and I5, 
where a cytosine replaced the guanosine (Table 4.3). The 3’ intronic AG dinucleotide was 
conserved in all the sequences included in the screening analysis (Table 4.3). The non-
adherence to consensus sequence may indicate obscure or ‘weak’ splice sites, where the 
inclusion of exons requires additional specific factors, which may be cell or condition 
specific. 
4.4.2  Investigation into protein expression of the novel DLG1 isoform  
4.4.2.1 In silico screening suggests interacting proteins for novel insertion  
In order to investigate the potential roles for the novel DLG1 sequence, the nucleotide 
sequence was translated in silico using the ExPasy resource and the resulting amino acid 
sequence of the insert I6 and upstream I2 was screened for potential protein-protein 
interactions using ScanSite software. An amino acid sequence of 20 residues was 
predicted, followed by a stop codon (Figure 4.7). In the context of the whole DLG1 
protein, inclusion of this sequence would produce a truncated protein containing the three 
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PDZ domains, followed by the SH3 domain, I2 and a novel sequence of 21 amino acids; 
the truncated protein however would lack the GK domain (Figure 4.7). Furthermore, the 
final lysine of I2 is not included, instead an isoleucine takes its place. Similar alternative 
inclusion of single amino acids in insertions has been observed with the glutamine residue 
at the beginning of DLG1 I3 (McLaughlin et al., 2002). The predicted molecular mass of 
the novel isoform is 60 kDa, compared to the full-length protein of 120 kDa. 
Table 4.4: Potential protein interactions with I2-I6 sequence 
Motif Group Motif Gene  Sequence target Score 
Kinase binding 
site group 
Erk D-domain MAPK1 DMGSKGLIVLPVCPF 0.868 
GSKGLIVLPVCPFLA 0.798 
KGLIVLPVCPFLAHE 0.726 
Src homology 
group (SH3) 
Cbl-associated protein 
CSH3 
SORBS1 LIVLPVCPFLAHELP 0.909 
Cortactin SH3 HCLS1 LIVLPVCPFLAHELP 0.760 
PLCg SH3 PLCG1 LIVLPVCPFLAHELP 0.687 
Src SH3 SRC SKGLIVLPVCPFLAH 0.658 
P85 SH3 mode 1 PI3KR1 SKGLIVLPVCPFLAH 0.665 
Target residues underlined. The SH3 domain binds proline residues, the Erk D-domain consensus sequence 
is φ-X-φ-P, where φ indicates a hydrophobic residue. 
 
The translated protein sequence of I2-I6 was analysed for secondary structure motifs to 
predict protein interacting domains, with a score to indicate the probability of an 
interaction, where 0 indicates an unfavourable interaction and 1 a highly favourable 
interaction (Table 4.4). Two protein binding motifs were highlighted via the screen: the 
kinase binding site group and the SH3 group (Table 4.4). Five protein families were 
suggested to bind the central proline of the novel insertion via an SH3 domain, including 
regulatory subunits of the kinases PI3K and PKCγ (Table 4.4). The mitogen-associated 
kinase MAPK1 was also predicted to bind to three residues within the insertion, an 
isoleucine, leucine and a valine, all predicted to bind with a score of over 0.7 (Table 4.4). 
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These residues stand in the place of ‘X’ in the Erk D (docking)-domain binding consensus 
sequence (φ-X-φ-P, Table 4.4, Sheridan et al., 2008; Fernandes and Allbritton, 2009).  
4.4.2.2 DLG1 isoform expression analysis using antibodies  
In order to identify whether a truncated form of DLG1 is expressed, several antibodies 
against DLG1 were used to detect protein extracted from cellular fractions of HPV16 and 
HPV18 genome containing keratinocytes, as well as from the HPV18 positive cancer cell 
line HeLa. These antibodies were a selection of commercial and non-commercial 
antibodies raised to different regions of DLG1 (Table 4.5). Control blots incubated with 
either secondary anti-mouse or anti-rabbit IgG antibody were carried out to highlight any 
non-specific binding (Figure 4.8). In these control blots, a non-specific band can be seen at 
30 kDa in both the nucleus and cytoskeleton, when incubated with the anti-rabbit IgG 
horseradish peroxidase (HRP) -conjugated secondary antibody whereas no bands were 
detected in blots incubated with the anti-mouse IgG secondary antibody, which was 
conjugated to HRP (Figure 4.8).  
Table 4.5: DLG1 Antibodies 
Antibody 
name 
Source Animal 
origin 
Region of DLG1 Reference 
2D11 Santa Cruz Mouse 1-229 DLG1β - 
H-60 Santa Cruz Rabbit 49-108 DLG1β - 
NAG S. Roberts Rabbit 1-200 DLG1β Roberts et al., 2007; 
McLaughlin et al., 
2002  
NT L. Banks Rabbit  - 
DLG1α S. Roberts Rabbit DLG1α N-terminus: 
KGSSDELQAEPEPSR 
Designed during 
this thesis 
 
The predicted molecular mass of the truncated form of DLG1 was 60 kDa. The mouse 
monoclonal antibody 2D11 and the rabbit polyclonal antibody H60 were both raised to the 
N-terminus of DLGβ. As expected, both antibodies detected DLG1 migrating at 
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Figure 4.8: Cross-reaction of  subcellular fractions with HRP-conjugated 
secondary antibody 
HeLa and HPV18 genome containing keratinocytes were cultured in monolayer to 
70% confluency and subjected to subcellular fractionation. The cytoplasmic (F1), 
membrane (F2), nuclear (F3) and cytoskeletal (F4) fractions were then separated by 
SDS-PAGE and probed with anti-mouse (top panel) or anti-rabbit (top panel) 
HRP-conjugated secondary antibody. Molecular weight markers show kDa. 
 
F1, Cytoplasm    F2, Membrane    F3, Nucleus    F4, Cytoskeleton
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approximately 120 kDa in both HeLa cells and in the genome containing keratinocytes 
(Figure 4.9 A). As noted previously, the majority of DLG1 was located in the nucleus. 
(Figure 4.9 A). Detection with 2D11 revealed no smaller bands, but the H60 antibody 
identified a number of small bands in the cytoplasmic fraction including several between 
60-80 kDa in both donors and to a lesser extent in HeLa.  
Likewise, the NT antibody detected full-length DLG protein plus an array of faster 
migrating proteins, but the profile differed from the one recognized by H60. NT detects 
several bands between 40 and 80 kDa in the membrane and cytoskeleton and at 80 kDa in 
the cytoplasmic fraction, all of which are stronger in the keratinocytes containing HPV 
genomes than in HeLa cells (Figure 4.9 B).  
The N-terminal NAG antibody NAG is raised to a region of DLG1 encompassing the 
insertions I1A and I1B (McLaughlin-Drubin and Meyers, 2004; Lue et al., 1994). As with 
H60 and NT, the NAG antibody detected full length DLG1 and a number of smaller 
species (Figure 4.9 D). In particular, protein detected at approximately 65 kDa in the 
membrane and nuclear fractions are more prominent in genome containing cells than in 
HeLa (Figure 4.9 D).  
Thus, protein analysis with a number of DLG1-specific antibodies suggested the existence 
of smaller (less than 120 kDa) species, including a form of approximately 60 kDa. 
However, the analysis of the I6 containing transcripts indicated a α isoform although it 
cannot be ruled out that β forms contain the I6 insertion too, and none of the existing 
antibodies recognised this isoform of DLG1. In order to assess the expression of DLG1α, 
an immunogenic peptide was designed from the N-terminus sequence unique to 
DLG1α by a commercial company (Generon, Figure 4.2). The peptide 
(KGSSDELQAEPEPSR) was used as an immunogen in rabbits and the subsequent 
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Figure 4.9: Detection of  DLG1 protein in cellular compartments of  HeLa 
and HPV18 genome containing keratinocytes 
The cytoplasmic (F1), membrane (F2), nuclear (F3) and cytoskeletal (F4) fractions 
were sequentially extracted from monolayer grown HeLa and HPV18 genome 
containing keratinocytes derived from two donor backgrounds, separated by SDS-
PAGE and detected using various antibodies against regions of  DLG1. Both 2D11 
(A) and H-60 (B) are specific to the N-terminal region of  DLG1β. The NT- 
antibody (C) detects…..The N-terminal antibody NAG (D) was developed in-
house by the Roberts lab.  
In each case, the bands corresponding to full-length DLG1 protein (100-120kDa) 
is indicated by the arrow head. Molecular weight marker indicates kDa. 
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antibody (DLG1α 1524) recognised the peptide in ELISA based assay (performed by 
Generon). The antibody was then tested upon protein extracted from keratinocytes 
containing HPV16 and HPV18 by western blotting. Rabbit serum extracted before 
exposure to imunogen (pre-immune) was used as a control for non-specific binding. No 
non-specific bands were detected using the pre-immune serum (Figure 4.10 A). In parallel 
experiments on the same lysates the 2D11 antibody confirmed the presence of full-length 
DLG1 migrating at approximately 120 kDa (Figure 4.10 B). The full-length protein was 
present in primary cells and in the genome containing keratinocytes when using the 
DLG1α antibody and a number of additional bands were detected in all lysates (Figure 
4.10 C). Furthermore, in keratinocytes the bands detected by the DLG1α specific antibody 
migrated slightly faster than in HeLa, indicating differences in phosphorylation of the α 
forms between HeLa and other cells (Figure 4.10 C). Upon longer exposure, a profile of 
faster migrating bands were visible including several bands between 50 and 60 kDa, 
suggesting the presence of truncated forms of the proteins. However, there was no obvious 
change in the level of these smaller species between primary cells and those containing 
HPV genomes (Figure 4.10 C), which would be expected if the bands corresponded to the 
I6-containing form of DLG1 upregulated by HPV. 
4.4.3  Investigation of DLG1 isoform expression 
Chapter 3 details the expression of the HOOK domain containing transcripts of DLG1 in 
keratinocytes containing high-risk HPV genomes. Having identified that this corresponded 
to a region of DLG1, which was previously not known to be expressed, here expression 
analysis was extended to characterise the expression of DLG1 transcripts containing this 
novel insertion. In addition, the expression of the two main isoforms, DLG1α and 
DLG1β was also characterised because studies in Chapter 4 (Section 4.3.2) suggested that 
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Figure 4.10: Detection of  DLG1α protein  
Total protein was extracted from untransfected HFKs as well as HFKs containing 
HPV16 and HPV18 genomes from two donor backgrounds and from HeLa cells. 
All cells were grown in monolayer culture, harvested at 70% confluency and lysed 
in urea buffer. Protein was separated by SDS-PAGE and probed with pre-immune 
serum (A), commercial DLG1 antibody (2D11, B) and DLG1α 1524 (C). 
In each case, the bands corresponding to full-length DLG1 protein (100-120kDa) 
is indicated by the arrow head and loading control (β-actin) is positioned beneath. 
Molecular weight marker indicates kDa.  
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the novel insertion was expressed primarily as part of the α isoform. Moreover, our current 
knowledge of DLG1 is focussed on the β isoform and little is understood of DLG1α 
expression. In qRTPCR analysis, primers were utilised that corresponded specifically to the 
DLG1α N-terminus, to the DLG1β L27 domain or to the HOOK domain I6 insertion 
(see Section 2.2.1.2, Table 2.2). cDNA was transcribed from DNAse treated RNA using 
oligodT primers before being subjected to qRTPCR. Gene expression was calculated 
relative to the number of transcripts of the internal control β2microglobulin (B2M), before 
comparison to external control (e.g. untransfected keratinocytes), to generate ddCt fold 
change. 
4.4.3.1 DLG1 isoform expression in keratinocytes containing high-risk HPV genomes 
As previously described, a screen of DLG1 expression levels in keratinocytes containing 
high-risk HPV genomes was carried out by microarray, and was validated using qRTPCR 
(Chapter 3). The microarray included two probes corresponding to different regions of 
DLG1, the aforementioned HOOK region, and a probe that aligned to the N-terminus of 
the DLG1β isoform (Figure 4.11). Microarray analysis showed an increase in DLG1 
transcripts containing the HOOK domain in monolayer-grown keratinocytes containing 
either HPV16 (11-fold) or HPV18 (7.5-fold) compared to untransfected keratinocytes from 
the same donor background (Table 4.6). Conversely, microarray analysis of DLG1β 
transcripts was not above the limit of 2.5 fold (Table 4.6). Gene expression analysis by 
qRTPCR verified the trend seen by microarray; in two donors a 18-20-fold increase in the 
DLG1 I6 insertion was observed in the presence of HPV16 genomes, and a 5-6-fold 
increase in HOOK transcripts was detected in HPV18 genome containing cells (Figure 
4.11). Although there was no microarray probe corresponding to DLG1α transcripts, the 
use of specific primers to this isoform in qRTPCR demonstrated that DLG1α transcripts 
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Figure 4.11: DLG1 isoform expression in primary keratinocytes 
containing α-HPV genomes 
RNA was extracted from primary keratinocytes containing HPV16 or 
HPV18 genomes, alongside untransfected HFKs, from two donor 
backgrounds. Following DNAse treatment and translation using oligodT 
primers,  cDNA was subjected to SYBR green qPCR, using primers specific 
to the DLG1α or DLG1β N-terminus, and to the I6-conatining HOOK 
region.  
Transcript levels were normalised to an internal B2M control and then to 
transcript levels in HFKs of  the same donor background (indicated by 
dotted line).  Error bars ±SEM of  three experimental repeats and star (*) 
indicates a p value of  <0.05. 
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were increased in both HPV16 and HPV18 genome containing keratinocytes, by more than 
~10- and ~4-fold respectively (Figure 4.11).  
Table 4.6: Microarray and qRTPCR analysis of DLG1  expression. 
Region of DLG1 HPV16 HPV18 
Microarray qRTPCR Microarray qRTPCR 
DLG1α N-terminus - 12.20 - 4.73 
DLG1β N-terminus 1.70 1.97 2.02 2.48 
HOOK Region 11.67 17.56 7.50 5.7 
 Microarray and qRTPCR analysis of DLG1 expression. Fold change relative to HFKs and average 
from 2 donor backgrounds. 
 
Both DLG1α and I6-containing transcripts were elevated to greater levels in keratinocytes 
containing HPV16 genomes than cells containing HPV18, and this was consistent in two 
donor keratinocyte backgrounds (Figure 4.11). Data is summarised in Table 4.6. 
4.4.3.2 DLG1 isoform expression during the productive life cycle 
To establish whether the DLG1 isoforms are affected upon activation of the productive 
virus life cycle, HPV18 genome containing keratinocytes were grown in semi-solid media 
(1.5% methylcellulose), which stimulates differentiation and activates productive viral 
events including viral genome amplification (Wilson and Laimins, 2005). Total cellular 
RNA was extracted from cells harvested at 0, 24 and 48 h and DLG1 isoform transcripts 
analysed using the primers in RTPCR analysis. Transcript level quantification at 24 and 48 
h was normalised to 0 h. DLG1α and DLG1β exhibited a ~3-fold increase in transcripts 
after 24 and transcript levels remained elevated at 48 h (Figure 4.12). DLG1 transcripts 
containing the novel HOOK region insertion demonstrated a 2-fold increase after 24 h 
growth in methylcellulose and remained at this levels at 48 h (Figure 4.12). 
Figure 4.12: Expression of  DLG1 in differentiating keratinocytes containing 
HPV18 
Primary keratinocytes containing HPV18 genomes cultured in semi-solid media 
(methylcellulose) and harvested at 24 and 48 h. Total RNA was extracted and 
transcribed to cDNA using oligodT primers, following treatment with DNAse. 
Three primer sets utilized in SYBR green qPCR, to measure transcript levels of  
DLG1α, DLG1β and the I6-containing HOOK region. Fold change in expression 
was calculated relative to the internal control B2M, and then to corresponding 0 h 
timepoint. Error bars show ±SEM of  three technical repeats. 
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4.4.3.3 Investigating HPV regulation of DLG1 isoform expression 
Although changes in E6 PBM activity are unlikely to have an effect upon the transcription 
of DLG1 isoforms, the change in E6 PBM activity is associated with alterations in 
proliferation of the genome containing cells (Delury et al., 2013), which may be reflected by 
changes in DLG1 isoform expression. Therefore, qRTPCR analysis was carried out upon 
monolayer keratinocytes containing HPV18 WT genomes or cells harbouring the ΔPDZ 
and ΔPKA genomes. The data showed that transcript levels of DLG1 isoforms - DLG1α, 
DLG1β and HOOK (I6) - were unchanged in the presence of genomes that have alteration 
on E6 PBM activity compared to the WT cells (Figure 4.13). At this stage of the study, it is 
not understood how the virus regulates DLG1 isoform expression.  
The studies to date have focussed on cells harbouring the viral episomes, which replicate as 
low copy extra-chromosomal plasmids. It may be that this effect on DLG1 is specific to 
this stage of virus replication and if so it would be expected to change if the episomes were 
lost and the viral genomes integrated into the host chromosomal DNA. To examine this, 
the expression of the different DLG1 isoforms was assessed in monolayer keratinocytes 
containing HPV18 genomes at early (P8, viral genomes are episomes) and late (P21, viral 
episomes are lost and viral DNA integrated) passages (E. Marsh, personal communication). 
When compared to episomal genome containing keratinocytes, the levels of DLG1β 
transcripts remain unchanged (Figure 4.14). Although the trend indicates that DLG1α and 
HOOK domain containing transcripts were decreased in cells containing integrated 
HPV18; this is based upon three technical repeats in one donor and therefore requires 
further experimental repeats across multiple donors (Figure 4.14). 
Figure 4.13: DLG1 isoform expression in keratinocytes containing HPV18 
genomes 
RNA extracted from primary keratinocytes containing HPV18 WT, ΔPDZ or 
ΔPKA genomes was DNAse treated and reverse transcribed using oligodT 
primers. The transcript levels of  DLG1α, DLG1β and the I6-containing HOOK 
region were measured by SYBR green qPCR, values were normalised to internal 
control (B2M) and then to levels of  cells containing WT HPV18 genomes. Error 
bars show SEM of  three technical repeats in two donors.  
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Figure 4.14: DLG1 isoform expression in keratinocytes containing episomal 
and integrated forms of  the HPV18 genome 
RNA extracted from primary keratinocytes containing HPV18 genomes was 
DNAse treated and reverse transcribed using oligodT primers. The transcript 
levels of  DLG1α, DLG1β and the I6-containing HOOK region were measured 
by SYBR green qPCR, values were normalised to internal control (B2M) and then 
to levels of  cells containing episomal genomes. Error bars ±SEM of  three 
technical repeats. 
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4.4.3.4 DLG1 isoform expression in normal tissue 
DLG1 is expressed in a range of tissue types and isoforms are likely to be expressed in a 
tissue specific pattern (McLaughlin et al., 2002; Mori et al., 1998; Godreau et al., 2003). 
Thus, the expression of DLG1 isoforms DLG1α, DLG1β and HOOK region-containing 
transcripts were investigated in normal tissues of the brain, skin, kidney and live and in 
normal immune cells (T-cells). For comparison of transcript levels, fold change was 
calculated relative to DLGα transcripts. In all the tissues analysed, DLG1β transcripts were 
more abundant than DLG1α or the HOOK region (I6) containing transcripts. Expression 
of DLG1β in kidney and skin was more than 7-fold higher and the level of DLG1β 
transcript in the liver was 4-fold higher than DLG1α (Figure 4.15). In brain tissue, the 
difference in expression between the α and β isoforms was the largest of the tissues 
analysed; expression of DLG1β was 11.9-fold higher than DLG1α (Figure 4.15). The 
expression of HOOK domain containing transcripts varied in the tissue analysed. In brain 
and liver the transcripts were less abundant than DLG1α transcripts, whilst in kidney tissue 
HOOK domain containing transcript levels were more than 3-fold higher than the 
DLG1α−containing transcripts (Figure 4.15). HOOK domain containing transcripts were 
expressed equally with DLG1α in skin (Figure 4.15). Analysis of DLG1 expression in T-
cells revealed equal levels of expression of the three transcripts assessed (Figure 4.15).  
4.4.3.5  DLG1 isoform expression in cancer cell lines 
Analysis of DLG2 expression has shown transcriptional upregulation of specific spliced 
variants in kidney cancer precursor growths (Zubakov et al., 2006). Furthermore, several 
studies have demonstrated differential expression of DLG1 in cancers (Watson et al., 2002; 
Frese et al., 2006; Cavatorta et al., 2004). To investigate the expression of DLG1 isoforms 
Figure 4.15: DLG1 isoform expression in normal tissue 
Total RNA was extracted from human brain, kidney, liver and skin tissue 
samples, as well as from T-cells. Following DNAse treatment and reverse 
transcription using oligodT primers, the levels of  DLG1α, DLG1β and the 
I6-containing HOOK region transcripts were measured by SYBR green 
qPCR, values were normalised to internal control (B2M) and then to the 
levels of  DLG1α transcripts. Error bars ±SEM of  three technical repeats. 
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during growth of cancer cells, qRTPCR analysis was applied to epithelial cancer cell lines. 
These cervical cancer-derived cell lines comprise the HPV18 positive line HeLa, the 
HPV16 positive cell lines SiHa and Caski and the HPV negative cervical cancer cell line, 
C33A. The fold change in DLG1 expression in these cells was calculated relative to the 
primary cervical keratinocytes (Cx129), which were isolated from uterine cervical tissue 
removed for a non-cancerous condition and therefore are considered non malignant. None 
of the cervical cancer cell lines analysed exhibited a change in DLG1 isoform expression 
levels; with the exception of the HPV16 positive cell line Caski, which demonstrated a 4.9-
fold increase in DLG1α transcripts (Figure 4.16). A trend towards a decrease in transcript 
levels was observed in the HPV negative cell line C33A, but this was not statistically 
significant (Figure 4.16). Expression of both DLG1β and HOOK domain containing 
transcripts remained unchanged in HeLa, SiHa and Caski (Figure 4.16).  
Since high-risk HPVs have also been etiologically linked to the development of head and 
neck cancers (Gillison and Shah, 2001), DLG1 expression analysis was extended to HPV 
positive and HPV negative head and neck cancer derived cell lines. Four HNSCC cells lines 
were examined; SCC040 and Vu40T, which are both HPV negative, and the HPV16 
positive cell lines SCC154 and Vu147 (Steenbergen et al., 1995; Rampias et al., 2009). 
Transcript levels in HPV positive cells were normalised to their HPV negative counterpart. 
All DLG1 transcripts detected were less abundant in SCC154 (HPV16+) compared to the 
SCC040 (HPV-), whereas DLG1α and HOOK domain containing transcripts are increased 
nearly 2-fold in the HPV positive Vu147 compared to Vu40T (Figure 4.17). The 
abundance of DLG1β was equal in Vu147 to Vu40T cells (Figure 4.17). 
In summary, transcription of DLGβ is unaffected by HPV, whereas α is upregulated along 
with the I6-containing isoform in episomal genome containing cells. The DLG1α, DLG1β 
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Figure 4.16: DLG1 isoform expression in cancer cell lines 
Transcriptional analysis performed the HPV positive cervical cancer cell lines 
HeLa (HPV18), SiHa (HPV16) and Caski (HPV16), and the HPV negative cervical 
carcinoma-derived cell line, C33A. The levels of  DLG1α, DLG1β and HOOK 
region containing transcripts were measured by SYBR green qRTPCR, using 
DNAse treated RNA transcribed to cDNA with oligodT primers.  
Expression levels were calculated relative to internal control (B2M), and then to  
non-cancerous cervical epithelial cells (Cx129 cells, indicated by dotted line). Error 
bars ±SEM of  three experimental repeats, * denotes p<0.05.  
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Figure 4.17: DLG1 isoform expression in head and neck cancer derived cell 
lines 
Transcriptional analysis performed on HPV negative (SCC040 and Vu40T) and 
HPV16 positive (SCC154 and Vu147) HNSCC derived cell lines. RNA was 
extracted, treated with DNAse and transcribed to cDNA using oligodT primers. 
SYBR green qPCR was then carried out using three primer sets, to measure the 
levels of  DLG1α, DLG1β and HOOK region transcripts. Relative expression 
levels were calculated relative to the internal control B2M, and then to the 
corresponding HPV negative cell line. Error bars show ±SEM of  three technical 
repeats. 
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and I6-containing transcripts were detected in a range of cell types and, although the β 
form appears to be the predominant form in normal tissue, the observed change in the 
ratio between the two main isoforms in certain cancer derived cell lines indicates that 
perturbing the balance of DLG1 isoforms may play a role in cancer development. 
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4.5 Discussion 
4.5.1  Identification of a novel insertion 
DLG1 encodes five known insertions, occurring in two regions of the protein (McLaughlin 
et al., 2002). This study has identified a new exon in the DLG1 gene, which is inserted into 
an area of DLG1 where alternative splicing has already been identified (the HOOK 
region). The new insertion has been named I6. DLG1 transcripts containing the I6 
insertion were detected in in normal human liver, kidney, brain, skin and immune cells 
indicating that I6 is important in DLG1 function in normal tissue. 
Interestingly, in primary human foreskin keratinocytes, transcripts containing I6 were 
upregulated by both high-risk viruses analysed, although the increase was greater in the 
presence of HPV16. The levels of these I6 containing transcripts were further increased 
upon activation of the productive virus life cycle. Together, these data indicate that I6-
containing variants of DLG1 are important in the replication of the viral genome. Indeed 
when the expression of I6-containing transcripts was examined in cells containing 
integrated α-HPV genome containing cells, the levels were decreased compared to cells 
containing episomal genomes, perhaps suggesting that the inclusion of I6 is required for 
the maintenance of episomal genomes.  
It may be that the increased inclusion of I6 in DLG1 is a function of the complete HPV 
genome. As integration disrupts the viral genome, and this data revealed a decrease in I6 
upregulation upon integration, it follows that viral factors are perhaps involved in the 
upregulation of the I6 spliced variant. The viral E2 protein has been shown to affect the 
transcription and splicing of a number of human genes, particularly those implicated in 
cancer development and in cell motility (Gauson et al., 2014; Bouvard et al., 1994a). 
Investigation by (Gauson et al., 2014) identified 522 genes with differentially spliced exons 
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in the presence of HPV16 E2. Although the mechanism of this is not known, E2 is known 
to bind to host transcription factors and may be able to bind and recruit splicing factors 
also (Johansson et al., 2012). Furthermore, E2 transcriptionally upregulates splicing factors, 
for example the factor SRSF1 (Mole et al., 2009). It is feasible that an increase in this factor 
increases splicing in the DLG1 HOOK region and promotes the inclusion of I6 in E2-
expressing cells. In addition, work in the Roberts lab has recently identified relationships 
between HPV and splicing regulators (Prescott et al., 2014). As the virus is able to 
manipulate splicing machinery, it may be that such manipulations cause or lead to the 
alternative splicing in the HOOK domain and inclusion of I6. Furthermore, splice site 
analysis revealed that the I6 exon did not completely adhere to the established consensus 
sequence; the acceptor sequence conformed to consensus but the 5’ donor was a weak 
match. This reflects a requirement for additional specific factors in splicing, a process 
which may be facilitated by the virus. 
The question remains as to why this variant is upregulated in the presence the high-risk 
viruses. Perhaps the ability of the virus to target DLG1 protein via the PBM is a 
mechanism of control to counter virally induced overexpression of the protein, or perhaps 
upregulation of DLG1 containing I6 is a consequence of viral interactions with cellular 
splicing and transcription machinery. Investigation into the functional consequences of the 
variant should help to answer this. 
As both the HOOK domain and α isoform were upregulated in HPV genome containing 
keratinocytes and were both downregulated upon integration of HPV18 genomes, it can be 
inferred that I6 is included in α N-terminus containing isoforms. Amplification using 
forward primers corresponding to DLG1α in combination with the reverse primer within 
the identified I6 insertion amplified a number of bands within the predicted size range of 
the mRNA (~1500 bp). Although sequencing of amplified fragments confirmed the 
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presence of the DLG1α 5’ sequence, further analysis is required to eliminate the possibility 
of an I6-containing DLG1β isoform. Cloning the entire cDNA would not only confirm 
this, but also allow endogenous expression of the variant and thus in depth analysis of the 
functional consequences of I6 inclusion.  
4.5.2 Consequences of I6 inclusion on DLG1 function 
Translation of I6-containing transcripts is predicted to produce a truncated form of DLG1 
protein (Figure 4.18). There is a precedence for alterative splicing as a mechanism of 
generating PDZ protein diversity; notably alternative splicing of the related PDZ protein 
CASK results in the inclusion of a 40 residue loop within the GK domain and ERBIN is 
predicted to encode a variant with a truncated PDZ domain, which has yet to be 
characterised (Favre et al., 2001). Given the specificity of DLG1 isoform interactions in T-
cells, where I1A-containing but not I1B-containing proteins are able to facilitate release of 
granules (Crocetti et al., 2014), and the tissue-specific nature of DLG1 expression, where I3 
is predominantly in mammalian cardiac tissue whereas the I2-containing form appears to 
be restricted to neurons and liver (Mori et al., 1998; McLaughlin et al., 2002; Godreau et al., 
2003), it is probable that I6 expression is tissue and cell dependent (Godreau et al., 2003; 
Lue et al., 1994).  
The predicted truncated protein would lack the GK domain. Without the GK domain, 
DLG1 can no longer form associations with the cytoskeleton (Wu et al., 2000; Manneville et 
al., 2010). Furthermore, absence of the GK domain would remove the ability of DLG to 
bind to phosphorylated proteins LGN and LGL, thus affecting Scribble complex 
regulation. The GK domain is involved in localising DLG1 to the midbody of the cell 
during asymmetrical cell division. It has been observed that truncation of the Drosophila Dlg 
C-terminus negatively affects the ability of neuronal cells to divide asymmetrically but did 
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Figure 4.18: Predicted protein structure of  I6-containing DLG1 
(A) Translation of  the new exon would produce a C terminal truncation, removing 
the DLG1 GK domain. We also suggest that this isoform lacks the N-terminal 
L27 domain. 
(B) The absence of  the GK domain may remove the ability of  DLG1 to associate 
with cytoskeletal filaments, although homodimersation is still possible with an 
intact SH3 domain. The presence of  the PDZ and SH3 domains, as well as I2, 
may still influence DLG1 localisation and cellular interactions. Question marks 
imply suggested consequences of  I6 inclusion. 
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not affect epithelial polarity (Bellaïche et al., 2001); mouse models expressing a truncated 
form of DLG1 lacking the SH3, GK and HOOK region display growth retardation, severe 
craniofacial abnormalities and perinatal death (Caruana and Bernstein, 2001; Klocker et al., 
2002). Although no effect was observed by Caruana and Bernstein (2001) on synaptic 
clustering of the protein, the domain obviously facilitates important interactions during 
mammalian development. Interestingly studies in mice showed that, in the absence of the 
GK domain, DLG1 was restricted to adherens junctions (Naim et al., 2005). This may be 
due to the presence of the I3 insertion, which has been shown to direct membrane 
localisation of the protein (Naim et al., 2005; Roberts et al., 2007; McLaughlin et al., 2002). 
Altogether, in vivo studies indicate that the GK truncated form of DLG1 does not perform 
functions in cell division or development, eliminating a role for I6-containing variants in 
these functions.  
As the I2 insertion has been identified as predominantly nuclear, and the GK nuclear 
export signal is predicted to be absent in this truncated variant, there is an expectation that 
the I6-containing protein residues in the nucleus (Roberts et al., 2007; Kohu et al., 2002). 
However, the precise role of nuclear DLG1 has not yet been elucidated; it is known to be 
important in the growth of undifferentiated epithelial cells (Roberts et al., 2007). Notably, 
I2 has been implicated in in chromatin-association (Kohu et al., 2002; McLaughlin et al., 
2002); as the I6 isoform was identified downstream of I2, the insertion may contribute to 
DLG1 interactions with cellular chromatin. The nuclear protein NET1 has been shown to 
interact with DLG1 to promote translocation of the complex to the nucleus and, based on 
its function at the plasma membrane, the PDZ protein may act as a scaffold protein, 
organising protein complexes and nuclear filaments (Garcia-Mata et al., 2007; Sabio et al., 
2010). The related MAGUK proteins CASK and ZO-1, which are involved in organisation 
of protein complexes at cell-cell junctions and synapses, are able to translocate to the 
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nucleus and contribute to the transcriptional regulation of specific genes; the truncated 
form of DLG1 may function similarly. Moreover, DLG1 has been shown to interact with 
the nuclear RNA-binding protein PSF (protein-associated splicing factor, Sabio et al., 2010). 
Via the PSF interaction, DLG1 binds to various RNAs (Sabio et al., 2010). Although the 
domain of DLG1 responsible has not been identified, this is another indication that nuclear 
DLG1 is involved in the regulation of gene transcription. This, with the observation that 
the GK domain forms interactions with a number of cytoskeletal filaments, could suggest 
that a nuclear form of GK-truncated DLG1 performs nuclear-specific functions.  
Alternatively, the truncated form of DLG1 may act in a regulatory fashion and modify full-
length protein function in a dominant negative manner. A number of PDZ proteins have 
been shown to act in this fashion. For example dynamin-2 sequesters GOPC at the cell 
periphery to block clathrin-mediated endocytosis (Cheng et al., 2004) and overexpression of 
the PDZ containing chromatin organiser SATB1 exerts a dominant negative effect upon 
itself, completely removing the transcriptional repressor functions (Notani et al., 2011). 
Indeed, overexpression of a dominant-negative isoform of CASK results in the 
mislocalisation of endogenous DLG1 (Lee et al., 2002). The I1A and I1B insertions, as well 
as the DLG1 SH3 domain have all been shown to facilitate DLG1 homodimerisation 
(McLaughlin et al., 2002; Hanada et al., 1997) and these are likely present in the I6-
conatining form. Interestingly, in Drosophilia, the expression of a DlgA isoform lacking the 
GK domain bound endogenous Dlg1 to enable trafficking of the truncated protein, acting 
as a ‘hitchhiker’ (Mendoza et al., 2003; Mendoza-Topaz et al., 2008; Asaba et al., 2003). Such 
a mechanism may also be employed by truncated I6-containing forms of DLG1. Moreover, 
functional screening of the I6 protein sequence hyopthesised an SH3 binding site, which 
has the potential to interact with the full-length DLG1 SH3 domain. Altogether, it is 
possible that the full-length and truncated forms of DLG1 are able to bind each other, 
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forcing other cellular proteins compete for binding to full-length protein and thus control 
DLG1 interactions.  
Screening indicated that inclusion of I6 introduces a MAPK1 binding site to DLG1. Upon 
activation, MAPK1 phosphorylates nuclear proteins to activate or repress transcription of 
genes involved in proliferation, differentiation and apoptosis. The interaction with I6-
containing DLG1 may facilitate interactions with, and thus phosphorylation of, specific 
transcription factors, and thus direct transcription of viral life cycle promoting genes. 
Interaction with MAPK1 may also facilitate phosphorylation of DLG; the PDZ protein is a 
known target of the MAPK cascade proteins ERK5, 
p38γ and cell cell cycle regulators CDK1 and CDK2 and the interaction with I6 may 
regulate the location and stability of the isoform in a similar fashion (Sabio et al., 2005; 
Narayan et al., 2008; Iñesta-Vaquera et al., 2010). 
Likewise, screening has suggested an SH3 binding site within the insertion, which may 
allow binding of the kinases Src or PI3K to enable DLG1 phosphorylation or interaction 
with the membrane located proteins phospholipase C, cortactin or SORBS1 to facilitate the 
formation of protein complexes at the cell periphery. 
It is interesting to speculate whether the inclusion of I6 affects DLG1 mRNA stability. 
Cavatorta et al. (2011) have identified two alternative 5’UTRs of DLG1 which are likely to 
affect the stability of transcribed mRNA and efficiency of translation. Elements within 
mRNA have been shown to effect the stability of β-catenin transcripts and isoforms of 
ZO-1 exhibit different mRNA stabilities (Reichert et al., 2000; Bachurski et al., 1994). 
Alternatively, I6 transcripts may act at an mRNA level to regulate other DLG1 transcripts. 
For example, genes encode long non-coding RNAs (lncRNA) or microRNAs (miRNA), 
which partially anneal with their target protein coding mRNAs, which can trigger 
degradation and regulate expression (Hannon et al., 2006; Ponting et al., 2009; Wilusz et al., 
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2009; Wu and Brewer, 2012). In this manner, the I6-containing transcripts may act as a 
dominant-negative regulatory element. Although we hypothesize that this novel DLG1 
spliced variant is expressed as protein, the precise function will be characterized in more 
detail in future studies (see Section 4.4.4).  
4.5.3  Differential expression of DLG1 isoforms 
DLG1 isoforms are differentially expressed in human tissues and deregulated in cancers 
(Godreau et al., 2003; Fuja et al., 2004). Thus, the expression of DLG1 α and β isoforms 
was investigated in various stages of HPV-associated malignant disease. Previous studies 
from the Roberts lab have shown that DLG1 protein is overexpressed and mislocalised at 
early stages and then disappears in late stages of cervical cancer (Watson et al., 2002). In 
this study, DLG1α, but not β, transcripts were increased by the presence of high-risk HPV 
genomes in primary keratinocytes and upon integration of HPV genome, the abundance of 
β transcripts decreased. However, in the cervical epithelial cells analysed, only the α form 
was upregulated in Caski cells, other cell lines indicated no change in expression of either 
of the DLG1 isoforms investigated. Cells containing HPV16 (Caski and SiHa) or HPV18 
(HeLa) and HPV negative (C33A) cells were included in the analysis, which indicates that 
the effect upon DLG1 expression is not HPV specific. Both Caski and SiHa are HPV16 
positive, but differ in the number of integrated genomes; more than 600 have been 
detected in Caski and one in SiHa (Raybould et al., 2014). The difference in DLG1 
expression between the two HPV16-driven cancer cells may be attributed to the vast 
difference in copy number, but it is more likely that there are other mutational changes that 
have occurred in the different malignancies from which the cells are derived. It has been 
noted that DLG1 expression in C33A cells is low and, as the PDZ protein is deregulated at 
either the gene or protein level in a number of cancers, it is likely that the cancers from 
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which these cell lines were generated had developed mechanisms other than via HPV to 
disrupt DLG1 expression (Fuja et al., 2004; Watson et al., 2002; Cavatorta et al., 2004; Frese 
et al., 2006). 
Although the presence of HPV in HNSCC cells lines correlated with effects upon the 
expression of DLG1 isoforms, it varied amongst the cell lines as to whether the levels 
decreased or increased. Both SCC154 and Vu147 are HPV16 positive; the former indicated 
a decrease in all DLG isoforms whereas there was a trend towards an increase in α-DLG1 
transcripts in Vu147 cells. The disparity between cell lines may be due to a difference in cell 
background; SCC154 and SCC040 are derived from tongue, whereas Vu40 and Vu147 are 
both from floor of mouth cancers (Steenbergen et al., 1995; Rampias et al., 2009). This 
implies that DLG1 expression is context specific, but needs to be confirmed experimentally 
by further repeats, and could be extended by analysis of further HNSCC derived lines.  
This expression analysis included differentiated cells and healthy tissue, where DLG1β was 
more abundant than the α form. As keratinocytes were stratified in culture, the abundance 
of both DLG1 isoforms increased, which correlates with the established knowledge that 
DLG1 is upregulated during differentiation of epithelium (Rivera et al., 2009). The 
combinations of insertions included in DLG1 are known to depend upon the tissue in 
which they are expressed (Godreau et al., 2003; McLaughlin et al., 2002; Roberts et al., 
2007). The presence of an L27 domain is important in targeting the β isoform to the 
membrane, via DLG2, and specifically to the baso-lateral membrane of epithelia via CASK 
(Lozovatsky et al., 2009; Hanada et al., 2003). The DLG1-mediated formation and 
maintenance of cell-cell contacts is a crucial function of the PDZ protein in cells and the 
abundance of the DLG1β isoform may therefore be unsurprising.  
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The specific functions of the α isoform have not been extensively studied, although it is 
known that the α and β forms differentially traffic AMPA receptors at the synapse (Waites 
et al., 2009). The specific upregulation of the α-isofom during episomal HPV genome 
replication may reflect the viral requirement for increased nuclear functions of the protein. 
In the nucleus, DLG1 has been implicated in chromatin reorganization, in the regulation of 
transcription, splicing and as a scaffolding protein (Kohu et al., 2002; Lue et al., 1994; 
Huang et al., 2000). Upregulation of DLG1α in epithelia may therefore promote the 
transcription of growth-promoting genes and/or promote viral genome replication in order 
to create an environment beneficial to viral propagation. In addition, DLG1, specifically I2-
containing isoforms, is known to be important in the growth of undifferentiated epithelial 
cells (Roberts et al., 2007) and thus HPV upregulation of DLG1α may be a viral 
mechanism to promote the growth of keratinocytes. 
4.5.4 Future directions 
Although protein analysis using a range of DLG1 antibodies revealed a number of lower 
molecular species, none were obviously suggestive of a truncated isoform. However, this is 
limited by the absence of an untransfected keratinocyte control, which would enable a 
comparison of expression levels and thus the identification of the expected truncated 
protein expressed to a lesser degree. Design and use of an α-specific antibody did not 
identify a smaller form that would be expected if the upregulated I6 form were detected. 
Thus, further work aims to dissect the downstream consequences of I6 inclusion in DLG1 
mRNA and/or protein. In the short term, as the I2 sequenced has been identified 
upstream of I6, antibodies specific to I2 could be applied to protein extracted from primary 
cells and from cancer cell lines.  
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Further characterisation of I6 expression will be carried out; production of an I6-specific 
antibody has not yet been successful, but expression of the sequence can be achieved by 
cloning techniques. In this way, an investigation into the consequences of endogenous 
expression of this novel variant in cells could clarify the effect upon full-length DLG1 
subcellular localisation, identify interacting proteins and infer function, as well as assess the 
phenotype of cells where this protein is overexpressed. Furthermore, it would be of 
interest to identify the presence of I6-containing isoforms in a larger range of tissue than 
was investigated here, including primary cancer tissue. 
Having generated an antibody specific to the α isoform of DLG1, future work could 
investigate whether the ratio of α and β isoforms mRNA corresponds to protein levels and 
could more specifically identify the localisation of the isoforms in epithelia. Moreover, 
immunoprecipitation experiments with this antibody will enable the identification of 
cellular interactors and refine our knowledge of the functions of DLG1 isoforms.  
There is also further characterisation of spliced variants of DLG1 to be carried out. An I3 
and I6 containing isoform was identified but not studied in this thesis. Work by 
McLaughlin et al. suggests that transcripts containing both I3 and I2 produced a protein 
truncated after the I3 region in vitro, but the presence and consequence of combinations of 
insertions can be additional investigated. The spliced insertions present in DLG1 HOOK 
region are likely to exist in a range of combinations (there are more than 500 mathematical 
possibilities), the investigation of which across different tissues and cells would greatly 
expand current knowledge of DLG1 isoform expression.  
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CHAPTER 5: REGULATION OF THE HUMAN PAPILLOMAVIRUS E6 PDZ 
BINDING MOTIF DURING THE VIRUS LIFE CYCLE 
5.1 Introduction 
5.1.1 Cellular PDZ interactions  
In vivo many cellular PDZ-PBM interactions occur, acting to orientate cells, receptors and 
organise signalling scaffolds (Fan and Zhang, 2002). The PDZ domain is composed of six 
β-sheets and two α-helices; a groove between the second β-strand and the second α-helix 
forms the hydrophobic pocket where the PBM peptide binds, serving as an extra β-strand 
(Doyle et al., 1996; Songyang et al., 1997; Niethammer et al., 1998). Further interactions 
between main chain residues stabilise and add specificity to the binding, for example a loop 
at the end of the binding groove is involved in positioning the PBM peptide and the 
terminal COOH of the PBM is coordinated by a network of hydrogen bonds to main-
chain amide groups (Doyle et al., 1996). When bound within the PDZ groove, the side 
chain of the terminal and -3 residues of the PBM peptide point towards the base of the 
peptide-binding groove (Songyang et al., 1997; Doyle et al., 1996). In some cases, 
recognition of the PBM involves residues outside of the four amino acid consensus motif, 
enabling specificity of interactions unique to individual PDZ domains (Figure 1.11, 
Niethammer et al., 1998). 
The specificity of PDZ:PBM must be regulated in order to coordinate interactions spatially 
and temporally. As such, many PDZ:PBM interactions are regulated by phosphorylation of 
the PDZ-binding peptide (Table 5.1 and Table 5.2). Due to the charge and size of a 
phospho group, its introduction can prevent the PBM sterically from binding within the 
PDZ pocket (Akiva et al., 2012, Figure 1.11). For example, phosphorylation of the PBM 
CHAPTER 5: REGULATION OF THE HPV E6 PBM DURING THE VIRUS LIFE CYCLE 
-168- 
serine residue of the glutamate receptor subunit GluR2 (SVKI) prevents its interaction with 
PICK (protein that interacts with C kinase 1) and reduces affinity for GRIP (glutamate 
receptor interacting protein, Shao et al., 2010; Matsuda et al., 1999). Interaction with PICK1 
and GRIP modulates the location of the receptor and influences AMPAR clustering at the 
cell membrane, which in turn controls the transmission of synaptic impulses (Matsuda et al., 
1999). Thus, phosphorylation of the GluR2 C-terminus may regulate postsynaptic 
clustering in neurons and downstream transmission of impulses (Matsuda et al., 1999; Shao 
et al., 2010). 
Table 5.1: Examples of PBM phosphorylation  
PDZ containing 
protein 
Binding 
partner 
PBM Kinase Reference 
DLG4 and TIP-1 Kir 2.3 RREESRI PKA Tanemoto et al., 
2002 
DLG4 Stargazin RRTTPV PKA/MA
PK 
Choi et al., 2002 
DLG4 and DLG3 NR2B subunit of 
NMDAR 
SSIESDV CK2 Chung et al., 
2004 
GRIP1 GluR2 subunit of 
AMPAR 
GIESVKI PKC Matsuda et al., 
1999 
DLG4 and DLG1 NR2B subunit of 
NMDAR 
SSLESEV PKA/PK
C 
Chung et al., 
2004 
DLG4 LRP4  SSESQV CaMKII Tian et al., 2006 
GRID2IP GluR2 subunit of 
AMPAR 
DPDRGTSI PKA Sonoda et al., 
2006 
DLG1 HTLV-1 Tax-1 SPGGLEPPSEKHFRETEV CK2 Bidoia et al., 
2010 
Phosphorylated residue highlighted in bold, PBM underlined.  
 
Conversely, phosphorylation of a residue adjacent to the PBM of the mutated in colorectal 
cancer (MCC) protein increases the affinity of MCC for the polarity protein SCRIB, 
indicating that phosphorylation can also promote interactions (Pangon et al., 2012). The 
binding affinity is thought to increase due to the availability of additional interactions 
between MCC and the SCRIB PDZ domain upon PBM phosphorylation (Pangon et al., 
2012). It has been suggested that the interaction between SCRIB and MCC regulates the 
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formation of lamellipodia in migrating cells, and that this is regulated by MCC 
phosphorylation (Pangon et al., 2012). 
In the case of the membrane protein apactin, phosphorylation of the PBM decreases 
affinity for the second PDZ domain of NHERF1 but increases binding affinity for the first 
PDZ domain and for fellow PDZ protein PDZK1 (Tandon et al., 2007). PBM 
phosphorylation also increases apactin association with the cytoskeleton, implying that the 
switch in interaction promotes the function of apactin in maintaining actin filament 
bundles at the apical surface (Tandon and De Lisle, 2004). Moreover, it has been suggested 
that, as apactin and NHERF1 function together in exocytosis, switching the PDZ binding 
preference allows NHERF1 to act as a scaffold and bring together an alterative 
combination of proteins via their PBMs (Tandon et al., 2007; Tandon and De Lisle, 2004).  
Interestingly, regulatory phosphorylation outside of the PBM can affect PDZ binding, 
leading to a change in protein structure that affects the availability of the PBM for cognate 
binding. For example, regions of the pleckstrin homology (PH) domain of Kalirin-7 are 
heavily phosphorylated in neuronal cells and this is predicted to affect the interaction with 
a number of PDZ substrates, including DLG4, at the synapse (Kiraly et al., 2011). 
Furthermore, different patterns of phosphorylation depend upon cellular context; Kalirin-7 
sites at the N terminus were phosphorylated in mouse brain by PKA, PKC and CaMKII 
but phosphorylation was not identified in non-neuronal cells (Kiraly et al., 2011). Thus, 
phosphorylation of PDZ-binding proteins both within and outside of the PBM can have 
varying affects upon PBM:PDZ interactions, and is likely to depend upon the cellular 
context and the proteins in question (Table 5.2).  
5.1.2 Viral PBM regulation  
Post-translational modifications of HTLV-1 Tax have been suggested to regulate the 
activity of the viral PBM (Bidoia et al., 2010; Lodewick et al., 2013). HTLV-1 Tax is 
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phosphorylated within the PBM at threonine 351 by CK2 and is acetylated proximal to the 
PBM at lysine 346 by p300 (Bidoia et al., 2010; Lodewick et al., 2009). Phosphorylation of 
the Tax PBM interrupts the proteins ability to interact with DLG1 and disrupts viral 
activation of the NFκB pathway, whilst acetylation promotes activation of the NFκB 
pathway (Suzuki et al., 1999; Bidoia et al., 2010). The NFκB family of transcription factors 
regulate the expression of a number of cellular genes associated with cell growth, 
apoptosis, embryonic development, immune responses, stress responses and oncogenesis 
(Pahl, 1999). HTLV-1 mediated activation of these genes is likely to promote viral 
replication, indeed the PBM is crucial to Tax-induced T-cell proliferation (Xie et al., 2006). 
Phosphorylation of the Tax PBM may be a mechanism to impair PBM binding when 
NFκB activation is not required (Bidoia et al., 2010). Furthermore, as Tax binding to 
MAGI-1 alters the localization of both proteins, interruption of this by phosphorylation 
may act to regulate Tax location and thus control the interactions that the viral protein is 
able to make spatially during stages of viral replication (Ohashi et al., 2004). However, the 
functional consequences of Tax PBM phosphorylation during HTLV-1 replication have yet 
to be fully characterized. 
Crystal structures have revealed that, as well as the four residue class I PBM, residues 
upstream are also involved in recognition by DLG1 and MAGI-1 PDZ domain recognition 
(Zhang et al., 2007; Charbonnier et al., 2011; Mischo et al., 2013). Moreover, a peptide-
binding loop of the PDZ domain specifically interacts with an arginine residue at the -5 
position the HPV18 E6 peptide which, when mutated, was demonstrated to be crucial in 
HPV-mediated degradation of DLG1 and MAGI-1 (Zhang et al., 2007). The presence of 
the binding loop and the interaction with six of the E6 PBM residues may explain the 
specificity of high-risk HPV E6 proteins in their ability to target cellular PDZ domain 
containing proteins (Zhang et al., 2007; Charbonnier et al., 2011).  
CHAPTER 5: REGULATION OF THE HPV E6 PBM DURING THE VIRUS LIFE CYCLE 
-171- 
As phosphorylation is an established mechanism by which binding to PBMs is controlled, 
cellular kinases may also regulate the E6 PDZ binding function during the HPV life cycle. 
As with cellular proteins, phosphorylation within the PBM of E6 has been predicted to 
affect binding activity. Recognition sites of the serine/threonine kinases protein kinase A 
(PKA) and AKT have been identified proximal to the PBM (Figure 5.1). Structural analysis 
of the E6 PBM bound to PDZ proteins DLG1 and MAGI-1 indicates that a phosphate 
group would not fit in the interacting groove and would therefore disrupt E6-PBM binding 
to cellular PDZ proteins (Zhang et al., 2007; Charbonnier et al., 2011).  
In vitro kinase assays have shown that the HPV18 E6 PBM is phosphorylated by PKA and 
studies have identified phosphorylated E6 in human epithelial cells (Kühne et al., 2000). 
Furthermore, stimulation of PKA activity inhibits the degradation of DLG1 induced by 
HPV18 E6, indicating that phosphorylation inhibits E6-PDZ interactions (Kühne et al., 
2000). Moreover, mutating the PKA recognition site proximal to the PBM, by substituting 
an arginine residue for a leucine residue at position 153, removes the sensitivity of HPV-
mediated DLG1 degradation to PKA activity, indicating that regulation of PBM activity is 
removed once the PKA recognition site is mutated (Kühne et al., 2000). It is suggested that 
this substitution enables E6 to degrade DLG1, and other PDZ targets constitutively, 
regardless of PKA activity (Kühne et al., 2000). Thus phosphorylation of the E6 PBM is 
able affect E6 PDZ interactions. 
Different HPV E6 proteins exhibit different susceptibilities to PKA phosphorylation; 
HPV18 E6 shows a higher susceptibility to PKA phosphorylation than HPV16, and 
HPV31 was shown to be a weak PKA substrate (Kühne et al., 2000; Boon et al., 2014). The 
kinase AKT (also known as protein kinase B) is another candidate for recognizing and 
phosphorylating high-risk HPV E6 PBMs (Figure 5.1). Conservation of a kinase 
recognition site in high-risk HPV types suggests that phosphorylation of the PBM is 
Group 1
HPV 16 CMSCC      RSSRTRRETQL  
HPV 18 CHSCCNRARQE RLQRRRETQV  
HPV 31 CIVCW        RRPRTETQV  
HPV 33 CAACW      RS  RRRETAL
HPV 35 CMSCW        KPTRRETEV
HPV 39 CRRCWTTKRED RRLTRRETQV
HPV 45 CNTCCDQARQE RLRRRRETQV
HPV 51 CANCW    Q  RTRQRNATQV
HPV 52 CSECW         RPRPVTQV 
HPV 56 CLGCW   RQ  TSREPRESTV
HPV 58 CAVCW  RPRRRQTQV
HPV 59 CRGCRTRARHLRQQRQARSETV 
 
Group 2A
HPV 68 CRHCWTSKRED RRRTRQETQV
 
Group 2B
HPV 26 CTNCW       RPRRQTETQV 
HPV 30 CLQCW       RHTTSTETAV
HPV 34 CRQCW          RPSATVV 
HPV 53 CLTCW       RHTTATESAV
HPV 66 CLQCW     RHTSRQATESTV 
HPV 67 CSVCW        RPQRTQTQV 
HPV 69 CTNCW      RPRREATETQV 
HPV 70 CRHCWTSNRED RRRIRRETQV
HPV 73 CTRCW    RPSATVV
HPV 82 CANCRTAA   RQRSETQV 
HPV 85 CRRCMTRA QE QQGSRRETQV
HPV 97 CNSCYNQSRQE RLSRRRETQV
 
Group 3
HPV 6       CLHCWTTCMED       MLP
HPV 11 CLHCWTTCMED       LLP
 
 
PDZ binding motif (PBM)
 
Bold and arrow indicates residue targeted
 
PKA recognition sequence (R-R-S/T-Y) 
 
Akt recognition motif (R-X-R-X-X-S/T)
Key:
Consensus PBM: RXSTXLV
Figure 5.1: Alignment of  E6 C-terminal sequences  
Alignment of  the C terminus of  the E6 protein from HPV types belonging to 
IARC Groups 1, 2A, 2B  and 3. PBM shaded in grey, PKA recognition site boxed 
and AKT recognition site underlined, target residue for phosphorylation indicated 
in bold. 
The consensus PBM sequence is shown. Number above PBM indicates residue 
nomenclature, numbered in reverse from the C-terminal amino acid. 
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important during the viral life cycle, and that it may be an important feature in viral 
oncogenesis. 
Table 5.2: Consequences of cellular PBM Phosphorylation 
PBM-
containing 
protein 
Protein 
function 
Consequences of 
phosphorylation Kinase Reference 
 MCC 
protein 
Cell cycle 
regulator 
Increase binding affinity with 
SCRIB PAK1 
Pangon et al., 
2012 
GluR2  
Glutamate 
receptor 
subunit 
Disrupted interaction with PICK1 
Disrupted binding to glutamate 
receptor interacting protein 
CK2 
 Shao et al., 
2010; Matsuda et 
al., 1999 
Kir2.3 Potassium ion channel 
Interruption of colocalisation with 
DLG4 at postsynaptic 
membrane  
TIP-1 interaction through its 
PDZ domain is abolished 
PKA 
 Yan et al., 
2009a; Cohen et 
al., 1996 
MMAC1/P
TEN 
Membrane 
tethered 
phosphatase 
Promotes binding with DLG1 
and hMAST205  Unknown Adey et al., 2000 
Ephrin B 
Receptor 
tyrosine 
kinase 
Syntenin binding hindered 
PTPN13 binding unchanged 
RGS3 binding unchanged 
Par6 interaction disrupted  
PKA Lu et al., 2001; Lee et al., 2008 
Jagged-1 Membrane bound ligand  Binding to AF-6 disrupted Unknown 
Popovic et al., 
2012; Chetkovich 
et al., 2002; Stein 
and Chetkovich, 
2010 
Stargazin Calcium ion channel Binding to DLG4 inhibited PKA 
Chetkovich:2002
wg, 
Stein:2010gb} 
NR2B  
Subunit of 
NMDA 
receptor 
Affects binding to DLG4 and 
DLG2 CaMKII 
Chung et al., 
2004 
Apactin  Membrane glycoprotein 
Decreased affinity for NHERF1 
PDZ2. Increased affinity for 
PDZK1 and NHERF1 PDZ1 
Unknown Tandon et al., 2007 
Kalirin-7 RhoGEF kinase 
Decreased affinity for DLG4 
suggested 
Fyn, PKA, 
PKC, 
CK2, 
CaMKII 
Kiraly et al., 2011 
β2-
adrenergic 
receptor 
GPCR 
NHERF1 interaction disrupted, 
leading to mis-sorting of 
receptor  
GRK5 Cao et al., 1999 
LRP4  
Wnt 
signalling 
regulator 
Suppressed its interaction with 
DLG1 and DLG4   CaMKII Tian et al., 2006 
Syndecan-
1 
GPCR 
coreceptor 
Interaction with syntenin-1 
promoted by dephosphorylation Unknown Sulka et al., 2009 
 
HTLV-1 
Tax 
Viral 
oncoprotein 
Impair binding to DLG1 
Affects NFkB pathway 
interaction 
CK2 Bidoia et al., 2010 
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As well as interrupting PDZ interactions, phosphorylation of the E6 PBM enables 
alternative protein interactions (Figure 5.2). Phosphorylation of exogenously expressed 
HPV18 E6 by PKA promotes an interaction with the adapter protein 14-3-3ζ (Boon and 
Banks, 2012a; Boon et al., 2014). This suggests that phosphorylation of the PBM can act as 
a switch, changing the binding profile of the PBM. The same study demonstrated that 
binding of 14-3-3ζ increased the stability of the viral oncoprotein (Boon and Banks, 
2012b). 
Thus, the PBMs of high-risk α-HPV E6 proteins are highly likely to be phosphorylated 
during the viral life cycle. However, the affect of PBM phosphorylation upon E6 
interactions during the viral life cycle is largely unknown. 
 
  
RLQRRRETQV -C
A
N C
PDZ protein binding 
and degradation
148$ 151$30$ 33$ 63$ 66$ 106$ 109$ 139$ 142$
9$ 13$
E6AP 
binding$
Zinc Finger Zinc Finger
CXXC CXXC CXXC CXXC
HPV18 E6 C terminus:
CHSCCNRARQERLQRRRETQV-C
PBM
PKA recognition
Figure 5.2: The HPV18 E6 PDZ binding motif  
(A)  The amino acid sequence of  the HPV18 E6 
(B)  The HPV18 E6 PBM sequence and current binding models: A number of  
E6 oncoproteins have been shown to bind cellular PDZ proteins via a C-
terminal PBM, leading to their proteasome mediated degradation. The PBM 
overlaps with a PKA recognition site, phosphorylation of  which sterically 
hinders PDZ protein binding. Boon et al. have shown that the 
phosphorylated PBM can bind to 14-3-3ζ. 
B
PDZ protein binding 
and degradation
RLQRRRETQV -C
P PDZ protein binding 
and degradation
PKA
RLQRRRETQV -C
P
14-3-3
14-3-3ζ binding
XSTXLV
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5.3 Hypothesis and objectives 
Studies to date have shown that the PBM of HPV18 E6 is phosphorylated by PKA, and 
that this alters the interactions that E6 is able to form with cellular factors. The 
experiments described in this chapter aimed to study phosphorylation of the PBM within a 
model of the HPV18 life cycle: Specific objectives were to: 
i. Identify kinase recognition sites overlapping the PBMs of high-risk α-HPV E6 
oncoproteins 
ii. Determine whether the HPV18 E6-PBM is phosphorylated by PKA in the HPV18 life 
cycle model 
iii. Determine whether phosphorylation affects HPV18 E6 protein levels in viral genome 
containing cells 
iv. Determine whether E6 PBM phosphorylation affects PBM-PDZ interactions during 
the HPV life cycle.  
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5.4 Results 
5.4.1 Computational screening predicts phosphorylation of α-HPV E6 PBMs  
To date, twelve HPV types have been defined by the International Agency for Research on 
Cancer (IARC), a department of the WHO, as ‘high-risk’ with respect to causing cancer 
(group 1), and a further ten types are recognised as ‘probably and ‘possibly’ cancer-causing 
(group 2A and 2B, Table 1.3, Bouvard et al., 2009). To initially assess the susceptibility of 
high-risk HPV E6 proteins to phosphorylation, a Scansite motif screen was performed on 
the amino acid sequences of HPV E6 proteins from the IARC groups 1, 2A and 2B 
(Figure 5.3). The screen assessed the likelihood of peptide phosphorylation to produce a 
probability score within the range of 0 to 1. All of the group 1 HPV types are predicted in 
this screen to be targeted by a kinase within, or proximal to the PBM, with a probability 
score of 0.49 or more (Figure 5.3). Furthermore, the cellular kinases predicted to perform 
this phosphorylation included the AGC kinase family members PKA, AKT, protein kinase 
C (PKC) and AMPK (AMP-activated protein kinase) (Figure 5.3). Both PKA and AKT 
were predicted to phosphorylate the HPV16 PBM with scores of 0.49 and 0.52, whereas 
the PBM of HPV18 E6 was a predicted target of PKA alone, with a score of 0.46 (Figure 
5.3). Phosphorylation of HPV16 by AKT produced a higher probability score than for 
PKA (0.53 cf. 0.49). During this study, it was confirmed in vitro that AKT is able to 
phosphorylate purified HPV16 E6 at the PBM and that PKA is able to target the PBM of 
both HPV16 and HPV18 E6 proteins (Boon et al., 2014; Boon and Banks, 2012b). Boon et 
al. confirmed that α-HPV E6 proteins are susceptible to phosphorylation at the PBM and 
further investigations in this study focussed on this in the context of whole genome 
replication in primary cells. In contrast to the group 1 viruses, not all members of group 2 
Virus Kinase Scansite Score 
Protein Kinase A  0.4969
Akt Kinase 0.5272
HPV 18 Protein Kinase A 0.4626
HPV 31 Akt Kinase 0.5565
HPV 33 Protein Kinase A 0.4939
HPV 35 Protein Kinase A 0.5472
Protein Kinase A 0.5054
Protein Kinase C 0.5663
Protein Kinase A 0.4207
Akt Kinase 0.5451
HPV 51 Akt Kinase 0.6631
HPV 52 Akt Kinase 0.6997
HPV 56 Akt Kinase 0.5733
HPV 58 Protein Kinase 0.4892
HPV 59 Akt Kinase 0.616
HPV 68 Akt Kinase 0.6313
Protein Kinase A 0.6086
Akt Kinase 0.6564
AMP Kinase 0.661
HPV 34 AMP kinase 0.7454
HPV 66 PKC 0.4996
HPV 67 AMP kinase 0.6841
HPV 69 AMP kinase 0.7299
PKA 0.4931
Akt 0.62
Akt 0.5272
AMP kinase 0.6779
HPV 85 Protein Kinase A 0.5563
HPV 16 
HPV 39 
HPV 45 
HPV 26 
HPV 82
HPV 70
Figure 5.3: Computational screen of  E6 C-terminal sequences  
A screen of  the peptide sequence of  E6 proteins from HPV types classified by 
the IARC as cancer causing (Group 1) and probably (2A) and possibly (2B) cancer 
causing was carried out using Scansite software (http://scansite.mit.edu/). The 
probability score for each kinase targeting the E6 C-terminus is indicated by green 
bar and number. 
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had predicted kinase sites within the C-terminus of E6. These included HPV types 53, 73 
and 97 (Figure 5.3).  
5.4.2 Investigation into the effect of PBM phosphorylation upon E6 
5.4.2.1 E6 is phosphorylated in primary keratinocytes harbouring HPV genomes 
In order to assess whether phosphorylation of the PBM occurs during the HPV life cycle, 
primary keratinocytes containing HPV18 genomes were grown in monolayer and treated 
with the PKA activator forskolin (FK), or with vehicle (DMSO) for 6 hours. The HPV18 
DNA positive HeLa cells were included in the assay since the E6:PDZ protein interactions 
in theses cells can be modulated by PKA activation (Kühne et al., 2000). Total protein was 
extracted from the cells in urea buffer and then subjected to western blot analysis using an 
antibody that recognises the phosphorylated form of the HPV18 E6 PBM (E6P, a kind gift 
from L. Banks). Under conditions of PKA activation, phospho E6 was detected in both 
HeLa and genome containing cells; the levels of phosphorylated E6 (E6P) detected were 
higher in cells exposed to PKA activator, whereas it was barely detectable in vehicle-treated 
cells (Figure 5.4 A). Furthermore, when the same treatment was applied to wild-type 
genome containing cells alongside cells containing ΔPKA genomes (the mutation abrogates 
the PKA recognition site), the levels of phosphorylated E6 (E6P) were again higher in cells 
harbouring the wild type genomes exposed to PKA activator (Figure 5.4 B). In this 
analysis, there was no significant detection of the mutated protein (∆PKA) (Figure 5.4 B). 
Untransfected HFKs were included to show that neither the E6 nor the E6P antibodies 
detected proteins in these cells (Figure 5.4 B). An increase in E6 levels in HeLa and WT 
genome containing cells was observed in many, but not all studies, where cells were treated 
with PKA activator (Figure 5.4 A). This suggested an effect of the kinase upon E6 protein 
stability.  
Figure 5.4: Phosphorylation of  E6 in HPV18 positive cells 
(A) HeLa and HPV18 genome containing keratinocytes, grown in monolayer, were 
treated with the PKA activator forskolin (FK,+) or the vehicle DMSO (-) in 
serum-free media. After 6 hours, protein was harvested and separated by SDS-
PAGE. Membranes were blotted with mouse anti-HPV18 E6 (Santa-Cruz) or 
rabbit anti-HPV18 E6P, alongside β-actin as a loading control. Molecular 
weight markers indicated in kDa 
(B)  From Delury et al. 2013. HPV18 genome containing keratinocytes were  grown 
in monolayer alongside ΔPKA genome containing cells and were treated with 
the PKA activator forskolin (FK) or the vehicle DMSO (-) in serum-free 
media. After 6 hours, protein was harvested and separated by SDS-PAGE. 
Membranes were blotted with mouse anti-HPV18 E6 (Santa-Cruz) or rabbit 
anti-HPV18 E6P, alongside β-actin as a loading control. HFK was included as 
a negative control. 
 
Numbers indicate fold change in E6P relative to E6, following normalisation of  
each to the respective loading control. 
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In order to assess whether specific cellular pools of E6 were phosphorylated by PKA, 
HPV18 genome-containing cells were grown in monolayer culture and subjected to 
subcellular fractionation, alongside the HPV18 positive cancer cell line HeLa. 
Housekeeping gene analysis confirmed enrichment of four subcellular compartments; 
cytoplasmic (F1), membrane (F2), nuclear (F3) and cytoskeletal (F4). As E-cadherin was 
not detectable in HeLa cells, ZO-1 was included to demonstrate enrichment of the 
membrane fraction in these cells (Figure 5.5 A).  
The E6 oncoprotein was predominantly nuclear with a small amount of protein detected in 
the cytoplasmic, membrane and cytoskeletal fractions (Figure 5.5 B). Immunoblotting with 
the phospho-specific E6 PBM antibody detected protein primarily in the nuclear fraction 
of the HPV18 containing cells. Similarly, in HeLa cells the nuclear fraction of E6 was 
detected with the phospho E6 antibody, and this was consistent across three experiments 
(Figure 5.5 B and C).  
Whilst the profile of E6 distribution is similar between genome containing cells and HeLa 
cells, where the viral DNA is integrated into the host genomes, a very small increase in E6 
present in the cytoplasm was observed in the cancer cells (Figure 5.5). This modest change 
did not appear to relate to phosphorylation of E6, but this may be unclear due to the 
sensitivity of the E6P antibody. To establish whether localisation of the other viral 
oncoprotein E7 was altered upon disease progression, the fractionation lysates were 
immunoblotted with an anti-E7 antibody. The HPV18 protein E7 was detected in all 
subcellular fractions of primary keratinocytes harbouring the HPV18 genomes (Figure 5.5). 
E7 was detected primarily in the membrane fraction, with less protein observed in the 
cytoplasm and nucleus and a small amount in cytoskeletal fraction (Figure 5.5 B). In HeLa 
cells, E7 was predominantly detected in the cytoplasm, with small amounts of the protein 
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Figure 5.5: Distribution of  phosphorylated E6 in monolayer-grown cells 
HeLa and HPV18 genome containing keratinocytes, form two donor backgrounds, 
were grown in monolayer to approximately 70% confluency before subjection to  
subcellular fractionation. Western blots were quantified by densitometry and are 
representative of  three repeats. 
(A)  Housekeeping gene analysis indicated sufficient enrichment of  the 
cytoplasmic, membrane, nuclear and cytoskeletal fractions (F1-F4), as 
described in Section 3. 
(B)  HPV protein distribution was analysed by subcellular fractionation followed by 
by western blot using mouse anti-HPV18 E6 (Santa Cruz), rabbit anti-HPV18 
E6P or mouse anti-HPV18 E7. 
(C) Three subcellular fractionation repeats with detection of  E6P. 
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in the membrane and in the nucleus (Figure 5.5 B). These data indicate that the subcellular 
localization of both oncoproteins changes upon disease progression. 
5.4.2.2 E6 protein levels are affected by PKA activity  
In some experiments, treatment of the HPV18 genome containing cells with a PKA 
activator led to an increase in E6 protein suggesting that PKA mediated phosphorylation 
of the E6 PBM regulates E6 stability (Figure 5.4 A). Indeed, it has been suggested by 
knockdown of 14-3-3ζ expression in HeLa cells that the association between the viral 
oncoprotein and the cellular adapter protein regulates E6 protein stability (Boon and 
Banks, 2012b). Thus, to investigate the relationship between PKA activity and E6 protein 
stability in the viral genome containing cells, monolayer-grown cells were treated with the 
PKA inhibitor dihydrochloride (H89). The cells were harvested after 4 and 6 hours 
incubation with H89 and E6 protein levels assessed by western blot. Following both 4 and 
6 hours of treatment with H-89 led to a marked decrease in E6 protein in two different 
donor backgrounds (Figure 5.6).  
Because the inhibitor H89 is not a selective inhibitor of PKA but has been shown to 
inhibit at least 8 other kinases, including AKT, ribosomal S6 kinase (RSK) and Rho-
associated protein kinase II (ROCKII, Lochner and Moolman, 2006), the effect of PKA on 
E6 stability was also examined by transfecting the cells with a plasmid expressing the PKA 
inhibitor peptide (mPKI). This plasmid (a kind gift from M. Diskar) expresses a GFP 
fusion of protein kinase inhibitor peptide (PKI), which has been identified as an 
endogenous specific inhibitor of PKA (Dalton and Dewey, 2006). Transfection efficiency 
was estimated via observation of the GFP reporter, typically 50-60% in HeLa and 30-40% 
in HFKs following incubation for 48 hours. In genome containing cells and in Hela cells 
transfected with the specific inhibitor, the levels of the E6 protein were decreased 
Figure 5.6: The effect of  PKA inhibition upon HPV18 E6 protein 
Keratinocytes containing HPV18 genomes were treated with the PKA inhibitors 
H89 or PKI for 4 and 6 hours. Control cells were treated with the vehicle DMSO 
alongside H89 or 1% BSA alongside PKI. Protein extracted in urea buffer from 
cells derived from 2 donor backgrounds. Western blot analysis was applied using 
antibodies specific to HPV18 E6 protein and βactin loading control. 
Representative of  two repeats. 
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compared to the untransfected cells (Figure 5.6). Together these data suggest that PKA 
phosphorylation regulates E6 steady state stability. 
The next step aimed to examine whether the observed change in E6 levels reflected a 
change in a specific cellular pool of E6. Firstly, HeLa cells were transfected with the mPKI 
plasmid, incubated for 48 hours and then equal numbers of treated and untreated cells 
were subjected to subcellular fractionation. Firstly, housekeeping gene analysis confirmed 
that the enrichment of the cytoplasmic, membrane, nuclear and cytoskeletal compartments 
was successful (Figure 5.8). As noted previously (Figure 5.4) HPV18 E6 was present in all 
four fractions analysed and was detected predominantly in the nucleus of HeLa cells 
(Figure 5.7). Where PKA was inhibited (+mPKI), less E6 was detected in the cytoplasmic 
fraction along with a subtle shift from the membrane to the nucleus compared to 
untransfected cells (-mPKI) (Figure 5.7). The distribution of the phosphorylated form 
remained nuclear and cytoskeletal in the presence and absence of mPKI, although less E6P 
was detected where PKI was expressed, indicating that phosphorylation of E6 was 
inhibited (Figure 5.8). As an equal number of cells were subjected to fractionation and less 
total E6 was detected where PKA was inhibited, this supports the earlier data where PKA 
phosphorylation stabilised E6 protein levels (Figure 5.6). 
To determine whether these changes in distribution and abundance were specific to E6, the 
distribution of the viral protein E7 was included in the analysis and was shown to reside 
predominantly in the cytoplasmic and membrane fractions, with lower levels detected in 
the nuclear and cytoskeletal fractions, irrespective of mPKI expression (Figure 5.7).  
Next, the sensitivity of E6 localization to changes in PKA signalling was examined in 
HPV18 genome-containing cells. Keratinocytes were transfected with the GFP-mPKI 
expressing plasmid and fractionated as described. Detection of GRB2, E-cadherin, p53 and 
K18 confirmed successful enrichment of the subcellular compartments (Figure 5.8 A). As 
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Figure 5.7: HPV oncoprotein expression in HeLa expressing mPKI 
HeLa were transfected with plasmid expressing peptide inhibitor of  PKA (+PKI) 
or vehicle (-PKI), quenched with serum-containing media after 8 hours and 
protein harvested subcellular fractionation after a further 40 hours. Left-hand key 
describes each fraction number corresponding to a subcellular compartment.  
(A)  Lysates probed for GRB2, ZO-1, p53 and K18 to show enrichment of  the 
cytoplasmic, membrane, nuclear and cytoskeletal fractions, respectively.  
(B)  Fractions probed for analysis of  HPV protein distribution.   
Densitometry was perform on scanned film using ImageJ. Representative of  three 
repeats. 
Figure 5.8: HPV oncoprotein expression in primary cells expressing mPKI 
HPV18 genome containing keratinocytes derived from two donor backgrounds 
were treated with transfection vehicle (-mPKI) or plasmid expressing peptide 
inhibitor of  PKA (+mPKI). Following 48 hours, cytoplasmic (F1), membrane 
(F2), nuclear (F3) and cytoskeletal (F4) fractions were sequentially extracted and 
subject to western blot analysis. The top panel (A) shows an example of  
housekeeping gene analysis to confirm enrichment of  each fraction. The lower 
panels (B and C, on next page) shows detection of  HPV18 E6, E6P and E7 in 
lysates. Densitometry analysis perform using ImageJ software. Representative of  2 
repeats per donor background. 
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in HeLa cells, E6 was predominantly localized to the nucleus of keratinocytes, with the 
remaining protein distributed across the other three cellular compartments (Figure 5.8 B 
and C). This fractionation also agrees with previous detection of E6 in fractions of genome 
containing cells (Figure 5.5). In cells derived from two donor backgrounds, no major 
change in E6 distribution was observed where PKA was inhibited (Figure 5.8 B and C). 
Phospho-E6 was primarily detected in the nucleus of HPV18 positive keratinocytes, with 
some protein detected in the cytoskeletal fraction of keratinocytes, and this was not 
significantly affected by the expression of mPKI (Figure 5.8 B and C). The E7 protein 
remained within the cytoplasmic and membrane fractions in the presence and absence of 
mPKI (Figure 5.8). Together these data suggest that phosphorylation by PKA does not 
alter the stability of a specific subcellular pool of viral oncoproteins. 
5.4.2.3 E6 levels are affected by PDZ binding activity 
If phosphorylation of the E6 PBM mediates interactions with cellular factors that stabilize 
E6, then mutations of the E6 domain that prevent phosphorylation would be expected to 
affect E6 protein levels. To test this hypothesis, E6 protein levels were examined in 
keratinocytes harbouring the HPV18 mutant genomes that either lack the E6 PBM 
(∆PDZ), or genomes that express a mutant form of E6 that is not sensitive to PKA 
phosphorylation (∆PKA). Interestingly, comparison of levels of the E6 oncoprotein to wild 
type genome containing cells showed decreased levels of E6 where the PBM was removed 
and this was consistent between two donors. However, there was no consistent change in 
E6 levels in the presence of the ∆PKA genomes; in one donor E6 protein levels were 
comparable to WT genome containing cells and in the second donor E6 levels were 
decreased (Figure 5.9). This indicates that the PDZ binding activity of E6 is influential in 
the protein’s stability. Moreover, the alteration in viral protein levels was not restricted to 
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Figure 5.9: E6 protein in HPV18 genome containing HFKs 
Protein was extracted from HFKs containing WT HPV18, ΔPDZ or ΔPKA 
genomes, from two donor backgrounds, and subject to western blot analysis to 
assess HPV18 E6 and E7 oncoprotein levels. Untransfected keratinocytes (HFK) 
included as a control. Densitometry performing in ImageJ, values first normalised 
to β-actin and then to levels of  protein in WT genome containing cells to calculate 
a relative fold change. Representative of  two repeats. 
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E6, analysis of E7 protein levels also revealed a decrease in protein levels in cells containing 
ΔPDZ genomes (Figure 5.9). This decrease was sustained in the presence of ΔPKA 
genomes, albeit to a larger extent in donor 1 (0.5-fold) than donor 2 (0.7-fold, Figure 5.9). 
5.4.3 14-3-3ζ 
Phosphorylation of the HPV18 PBM allows an alternative interaction with 14-3-3ζ (Boon 
and Banks, 2012b). To investigate whether interaction with the viral protein alters 14-3-3ζ 
levels and/or localization in the life cycle, the overall abundance of the scaffold protein was 
assessed in primary keratinocytes containing high-risk α-HPV types 16 and 18 and in the 
cervical cancer cell line HeLa. Although 14-3-3ζ levels decreased in HeLa compared to 
untransfected HFKS, there was no change in abundance of the scaffold protein where 
intact α-HPV genomes were present (Figure 5.10 A). Furthermore, perturbing the activity 
of the HPV18 E6 PBM activity had no effect upon the abundance of 14-3-3ζ (Figure 5.10 
B).  
To determine if PKA activity was inhibited via the expression of mPKI in HeLa or HPV18 
genome containing cells. There was no effect upon the distribution of the scaffold protein 
in monolayer cells, where the majority of the protein was in the cytoplasmic and membrane 
fractions, with some protein detected in the nucleus and a little at the cytoskeleton (Figure 
5.10 C). 
The distribution of 14-3-3ζ was further investigated in differentiated keratinocytes by 
immunofluorescence of cells stratified in raft culture. Together, these data indicate that the 
expression levels or the localization of cellular factor is not affected by changes in E6 PBM 
activity.   
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Figure 5.10: 14-3-3ζ protein expression in HPV genome containing 
keratinocytes 
(A)  Total protein was extracted from primary keratinocytes and from HPV16 or 
HPV18 genome containing cells from two donor backgrounds and subject to 
western blot analysis. Representative of  two repeats. Fold change calculated 
relative to levels in HFKs of  the same donor background, following 
normalisation to β-actin loading control. 
(B)  Total protein was extracted from HFKs and from HPV18 WT, ΔPDZ and 
ΔPKA genome containing cells from two donor backgrounds and subject to 
western blot analysis. Representative of  two repeats. Fold change calculated 
relative to levels in WT genome containing cells of  the same donor 
background, following normalisation to β-actin loading control. 
(C)  Analysis of  14-3-3ζ distribution in monolayer-grown HeLa cells and 
keratinocytes containing HPV18 genomes, from two donor backgrounds. Cells 
were transfected with vehicle (-mPKI) or mPKI plasmid and subjected to 
subcellular fractionation. Representative two repeats.  
Densitometry analysis perform using ImageJ software.  
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5.5 Discussion 
This study showed for the first time that the E6 PBM is phosphorylated during the life 
cycle of the high-risk virus HPV18. The data suggests that phosphorylation occurs 
principally to the nuclear pool of E6. The nuclear localization of E6 observed in monolayer 
grown keratinocytes agrees with established knowledge; three nuclear localisation signals 
have been identified in HPV16 E6 and exogenous expression of the oncoprotein in 
cervical cells leads to a predominantly nuclear subcellular location (Masson et al., 2003; Tao 
et al., 2003; Liang et al., 1993). However, as the E6P antibody detected the phospho form 
weakly, it is possible that the phosphorylated protein was only detected in nuclear fractions 
because this is where the majority of the E6 protein resides. If E6 phosphorylation occurs 
mainly to protein in the nucleus, then activation of PKA could be expected to lead to an 
increase in nuclear DLG1, and inhibition of PKA to a decrease of the cellular protein. Due 
to time constraints, this study was unable to investigate the distribution of DLG1, and 
other PDZ targets, during the expression of mPKI, and so this requires further 
characterisation, perhaps with additional investigation including small molecule inhibitors 
and activators of PKA.  
Activation of PKA using forskolin led to an increase in E6 abundance and correspondingly 
inhibition of PKA by both specific and less-specific inhibitors led to a decrease in 
oncoprotein levels. Although no change in a specific pool of phosphorylated E6 was 
observed upon PKA inhibition of keratinocytes, there may be an alteration in E6 
distribution in mPKI treated cancer cells. The differences observed between cancer cells 
and primary cells may be attributable to differences in mPKI transfection efficiency, which 
could be overcome using small molecule inhibitors in combination with the subcellular 
distribution analysis.  
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It has been demonstrated that E6 binding to the PDZ protein SCRIB stabilizes the 
oncoprotein (Nicolaides et al., 2011). Phosphorylation of the PBM is likely to disrupt this 
interaction and thus destabilize the protein. However, since phosphorylation presents novel 
interactions for E6, it is feasible that this compensates for any interruption in the stability 
provided by PDZ interactions (Figure 1.12). In this study, lower levels of E6 were 
observed where the PBM was removed, indicating that an interaction 14-3-3ζ may stabilise 
E6 in primary cells. However, if this were the case E6 levels where the PKA recognition 
site is altered would exhibit the same decrease in protein levels, and this was not 
consistently observed. As the ΔPKA mutation allows constitutive binding to PDZ proteins 
and interaction between E6 and SCRIB has been shown to promote the stability of both 
proteins (Nicolaides et al., 2011), perhaps the inability of the ΔPDZ mutant to interact with 
either PDZ proteins or 14-3-3ζ  has negative consequences on protein stability (Figure 
5.11).  
It should also be noted that other sites within the E6 protein may be recognised by PKA, 
for example HPV18 threonine 86 was identified in the Scansite screen as a potential target 
for basophilic kinases (data not shown), phosphorylation of which may have an effect 
upon E6 stability. In addition deletion of the E6 PBM was associated with a moderate 
decrease E7 oncoprotein levels (Figure 5.9) and so an effect of the mutation upon E6E7 
mRNA transcription cannot be ruled out completely. 
It may also be that binding to either PDZs or 14-3-3ζ functions to control the stability of 
E6 at different times during the viral life cycle. The aforementioned analysis of the effect of 
phosphorylation on PDZ protein expression levels and distribution could aid this 
investigation. Further work could also include the analysis of PDZ protein levels and/or 
14-3-3 isoforms in differentiated keratinocytes, perhaps in the presence of PKA inhibitors 
14-3-3ζ binding
E6 stabilised
E6 destabilised
RLQRRRETQV -C PDZ protein binding and degradation
RLQRRRETQV -C
P PDZ protein binding 
and degradation
PKA
RLQRRRETQV -C
P
14-3-3
14-3-3ζ binding E6 stabilised
RLQRRR -C
PDZ protein binding 
and degradation
Figure 5.11: The consequences of  E6 phosphorylation 
A number of  E6 oncoproteins have been shown to bind cellular PDZ proteins via 
a C-terminal PBM.  
(A)  Work by Nicolaides et al. has shown that the interaction with SCRIB stabilises 
the viral protein. 
(B)  Phosphorylation of  the PBM sterically hinders PDZ protein binding and Boon 
et al. have shown that the ability of  14-3-3ζ  to bind the phosphorylated PBM 
promotes the stability of  HPV18 E6. 
(C)  Removal of  the PBM removes the ability of  E6 to interact with both cellular 
PDZ proteins and 14-3-3ζ, and may therefore be the cause of  the observed 
E6 destabilisation. 
 
C
A
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or activators. In this study, investigation into the degree of E6 phosphorylation in 
differentiated cells was investigated by applying western blot analysis to protein extracted 
from keratinocytes grown in organotypic raft culture. However, the results from multiple 
experiments were inconsistent and thus inconclusive. Due to this, and the challenging 
nature of immuno staining for E6, calcium-induced and/or methylcellulose differentiation 
may present a more practical option to observe E6 interactions during productive viral life 
cycle. 
It seems that the steady state stability of E6 is affected by PKA phosphorylation. This may 
be due to the increased ability to interact with 14-3-3ζ, which has been previously shown 
to stabilise E6 (Boon and Banks, 2012b). To examine this further and identify whether an 
interaction between E6 and 14-3-3ζ occurs in primary keratinocytes, attempts were made 
to co-immunoprecipitate E6 and 14-3-3ζ in cells were treated with vehicle (DMSO) or 
with PKA activators. These were unsuccessful, but with further optimisation pose an 
interesting avenue of investigation.  
As E6 exists in more than one subcellular compartment, it is likely that the different pools 
perform different functions during viral replication. Phosphorylation of E6 may affect 
pools of protein differently, depending on the proteins available for interactions. For 
example, the interaction with 14-3-3 ζ has been shown to stabilise E6 protein and this may 
be specific to E6 located at the membrane (Boon and Banks, 2012b). Such 
phosphorylation of the PBM may promote 14-3-3 ζ binding to the PBM and thus organise 
E6 with other junctional proteins at the nuclear membrane. Equally, in the nucleus, PBM 
phosphorylation may prevent binding to cellular PDZ proteins where (or when) the 
interaction is not required, thereby allowing spatial and temporal regulation of E6 PBM 
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interactions. This speculation requires further investigation, perhaps in stratified cells for 
better observation of E6 distribution during differentiation. 
Work by Delury et al. showed that loss of the PKA recognition site proximal to the E6 
PBM was associated with an increased cell growth rate, whilst WT genome containing cells 
treated with PKA activators exhibited a slowed growth rate. Here, no difference was 
observed in E6 levels between ΔPKA and HPV18 WT genome containing cells, which may 
indicate that the difference in growth rate phenotypes are due to the regulation of E6 
interactions. The absence of PBM phosphorylation confers constitutive PDZ binding and 
an increased capacity of E6 to promote cell growth, whereas, in WT cells, PKA 
phosphorylation regulates E6:PDZ interactions to prevent uncontrolled growth. This could 
be further investigated using specific kinase inhibitors such as mPKI. In conditions of 
PKA inhibition, it is expected that growth levels of WT genome containing cells increase as 
PDZ protein interactions would no longer be sterically hindered by a phosphate group, 
resembling the constitutive binding conditions of the ΔPKA mutant. The PBM function is 
linked to the maintenance of episomal genomes and thus observation of the state of HPV 
genomes under conditions of PKA activation and inhibition may also be of interest 
(Delury et al., 2013). 
A kinase screen of high-risk HPV E6 proteins revealed that the group 1 proteins are 
targeted at a common site within the PBM by either PKA or AKT. Less of the group 2 E6 
proteins were predicted to be phosphorylated by PKA or other kinases, and in some cases 
(e.g. HPV 34 and 53) this phosphorylation is predicted to occur outside of PBM. The 
conservation of this site in these high-risk viruses may reflect a role for the modification in 
HPV-mediated cancer development. Indeed, both kinases have been implicated in growth 
factor-induced proliferative pathways (Jang et al., 2012). However, the recognition sites of 
these kinases differ by an extra amino acid between the double arginine and target 
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serine/threonine residues (PKA, RRXT/S and AKT, RRXX
T/S) and both HPV16 and 
HPV58 are phosphorylated by both in vitro (Boon et al., 2014). Furthermore, HPV31 has 
been shown to be phosphorylated by PKA within the core of the E6 protein with no effect 
on PDZ interactions (Boon et al., 2014). Thus, the Scansite screen is limited and unable to 
recapitulate in vivo interactions, it is important to confirm PBM phosphorylation via in vitro 
assays and to test the role of phosphorylation in the primary keratinocyte model of HPV 
propagation.  
It has been demonstrated that HPV16 is phosphorylated by the kinase AKT and that 
expression of HPV16 E6 in HFKs causes accumulation of the active phosphorylated form 
of AKT (Spangle and Münger, 2010; Boon et al., 2014). Furthermore, deletion of the 
HPV16 E6 PBM was unable to activate AKT and degradation of NHERF-1 mediated by 
HPV16 E6 correlates with the activation of the AKT signalling pathway (Accardi et al., 
2011; Spangle and Münger, 2010). This indicates a strong relationship between the HPV16 
PBM function and cellular kinase activity, and has been suggested to be important during 
the differentiation dependent stage of the virus life cycle. While analysis of the PKA 
pathway in the life cycle of HPV18 is currently under investigation in the Roberts lab, it 
may also be of interest to the field to investigate the phosphorylation of the HPV16 PBM, 
perhaps using mutations in the PBM analogous to those used in the context of HPV18 
during this thesis.  
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6.1 Overview of findings 
High-risk HPV types 16 and 18 encode a C-terminal PDZ-binding motif in the E6 
oncoprotein. Although this motif has been shown to direct the degradation of a number of 
cellular PDZ domain containing proteins, is known to influence the maintenance of viral 
genomes and is essential to the productive viral life cycle, the precise function of the 
interactions in the context of the virus life cycle has not been fully characterized. More 
recently, HPV16 studies demonstrated that expression of the E6 and E7 oncoproteins had 
no effect upon degradation nor altered cellular localization of endogenous PDZ proteins in 
primary keratinocytes (Choi et al., 2013). The study described in this thesis investigated the 
expression of known and suggested PDZ targets of E6 in the presence of whole HPV 
genomes. In the main, results in this thesis agree with Choi et al., 2013; the major known 
targets of HPV genomes were unaffected by the replicating virus at a protein level. 
Unexpectedly, the tight junction proteins ZO-1 and ZO-2 were affected by HPV18 and 
HPV16 respectively; ZO-2 protein was decreased whilst ZO-1 protein increased in 
keratinocytes. Both ZO-1 and ZO-2 proteins have been suggested to interact with E6, 
although this has yet to be confirmed in primary cells (Hernandez-Monge et al., 2013; 
Belotti et al., 2013). Thus, the next step would be to identify an interaction with the E6 
PBM and utilize transcriptional analysis to identify whether HPV is exerting an effect at a 
gene level.  
A number of microarray studies have identified changes in protein expression in the 
presence of HPV genomes, and when expressing HPV oncoproteins alone (Duffy et al., 
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2003; Chang and Laimins, 2000; 2001; Karstensen et al., 2006; Reiser et al., 2011). The 
deregulated genes identified in these studies are mostly downstream of the p53, pRb/E2F 
or interferon-responsive pathways, and thus changes are likely due to the effect of the E6 
and E7 oncoproteins upon pathway components (Chang and Laimins, 2001; 2000; Nees et 
al., 2001; Karstensen et al., 2006). Work in this thesis demonstrates that HPV genomes 
exert an influence over the transcription of specific PDZ-domain containing protein genes, 
including DLG1, PTPN13, NHERF1 and PATJ. HPV-mediated upregulation of these 
genes may occur indirectly, via p53, pRb etc. or directly via a virally encoded factor. 
Moreover, HPV differentially affects the transcription of DLG1 isoforms, with the 
DLG1β form largely unaffected by viral genomes and upregulation of an isoform 
containing a previously unidentified exon. In this study, an exon was identified in the 
DLG1 HOOK region, which exists in DLG1α transcripts. This insertion (I6) is predicted 
to include a 20-amino acid sequence and produce a truncated form of the DLG1 protein. 
However, it is also possible that I6 acts at an mRNA level. 
Finally, studies described in this thesis investigated the role of PBM phosphorylation in the 
context of genome replication. The phosphorylation of the HPV18 E6 PBM in primary 
cells was confirmed. Although this did not affect E6:PDZ interactions in monolayer grown 
cells, much of this preliminary work forms some foundation for ongoing investigations in 
the Roberts lab which focuses upon the influence and importance of PKA in the HPV life 
cycle. As the motif is conserved amongst high-risk α-HPV types, these data suggest that 
phosphorylation of the PBM performs a crucial role in regulating E6 interactions during 
the virus life cycle. 
 
As tight junctions regulate epithelial integrity and polarity, viral targeting of these proteins 
may be advantageous to HPV by interrupting differentiation of the infected basal 
CHAPTER 6: FINAL DISCUSSION 
-189- 
keratinocytes that would otherwise cause exit from the cell cycle. The PDZ proteins are 
multifunctional and thus there are likely to be functions, including the control of 
proliferation and pro-proliferative transcription factors, which are required at different 
stages of viral propagation. Especially since HPV targets subsets of PDZ proteins 
depending upon post-translational modifications, cellular localization or differential 
splicing of cellular proteins. As there is such specific PDZ targeting by E6 during the HPV 
life cycle, it can be assumed that the deregulation of the viral protein observed in 
transformed cells, and the ensuing disruption of polarity complexes, enhances HPV-
mediated malignant progression. 
6.2 Future directions 
Despite the increase in transcript levels, no change was observed in the abundance or 
distribution of major known E6:PDZ targets, DLG1 and SCRIB during the early stages of 
the HPV life cycle. Although no changes in the protein abundance of PDZ targets (DLG1, 
PTPN13, NHERF1, PATJ) was observed in monolayer grown cells, some changes in 
protein distribution were observed in differentiated cells. However, more thorough 
investigation of degradation pathways may identify an increase in transcript correlates with 
translation, but also with an increase in protein turnover. Alternatively, the transcripts may 
be unstable or again turned over by infected cells more quickly to counter the detrimental 
effects of increased PDZ mRNA. Studies by Watson et al., 2002 revealed an increase in 
cytoplasmic DLG1 in CIN1. Further investigation of DLG1, SCRIB and of other PDZ 
protein gene expression during neoplastic progression, for example following viral genome 
integration and in increasing CIN stages, would provide an insight into these interactions 
during the development of HPV-mediated cancers. 
As well as the consequences of PDZ gene upregulation, it is also of interest to identify the 
viral mechanisms promoting upregulation of PDZ genes in such a selective fashion. This is 
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especially interesting in the case of DLG1 isoform expression; the ability of HPV to 
promote the inclusion of exons and the transcription of certain isoforms merits further 
exploration.  
Replication of high-risk α-HPV genomes led to an increase in transcription of selected 
PDZ domain containing targets, and affected proteins ZO-1 and ZO-2. The effect of HPV 
appears to concentrate upon the tight junctions and their protein partners, which may aid 
viral propagation by promoting growth factor signalling or the release of proliferatory 
transcription factors (Balda and Matter, 2000; Betanzos et al., 2004). These proteins warrant 
further study in the HPV life cycle model and it may be of interest to investigate the 
consequences of kinase activation or inhibition on the tight-junction proteins. 
Analysis of PDZ gene expression during the HPV life cycle identified the upregulation of a 
novel variant of DLG1. Expression of this form identified differential expression in HPV 
genome containing cell but not in cancers, suggesting that the form is not required during 
carcinogenesis but may be important in viral propagation. This work provides an exciting 
foundation for further investigation into the expression of this variant, and indeed of 
DLG1 isoforms, during HPV replication, in carcinogenesis and across tissue and cell 
contexts. 
Although challenging to study, E6 PBM phosphorylation is likely a key influence in PDZ 
interactions. Thus, future studies investigating the effect of phosphorylation in 
differentiating cells, following genome integration and during the progression of HPV-
driven cancers will further our understanding of E6:PDZ interactions.  
6.3 Final statement 
Overall, this study has contributed to current knowledge of HPV interactions with cellular 
PDZ proteins by performing a systematic analysis of PDZ proteins in the context of viral 
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replication. Although a number of major targets were unaffected by α-HPV types at a 
protein level, it was shown the virus acts on DLG1, PATJ, NHERF1 and PTPN13 at a 
gene transcription level and on ZO-1 and ZO-2 at a protein level. Furthermore, it was 
observed that HPV genomes promoted inclusion of a novel insertion of DLG1.  
Together, data from this study offers a new perspective on the interactions between 
oncogenic HPV types and PDZ domain-containing targets, indicating that deregulation of 
PDZ protein function by the virus occurs via multiple mechanisms. 
Disruption of cell-cell junctions contributes to invasive growth and, ultimately, metastases. 
A thorough knowledge of E6:PDZ interactions and their regulation may aid their 
manipulation during HPV-mediated cancers and thus the development of therapeutic 
strategies targeting the PDZ:PBM interaction. 
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